1 - Cade

o
SERVIÇO PÚBLICO FEDERAL
JdvnJ
INTERESSADO:RFØLJFRFNTF& PFZIER. INC. ("PFIZER")
- e WYETH rYVYt 1
02
ASSUNTO:
CÓDIGO:
no
0 op
O
OUTROS DADOS:
o
o
o
MOVIMENTAÇÕES:
SIGLA
DATA
EQ
01
/
/
03
/
,
p
o
o.
CÓDIGO
04
I
SIGLA
CÓDIGO
15
17
18
05
/
/
19
06
/
/
20
07
/
/"
21
08
/
1)
22
09
/
f
23
10
/
/
24
II
/
»
25
12
/
/
26
13
/
/
27
/
28
'IMENTAÇÕES DEVERÃO SER COMUNICADAS AO PROTOCOLO
ANEXOS
DATA
-
-
-
t
FRANCESCHTNT
e MIRANDA
4dvogados
José Inácio Gonzaga Franceschiní
Custodio da Piedade U. Miranda
Fernando Eduardo E. Ferreira
Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Motta
Gianni Nunes de Araujo
Ana Carolina Pinto Couri Smith
Paulo Messias Pedrassoli
Walter Basílio Bacco Júnior
Camila Castanho Girardi
Sandra Gomes Esteves
Maria Eugênia Dei Nero Poletti
Camila Pimentel Porto Daria
Bruno Greca Consentino
Flávia Maria Pelliciari Salum
Bruna Cantergiani Martineili
Crlsthiane Helena Lopes Ferreiro
André Pissolito Campos
Silvia Cristina Landi Bernardes
Marcos Paulo Amorim
Claudia Nastari Capanema
Patricia Bandouk Carvalho
Av. Brig Faria Urna, 1461- 13 and&- São Paulo. SP .01480.!
Tal.: +5511 3095-2566-Fax: +5511 3813-9693
fl-frntfndvooaios wn br
SECRETARIA DE DIREITO ECONÔMICO - SDE
11
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA
MINISTÉRIO DA1JUSTIÇA - MJ
§
Recebidgsm- VIs 8
'Ramo de Atividade: Indústria
Farmacêutica.
Operação: Aquisição da WYETH pela
U
PFIZER.
-
SDEJGJÍCAPRO
oorden*çIO de Apoio Procotuti
1
1M111111111
08012.001157/2009-71
PFZIER, INC. sociedade com sede em 235 East 42
Street, Nova lorque, Estados Unidos (doravante designada "PFIZER") e WYETH,
empresa co m sede em 5 Giralda Farns, Madison, Es tados Unidos (doravant e
designada "WYETH"), por seus advogados, vêm, respeitosamente, ad cautelam,
em observância ao disposto no § 40 do artigo 54, da Lei n.° 8.884/94, apresentar
para exame e aprovação do Egrégio Conselho Administrativo de Defesa Econômica
- CADE, após a realiúção de instrução e devida manifestação, nos termos da Lei,
das Ilustradas Secretaria de Acompanhamento Econômico - SEAE, do Ministério da
Fazenda, e Secretaria de Direito Econômico - SDE, do Ministério da Justiça, em 03
(três) vias, o Agreement and Plan of Merger ("Contrato"), em 25 de janeiro de 2009,
além do Anexo 1, a que se refere a ResolLção CADE n.° 15/98.
11
1
r
FRANCÊS CHINI
e MIRANDA
4dvogados
/
(F..
iÇ
DA OPERAÇÃO
A operação eni referência trata da aquisição da WYETH
pela PFIZER, empresas de produtos farmacêuticos e veterinários, as requerentes
celebraram o Agreement and Plan of Merger ("Contrato"), em 25 de janeiro de
2009, mediante o qual a PFIZER adquirirá a WYETH, pelo valor aproximado de
US$ 68 bilhões. Para a realização da operação será pago determinado montante
em dinheiro, bem como realizada troca deH ações.
Observados os termos e as condições dispostos no
Contrato, as empresas irão fundir, conforme detalha o Artigo 1 ("Fusão"). O Contrato
prevê condições costumeiras para o féchamento, incluindo a aprovação pelos
acionistas da WYETH, bem como a aprovação de órgãos de defesa da
concorrência. O fechamento está previsto para ocorrer no final do terceiro ou
quatro trimestres de 2009.
DOS EFEITOS
A PFIZER é uma empresa farmacêutica global que
produz medicamentos destinados á saúde humana e animal. No Brasil, a PFIZER
produz e comercializa ampla gama de produtos para a saúde humana, para
diversas aplicações terapêuticas. O mesmo ocorre no campo da saúde animal, em
que a PFIZER possui atividades de produção e comercialização de produtos para
bovinos, suínos e animais de companhia.
Ademais, no Brasil, o grupo PFIZER desenvolve
atividades relacionadas à fabricação e , comercialização de cápsulas gelatinosas
para medicamentos, fertilizantes, defensivos, fungicidas e produtos antibacterianos
para a agricultura, além de arrendar sistemas de vacinação in ovo.
De outro lado, a WYETH, também é uma empresa que
tem atuação mundial dedicada ao tratamento da saúde humana, produzindo
'A
FRANCE,SCHINI
e MIRANDA
F;$
03
-~ppo~-_
Ádvogados
comercializando produtos farmacêuticos que exigem ou não prescrição médica,
9
bem como produtos para a saúde animal.
As atividades das Requerentes, no Brasil, sobrepõem-se
em duas áreas, conforme se verifica na tabela abaixo:
Linha de Produto'
i
Pfizer
Wyeth
Medicamentos para Saúde Humana
X
X
- Medicamentos com Prescrição -
X
X
- Medicamentos sem Prescrição
X
Medicamentos para Saúde Animal
X
Cápsulas para medicamentos
X
Produtos para nutrição e proteção foliar
X
Sistemas de vacinação in ovo
X
X
t
Os Anexos 1 e ;II contêm a lista de todos os produtos
para a saúde humana e animal que são atualmente comercializados pelas
Requerentes no Brasil, separadamen e. Conforme doravante se verá, as
Requerentes permanecem diligenciando io sentido de obter informações precisas
sobre os efeitos da operação no mercadc brasileiro e sobre as áreas em que possa
informações requerido, bem como a
haver concentração. Dado o volume
extensa lista de produtos de cada Requerente, não foi possível concluir o trabalho
até o momento. De toda a sorte, as Requerentes informam que despenderão os
O
melhores esforços para concluir, tal tarefa, comprometendo-se, desde logo, a
submeter informações acuradas eladicionáis nestes autos tão-logo quanto possível.
Como é sabido, a identificação precisa de mercados
relevante, bem como produtos substitutos, quando se trata da indústria
farmacêutica, não é uma tarefa trivial.
Produtos para a Saúde Humana
Tendo-se
tocante a medicamentos para a
conta a complexidade envolvida, no
humana, as autoridades de defesa da
(1
FRANCESCHINI
e MIRA$IDA
Advogados
ORDE
concorrência contrataram uma áonsultoria especializada, a ser prestada pela
Associação Nacional dos Centros de Pós Graduação em Economia - ANPEC, que
contou com a colaboração técnica'do Instituto de Pesquisa Econômica Aplicada IPEA, para desenvolver um estudo, econômico,bem como métodos quantitativos no
tocante à política concorrencial e regulatória, além de preparar base de dados para
ser empregada e fundamentar os referidos estudos'.
Em termos gerais, o estudo, que vem sendo adotado
pelos órgãos do Sistema Brasileird de Defesa da Concorrência - Si para definir
•mercado relevante em operações envolvendo medicamentos, propõe uma
metodologia cujo ponto de partida é
aplicação da Classificação Química
uro
pean
Anatômica (ATC) da E
Pharmaceutical Market Research Association
(EphMRA), utilizada pelo Intercontinental Marketing Services (IMS) e,
posteriormente, desenvolve-se para o agrupamento devido à indicação terapêutica
do produto.
De fato, a apliciação da referida classificação (ATC4), em
determinados casos, não é a metodologia mais acurada para se definir mercado
relevante. Isso porque há situações em que é mais indicada a combinação de uma
série de produtos classificados em subclasses distintas da ATC, por serem
substitutos para o tratamento de uma mesma doença. Por outro lado, produtos
11
agrupados na mesma subclasse: podei
ter aplicações e indicações terapêuticas
distintas. Assim sendo, existirão casc
em que a análise da substitutibilidade
deverá desenvolver-se no sentido de
as aplicações terapêuticas do
produto e as doenças para as quas ele
Produtos para a Saúde Animal
A definição é determinação das sobreposições, no
tocante aos produtos veterinários também é complexa.
As difiduldades residem, especialmente, na inexistência
de fonte de dados oficial, nas diversas aplicações do mesmo produto, na forma de
administração das doses prescritas, quS podem variar substancialmente entre os
1
'Procedimentos para a Definição e Análise Antitkiste de Mercados Rélevàntes de Medicamentos".
Contrato SDE/MJ n° 1 ANPEC/IPEA.
4
/
FRANCESCHINI
e MI RANDA
Advogados
k _o.a_
OPD
produtos e, finalmente, nas diferentes reações provocadas pelo produto no
tratamento do animal.
O PAIVET, Painel da Indústria Veterinária, elaborado
pela empresa SINAPSE, que também já foi objeto de adoção pelos órgãos
brasileiros de defesa da concorrência, para definir mercado relevante no setor de
saúde animal, também pode ser, dependendo do caso, bastante impreciso. Em
determinadas situações, sua aplicação isolada não é recomendada, diante das
distorções analíticas que provoca, distanciando os resultados da realidade do
mercado, pelas razões retro discutidas. Nessas hipóteses, a análise antitruste deve
ser mais aprofundada, considerando-se ás indicações terapêuticas do produto e as
doenças para a quais ele é prescrito.
Considerando-se as discussões e complexidades
envolvendo a definição de mercados relevantes para produtos farmacêuticos de
forma geral, tanto para a saúde humana, quanto para a veterinária, como dito, não
foi possível identificar as concentrações de mercado resultantes da operação até o
momento. Mais que as dificuldades mencionadas à aplicação da metodologia,
mencione-se que as partes comercializam uma ampla lista de produtos (Vide
Anexos 1 e II) em ambos os segmentos no Brasil. Nestes termos, dado o tempo
disponível, desde a celebração do contrato, não foi possível determinar com
precisão as áreas em que ocorrerá, sobreposição de atividades entre as
Requerentes. É certo, todavia, que as Requerentes se encontram despendendo
todos os esforços para identificar as características de substitutibilidade de cada
produto envolvido no ato, demandando tempo suplementar para tanto. Isto posto,
as Requerentes comprometem-se a apresentar tão-logo possível o resultado desta
tarefa, peça esta em que conterá tanto as áreas de sobreposição, como as
respectivas estruturas de mercado, para melhor instruir o presente ato.
Informa-se, ainda, que as linhas de produtos
comercializadas pelas Requerentes, no Brasil, considerando-se as indicações
terapêuticas mais abrangentes dos produtos, são, de forma geral, complementares.
Finalmente, sobÊé as relações verticais, informa-se que
as Requerentes não vendem principiosi ativos no Brasil. No tocante às cápsulas
gelatinosas vendidas pelo grupo PFIZER, informa-se que elas poderiam ser
11
empregadas pela WYETH para a fabricção de medicamentos, todavia, conforme
5
1
ÇpEi
FRANCESCUINI
e MIRANDA
Advogados
\---
dito, informações adicionais sobre os efeitos da operação serão submetidas
brevemente, tão-logo possível.
DO PEDIDO
_______________
lnicialménte, requer-se seja concedido tratamento
1
EONFIDÉNÕjiL às informações/documetos abaixo relacionados, por se tratar de
segredos de negócio e, portanto, protegidos por Lei, em especial pelas Portarias n.°
4/2006ISDE e n.° 4612006/SEAE, dos Ministérios da Justiça e da Fazenda,
respectivamente:
• Faturamento das Partes, constantes dos itens 1.9 e
IV.3, do Arjexo 1, a que se refere a Resolução CADE
n.° 15/98, nos termos do art. 26, inciso VI da Portaria
n.° 412006/SDE;
• Clientes e fornecedores listados no item Vl.1 do
Anexo 1, nós termos do art. 26, inciso Xl da Portaria
11
n.° 4/2006/SDE; e
o Contrato, anexo, nos termos do art. 26, inciso VIII da
Portaria n.° 4/2006/SDE.
1
Requer-se, outrossim, a posterior juntada, no prazo legal,
dos seguintes documentos: (i) instrumento de mandato outorgado pela PFIZER, (ii)
cópias autenticadas dos competentes comprovantes de recolhimento da Taxa
Processual de Apresentação de Atos de Concentração, além do original deste; e
(iii) a tradução do Contrato para o vernáculo, para os devidos fins de direito.
Isto posto, tendo-se em conta que o presente Ato de
Concentração é não gera preiuízos à Loncorrência, merece ser aprovado sem
restrições e é o que ora se requer.
Solicita-se, ror fim, que toda e qualquer notificação,
intimação, convocação ou comunicação,relativa ao presente Ato de Concentração
seja endereçada aos advogados das Requerentes, qualificados no anex2er
11
r / £
FRANCESCHINI
e MIRANDA
Advogados
.5.
instrumento de mandato, a saber: Franceschini e Miranda - Advogados, alc José
Inácio Gonzaga Franceschini e Camila Castanho Girardf, Av. Brigadeiro Faria Lima,
ri.0 1461, 130 andar, Torre Sul, São Paulo SP, CEP 01452-904, telefone: (11) 3095
2566, fax: (11) 3813 9693, e-maiL cgi rara ifm-advogados. com. br.
Termos em que,
Pede Deferimento,
De São Paulo para Brasília, 13 de fevereiro de 2009.
PFIZER, INC.
Pp.
José Inácio Gonzaga Franceschini
OAB/SP h.° 28.711
Pp. _______________________________
Camila Castanho Girardi
OAB/SP ri.° 175.500
.._res2 Ip
Assessoria Econômica de:
EDGARD PEREIRA & ASSOCIADOS
Edgard Antônio Pereira
CORECON 17.677 2a Região
7
Fiz
n.o
PARTE 1— DAS REQUERENTES
1.1. Nome de acordo com o estatuto sodial, nome dos estabelecimentos,
1
nome do representante legal, CGC/MF e inscrição estadual
Requerente A
Razão social: PFIZÉR, INC. ("PFIZER")
Representante legal: Marc Brotman
CNPJ: Não se aplica. Empresa estrangeira.
Inscrição estadual: Não se aplica. Êmprõsã estrangeira.
Requerente B
Razão social: WYETH ("WYETH")
Representante legal.- Gesilaine Macedo Chaves
CNPJ: Não se aplica. Empresa estrangeira.
Inscrição estadual.- Não se aplica. Empresa estrangeira.
il
1.2. Principal setor de atividades das
Requerente A - PFIZER
14.01 - Indústria Farmacêutica - Pr
14.99 - Indústria Farmacêutica - D
Farmacêuticos e Veterinários;
Requerente B -WYETH
14. 01 - Indústria Farmacêutica - Produtos Farmacêuticos e Veterinários.
F
ANEXÕ 1
\ç7'
1.3. Endereço da sede, número do telefonõ e do fax e endereço do correio
eletrônico
Requerente A - PFIZER
235 East 42 Street,
Nova lorque (NY) 10017, EUA.
Tel. / Fax: 1212 733 6098 1573 0768
C
www.pfizer.com
Wyeth
5 Giralda Farms
Madison, (NJ) 07940, EUA.
Tel / Fax: 1 973 660-5000
www.wyeth.com
1.4. Nome dos acionistas ou quotistas com as respectivas participações no
o
capital social, discriminando a natureza da participação societária
Requerente A - PFIZER
A PFIZER é a sociedade controladora do Grupo PFIZER. As ações são
negociadas na Bolsa de Valores de Nôva Iorque e estão pulverizadas. A
Pfizer não é controlada por qualquer pessoa jurídica ou indivíduo.
Requerente 8— WYETH
Acionista
Wyeth
Wyeth Pharmaceuticals Inc.
1
F 1
1
Ações
581.880.2891 85,65421%
116.6721
0,01717%
H
ANEXO 1
Wyeth Advertising Inc.
1.5. Grupo de empresas da qual faz parte
Requerente A - PFIZER
Grupo PFIZER
Requerente B WYETH
Grupo WYETH
1.6. Nacionalidade de origem do grupo
Requerente A - PFIZER
Grupo PFIZER - norte-americano
Requerente B - WYETH
Grupo WYETH - norte-atnèricano.
1.7. Principal setor de atividades do g
Grúpo da Requerente A - PFIZER
Vide item 1.2.
deitem 1.2.
1.4951 0,00022%
a
ANEX
1.8. Relação de todas as empresas direta
grupo, com atuação tio Brasil e no M
nas quais pelo menos uma das
participação no capital social superior
Mercosul.
indiretamente componentes do
osul, bem como das empresas
tegrantes do grupo detenha
5%, com atuação no Brasil e no
Requerente A - PFIZER
Brasil
Pharmacia do Brasil Ltda.
Laboratórios Pfizer Ltda.
Uruguay
:1 Argentina
Pfizer Corporation S/A
11
Pfizer SRL
Pfizer Health AB (Argentina Warner Lambert dei
Branch)
Uruguay S.A.
Searle Argentina S. R. L.
Requerente 8 -WYETH
Brasil
São Cristóvão
Participações Ltda.
Fort Dodge Saúde Animal
Ltda.
..
Fort Dodge Manufatura
Argentina Cyanamid de
Argentina S.A.
Argentina
Fort Dodge Sanidad
Animal S.A.
Argentina Wyeth S.A.
Uruguay
Whitehall Laboratorios
S.A.
Ltda.
RMV Produtos Veterinários
Ltda.
1.9. Faturamento, no último exercício, da(s) Requerente(s), da totalidade das
empresas do grupo no País, no Morcosbl e no mundo.
Requerente A - PFIZER
4EI\
(Fie.
ANEXO i
Participante
(2007)
Grupo - Brasil
(2007)
5
Grupo - Mercosul*
(2008)
Grupo - Mundo
(2007)
Grupo - Mercosul
(2007)*
Grupo - Mundo
(2007)
(*) Valor não inclui o Brasil
Requerente - WYE
Participante
(2007)*
Grupo - Brasil
(2007)
(*) Faturamento em dólares convertido para reais a taxa de
lt3b2/Ub$ 1,UUU
tiO. Relação das aquisições, fusões, associações e constituições conjuntas
de novas empresas efetuadas pelo gkpo no Brasil e no Mercosul, nos
últimos 3 anos
Reauerente A - PFIZER
- Em Junho de 2006, o Grupo J&J adquiriu os ativos e ações do negócio da
11
Pfizer referentes à divisão de cohsume1 healthcare, incluindo produtos para
cuidado e higiene pessoal e medicamentos de venda livre (Ato de
Concentração n°08012.007138/2006-14 L Operação aprovada pelo CADE).
- Em 14 de novembro de 2006, Embre, Inc. tornou-se uma subsidiária da
Pfizer, Inc. mediante a celebração do Agreernent and PIan of Merger (Ato
de Concentração n° 08012.011008/2006-78 - Operação aprovada pelo
CADE)
Requerente B - WYETH
Não houve.
U
í
E
ANEXÓ 1
e
PARTE II— DO ATO OU CONTRATO NOTIFICADO
11.1. Descrição resumida da operação indiàando sua modalidade (aquisição
fusão, constituição de nova empreia, contrato, associações / joilU
ventures etc.)
As Requerentes celebraram o Agreement1 and Plan of Merger ("Contrato"), em
25 de janeiro de 2009, mediante o quala PFIZER adquirirá a WYETH pelo
valor aproximado de US$ 68 bilhões. Fara a realização da operação será
pago determinado montante em dinheiro, em como realizada troca de ações.
Ambas as Requerentes têm ativos e operàm no Brasil
li
Observados os termos e as condições dispostos no Contrato, as empresas
irão fundir, conforme detalha o Artigo 1 ("Fusão"). O Contrato prevê condições
costumeiras para o fechamento, incluindo a aprovação pelos acionistas da
WYETH, bem como a aprovação de órgãos de defesa da concorrência. O
fechamento está previsto para ocorrer no final do terceiro ou quatro trimestres
de 2009.
11.2. Setor(es) de atividade em que ocorreu o ato ou contrato notificado
14.01 - Indústria Farmacêutica - Podutos Farmacêuticos e Veterinários.
11.3. Esclarecer se o ato ou contrato é conseqüência de operação realizada
entre empresas/grupo de empresas fota do País
Operáção realizada envolve as operações das Requerentes no mundo,
inclusive no Brasil.
(111,
is J__)
7
11.4. Relação de ativos envolvidos e sua
A operação envolve todos os ativos pertencentes ao grupo WYETH no
mundo.
11.5. Data e valor da operação
Data: 2510112009.
Valor da Operação: Aproximadamente US$ 68 bilhões
11.6. Nas operações que envolvem alteração da composição do capital social,
1
apresentar quadro contendo sua estrutura antes e após a realização do
ato ou contrato notificado
PFIZER, após a satisfação das
Haverá a fusão dos grupos WYETH
condições contrâtuais. A operação envolve troca de ações, bem como
pagamento de quantia em dinheiro. Para maiores detalhes, vide Contrato.
11.7. Razões consideradas decisivas' para a realização do ato ou contrato
notificado
A operação possibilitará a criaçãode uma empresa diversificada no universo
globalizado da indústria farmacêutica. É esperado que ela possa oferecer uma
ampla gama de produtos para` todos, os estágios da vida, em áreas
terapêuticas essenciais, incluindo drogas para o tratamento cardiovascular,
doenças oncológicas, da mulher, do sistema nervoso central, bem Como
infecto-contagiosas.
A operação também possibilitará que as' Requerentes agrupem os negócios
de produtos para saúde animal como os biológicos, os antibióticos e os
destinados a animais de companhia.
ANEXO 1
III - DA DOCUMENTAÇÃO
/11. 1. Cópias dos documentos que
Segue anexa cópia do Agreement and
111.2. Cópia do último relatório anual
o ato ou contrato notificado
ofMerger de 25/01/2009.
para acionistas ou quotistas.
Seguem, anexas, cópias dos seguintes
•
•
Relatório de Responsabilidade Corpoiativa do grupo PFIZER relativo ao
ano de 2007, e
Relatório Anual do grupo WYETH relativo ao ano de 2007.
111.3. Quaisquer atos e contratos
ou adicionais firmados
entre as partes
Não há.
111.4. Relação dos membros da direção do grupo que, igualmente, sejam
membros da direção de quaisquer outras empresas com atividades nos
mesmos setores das Requerentes
Requerente A - PFIZER
Não há.
Requerente B - WYETH
Não há.
T
'E.
1;
iii;s. Acordos de acionistas, quot:stas
todas e quaisquer: acordos que
incluam reqras relacionadas com a administração
10
Au 1'
PARTE IV
4-
FIS
DOS MERCADOS DE ATUAÇÃO
IV. 1. Relação das linhas de produtosl serviços ofertados por cada uma das
Requerentes no Brasil e no Mercosul
Requórénte A - PFIZER
A PFIZER é uma empresa estrangeira e Çiolding que desempenha operações
no Brasil, indiretamente, medianteas subsidiárias brasileiras pertencentes ao
grupo PFIZER. Vide item 1.8.
Requerente 8— WYETH
A WYETH é uma empresa estrangeira quê desempenha operações no Brasil,
indiretamente, mediante as subsidiárias brasileiras pertencentes ao grupo
WYETH. Vide item 1.8.
IV.2. Relação das linhas de produtos / serviços ofertadõs pelas demais
empresas que pertencem aos mesmos brupos das Requerentes no Brasil
e no Mercosul
Grupo da Requerente A - Grupo PFIZER
Brazil / Mercosur
Produtos para a Saúde Humana
Produtos para a Saúde Animal
Cápsulas gelatinosas para a indústria farmacêutica
Defensivos, Fungicidas, Antibacterianos e
Fertilizantes para a Agricultura
Grupo da Requerente B - Grupo WYETÀ
Brazil / Mercosur
Produtos para a Saúde Humana
li 1
Produtos para a Saúde Animal
IV.3. Identificar os produtos / éerviç& em que se verificam relações
horizontais ou verticais entre os grupo das Requerentes.
A PFIZER é uma empresa farmàcêutic global que produz medicamentos
destinados à saúde humana e animall No Brasil, a PFIZER produz e
comercializa ampla gama de produtos pára a saúde humana, para diversas
aplicações terapêuticas. O mesmo ocorre no campo da saúde animal, em que
a PFIZER possui atividades de produção é comercialização de produtos para
bovinos, suínos e animais de companhia.
Ademais, no Brasil, o grupo PFIER desenvolve atividades relacionadas à
11
fabricação e comercialização de 'cápsulas gelatinosas para medicamentos,
fertilizantes, defensivos, fungicidas e [produtos antibacterianos para a
agricultura, além de arrendar sistemas de vacinação iii ovo.
De outro lado, a WYETH, também é umaempresa que tem atuação mundial
11
dedicada ao tratamento da saúde humana, produzindo e comercializando
produtos farmacêuticos que exigem ou ião prescrição médica, bem como
produtos para a saúde animal.
As atividades das Requerentes, !no Brasil, sobrepõem-se em duas áreas,
conforme se verifica na tabela abaixo:
IL
Linha de Produto
Medicamentos para Saúde Huriana 11
- Medicamentos cm Prescrição
- Medicamentos sem Prescrição
Medicamentos para Saúde Animal
Cápsulas para medicamentos «
Produtos para nutrição e proteção foliar
Sistemas de vacinação in ovo
Pfizer
X
X
X
X
X
X
Wyeth
X
X
X
X
Os Anexos 1 e II contêm a lista de todos os produtospara a saúde humana e
animal que são atualmente com&cializados pelas Requerentes no Brasil,
ANEXO
12 (
r13
separadamente. Conforme doravante se 'ierá, as Requerentes permanecem
diligenciando no sentido de obter informáções precisas sobre os efeitos da
operação no mercado brasileiro e sobra as áreas em que possa haver
concentração. Dado o volume de informaçbes requerido, bem como a extensa
lista de produtos de cada Requerente, não foi possível concluir o trabalho até
o momento. De toda a sorte, as Requerehtes informam que despenderão os
melhores esforços para concluir tal tarefal,1 comprometendo-se, desde logo, a
submeter informações acuradas e adicionais nestes autos tão-logo quanto
possível.
Como é sabido, a identificação precisa de mercados relevante, bem como
produtos substitutos, quando se trata da 'indústria farmacêutica, não é uma
tarefa trivial.
Produtos cara a Saúde Humana
Tendo-se em conta a complexidade envolvida, no tocante a medicamentos
para a saúde humana, as autoridades de defesa da concorrência contrataram
uma consultoria especializada, a ser prestada pela Associação Nacional dos
Centros de Pós-Graduação em Economia - ANPEC, que contou com a
colaboração técnica do Instituto de Pesquisa Econômica Aplicada - IPEA,
para desenvolver um estudo econômico, bem como métodos quantitativos no
tocante à política concorrencial e regulatá1ia, além de preparar base de dados
para ser empregada e fundamentar os referidos estudos'.
Em termos gerais, o estudo, que vem sendo adotado pelos órgãos do Sistema
Brasileiro de Defesa da Concorrência - SDC para definir mercado relevante
em operações envolvendo medicamentos, propõe uma metodologia cujo
ponto de partida é a aplicação da Classificação Química Anatômica (ATC) da
European Pharmaceutical Market Research Association (EphMRA), utilizada
pelo Intercontinental Marketing Services (I MS) e, posteriormente, desenvolvese para o agrupamento devido à indicação terapêutica do produto.
1
'Procedimentos para a Definição e Ariáliei Antitruáte de Mercados Relevantes de
Medicamentos". Contrato SDE/MJ no 1 ANPEC/IPEA.
_m 11
E/
ANEXO
1
(
13 1
-- O
OPDE
De fato, a aplicação da referida classificação (ATC4), em determinados casos,
não é a metodologia mais acurada parase definir mercado relevante. Isso
porque há situações em que é mais indicada a combinação de uma série de
produtos classificados em subclasses distintas da ATC, por serem substitutos
,para o tratamento de uma mesma doença. Por outro lado, produtos agrupados
na mesma subclasse podem ter aplicações e indicações terapêuticas
distintas. Assim sendo, existirão casos er 1i que a análise da substitutibilidade
deverá desenvolver-se no sentido de examinar as aplicações terapêuticas do
produto e as doenças para as quais ele é indicado.
Produtos para a Saúde Animal
A definição e determinação das sobreposições, no tocante aos produtos
veterinários também é complexa.
As dificuldades residem, especialmente, na inexistência de fonte de dados
ofYcial, nas diversas aplicações do mesmo produto, na forma de administração
11
das doses prescritas, que podem variar substancialmente entre os produtos e,
finalmente, nas diferentes reações' provodadas pelo produto no tratamento do
animal.
O PAIVET, Painel da Indústria Veterináriai elaborado pela empresa SINAPSE,
que também já foi objeto de adoção pelos órgãos brasileiros de defesa da
concorrência, para definir mercado relevante no setor de saúde animal,
também pode ser, dependendo do caso, bastante impreciso. Em
determinadas situações, sua aplicação isolada não é recomendada, diante
das distorções analíticas que provóca, distanciando os resultados da realidade
do mercado, pelas razões retro discutidas. Nessas hipóteses, a análise
antitruste deve ser mais aprofundada , considerando-se as indicações
terapêuticas do produto e as doenças para a quais ele é prescrito.
Considerando-se as discussões e complexidades envolvendo a definição de
mercados relevantes para produtos farmacêuticos de forma geral, tanto para a
11
saúde humana, quanto para a tveterinária, como dito, não foi possível
11
identificar as concentrações de mercado resultantes da operação até o
momento. Mais que as dificuldade mencionadas á aplicação da metodologia,
li
mencione-se que as pàrtes comercializari uma ampla lista de produtos (Vide
ANEXO 1
Anexos 1 e II) em ambos os segmentos no Brâsil. Nestes termos, dado o
11
tempo disponível, desde a celebração do contrato, não foi possível determinar
com precisão as áreas em que ocorrerá obreposição de atividades entre as
Requerentes. È certo, todavia, que as Requerentes se encontram
despendendo todos os esforços para identificar as características de
substitutibilidade de cada produto envolvido no ato, demandando tempo
1
suplementar para tanto. Isto posto, as Requerentes comprometem-se a
apresentar tão-logo possível o resultado desta tarefa, peça esta em que
conterá tanto as áreas de sobreposição, como as respectivas estruturas de
mercado, para melhor instruir o presente ato.
Informa-se, ainda, que as linhas de produtos comercializadas pelas
Requerentes, no Brasil, considerando-se as indicações terapêuticas mais
1
abrangentes dos produtos, são, de forma geral, complementares.
Finalmente, sobre as relações verticais, informa-se que as Requerentes não
vendem princípios ativos no Brasil. N9 tocante às cápsulas gelatinosas
vendidas pelo grupo PFIZER, informa-se que elas poderiam ser empregadas
pela WYETH para a fabricação de medicamentos. Todavia, conforme dito,
11
informações adicionais sobre os efeitos da operação serão submetidas
brevemente, tão-logo possível.
EI
PARTE V L DOS'MÈRCADOS RELEVANTES
V.1. Estimativa dos mercados relevantes identificados em termos de valor
(R$) e quantidade das vendas no último ano
li
1
Vide item IV.3, acima.
•V.2. Valor (R$) e quantidade das vendas eu
de cada Requerente, em cada mercado
Considerando-se o elevado númerà
Requerentes no País e pelo fato de qi
identificar as eventuais sobreposições ex
se apresentar as vendas, separadament
Anexos 1 e II, informação que, além de
presente análise. As vendas das Reque
em que se verificarem concentraçõe
informadas, tão-logo possível.
termos absolutos e percentuais,
levante, no último ano
produtos comercializado pelas
não foi possível, até o momento,
entes, não há por ora condições de
)aratodos os produtos listados nos
istosa, data venia, não auxiliará a
ites, considerando-se os produtos
de mercado serão prontamente
V.3. Estimativa da participação de: mercado dos principáls concorrentes
(mais de 55/5) em valor (R$), tio último ano. Caso não seja possível,
apresente estimativa em quantidade. Indicar endereço, número do
11
telefone e fax de cada um dos concorrentes, além da metodologia e fonte
utilizadas na estimativa.
Até o momento, nãõ foi possívêl apresentar as estruturas de oferta, nos
termos que constam do item lV3. Todavia, de forma a melhor instruir o
presente ato, encontre-se, abaix8, os principais concorrentes que atuam no
mercado brasileiro, considerando-se, seprãdamente, os produtos para saúde
animal e para saúde humana.
Concorrentes
ANEXO 1
Produtos para a Saúde Humana
Eh LilIy do Brasil Ltda.
Av. Morumbi, 8264 - Brooklin
São Paulo - SP
CEP: 04703-002
Astra Zeneca Brasil Ltda.
Rodovia Raposo Tavares, km 26,9.
Cotia — SP
Tel.: 11 3737-1200
Môrõk Sharp Domme
Alexandre Dumas, 2092.
São Paulo - SP
tél.: 11 5189-7700
Novartis Biociência S.A.
Avenida Professor Vicente Rao, 90:
São Paulo - SP
Tel.: 11 5532-7122
Roche Brasil
Endereço Av. Engenheiro Billings, 1729 - Jag ré
São Paulo - SP
CEP: 05321-900
Tel.; 11 3719-4566
Fax: 11 3719-4981
Sanofi-Aventis Farmacêutica Ltda.
Av. Major Sylvio de Magalhães Padilha, 5200
São Paulo - SP
Tel.: 11 3759-6000
ANEXO 1
Produtos para a Saúde Animal
Merial Saúde Animal
Av. Carlos Grimaldi, 1701, 40 andar..
Campinas - SP
CEP 13091-000
Schering-Plough Saúde Animal Indústri e Comércio Ltda. e
lntervet Sõhering Plough Animal Health
Av. Sir Henry Wellcome, 335 - Jd. Moinho
Cotia - SP
CEP: 06741-050
Tel.: 1146134000
Fax: 1146134098
VaIlée S.A.
Av. Eng. Luis Carlos Berrini, 716, 2° a
São Paulo - SP
CEP: 04571-000
Tel.: 11 5504-4333
Fax: 11 5505-5448
Ouro Fino Agronegócio
Rodovia Anhanguera SP 330, km 298.
Cravinhos - SP
CEP: 14.140-000
TeI./Fax: 16 3518-2000
Industrial.
17
(
Fla
DPty
DPfla
PARTE VI— CONDIÇÕES GERAIS NOS MERCADOS RELEVANTES
VI. 1. Os 5 (cinco) maiores cIientes e fornecedores independentes nos
11
mercados relevantes de cada: requerente (indicar nome, endereço,
número do telefone, número do fax e e-mail de pessoa para contato)
ANEXO 1
- 5 nrinrinn,c rlinntnc
50
ANEX
e
-4
ANEXO 1
e
Fiz.
ID PC E
PFIZER - 5 principais fornecedores
AN
c
ANEXO
,cá__
-C
b
ANE4I
Vt2. Código da Tarifa Externa Comum
imposto de importação. Incluíras ali
Em virtude do exposto no item V13
2
e a respectiva alíquota do
previstas na alíquota
os códigos TEC não são
relevantes para a análise desta operaçãi
e
VL3. Estimativa da participação das
independentes no mercado
nacional
A comercialização de produtos de saúde humana e animal depende do
registro perante o Ministério da Saúde e o Ministério da Agricultura, Pecuária
e Abastecimentos, o que dificulta a importação independenté na maior parte
desse mercado.
VL4. Identificação dos fatores que influenciam positiva e negativamente a
entrada nos mercados relevantes
As Requerentes não têm ciência de barreiras significativas para o ingresso ou
à
expansão das atividades no Brasil nos egmentos de produtos para a saúde
humana e animal objeto do presentJ Nota-se que existem diversos e
significativos concorrentes, em ambos os segmentos analisados, que também
têm atuação global, conforme se veem listados no item V.3. Após a operação,
a nova empresa continuará enfrent
ando pressão competitiva das referidas concorrentes, bem como da indústria
de genéricos.
4E/47
1
ANEXO 1
VII INFORMAÇÕES FINAIS
V11.1. Informações adicionais que
serem consideradas
empresas julgarem relevantes a
Não há.
VlI.2. Informar as demais
apresentado
em que este ato ou contrato foi
O ato também está sendo notificadô às autoridades de defesa da
concorrência nos Estados Unidos, Canadá, Comunidade Européia, China e
Austrália.
V11.3. Nome, endereço, número do telefone, número do fax, endereço
eletrônico do funcionário da empresa encarregado de gerar informações
referentes à notificação. No caso de apresentação por meio de
procurador dotado de mandato, apresentar as mesmas informações
acompanhadas da procuração.
Franceschini e Miranda Advoaàdos
José Inácio Gonzaga Franceschini -Advogado
Camila castanho Girardi - Advogada
Av. Brig. Faria Lima, 1461, 13° andar
São Paulo - SP
Telefone: (11) 3095-2566
(11)3813-9693
Fax:
E-mail: cgirardkâfm-advogados. com.br
cuyaiu nrituuiuu reteita
- cçuiiuriiis
Rodrigo Hussne - Economista
Av. Brig. Faria Lima, 1461, 70 andar
São Paulo - SP
Telefone: (11) 3037-3777
Fax:
(11)3032-7861
E-mail: edpardedap.com.br
càdgob RecStiwt
MINIVTtRIO DA FAZENDA
-
NúnwadeRdascta
.4-
S
145000
caprt IbA DO 1E$OURQ CIOMAI.
--
1)
-
C2
OuI do Piocoltà,fl daçmfló CRU
IVOV2O
à;;
Nome d3 tiflicade Çwtwo:
~EIXO ADMINISTRATIVO DE DEFESA ECQNa4ICA
30 001130211
45.000.00
AS friom'.çÕn ,medss nnsa gula %24S s*.'a
tøo.t,*dade do conotoks. Que deà..m a.w de
0Ú4%d5. oonctna' e 1~Favorecida dc, rnc,.
4.)
LIOW** $G$Øõ*
(.)
CRU SIMPLES
-
/
vi
Pagamento excIu&vo no Cnn do Brasa SÃ.
f$NFFDfl44SIISCE4O4BSBEFBffC1 2t1MZal
4500&O0
S903004504 000000010104 fl1231S145*0 0045352300*0
- BANCU
- t4;5Q38
0450
$5t9t97
CDHPRtVAUW W. PA!A
Cotwcvio flRU4tflf,
Ccdtn de irra
ft%tli da PIRIORnto
*IRO de Referencia
Ccwaeteacia 1*VAAAA
COM CUtl.SARRA
5. UNIÃO
!i5-9 •flt$nteto -3
49e@45!s23eee-4
1410212n?
i
e2feo9
flata de Venciir,to
cnn
Valor Ptindit
Valor Total
•
flttoe:
NR,WJTEIITTCACAO
45,940.00
tn
.D.F5, 437• !73.ryt .
2007 Corporate Responsibflity Report
Stirong Actions
Partnering for Positive Change
fG7
(ris.
.j
DPD
1
We lursue Innovative
Solijtioi+. to Heaith Chailenges
Aroiind the World.
Medical innovation is the core of our business.
Tt's a fdrceforoõd—for patients, for those who seek
to stay,
healthy, and for society at large. Yet, our
respon.sibiIities and potential impact go far beyond
Lhe medicine4we discovei and develop They mclude
providing the value that our stakehoideis seck.
We enage our stakeholders and partners to address
socieiy's evo1vng needs on broad social, ethical and
environrnental fronts. There are many ópportunities
to par+ier on the sàfety of and access to our medicines,
011 new cures and treatments, and on better health for
people around tbe world.
We ai.sÇ beije that good ccirporate responsibihty can
be a soürce o] .isiness innovation. New partnerships
that acldress
iai needs through busiuess practices
can foster sw inable healthcare solutions. Pfizer seeks
more ofthese ikageè so we can heip make the world
better foicúr mmunities, our keystakeholders, and
ali thoe who int a healthier tornorrow.
OVERV!EW
Pfi?qr
, 2007 Go,pora, Respon.5ihility R.'porL
-r
1
C
FS ?
CHAIRMANS LETTER TO STAKEIIOLDERS
a.
.
lfl
lIkÇ Á ávIN
1I -'
,
JeffKindler
C)iairrnan o! flu iloard
and Chie! Exocutive Oøtc
ir
4
-
1t
'
-
To Our Stakeholders,
Pfizer's most important contrbutjon to society
Oremarns d1scovenng, developing and brrnging to
market new medicines. But producing even a great
treatment is not enough. What's
li also essential is
how responsibly we use our skills and resources to
invest in health around the w6rld.
2
Pfizer 2007 ('orporol,R..ponsibility fte.púrt
OVERVI EW
c
OPOE
OCR VALUES
INTEGR[TY
RESPECT FOR PEOPLE
CUSTOMER FOCUS
COMMUNITY
INNOVATION
That's why Iam pleased to share with you Pfizer's 2007 Corporate Responsibility
Report. It is much mre detailed than Lhe previous report because our commitment to serving socity reaches farther, includes more arcas, and involves more
partners than ever b'fore.
Of course, sustainable programs of corporate responsibility work best when
wè invest in Lhe health of communities and invest ia the health of our businees.
This means that for ïfizer, corporate responsibility must be Lhe work of every
department—on eve#y day.
And so you will see ia these pages the tangible results, throughout our
company, of commitr,ent to one of our chief priorities Lhis 'eár: collaborating
with and providing +0Te value to stakeholders—whether patients, doctors,
healthcare payers, nhngovernmental organizations or Lhe community.
You will see in this report aoL jusL rhetoric huL resulta, whether in reducing
accidents ia the workplace ar reducing Lhe energy we use. You will see us
reach out to the communities in which we operate, whether helping schools,
or promoting good health. You will see Lhe ways Pfizer colleagues partner with
stakeholders to supp11 innovative public health programa in oncology and
li
tobacco independeric
volunteer for work combating infectious diseases in
Lhe least-developed arena of Lhe world.
You will see inLius report new partnership and phiianthropy modela, creating
11
initiativesLhat ansvver questiona we've asked ourselves: How can we enhance the
healthcare nvai1ab1eLo Lhose in Lhe poorest arcas of Lhe world? Iiow do we malte
sare LhaL our custoners cnn be confident our medicines are safe and effectiveand LhaL we inform them al,out benefita and risks? Ia a world concerned about
greenhouse gases, how can we reduce our environmental footprint?
1
And while laws a d regulations mandate responsible acLion, at Pfizer we
are determined Lo go beyond compliance. We want aoL just to follow the lawbut lead the way: ThaL's especially true when iL comes to becoming more
LransparenV—in plan English, letting you know what we're doing.
And ao in Lhis report, you will algo soe ways to go online at www.pfizer.com
and discover how wq:
• PoaL Lhe status oÇour post'marketing studies—the first company todo ao
• Provide resulta of aD our registered clinical Lrial studies
ii
• Open to public view what's in our pipeline
Disclose US polit\cal contributions twice a year
Plan to disclose grants to US medical associations and patient groups,
beginning next ydar.
We cannot forgeLhaL as we Lalk abouL Lhe programa and initiatives described
here, Lhey stem frond Lhe work of real people, dedicated to change. These are
my Pfizer colleagues working in more than 100 countries. 1 applaud Lhem alI.
They symbolize Lhe
Pfizer: moving quickly to Lalce Lhe lead, embracing
li
innovation, achievin resulta responsibly—and improving life for others around
Lhe world.
11
TEAMWORK
PERFORMANCE
LEADERSHIP
QUALITY
Sincerely,
JeffKindler
Chairman of Lhe Board
and Chief ExecuLiv Officer
0V E RV tE W
Pfl:er 2007 (rporatv Ruponsibi/iry Report
li
Who We Are
Founded in New York iii 1849. Pfizer
is the world's largest research-based
pharmaceutical company. Taking new
approaches to betier health, we discover,
develop and cle].iver innovative medicines
to Lreat and help prevent disease in both
people and animais. Through consistent,
high-quality manufacturing and distribution
operations, our medicines reach pati.ents
iii more than 100 countries. We also partner
roviders, governments,
organizations, local
commurnties and other stakeholders around
the world to expand access to our medicines
!nd to provide better-quality healthcare
heaith system support. AL Pfizer, our
agues work every day to h.elp people
happier and heaithier longer. and to
reduce the human. and econoinic burden of
disease worldwide.
t
PFIZER FACTS
LEADING MEDICINES
Headquarters in New York City
Oncology
Meiabolic & Endocrine
89,000 employees worldwide
Lines of Business
- Human Hea!th Pharmaceuticals
- Animal Health Pharrnaceuticals and Vaccines
AROMÃSIN
CANPTOSAR
SIJTENT
Pain
LV A ICA'
RELPAX'
Operates in more than 100 countries
lnflammation
$48.4 billion in revenues, the world's largest
pharmaceutical company
$7.6 billion in Research & Development
CE LE A A E
11
Allergy & Respiratory
IRfectious Diseases
11 R&D therapeutic areas
CHANTIX / CHAMPIX'
'E A IS'
FEND'
One of the world's leading medicines, Lipitor',
which is a treatment for high cholesterol
Ophthalmology
XALATAN' / XALACOM
World's largest animal health company and leader
in annual animal health R&D investment
US EPA Climate Leader member
TO CONTACT IJS
$1.7 billion in Pfizer Inc philanthropic contributions
Accolades ai www.pfizer.com/accolades
P.iease see www.pfizer.com/contact or write to our
li
corporate mailing address ai Corporate Responsibility,
235 East 42nd Street, New York, NY 10017.
'Ali numben are for fiscal year 2006
4
.P/üer 2007 Q'rp.'rate !kspon,ih,liiy Jkpr,rL
E
OVERVIEW
Pfizer Corporate Responsibility
Why Corporate Responsibility (CR)?
In today's world, being a responsible company is the only
smart way to operate in both the short-term and long-terni.
To be responsible and accountable—socially, ethically and
environmentally—is to be trusted. We need that trust to serve
our dverse stakeholders and support a sustainable enterprise.
We know trust is built over time with actions, not words. This
report reflects progress in our actions and acknowledges
areas where we still need to improve.
Corporate Responsibility and
the Board of Directors
The Pfizer Board of Directors' Corporate Governance
Conimittee charter requires directors to 'consider the
perspectives of stakeholders in the company's decisions
regarding current and emerging political, social and public
policy issues." The Board receives information about
stakeholder perceptions and opinions by varlous means
including direct ernail from the public (see www.pfizer.com/
corpgov), Pfizer senior executivas' reports, annual shareholder
proposais, and Directors' own personal and protessional
networks.
Integration of Corporate Responsibility
lntegrating our corporate responsibility is not just updating
data and meeting certain social responsibility codes. It is
about changing our behavior and resource allocationchanging the way we operate, communicate and partner with
stakeholders.
On a daily basis, Pfizer Corporate Responsibility is
managed giobally by a team that is part of Worldwide Public
Affairs and Policy. The team is responsible for developing
this CR report, establishing Pfizer's CR partnerships with
vadous soclally responsible investors, nongovernmental and
multilateral organizations, and coordinating with different
global Pfizer functional and business areas. The team's focus
isto foster and support integration of CR throughout the
cornpany with a strong emphasis on stakeholder engagement.
The team siso serves as an Internal-external bridge to foster
communication for new ideas.
We integrate corporate responsibility into how we engage
on policy issues and even how we develop our medicines.
For example, see page 91 on the introduction of our smoking
cessation niedication Chantix® (called Champix' in Europe).
OVERVIEW
the Report
We are pleased to issue Pfizer's second report on our
corporate responsibility approach and activities. We decided
to publish this longer report to address key issues in detail,
supplemented by a sunimary of our corporate responsibility
activities in two printed documents—a 24-page summary
report and a brochure. Please note that even more information
about our corporate responsibility activities is available on our
website at www.pfizer.com/responsibility.
Scope of Reporting.
This report covers Pfizer's pharmaceutical and animal health
businesses. Pfizer's consumer products business was sold'
to Johnson & Johnson at the end of 2006. This Corporate
Responsibility Report includes activities and data from
the calendar year 2006, including data from our consumer
products business. The envlronmental performance data
does not include our consumer products business. Additional
updates from 2007 are referenced where relevant. We
remain cory-imitted to internatlonally recognized standards
for CR reorting and we will continue to review our reporting
practices in Iight of evolving standards including external
assurance standards.
Materiality
The content of this report is based on a materlality analysis
tocusing on two key factors—the importance to stakeholders
and the potential to influence business strategy. Materiality
was assessed by an interna] cross-divisional team representing
the key businesses and by an externai advisory group.
Stakeholder lnclusiveness
We listen to our stakeholders and value their perspectives.
In keeping with the principie of stakeholder inclusiveness,
we have identified our stakeholders in this report, the
feedback we have received, and how we have responded
to their expectations and interests. To contact us, please se
www.pfizer.com/contact.
Global Reporting Initiative Sustainability
Reporting Guidelines
We considered the Global Reporting !nitiativé (CRI)
Sustainability Reporting Guidelines (03) in preparing
this report and Include a comprehensive CRI index.
We self-declare this report to CRI Aflplication Levei A.
For information on CRI, please see www.globalreporting.org
P/i:er 2007 £01) orWv R'npcn.ihllitv R.'por
Global Public/Civil Sector View
To bailar understand the global civil sectoron a wide range othealthcareissues n2pqad?P96th, global research flrm Globescan conducted
intervi~on behalt of Pfizer with 350 healthcare opinion leaders from China Gret Britiin Japan Mexico South Afnca and the US with
representatives from government health policy, NGOs and multilateral organizations as shown below. Ttie results trom the 2004 survey were
included li our 2005 Corporate Ci~ Report.
• Respondente were asked for mutOple menlions; te measureis caiculeted as a percenlage cii total responderas sndne total can exceed 100.
OK! MA- Doei Kriow / Not Avaflabla
lhe sempia elas lo, ~ Orei tfly, oondiced e Selo. lia Us SineVW., FI.eO: lo 2re0 Ir. USiWle lias
Orc,eaeSIo n-Io0.k enwn000re.sbIlty010re 24 flMO das. ires ss.re,ed Ore., te 2®4das
J5— mes hesonleo W 'o IDO 'ewe,denls O,aI.eS ol 50. lo 1.m. ai ir. lotei .a.,eie, DE. IS ,espoed.nts teve moi. mei0ir O,.., note corei.. wtse 50 ai.tddea ores itnel..sl lo EDOI ad 20l.
UM
6
T5Çztr 20117 Coi -p,rote T€o'aoponsihtlity Rep'M
0V E 11V 1 E W
Our Corporate
Responsibility Standards
and Evaluation Partners
The Business Róun tãbi&s S.E.E. (Social,
Environmentai Economic) Change initiative is a
voiuntary program for rnernber companies to adopt
rsustainabihty principies as a business planning tooi
its of the Btjsines Roundtabie's
Ciiniate Resolve initiative and in 2007 agreed to a
new statement ohciimate change. 4;
00w Jones SustainableAsset Managemeni
(DJSAM)
www.s-group.com/htrnte/ain.cfm
a)
DJSAM is a research organization that evaluáesÇ
companies as sustainable investments Pfizer has been
seiected to be in the DJSAM Index since 20d0)Last
year, Pfizer had leading scores in corporate governance,
environmentai reporting taTent attraction and retention
and stakeholder engagement
Trnsparency International (Ti)
www.trans parency,o rg
An WGO wfth a ketwork of local chapters in more than
90 countnes, TI's goal isto combat corruption and
:bribery. Pfizer tias served on.Tl's Steering Cornmittee on
Busiiess Principies for Countering Bilbery since 2003,
and in 2005 j6irõdthe Board of Ti-USA
FTSE4dood
www.ftse49ood.com
US EPA Climate Leaders
www.epa.gov/staiepiy
Thiá index sedes, creatêd by the UK FTSE
medsures the performance of companies
giobaily recognized corporat responibiht
Pfizer has rnet FTSE4Good Sodial Resri&i
criteda since March 2002.
5
Global Accountability Project (GAP)
www oneworidtrust org
1~1.1U1101%
JN
Pfizer is a charter member company under the US
Environmental Protection Agency Chmate Leaders
Prograni1 This is a voluntary industry government
partnership that works with climate change strategies
and tf&house si i[&edõction dàTt
11
r
22
1
11H'1;
GAP is part of the Accountabiiity Prograrn at One World
Trust an NGO that anis to generate wider commitrnent
to the principies and values of accountability in
eceniber 2006,the GAP index rated Pfizer as among
the most transparent and accountabie organizations of
the 30 reviewed in detail
2r.
Institute for Suppiy Chain Managenient (ISM)
www.isrn.wsindex.ctm
PP
A rnember organization of supply chain professinaIs,
iSM deveioped suppiychaid standards for sociai~ 111M
responsibiiity that focus on community, diversity,
environment, ethics, human rights, íinanclei
responsibiiity and sàfety. Pfizer sighed on to these
principies in 2005.
0V E RV 1 E W
1'frrir 2007 Gorporafr Rea;'õnibititt RporL
Progress on 2006 Commitments
FOCUS MEÃ
2006 COMMITMENTS
PROGRESS
1
-.
I---
Submit 20 new medicinas for FDA
approval belw?en 2001 and 2006
t.Ilt1tfW
Disclose resulls cl ali late-stag
clinical trais on cur marlçeted
products
E
É
Pfizer has and continues to disclose lhe results of its late-alago clinloal tnais on
markeled producta. in additâon, in 2007, we expanded ou, commnilmont to Include
ever9 rer-sponsored clinical study in patienls on the NIH-sponsored website
www.clinicahrlals.gov. This includes Phase 1 trais and non-Interventional studies
with prospectNe data.
• t1rnlIFyh.,dlr,
Appltvancedscicnpe and
technolcgy fn lhe manufacture
of medicines lo produce cosieffeclive high-quality products
l
-
• A compreiteve Technology & innvFaion strategy is In place aimed at saving
$5 biflion over
years through the introduction of new technologies and processes.
• . Extensive use of enzyniesiristead of chemical reagents is an iniportani coniponent
and wili yield s gnificant environmental henefita as weli as cost reduction. For
example, a new procries
oy
acture which s not
s has b e
siniflcn cheaper but will eliminate up to 5 mullloale
ons p
of
o
solvent usage.
Pfizer submkteà 19 new niedicines for approval by lhe end of 2006.
I
Continue to reduce injuries,
eney use, wastes and emissuons,
relatuve to production leveis and
lhe number of coileagues
EE
--
,,
Ensure that contract
manufacturers and key suppliers
1.
have responsuble envuronrnent,
health and safely (EHS)
management relaled to productuon
of materiais for Pfizer
à
• Conipared to 2005, Plizer Global Manufacturing (PGM) Iost time accldent rate
decreased by 12 percenl and total injury rate went down by 8 perceno.
CM energy consumplion was redtuced by 10 percent compared to 2005. bringing
CO2 emiastons down by 9 peroent adjusted for asquisutions and duvestitures.
PGM hazardous waste was reduced by 18 percent and nonhazardous waste by
9 percent. Excludlng duvested and closed sitei, hazardous waste was reduced
by 10 percent and nonhazardous waste by 2 pekent.
•1
--'Mrx'r-'
—---
—
' ---'----'------
We review key suppliers of active pharmaceutical lngredlents (API) and ali contract
manutacturers til either API ar final 6wg products. In 2006, 100 EHS reviews were
completed k0 assure the respons'biiily til these key suppluers Reviews were done
giobally, with a partucular)-oc'u's on China açid Gidla. The results are consldered ,n our
supplier decusions.
-
r, e
Support lhe communitles in whih
we aparato nianufacturing plants
through communuty oulreach
activuties focuaed on education
public health, safety and
improvement of lhe envtronment —
• Ali PGM sltes, lncludlng majorioçlstics centers, established community outreach
programa. Over 140 projecta were umpiemented as pari of tênis effort.
• PGM altas obtalned 39 EHS awards from governnient and other externai
ii ri
organiatuons.
-
Offer our resoumoes and talent
to respondi to global disasters,
such as we dld wlth lhe Soulheast
Aslan tsunamu and 1-lurrícanes
Katrina and R
We continue to offer ourcoileagues and resouutes though the Pfizer Global Health
Feliows program, to combat infectious duseases In arfas where lhey aro most endomuc.
For more unformation on thus program plase see pagos 43-44 and 49.
1
1
- i
*
-
Ii
S
-
-
__*eP*tfNatn__
•y
lutnr
Follow internaluonaJty reoognuzed
standard for corporate
responsibiluty repartirá, such as
the Global Reporlung inutuative
1
i
Develop corporate responsubiluty
perfomiance measures
As slated in Pflie?s 2005 Corporate Cutizeqishp Report. Gtvert Ota tans4lion Pfizer
cl werar.ptzercom/mesponsibi5ly ln 2008.
J'fizmr 2007 Cuirporote Respoaauhilily Report
Pfizer consldered the GRI Sustainabiluty Reporling Guldelines (G3) in preparing thus
report and included accmprehensive GRI Index. We seil-declare thls report to GRI
Application Levei 8.
[Pfizer tuas worked wuth internai and oxternal stakeholders lo betler understand ou' CR
ig
tinis
esnh
Liruformation lo develop metrlcs for use in ou, next reportung cycle.
5
-1i*i
*J ,r
8 undergoing,
commttTents for 2008 wuii te posted on our Coporate AesponSbiity cobaIa
tiVE RVIEW
FOGUS ÁREA
PROGRESS
2006 COMMITMENTS
• Az of June 2007, Pfizer will have spent 11 months foliowing the commerclal
. availabdity'of Chantix in lhe US educating physicians about this product without
,' rur'ining any branded consumar TV or prini advertising. We wili continuo to educate
heailhcare professionals for sovraI moro months prior to beginning any brandod
$
consumer adverlising.
• Exubera randod advertlsing b gan In 2007, more than 9 months foliowing the first
*
cornmercial availability of lhe product in lhe US. During thls time, Pfizer has invesled
significanl rasources in educating yslcians and educators aboul Exubera and lhe
use of inhaled insulin.
Educate physlcians for a minimum
ai aix months aboul a new
prescription medicina prior lo
beginning TV and pfint advertising
Include language In prodúct'
TV and pnnl ads lnforming
consumos lhat doctos
may recornmend alternativo
Ireatments, including litestyle
changes, when appropriate
e
Pfizer rnedicines aro not for everyone and our advoitising makes that doar.
wr
ou
ngge in ai our advetsingto ensure lhal consumers know
that lhelr physiclan may recommend something other than lhe advertised product,
lncluding díat and exercise.
-
HN
IR
Stop ustng remlnder ads" on
in 2006. Pflz& has nol run anyjv or pnnl reminder advertsemenls.
1
TV and in consume, magazines
with lhe exceplion ofs
related activities
I
p
1
______
—
Use a new consumer-fdondlyF
~The_
majorily of Pfizer print advertisements have an Important Fada brlef summary and
and consumep-tested prinl brief
are in developmenl.
summary in ali product pdnt adE
RO ORIM
e*mtsut*qr
,
mms
,
j
Increase advertising eftorts
behind disease awarenese and r.
Pfizer Heipfui Answers
Plizereclucates people about pfizer Ijeiprul ,4nswers na nLjmber o? ways, including
campaigns cri radio, púnl and anime advertising and local avente to he1p uninsured
1
,Aj'ner(can iearn ab'out 'programa that can holp thom to save on medicines. Through
ur outreadi offorts, Pfizer is enrolling many new patienls in our patient assislance
P? ograma.
Pfizer submils ali new DTC TV advertising campaigns to lhe FDA for review in advance
1 of aiiing. Pfizer supports lhe FDA having lhe appropriate resources lo conduct these
'
reviews and has been a proponent ai advertising review fees as outlined in FDAIRA
legislalion
-
Submit tolhe FDA for review
ali new OTc TV ads in advance
e? ainng
Ensure ada ara trgeied to
approprlate audiences wmll air
erectile dysfunctmon ads cnly
during programa wilh moro than
90 percenl aduil viewership
Wfl'7flflfl,'.i,,r*-
.rnesn.spurnasprssrn.rnaslr
Viara advertising is placed on TV programming that has a rnínimurn of
gopercent adult v]ewprship.
''
1
jiTP
-
Provido lraining for empioyees to 1Lflizer commissioned indopendent monitonng and ovaIualior studies thiough lhe
most effeclively work wilh NGOs
Isoslon Universily $chool of Pubiic Heaith lo understand program impacta and how to
In developing countries
lincroase lhe program yalue for beneficiaries. As a result, a three-day Iraining has been
tincorporaled mio Pfizer's Global l-Iealth Feliows (GHF) program operations.
,s,,.wiew.waiaur
-
ne.aasaa seimum,
ejii a, eu i
ease'ms,,,eeefl
Presenl Global Healtb Feliows
rnodel and provide suppoit to
privale sector to repiicate 11
kwss*tnuarusie
------5 -
-
Provido 35 miflion doses of'
aniibiolic to lreal active trachoma
Infeclion worldwide
i,
,e'e-eta-usesa
'
Through a partnership wilh lhe Brookings lnslitulion's inlernalional Volunleerlsm
i ,iniliative, Pfizer has beert working to promote inlernalional Corporate Voiunteetlsm.
Meanwhiie; Ffizer has advised and supporled soveral companies in their efforls to
establ ah Fellowship programs, lnciuding 60 and Ernst & 'Young.
-
1
uOh lhe Internationai Trachoma Initiativo QTfl, 17 million trealmenls ol Zithromax
rornycir) wero proided in IS countries in 2006. The shortfail was due to delays
in-~ling up lhe progra in some counlries duo to bureaucratic or customs cleararVce
,r
s, lhe roducod incidence ai trachoma and zonas ai armed conflict. in 2007, asaS
time, lhe TI is on targel to reach 35 rniflion doses by yearend.jj
As siated in Pfizer's 2005 corporal. citzaui,Jiip Report Given ffie irnsibon Pfizer is undergoir,g, oomrnilrnenls for 2008 wa be poafled 0,1 Dor Corporal. Rasporeibety website
ai www.pflaerconilresponsiblrty In 2008.
OVE RVI EW
Pfrz,er 2007 Goiporcfe
Jk,põnnihilitv R.*pori
9
4vEf
F13
odel
Operating with a New Stake
c
Stakehoiders are peopie or groups who affect, or are affect
by, Pfizer's business activities. We share with them an
overarching goal—good health for ali people aI manageable
cosls, and a heaithcare systern that is sustainabie.
Our relalionships with stakeholders are at the heart of our
corporate responsibihty because they define what il means
for Pfizer to create value. That is why Jeff Kindier, afler being
named CEO in Juiy 2006, and the new senidr management
team met with a variety of stakeholders. They wanted to find
out what was on stakeholders' minds, what worked weu—and
what needed to be strengthened. Some of the cornpany's new
priorities and actions are a result of these discussions. Here
are just some of the stakeholders our senhor management mel
with in the past year:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
American Heart Association
American Lung Association
American Medical Association
Campaign for Tobacco Free Kids
Easter Seals (disabihly services)
Instilutional and other sharehoiders
international Alhance of Patienls' Organizations
National Alliance for the Mentaily iii
Nationai and local government leaders
Organizalion for Economic and Cooperation
Development (OECD)
Oxfarn Great Britain and Oxfam Arnedca
Pfizer coUeagues around the world
Pharmaceutical lndustry Labor Management Association
Sheel Metal Workers International Association
Women impacling Public Poiicy
World Health Organizalion
works as pari: of wider healthcare systems. We
ong and Irusting partnerships to make progress on
improving global heailh.
Given this reality, we wiili continue to engage stakeholders
regularly and continue to share knowledge, skiils and goais
on how to prevent or manage diseases, gel medicines to
lhe people who need them, and prornote good heaith aniong
diverse populations. These partnerships take many forrinsas described in this report.
1
for Engagirig Stakeholders:
• Advisory boards on isaues and producta
• Assoclallons and networks for palienl advocales
Conferencias aI internationai, regional and nationai leveis
•'
• Dialogues with multicultural slakehoider groups
•' Email and leItar responses
Externai compliance hollines
e'
Focus groups with different stakeholders
• Grassroots outreach programs within communitles
•jl Managemenl-employee advisory counciis and "lownhalis"
Media briefings and intervlews with journalisls
• Meelings, briefings and feedback sessions with inveslors,
Ii cuslomers, iegislators and regulators
' Partnerships in lhe fieid with NGOs and MI-Os
•
• Pfizercom website interactive features
• Professlonai Irade associatlons for sclence and business
• Seles cails to physicians
•, Surveys of colieagues and customers
Senior manaõement heard a spectrum of comments from
a stakeholders ranging fromPfizer being seen as an inflexible
business pariner, to questions about lhe stock price and from
awe at Pfizer s scientists for their skilis and dedicalion to
surprise at lhe scope of our partnerships in improving access
to medicines
However, most stakeholders agree lhat given lhe
compiexuly of public health probiems facing lhe world loday,
no single entity—governmenl corporalion academic
instilulion nongovernmenlai organization civic organizaluon
or others—can solve heallhcare ussues alone 1 takes ali of us
workung together, contnbuting our respectiva strengths
Some stakeholders have dilferenl views on how to
achieve heallhcare goais Our chalienge is to buuid on amas of
agreement and find common ground To achieve this, we seek
to constanlly improve our communications and transparency
to listen and respond better to stakeholders, and to learn
from them. We siso share insights on how lhe pharmaceutical
10
Pfi:er 2007 Qnporate Rcapon,ih,Iity
—1V4
RÁ
WI-10-Hálg Évidence Network
www euro ho nIJHEN
UM
Pfizer supports lhe important work of lhe World Heaith
Upr0arization MHO) Heaith Evidence Nelwork (HEN)
Which pVordiolicymaketwith independent and
readyto use evidence based infomal,on on publicNJI
health and heaithcare issues HEN
providesisy
access to olhar internalionai dalabases and sour&s of
lnforrnalion The scope of HEN s work oorresponds wuth
Ithe 14;straleguc technicai objectives of WHO in 2007
Pibased on stakehoider dialogue we ofereci suggestuons
on potential heaithcare topics and lhe crealion of work
groups and pohcy bnefs lo upport publuc healthcare
decus,on-makers while respectung their undependence
We siso supporl HEN with an unreslricted granl and
with
an scientifcpxpertise.
siso
-11.11
E
0V E RV 1 E W
\
4j.
Pfizer's old StàkéholdéYModel
a
Previously, we engaged with stakeholders
one on one in amas of shared interest
gI
a
S
1
2-
Pfiz&r's New Stakeholder Modal
TodayinahetworkedworId,wefocus
on mutual goals—on pursuing innovativo
solutions to global health challengos with
our slakeholders as partners. This also
helps build ec000mic prosperity.
'UàÁgi1034 p,
RW
t
3
AT ENTS
Rk
FM
IM
51
ru ir,
0V E B VI E W
im:rr 2007 (Mrparofr J.pon.thilttv Repõrt
11 EdI
Changing How We Integrate
StakehoMer Needs
We are seeking to provido more social value today, as well as
medica] resuits, because that is what society is asking of us.
By better serving our key stakeholders, we ultimately better
serve our shareholders.
For a macro view of this change, please soe the chart
on pago 11. We are hiring a diverso world orce to refiect the
diversa societias in which we operate. This Is one way to
give society a stronger "voice" within Pfizer—to employ in
influential positions coileagues from biotech firmo, patient
advocacy groups, health professionals' organizations,
insurance providers, governments, think tanks and academia
who influence our dialogue. This diversity changes how we
Õ
•
think and operate at the very core of our business. Changes
on the day-to-day levei, for example, are evident in our ACE
(Aiigning Customer Exceilence) Program in Europe (pago 84).
We also engage directly with stakeholdei's through issuo
advisory boards, employee surveys, conferences, small
meetings and public-private partnerships. Some approaches
have predefined feedback and follow-up methods. Other
approaches are more informal and help shape futuro goals
and activities.
Foliowing are two new initiatives from early 2007:
to
nficit
partner
uable worlç
partners to provide financial support and other..skill
for their activitiesThis is one way wd contributo to
the improvementof patients' lives beyond our core
business of developung unnovatrve médicunes For
92
In theVK..ye áfJréquire, as a
berofthe
itical lndustry,
:ations we work
vorkung with theseÇ
'ayPfizer.UK has]J;
ind described theq
full naturapt our relationships with ese groups, as i
noted on
above.
In the US: in 2008,'w&will dev
for educational grants and ind
planning process as noted on
wili enuFuikeholders' vie MI
12
Pízor 200fl Corporate Tksp.'nsihsfitv Repori
ove our
and
abáve. Thi
red as the
medical
0V E E vi E W
Cf4
sol
DPDE
j
Our Coliective Action
Some social ar environmental problems can only be solved
by coilective action, when stakeholders from an entire industry
ora cross-section of society band together for the greater
good—when "ali hands on deck" can provida solutions mo
effectively. We Iry to demonstrale our corporate responsibikty
by taking a leadershlp role in such collective actions, either
within lhe biomedical community ar in cross-sector initiatives.
We know thal working with our colleagues from other conipanies
and civil institutions resulls in more effective, iong-lerm
solutions.
- -
Examples include:
-
Partnership for Quality Medical Donations
www.pqmd.org
E
E
E
t
1
IE
PQMD is dedicaled to advancln the quality óf rhdichi
producls deliverod to urfderservedpeole and
eri'
viclims around the world. Pfizer sponsorod Iwo key
'
PQMD projects. We lunded a study to develop a'
p
melhodology for estimating the nurnber of patients
treated based on lhelu
vomes of medicinas shipped
to developing countries by PQMD members. We also
funded and direcled lhe creation of an educational
fim thal teaches lhe basics of medica] inventory
ET!?a9omont and raises awarenoss of lhe supply chain
management professuon globaily. The fimsaable o
lhe webbv
mPior
colieaguo.
E E
a
e
OVERVI EV
h
-,
Wârking to Provida Coverage for theUninsured
www.coalitionfortheuninsured.org
4,
UMIPiu
E,
With approxinialely 47 million Americans still lacking
healthcare coverage, Pfizer joined a hi y diverse
IM
h grãup of 16 public-private Sartners tti rethink lhe issue
and lay out a path for progress. Over the pasl two yearè,
t,thisi' oalition, the Health Coverage Coalition for the
Unlnsured (HCCU), cornprised of healthcare providers,
E
trade associations and activist groups, developed
consensus recornrnendalions for covering a signlficant
number ot the uninsured. On January 18, 2007, the
coalilion releasod an agreemenl which ali the parties
Eendorsed in whal we think is a national heailhcare first
in tle liS. For more information on lhe key principies
aridrecobrnendations, please soe pago 89,
1
'.EE
1
'E
WEtIWE,
E
.-
Thé Glóbal Environnientál Management lnitiative
J wwgemi.orgIwaterpIanner/
E
E
-
GEMI is a coahtion of companies committed to WNg
E
improving suslainabie business practices. The
initiative's recent effort is calied "Coilecting the
Drops: A ater Suslainability Plajiner." Pfizer piayed
a loading rSd in develop
wa
inabihly
bel by providing strateguc direclion on lhe approach
and technicai dontent, based on our own successos
and chalienges with maiagínb water. The planner is
designod te heip guide a facility through lhe process
of asssslng and idenlifying specific water uses and
Eneeds inèomparison to the availability of water in the
region; lhe impacto! operalions on the available water
E resources, and those factor; that may pose a risk to the
Pfizer 2007 Corporafv Reponsihitif ,- Report
13
L
j
finãltng
CURES AND TREATMENTS
0w, rnost important e dntfibution is discovering,
developing and de1iering innovative medicines
that society values to.prevnt and freat disease.
To achieve these goals, we arecornmitted
to improing R&D produqtivity, increasing the
transparency of our pipeline and chnical frial
practices, improvihg druíg safety monitoring, and
workingin partneshíp m, ith ourstakehoiders
to advancethe dWcoveryand deyelopment of
effective.new medicines.
}
16
f'fize.r 207 Corpurote Rnponsibilitv Report
Fia
DPDE
ii
2006/2007 KEY ACTIONS
Launched innovativõ new médicines
totreat major diseases—for two
-t
hard-to-treat cancers, diabetes,
tobacco dependence and blàodstream
infections.
Received FDA approval foreizentryTM
Ïmaraviroc), a breakthrough treatment
for HIV/A!DS.
unched www.pfizer.com/pipeline
improve R&D transparency.
Established astem ceil research policy
t6 guide ourexternal partnerships
beginnihg .in 2007.
artneréd with the National Institutes
ofHealth (NIH) and biotech firms to
dnravei the genetic causes of common
Established a couaboration with
the World Healthorganizatidn tálhélp t:
find new compounds for diseases
of thedeyeloping world.
Continued to develop 242 reearch
prorams—the most Pfizer hãs ever
had—spanning 11 therapeutic areas.
d the mainstream
:eutical industry's first
r" to supportearly-stage start-ups.
Expanded disclosure of our4
clinical triais.
SeIzent" will ba known as CaisanthO in ali countdes ouIsde the US pending reguiatory approval:
18
J'ficor 2007 corjmrrae Rrspanihility Reperi
R&D: FINDINO CURES AND TREATMENTS
Launching Medicines for
Unmet Medical Needs
Continuous hiomedical iimovation is
essential, not oniy to find cures and effective
treatments for patients, bui also to reduce
the direct and indirect costs of disease ou
society. which includes such things as Iost
job productivi.ty. In 2006, Pfizer introduced
several innovative medicines that are
expected to have significant beneflis for
patients and societ•v They are:
H1
Sutent' is the flrst medicine ever to be approved
simultaneously by the FDA to treat two types of deadly
cancer—advanced renal cell carcinoma, a tye of
kidney cancer,and gastrointestinal sttomal tumor,
I2nbn s GIST. Also approved to treM these diseases
by the European
Union, Sutent not only kilis cancer
10.
celis but starves the tumors of blood and nutrients.
Pfizer is now investigatingeits e a in .breast,lung
and colorectal cancers.
R&D FINDING CURES AND TREATMENTS
Ier2ÜO7Grpôrafef?epo,nzhitity.Rpon
19
Eraxis treats candidemitho mosfdéadIÇTfth JW
common hospital-acqurred bloodstream nfe6uons
which can spread qu'ckly especrally for patients with
weakened ínimune systeins Eraxis' san irrqortant
newtreatment for, the approximately60 000 patients
in the US who contract thisdangerous ínfeclinhJfl9
1
flfl n
%
eaoh year.
Mi!O P.qP,
In June 2007, the FDA approved Lyifor thê
management of fibromyalgia, a cornmo&chronic and
t
widespread pain condition. The a?&àI Mresents
a breakthrough for the more than six rnillion Arnedcans ,
indibâtion. Ii waíiiitiaIIyapproédfóitiõWián
of neuropathuc pain associated with1diabetic pe
neuropathy and postherpetio neuralgia and for
adjunctive use in the treatrnenfofepilepsy
20
J'/jr 2907Gorp,rte Prspo,u,,h,iitvReoori
R&D FINDINO CURES AND TREATMENTS
OFO
Expanding Research for Diseases
of the Developing World
We believe we have a responsibility to
conduct and support research for diseases
that affectt the developing world and are
expanding our efforts to help meet this
global health. chaileuge. As a single
cornpany, however, we are Iimited in our
ability to solve such universal health
problema and recognize that multisector
sotttioits are needed. Today, pubhc-pnvate
partnersh.ips are essential te inaking
progress ou this front.
proving Treatments for MaIana
Through our Zithromax/chloroquine clinicai trial prograni,
Pfizer scientists are developing a potential ralaria treatment
based on our widely used antibiotic, Zithrornax. Dosed in
conibination with chloroquine, Zithromax' démonstrated
positive results in the treatment of adults with mataria in
Africa. Currently, clinicai studies are ongoing at cantara in
South Arnenica, India and Africa.
Opening a New Front Against Infections
We expanded our commitment to fighting infectious diseases
in 2007 by acquiring UK-based PowderMed Ltd, whose
proprietary, DNA-based technology is designed to deliver a
new generation of vaccines.
This vaccine development program, with a needle-freo
delivery system, is at the forefront of a scientific effort to
overhaul a vaccine manufactuning systern that has remained
largely unchanged for the last 50 years. While the research is
at an early stage, this new DNA-based technology is quickly
adaptable to changing strains of influenza. The pipeline also
includes vaccines in phase 1 developrnent for herpes simplex
vitus (HSA as well as other vital diseases.
Collaborating with the World Health
Organízation
Our coliaboration with the World Health Organization's
Special Prograrn for Research and Training in Tropical
Diseases (WHO/TDR), announced in October 2006,
is an unprecedented partnership for a public company.
We are opening our library of medicinal compoundsthe world's largesi—to help search for new antiparasitic
medicines against such deadly diseases of the developing
world as maIana, leishmaniasis, African trypanosomiasis,
onchocerciasis, schistosomiasis, and Chagas' disease.
We will also bring scientists from developing countries into
our laboratonies for training in drug discovery technlques.
fl
"This collaboration is a stop forward
in expanding worldwide capacity in
tropical disease research, because it
enhances access to research tools for
developing country researchers and
expands access to large .numbers of
compounds for screening to identify
new Ieads."
DR. ROBERT RIDLEY
DIRECTOR OF WHO/TDR
R&D: FINDING CURES AND TREATMENTS
E
Pfi,.'r2OO7UorporateR.onibÜityReport
21
Bringing an R&D Pipeline Strategfy to bife
Our broad and diverse pipeline of new medi&ines will help drive the development
of new medicines for a wide variety of therapeutic areas over the next severa!
years. We determine our R&D priorities accrding to medical need, fo!!owed by
breakthrough potential, obstacles and comnïercial opportunities. The depth of our
-----rnid-stage pipelme gwes tis contidence that
À
---1
--À---
Cardiovascular, Metabolic and
Endocrine Disease
Qncology
There are seven main areas o! Iocus—atherosclerosis,
hypertension, obesity, diabetes, bane and muscle health,
thrombosis and growth hormone deficiency.' Pfizer is building
on its traditional strengths in cardiovascular research and is
The number of oncology R&D projects at Pfizer has increased
four-foId over the past tive years. At the annual Association
of Clinical Oncology meeting in .June 2007, we presented
52 abstracts on 10 different medicines. These presentations
expanding research in metabolio and endocrine diseases.
Drug candidates in late-stage development include a potential
new treatment for obesity now in Phase III studies.
highlighted 212 clinical triais under way in oncology, the most
in the industry. Late-stage development projects Include
Fhase III triais against melanoma and pancreatio, breast,
and Iurig cancers.
22
.T%cer 20117 Co,-porote Tkap,,naíh,litv Report
R&D: FINDINO CURES AND TREATMENTS
new medicines that will address significan unrnet medical needs. We now have
more drug candidates, more clinical triais, and more research programs than ever
before—a total of 242 programs spanning 1 therapeutic arcas. Our four major
arcas of concentration include:
N eu rosc i ence
This portfolio includes new drug targets in areas
of critical medical need—Alzheimer's disease, pain, cognition
and attention-deficit/tiyperactivity disorder, depression and
anxiety, and sleep disorders. Pfizer's Lyrica', the company's
new medicine for neuropathic pain, was recently approved
by the FDA for the treatment of fibromyalgia, which is
characterized by chronic, widespread pain that affects tens of
miflions of people worldwide.
R&D: FINDING CURES AND TREATMENTS
Diseases
We are targeting key bacterial agents and key vira? diseases.
Pfizer is breaking new ground in our approaches to the
treatment of HIV/AIDS, especially with the recent FDA
approval of Selzentry". We are siso exploring a nurnber of
other R&p approaches to find new treatments for HIV/AlDS.
Pftter 2007 (Jorporafe ReeponíhiUtv Report
23
•
7 iRIMgr
Increasing Pipeline Transparency
Pfizer's Eleven Therapeutic Areas
:Wifh aggressive targets, vlrtually across the board, we have
irnportant research programs underway in atherosclerosis,
oncology,diabetes, obesity, rheumatoid arthritis, HIV/AIOS,
schizophrenia, liver disease, and Alzheimer's, arnong others.
As a Ssuit, our portfolio of newmolecular entities (potential
new medicines as yet untested and unapproved) has aimost
trip!ed sihce the beginning of the decade.
We now expect that our Phase iii portfolio (when
compounds are tested in Iarge-scale clinicai triais) will grov
dramatically over the next three years. Four new programs
advanced into Phase III in Iate 2006 are:-
t
Vàrious stakeholders have told us they would like a
broader picture o! our pipeline and its potential, as weB as
a'transparent assessment of our opportunities and chaIIènes.
We are now posting infornation about our pipeline on
www.ptizer.com/pipclíne —where doctors, patients, investors
and tho public can track our progress over time. With a
pipeline that is 250 percent larger than it was just six years
ago, the new website provides details on ali major projecta
iii ali key disease areas. -
II
• Axitinib, a prornising new treatment for thyroid cance
CP-945,599, to treat obesity and its complications
SutentO for the treatment of metastatuo breast cancer
Pediatric studies of Zithromax'/chloroquine to treat
the single greatest kilierof chiidren in Africa.
.
R
o
1
tINFECTIOUS
DISEASES
ÁLi1r& &
IESPIRATORY'
ONGOLOGY
PAJN ..............
DERMATOLOGV
4;
-.
-
24
--
11fiSf2O7 ( ji,,+te fl jonsibftity E-w,rt
R&D: F1ND1t4OCURES AND TREATMENTS
t
t. ÇF
4
What Is a Clinical Trial?
Clinical Inala are crucial to discovering
and developing new medicines. This section
desenhes what clinical triais are and how
they work.A clinical tual is a research
study perfoi.rned with hurnan volunteers
to answer specific health questiona and to
prove the relative safety and effectiveness
of a potential medicine. Patients in clinical
triais are car efully selected by healthcare
professionalsfphysicians and closely
monitored to ensure their safety and the
integrity aí the resulta. Government agencies
regulate ali phases of clinical research up
te the approvai of a new drug. Carefu.Hy
conducted clinical triais are Lhe safest way
to fimd new or i.rnproved treatrnents. advance
medical knowledge, and improve clinical
practice in many areas of medicine.
ft&D. FINDING CURES AND TREATMENTS
What are the different phases
of clinicai triais?
Clinical triais are divided into the foliowing phases:
{
M
P9
PhaseI Iriais are the first studies of a drug
in human subjects. Phase 1 triais test the
safety and tolerability of a prospective
medicina, helping to determine which
dosages are safe and well tolerated. The
studies are typically in a sniall sample of
study subjects, who are usuaIIyheIthy
volunteers, although for some tÇipes of
drugs. Phase 1 triais niay be conducted in
patients who have the condition that the
drug is intended to treat.
Pfivr 2007 Uo,poratv Re;'on,ibiUtv Report
25
~Ê
S5
Iç
1
Maintaíning Clinical Trial Standards in
the Developing World
-C
-
In recent years there has been an increase in clinical triais
conducted in developing and emerging countries. While we
still conduct most of our triais in Worth Arnerica and Europe,
others are dono in advanced countries in Asia and Latin
Arnerica. Around 10 percent of study participants come from
Eastern Europe and another 10 percent from Asia, excluding
Japan. A very small percentage come from the Middle East
and Africa.
There are several reasons for this changing trend. Some
countries require local clinical triais before a medicine can be
registered there, even if it lhas been approved by regulators
elsewhere. There are siso specilic medical reasons, like
targeting certain diseases according te global incidence and
prevalence.
We conduct clinical triais in accardance with local laws
and regulations, and recognize internationai standards,
like the internationa! Conference cl Harmonization, Good
Clinical Practices (GCP) Guidelines (www.ich.org/LOB/niedial
ME0lA482.pd1) and the Declaration of Helsinki. We also
have the responsibility to ensure that GCPs are followed
by contract research organizations we hire.
Inereasing Clinical Triai Transpare
Ethicai standards for clinical researchare evolving
and stakeholders have a growing interest in greater
transparency.
W1tEI the expansion of our
pollcy In Janua& 2007, wen
e
p NlH-sponsoredwebsite www.clinh
Thls Includes Phase 1 trlals and nc
studies with prospectivo data. For
registers, we also disclosé the resi
Msults database (vi*.àlinicalstuc
ãpproval. As 01 Auõlist 8, 2007,
842 tudies on thNiH site and
on lhe PhRMA resulta sito. Jhis e
on our previous clinicai trials disc
which was based on the January
of the internationalederaionp
26
J'1zer 2007 tJo,porrste Rcsponihrhtv Rcp.rI
ovan Facing Chalienges in the
Leveloping World
Addresslng Stakeholders
Pharmaceutical companies face unique chailenges when
conducting drug triais for potentially Iife-saving medicines in
countries with weak, ambiguous ar nonexistent medical and
regulatory infrastructures. In recent years, companies have
been chailenged legaily and in the media regardless of their
scientific success ar failure, ar the humanitarian nature of
tleir elforts.
Pfizer is currently facing such a legal issue. The case
concerns a clinical fria! aI Pfizer's antibiotic, Trovan, and
children suffering from meningitis during a severo meningitis
epidemia in Mano, Nigeria in 1996. Eleven years later, in June
2907, Mano and federal autharities Iiled civil and criminal
Iawsuits in Nigeria against Pfizer.
One of the aliegations is that Pfizer failed to obtain proper
informed cansent from lhe children's families. As Pfizer stated
inEits responso to this action, Pfizer acted in lhe best interest
of1 the children and used lhe best medical knowledge available
tol treat patients. Bef ore any child was admitled ta the study,
tte entire process for conducting the trial was explained to
each parent ar guardian in their nativo language, and consent
was obtained oraiiy. The parents ar guardians were allowed to
re~nain with and soe their children during the treatment. The
study was conducled with the necessary approvais from lhe
relevant government agencies and in a responsible and ethical
way consistent with lhe company's commitment to palient
s4y.
felTrovan proved safe and elfective. The study's survival
rato lar both Trovan and the comparative drug exceeded lhe
sdrvival rato of any other treatment being adminislered at the
lnfectious Disease Hospital in Kano.
Addressing the Epidemia
Nieria's 1996 meningitis outbreak was the most serious
meningitis epidemia ever recarded in the country. It took
lhe lives of almost 12,000 people over aix months, and
significantly strained the country's health system. Pfizer's goal
vias te bring a lile-saving and innovative form of antibiotic that
could be used effectively in à meningitis epidemic.
Trovan was not only demonstrated in pre-clinical studies to
be effective at treating the meningitis pathogen, its oral form
a'joided lhe use of intravenaus administration ar intramuscular
injections.
At lhe lime of lhe study, Trovan was in late-stage
development and had been tested ciinically in more than
5.900 patients in lhe United States, Europe and eisewhere.
Pfizer was getling ready to begin a global pediatria meningitis
clinical study when the 1996 epidemic broke out. This
pediatria meningitis study was evenlually canducted in 1998
and the study concluded that Trovan raised no new sal ety
R&D: FINDING CURES AND TREATMENTS
.04
05
1
R,:,
QIJICK DECISION
TRANSPARENCY
i
MAKING
-
jov
e
*
*
STAKEI-1OLDER
COST OF
.
"!!
Torcetrapib: A Case $tdd ihRsponsibIe Actions
ÇNw
F6r5years, our scíentists had been
i; 1
w&kihg on a compound to dramaticaily
imrõve the treatnient of cardiovascular
disease. The compound, torcetrapib,
aimed to raise "good" cholesterol, and
the research iooked very promising.
this medicine. Deveioping torcetrapib
required innovation across ali amas of,
Pfizer—from biology and chemistry, to
manufacturing.
.
When we decided to terminate the
trial, our medical team immediateiy,
Then, in December 2006, to the surprlse L
reached out to hundreds of clinical
of many, we immediately terminated ali
t , 1 ,investigators to notify them of
clinicai triais for torcetrapib With our
the decislon, and we coritactedother
focus on patient safety, we knew we
-MIgkey audiences, nciuding regulatory
had to stop the triai wVen the Data and
agencies around the world. We
Safety Monitoring Board (DSMB), an
siso were open and accessible iii
•independent body overseeing the drug's
communicating with the media and
morbidity and mortahty study,aierted us
financial communities as weli as with
flbout a statistical irnbalance in rnortality
our employ'ees.
ali-cause and cardiovascuiar events il ÈPI U1~
$ k&oe il\3r liníng in ali of Uns ws
among triai participants.
te Çeraiiublic rectlon to
The data was both surprising and
Whiie our, stbk içt aproxirrt%i)
disappointing. We hád Óreat hopes for
10 percent of itsvaiue bythe end
the freatment and had aiready spent
of that first day, we receked praise
more than $1 bdii6n doflars deveioping
for our swift response from some of
our harshest media critics. As one
newsaper described it, the way we
1
1111
.
.
QP
handied the crisis heiped to "restore our
faith in the íntegrity of corporationsthat
play such a big role in safeguarding our
heaith and satety." The stock price later
recovered.
The torcetrapib story is a reminder
of the profound risks associated with
biomedicai R&D. The fact is, 75 percent
of ali biomedicai research ends in
faiiure, 50 the average cost to discover
and deveiop one approved medicine
has increased to more than $800
miflion, according to the Tuftsen
Cter for
te Study of Drug Development
As Pfizer's head of global R&D said
"We dá sêience to heip cure the
world'ieases, and when it works,
it's fantast ic. But no project advances
withoti a hitch and nothi ng
do is
truly unsuccessfui ... this is one of te
most important projects we've eyer
workecJ on and we wili iearn frorn this?
...y
.
ZW
ilp1iPb
R&D FINDING CURES AND
fl er2afltorparai, T'spôinth'Iih Ri pari
27
4
agâ
Pfizer's Stem Ceil Research Policy
When people th.ink of human embryonic
stem cells, they don't often imagine the
pover of these cel].s in drug d.iscõvery.
For more than a decade, Pfizer has been using animal or adilt
stem cells in its laboratories to help screen new compounds
and identify safer and more elfective medicines.
With compelling evidence from this research, Pfizer has
begun to explore accessing drug development technology
from leading academic, biotechnology or pharmaceuticãl
partners around the world, who also have experience with
currently-available, human embryonic stem cell lines that
meet the highest ethical standards set by leading scientific
authorities. This Pfizer Stem Ceil Policy guides the company's
• research activities and its exploration of new external
partnerships. The policy summary foliows:
Pfizer acknowledges the sensitive issues raised by
this research, and we support proper ethical safeguards
that take Into account both the moral Issues and public
sensitivities.
Pfizer will only engage in stem cell research projects
that meet the highest ethical standards set by leading
scientific authorities around the world, including
the Guidelines developed by the National Academy
of Sciences in the USA.
Pfizer strongly opposes any efforts to clone human belngs.
• Pfizer recognlzes the enormous potential of stem
cell research. Stem celis are important tools for modern
biomedical research, including Pfizer's search for
innovative new medicines.
• Pfizer has mede significant investments in animal
stem cells and in human adult hematopoietic (somatic)
stem cells. The company will continue to invest in
these stem cell technologies.
• Pfizer recognizes that human embryonic stem cells may
provide even greater potential dueto their increasd ability
for self-renewal and capacity to form a wide variety of
cells and tissues.
A human sten, cell culture.
28
J'/ÇT 2007 Corpo,cto tcspi,n,ihilityf?eport
R&D: FINDING CURES AND TREATMENTS
E/
Fia
ORDE
Pursuing a Humane Approach
to Animais in Research
J Weltare Policy
Ô
We understancl our stakeholders' concerns
atout the use of animais in research testing.
.Based on our Animal. Welfare polícy, we
proactively look for alteruatives that reduce,
replace or refine our work with animaIs.
Tu orcier to adopt new nonanimal test
met;bods, we engage in and Iead crossindustry efforts aimed at developing new
testing and inforniation systems that may
help accurately predict medical outeomes
and reduce the use of anjmals in testing.
necessary to use animais in the
anim
,such as
and in vit
and where animais must be'used:
the numbers of animais used in eaclt
the number of studies invóMng animais, to
minirnum necessary to obtain vaiidresuits
our research objectives; and
Currently and for the foreseeabie future, it is only through the
combination of animal-based research and alternatives that
we can understand the fundamental biology of the diseases
we are trying to treat, discover new medicines and assess
their safety.
While new technologies can reduce our use of animais,
most are applicabie only for safety evaluations, which are
the smalier portion of our animal use. The rnajority of lhe
animais utiiized in testing are used to understand basic
causes of disease and to test the efficacy of new candidate
compounds for medicines. A range of studies measure how a
new medicine is absorbed and how the body distributes and
breaks it down. Exploratory studies of this kind can be done
in tissues, but the pivotal studies have to be dono in whole
animais before we can conduct them in hurnans.
We work through pharmaceutical trade organizations
and relevant scientific boards, and directly with global
regulatory authorities, to increase the common understanding
and acceptance of appropriate aiternative methods. One
example of this is our strategic investment in the work
of lhe International Life Sciences lnstitutes/Health and
Environmental Sciences Institute. We are also members of the
In Vitro Testing Industrial Platforn, (IVTIP).
Pfizer cannot eiiminate our use of animais in research at
this time. But we can make sure that the tests we need to
carry out—some of which are required for.regulatory purposes
and others because it's the only way to get the necessary
medical answers—are cone tolhe very highest ethical
standards of animal weif are.
R&D: FINDINO CURES AND TREATMENTS
oi brocedure nvoivincj aniralso minimize
Improving Animal Health
Pfizer Animal Health (PAH) is dedicated to improving the
safety, quafty and productivity of the food supply and helping
pets live longer, heaithier lives through innovation in products
for livestock and companion animais. In 2006, PAH spent
$270 million on research to improve the health and welfare
'of animais. One recent Pfizer iaunch, lrnprovac—a novel
alternativo to surgicai castration of boars—is a good exam,ie.
The animal weifare community is appiauding this product
for its humane approach to a necessary animal husbandry
practice.
To advance canine cancer research, PAH announced that
it wili donate $1.1 million over two years to heip ostablish a
national canino tumor tissue bank. The Pfizer Ganine Tumor
Biospecimen Bank wili be housed at the Nationai Cancer
institute (NCI) in Bethesda, Maryland, and wilil be managed
by the Morris Animal Foundation (MAF)—the world's iargest
charitabie rionprofit organization funding research to
•protect, treat and cure animais worldwide. With this tissue
•bank, veterinary and medical investigators can explore
the mechanisms of cancer, evaluate promising new dnjg
candidates and possibiy deveiop a better understanding o!
•the reiationship between human and animal cancers.
E
Pfirer2OO7C,rporah'Re*;'onihilitvRepofl
29
Expanding Scientific
Coliaborations and Partnerships
V/e are increasingly open to new and
different approaches to maximize Lhe
potential of our R&D activi.ties—in
the form of scientiflc alliances and
partnerships wíth academia, publie research
institutions, foundations, nongovernmental
organizations, biotechirniogy compani.es
and governments,
Effective partnerships not orily help
na achieve scientific advances, but they
J' also help us streamline the com plex and
expensit'e R&D proceas. Pflzcïs aliiance
portfolio is large but focuseci, involving
parfners with expertlse that spans th.e
entire irocess of discovering, developing and
delivering new medicines for patents
in need.
30
TYieer 2107Corpor<te Rcspon,rbiütyReprt
1h
R&D; FINDING CURES AND TREATMENTS
ORnE
AND RECOGNITION
Two Pfizer scientists, along with a non-Pfizer
scientist, were presented inMarch 2007
with the PhRMA Discoverers Award. These
three scientists are responsible for the
discovery of Zyvox®, the first member of an
entireiy new class of antibacterial agents to
reach the market in Pie 35 years prior to its
approval in 2000.
A Pfizer scientist was appointed to Pie US
National Human Genome Advisory Council
in 2006.
In 2006, Pfizer La Joila was presented with
the Most Innovative Product Award for Sutent®
by CONNECT, a nonprofit group focusing
on technotogy growth.
Pfizer India won the 2006 Pharma Exceilence
•Award for Exubera* in the "Innovative
Products of the Vear" category.
R&D: FINDINO CURES AND TREATMENTS
I'ti;er 2007 torporrjfe Rçlpon.bi&ititv Report
31
1-
-
•
inves,ting
IN HEALTH
Improving access tomedicihe and strengthening
healthcare systems for lunderserved peopl.e aroun.d the
world are arnongthe•standaiMs by whiêh our success
as a pharrnaceuticàllúõi4ipany is measured.
Te that end, we are Árorking on newsolutions with
our partners. We are ihve'ting 1h effective and
sustainabie healthcafe delivSy resources, and working
with national governbierits, frntet national agencies,
nongoverurnental organizations, multilateral
organ.izations, acadernic institutionsand others to heip
people get the rnediéines and servicës thõy need.
32
flzer 2007 Go,-porate Responiihility Repr,rt
4Ei4'
r
EW
2006/2007 KEV ACTIONS
Launched "Mobilize Against MaIana"
with NGO partners and three African
governments to help in maIana
treatment.
aunched Global Health Partnerships
support innovative public health
rograms in the areas of oncology and
bacco dependence.
Launched ConnectHlV to support
20 community-based AIOS service
organizations working to stop the
spread of HIV/AIDS in the US.
eveloped disease management
rograms in the US, Italy and the UK.
§ Joined a new coalition created by
The Brookings Institution to increase
the number of US volunteers involved
in international service.
Implementing a Holistic
to Healthcare Delivery
broach
Making medicines acces
around the world
requires a commitment on ffiany fronts: engaging
and educati.ng providers anã patients about
diagnosis and treatment, bdilding healthcare
capacity, delivering the:me4cines where they
need to be and when they nted to be there, and
partnering effectively with çrganizations treating
patients on the ground.
34
Pfizer 2007 Co,porate Fkipon*ihihtv R,,,,1
k
INVESTI NG 1H H EALTH
)
Treat, Teach, Build, Serve
To invest in effective and sustainable
delivery of healthcare resources and
expertise to underserved people around
the world, Pfizer coordinates its efforts
under four major arcas of support.
We define thein as:
*
O.
TREAT Improving access to medicines
and heaithcare services.
• TEACH Increasing patient education
and healthworker training on health
issues and prevention.
• BUILD Working to strengthen
healthcare organizations and expand
their ability te serve their patients and
communities better.
• SERVE Advocating for improved
heaithcare for the underserved and
sharing best practices to improve
healthcare delivery to this populati.on.
This and the next two pages include
examples of programs that contribute in
ali Ibur arcas.
INVESTI NG IN H EALTH
1
Pftn.r 2007 Umparote Jkaponsihilitv Report
35
na
9'
36
Pficer 2007 Coporate Rnpon,ih,lity Report
INVESTING 1H HEALTH
Pfizer Global Health FelIow Elizabeth Gesierich with Irene Njoroge, an
administrator at the knu,1 HIV/AIDS Orphans Day Caro Centre in Nairobi, Kenya.
Pfizer Global Health FelIow O,. Ponni Subblah tralned new physlclans at
Mulago Hospital In Kampala, Uganda, with I-lealth Volunteera Overseaa.
INVESTING IN HEALTH
l>flrer
, 2007 ('mporot,' R,;'on sihi!itv Report
37
Additional Programs
Around the World
We support a range of sustaínable healtbcare
delivery resources in countnes where we
operate to help un.derserved peopie get the
care and treatments they need. Below is a
sample of these prograrns. More information
may be found on the Pfizer country-specific»
websites on www.pfizer.com.
Improving access to medicines and
healthcare services
38
, 07 Coiporate tkRpúníhTlttv Eeport
TYier 20
UNITEDSTATES
«I.lPiiiIWt
In the Unitéd States, the Pfiz& Helpful M
of patient assistance progranis h&ps Ame
presdription drug coveáeéave on man
ttfl
medicina s;no ae,eageo
timited income may quIi tet thelPfi
for free In the past tive years Pfizer had hc
tive mitlion patients receive nearly 50 rnhhic
prescriptions for free orat a savings.
Pfizer is also a member of the Partnersl
Prescription AssistanceQPA—a national
sponsored bíAmerica'spharrnaceuticaI r
cornpanies that heTps Iow-income, uninsur
underinsured individuàlsáteS pré&iti
medicines. The PPA cdhiects patiéhts in r
more than 475 publie and private patientpr8ams 'ncluding
re than 180 progra
t by pharmaceutical compnies As ofs se
aniversary in Apnl 2007rWie PPA has hi
than 3.6 mullion patients nationwide find pr
that provido more than 2,500 prescription
for free or nearly free. The PPAIso offers
toinform patients about free healthcare di
1communities and há connected moretha
tients with thesinis
in their
5;000
t
reach the age of 65. That's why
Pfizérfion-6d With the Hungaiian
Society of Hypertension and a national health program
oy a pUbhc private partnership
between Italy's Puglia regional
government ind Pfizer Italy.
lhe program takes a proactive
approach to ide ntifying and treating patients with such
chronic diseases as diabetes, congestive heart failure,
and other cardovascuIar conditions—as well as patients
with rsk tactors for cardiovascular disease. Pfizer
provides detailed operational, technical and clinical
consultation. This patient-centered prograrn is designed
to reduce cardiovascülar risk by modifying patient
Itt estyles, improve continuity of cará and appropriate
access to needed services, and implement consistent caro guidelines for thd program staif dnd physicians'
E
involved intheproiect.
i&ieasurmentwith an arteriograph, which'measures
arterial stiffness, Pfizeïis helping to increàse aWáréhés
ab6üt tiTe early phase of athero- and artenosclerosis
datiformation, andyesults of the workinjgroups will
bepubhhed in national specialist Journais.
Y tt
IWVESTING IN HEALTH
Su
P(i:er 2007 (jorporafe Re.ponsibilif v Report
39
QPOE
TEACH
Inoreasing patient education and health worker trainiqg on health issues and prevention
Soulherriuni4d States, we have responded to
In lhe
an alarming trend in lhe rales of HIV/AIDS infectlons
by partnering with community-based organizalions
in the regionto help prevent lhe spread ai HIV/AIDs
lhrough our Sàulhern HIV/AIDS Prevention lnitiative.
The Pfizr Foundalion and Pfizer commilled a total
of $6 iplilioçi over lhree years, beginning in 2004, to
stípport a nelwork ai more lhan 60 innovative HIV/AIDS
prevenlion programs across nine Soulhern slales. By,
provi ding training for heallh workers, educators and
Volunlears, lhese prograrns strengthened lhe capacity
ai cornmunlly-based organizations la reach and serve
â.lheir cammuniiies
Alter lhree 'ers ai &ants and intensive capacitybuliding support, lhe majority aI granlees demonslraled
sironger service dehvery, rmproved organizational
•capacity, and expanded nelworks with local and
regional AIDS service organizations. In addition, lhe
social impact of the initialive nas been significanl:
• More than 1,000 individuais were trained as
a peer educator or mentor,
• 3,000 individuais were provided with lesting and/or
counseiing,
• Morethan,11,000 rei errais were made to tesling,
i"'
counseling and healthcare services, and
• More than 50,000 community rnembers were
reached with
SA
Tiompo," Iaúnched 1h
Novemb&r 2006 ht lhe Afehtihe
Congress of Clinical 0nc4logy,
is an awareness cem paign
deslgned to inforrripaple abou
of early detion 4Pf'zer s obje
peoplá to get peno icei mediçz
to encourageeopfe tãrriakd li
quit smokihàrid ëát hâlthiéF1
that maytgFtie diee
This campaign is béing carri
with Lalceo (Argentino League
noroV&nmentaI organization
working on behalf of cancer pai
In Argentina.
40
Jcer 2007 Co'porate fkpôn,h,Uiv Jkpr,r
Hvrrtt
to
A nationwide mobile informalion
campaigri called lhe TMMemory
Bus" began in 2003. Witb
physicians, psychotherapists and
biher mental heallh experts on
the bus stops in 24 cities
ll pyr Aulria every year, oflenng help and information
hd the tbpic ai momory weakness, ilh a focus on
educaling the populalion aboul lhe importance of early
diaghosió ol dementia. Tbe bus enables visitors to
speak cardidly and anonymously with a doctor and gaiA
knowledge aboul this sensitivo subjecl. The Memory
Bus has become one of Auslria's mosl popular disease
awareness campaigns.
INVESTINO IN HEAI,TH
Childhood obesity 'San
epidemic in Ireland as it is
other developed countnes '
Way2Go For a Healthier
Vou" is a national public health
information prograrn designed tc
help familiesh,ake healthier cho
The focus ai this çirogrim is Õnj
parents,where strategiés on h6T
obesity are discussed. Neas co,
communIcation physical activit)
factors Another elernent is an e'
for the schools Way2Ga1materi
747 secondary schoals
used w,th students age1iji SYA
224,000 students have
the prgram throuáh helihhon
and/ar physical education classi
cancer
, India
group
their childreiv,
meetings foi
Idress childhood
ir
eseu
em -ii!r
TEAR Project is an initíitive
strengthening their relationshiptk
&i
network through work The r
partnership between Pfizer, Guarulhos City Hall andj
the Cornelia VilegAssociation strives to directly benetil
patients by helping themPedeern theWself-esteem,
encourage their incluston in society, and generate
income for their farn,l,es since they are often adults in
low income JObS Backed by a team ai psychiatnsts
psychologcsts social workers occupationat therapists
nstructors in industrial trades and nurse practitioners
the prograrrofferz seven different workshops printe
1P1
participants and to help sústain
INVESTING IN HEALTH
enfion, detectionandearly diji 1Al$
edwere awareness sessions run byoncoI6glsts
orations that have a largo populationbffemale
Kéy goals included traininggynecoIogists
ydetection, inoreasing refehàlé to onéolagists,
iorming patients about the írnpdrtance of early
dng.
initiative
0
0
As ii bnàny developed cour,tries,
dementia is an emerging
chalienge for the German
healthcare and Iong-terrn care
system. To oífer salutions for
1
Germany and co-proniotion partner Eisal developed
and init,ated a caro management project together with
Germany's largest statutory health insurance cornpany
AØK. The idcu of lhe projoct, which partners with
stkeholders, is to impróve theearly diagni
os' ai
Alzheimer's, delay the reductian af cognitive sk,lIs and
entry into nursing home care, and reduce the cost of
caro. IDA was launched in July 2005 and in January
2007 the recruitment ai physicians and patients was
completed. Now 129 physicians in theregion ci middle
Franconia (part ai Bavaria) are contributing with 390
patients for the project. The caremanagementproject
Is based on a broad perspective to evalüate real-life
quality of caro, complement drug treatment with other ,
treatmerit aooroaches. and iritearate the efforts ai
Pfi:er200Tta,porah'Rc,ponübílity &'porl
41
Tbe Pfuzerbain Foundation
createdaichool-based obesity
programtoproniote and spread
health habits for schooi children.
The program iifocüsed on diet,
exerãise and obesity prevention
and hetps to reaóh lOto 12-year-old children with a
tR
with tliiHõalth and Education Regional Ministríes
from Madrid and Valencia and trains elderly peopTe
(above age 60) as program instructors to provide
educational materiais and promote discussions with
the children. in the past year this program has reached
1
alrnost 40,000 children in more than 1,700 classrooms
1,1
and trained 45 instructorâMIOROL
.11
Pfier Sweden, in cooperation
with 22 ophthaimologusts,
developed an education program
in 2006 for general practitioners
andopticians. Tbe objective
was to help tinem make better
referrais to eye cliniès, with a focus on the niost
common eye disea&es—glaucoma, age-related macula!
degeneration, dry yes and diabetic retinopathy
lhe goal: "The right patient, at the righf time, with
the right levei of cara." In the program's first year,
36 nieetings were held with more than 500 attendees,
who sald fim prograrn was very heiptul and wouid heip
mprove ref errais. Additional proof of its initiai success
was that 90 percent of participatingophthalmoiogists
signed up for another year.
H
t
Foliowing the ávastatii
tsunaml in2ôO4tthe pfi
Foi.jndation donated $1
helptrairtfiVe psychiatd
Mákh
rio reclplenls.:itietraining was conducted
)OS at the University of Pennsyivania: Pfizer
isted the psychiatnsts in the socialization
watotreat RTSÕ at the Nationai Congress
(Bàtani;No'Jemb4y2006). PfizeïlndbIeiá
i a media briefing on PTSD, conducted in
which generated ctverage in 19 ottibts
he second patbf the program, àurrently
;iudes the deveiopment of a nat!bnai
a center, since indonesla Is prone to
ffite ;'
42
J%er 2007 (]orporato Ueapon*rh,?ily Report
-R
INVESTING IN H EALTH
40E
8Q_
\ DPE
Pfizer holds a workshop each
year,for volunlary healthcare mi
organizations to discuss
healthcare issues including I5P
awareness, comnunications
and improvements for patients,
families and healthcare professional The two-day
worksfiop is in its sevenitjyearand volves participante
from more than 50 voluntary IÇealthc e organizations.
Activieslinderwaji nciu&ëstudsí diagnosis notes,
àn education book fomSialtud ts, andá focus on KA
tearn-based healthcare.
VII
2
BUILD
Working to strengthen healthcare organizations andexpand their ability to serve
their patients and communities better
Pfiier Global Health Followsare poileagues called
upon to apply their professional skills to help improve
access to healthcare in local communitíes throughout
the developing world. The program was launched in
4 2003 and continues to hélio me-et the need for stronger
nted in partnership with nõhgovernnintal
eral organizàti6ri, Global Health Fellow
s are designed ând implemented according
s. The fellowships last for a period of
months, allo4ing Feliows time to integrate
LI community and host organization and
ie contnbutions. During their assignments,
rain and support their local counterparts,
skills so that the contributions they make
to
and
INVESTINO IN HEALTH
Pti2vr 2007 Corporuh' ResponübiIiiv Report
43
Taking Healthcare on the Road
Siovenia For those citizens ôf Siovenia who ddnot
live near a healtn conter. Pfizer hÉís teamed up with the
Sloveniân Heart Foundatin and the Siovenian Diabetics
Association to Iaunch lhe Cardicmoble. aspecially
converted camper Qan dedicated to reducing cdrdicvascula
disease. The van offers free lectures, an exhibition cn
Malaysia Mi ihitiative endorsed by Malaysia's Ministry
ot Healthj the Care-A-Van piovides troe health screenings
hea educa{on througiout lhe country lo frnprove lhe
standardièbf fieallh a Qrig t e population, espeçiatly(he Iess
privileged inírural and sernl-urbari cornmunitles Tie god ís
lo indease awareness about the importante of prevention.
Since its Iaunch in 1999, the Care-A-Van has visited more
tha 186 ocations and screened rridre than 80000 pàtients
natio nw ide
e
44
fler 2007 Corporate !.pnnsih'lity Rezw,rt
INVESTINU IN UEALTU
1
Advocating for improved healthcare for the undE
to improve healthcare delivery to this population
and sharing best practices
E
INVÉSTING IN HEALTH
Pft:er 2007 (J,ipor&e R.epnnthíi&ty Rgport
45
4
Pfizer Health So
Ef um
IP
.
•.
Chronic diseases-din "esses ! k!esr
diabet
heart disease asthma and abesity thatcariÇ
be managed butnot cüred—are thefr adig 4
causes of death and disabdity in the Uited
States. inaddition tothe human cost of
sunerindand prematur54ath thatr7%
accompãnchronic
diseãseíthe h'dàitcà4
............................................
system cannot effectiveiy address escaiatipg
costs without heiping peopie iearntprpnage
:
and prevent these diseases.
In thischauenging éhvironmentPir
Heaith Soiutcons (PHSÏriners
governments, payers and providers lo
impiement and support cuituraily senItive,
community-based programs that he!p peopie
engage in heaithy behaviors and be9ínore
4 4
active participants inmanaging theirpwn
health These partnerships have proen
tobe effective in hétping people preent
compilcations and ábute events. This, iniurn,
saves heaithcare yoCi rces by préQentin
the need for expensive services such as the
444
use of emergency rooms and hospitais
For,more
on these paitherships;
't piéàse see www.j5fi2erheaithsolutions.com.
.
.
11
1
-
q
4
i4j
:d!jhl
Nw
gá
46
Pfizcr 2007 Corporal., Responsibility Repon
:I$
1
HO
¶5Tf
I.partnerihip with local heali
dèsigned and implementedt
and peersupport program to
;services provided in six loW4i
commúnities aroijnd th&US.
cúlturall9 àppro*iate edüáati
k
tíiiR?idually and in groupsrír1
%community. Peer hlthe
'a,
"7
eral, and a
rRroniddiseas
;úblic healtFnitiati
l06,is designed td
id their fârfimlles, tlr
by addressing tisk
wíth the,
¼'4"
I'a ••C
•,,!w I
of the Amigos erj Salud prograrfl avallable jr th'epUbllc
domam.
•
1
behavlor
Arkan
pssesm
edlrnyc
Ni
-;
-
From 2001 through Septeber 2005, 0,15 partnerskip
between the State of Florida and Pfizeryeduced
,
healthcare costa by improving the health ofohronicaily
mil beneficlaries of Medicaid, state-sponsored
Jiealthcare assistanceJiThrough a netork of cbminunit
hospitais, physicians, civicorganizations and atient
groups Flokdas Ageno for
CareAdministration
(AHCA) and Pfizer designe
0"
a prograir that pro'Mded
care managementnewa!th benefs,
and ealtdare
h
support. in its fourth year, Florida' A Healthy State
saved the Stateof Florida $34.6 million ri medical
cost reductions. This is in addition to $7,4 milt(on in
investrnents that Pfizer mede to support prograni
operations across the state Frorn program Inception
through Septernber 2005, Florida: A Healthy State
generated $139,5 millíon in savins ànd rogram
investments and provided tcess to prviously
unavailable healthcare resourças to over 180,000
Mediçaid beneficiaries with chrond conditioris.The
State of Floria managed the Çloçid: A kea)thy State
program for an additional 15 mohths (Octdbé?200
through December 2006), during whiclqtlme Pfizer
provIdeatchnlcal and prograrn support.
INVESTINO IN HEALTH
mntLmSL9lilhSts$qL_
pl1l ?
Y OII1i
DPOE
Improving Access to Medicines
IMPACI ON SOGIETY
PARTNERS
TYPE OF PROGRAM & ACTIVITY
A famfty of patient prescr(ption assistance
progranis tini hdps patlenh without.
Pr
ri
dru cpyerage save on
Pfizer madto nos, no piatter th sg
income PabeMs witI bmhej incpm4erwrsly
'Iess ftian'io-bmes lhe Federal Poveay)IPr
Levei, adjustea for mIIy size me>' q&iifytor
Ires Pfizer medidnes, Programs 1hat pmvt&
Iree Pfizer medicines unclude' Connectlo-n to
C"
Siwinp ahe08y0tM• and lhe Pflzer
C
Hospital Partnership Pragram
A'Pfizer initiatrve,
Nailonal Governora Association, NatonaI
Assoozation o? Community Health liters.
r
tiiva2z na. "
Provides Pfizer niedicines lor free lo quabfied
patients throogh their doctors' offices.
-,4.,.,,,..,-,-.
ii
_aat,it._iunma 4.2oan$aaads.___,,tnLam
More tSan IDO 000 physic ano currently have
patients partloipatirig in tbe program.
1,1 2006, Pfizer helped nearly 650,000 patienta
More tian 40 larga urban hospitais
Ii
jo 2006, Pfizer helpeal moro than 142,000
patients receive 500,000 Pfizer prescriptions
for free through.the Pfizer Hospital
Partnershim(
5jJj
fifi
i
A patronal etfort sponsored ) Larica
harmaceutic& reshetch Coulpanles, lo
partnership v$th more
eo national
organizations including lhe Mierican Acad
o? Famlly PhyslclansEaster Seals, National
laoce for Hispan(c Health National Urban
______
ague1 Uriited Way o? Amorlca and NAACP
!p:nto;accohspc5uieet
patients In lhe (IS to more tÇan 475 pubáic and
jrivate patient assistanoe progranis. Inoíuing
Pfizer HeipluI Mswers.
Regional Ireatment and training fcility in '?
Uganda that strengthens local capaciW ir HrV/
AIOS, maiana and tubercuTosis.
48
lo 2006, Pfizer hetped more than 600,000
patients recelve more than 2 millíon Pfizer
prescriptions for freiethrough the Shanng Lhe
Cara program.
receive more than 6 mullion Pfizer prescriptions
for troe lhrough lhe Corinection to Caro
prograni.
i
Provides Pfizer medicines for troa through
disproportionate share hospitais across lhe US.
e
6, Pfizer, Holpful Mswêrs halped
oer 1,500,000 pailents r000ive over 9 million
Pfizer prescriptions and saved patients
àver $800 million.'
'Oased on wholesale ecqu sfin cosi 10 troe medicina
progranis and actuei savkigs recervod by salienta kr
progamt.
_________________________
Onro,11
Providas Pfizer medicines for me o eligibie
padents
moro than 40 participating
federaily qualified community health centers
across the lis,
r
r
9
['fizer 2007 Corporais Rnpoiisifiilltv &piit
MakereU,niversiy lhe Acadni?0 AllaÀ
Foundation, Mulago Hospital, San Francisco
AIOS FoundatsorvPangaea Global AIOS
Foundatjon lnfectious Diseases Soclety of
%nerlca, Tho AIOS Sopport Organlzatioo
(rASO).
1
In ZOOÇ, lhe Partnershrp for Prescription
Asslstance rniatched more than 2 million
patienis to prescription assistance programs.
Soca 200 , DI has trauried mora thaA
1400 heathoare provudars from 26 Átrlcan
countries lhe cantar currently providas cara lo
appmimately 1O,C00 pationts
INVESTI N O IN O EALTH
e
«SprIng 2007
AWARDS AND RECOGNITIONS
e
Pfizer was voted the top corporate giver by
The Chronicie af Phi/anthropy in 2006.
........................................
Pfizer Hong Kong received the Gold
Award from the Hong Kong Social Welfare
Department in recognition of its commitment
to volunteerism.
Pfizer Global Health Feflows received the first
annuat Corporate Citizenship award from
Global HF? News in May 2007.
INVESTI NO IN li EALTH
E
P/i:er 2007 Voiporah' Rç,ponsibititv Rpon
49
1:
1
H
1
strengt4'iening
1
PATIENT SAFFJTY
Patient safety is om top commitment
To make. skre our medicih4 are safe. and effective,
we have a ugoioits cva1ciiation process that
starts at the ear1iest stageL of drug discovery and
continues long after our ibedicines are on the
market. We continue to tak4new actions to improve
our transparency andi cornmunicatiõhs about safety.
-ç
1
i
50
.P[u.r 2007 Qirjiorate Rv,ponaih,Iitv Rcj'c,'t
-
k
Fia.
7
r- A,
1
t
í
n
FW
2006/2007 KEY ACTIONS
Established a new medical governance
process that strengthens internai
coordination and accountability
throughout product Iifecycles.
Launched a website to disclose safety
studies on our medicines after they are
on lhe market.
O
lntroduced new packaging and
shipping technology to support anticounterfeiting efforts.
52
flcer 2007Corporate &spon,;h'iityRejw,rt
lidentifying, Analyzing and
Reporting Safety Data
We ernploy about 2.000 professionaisincluding physicians, nurses, pharinacists,
medical research scientists, and statisticiansare dedicated to patient safety. Their
sole responsibility is to identifv, analyze and
report potential safety issues at every poit
in the life of a medicine—from a cornpound's
Jàrly discoverv phase, through clinical t.rial.s
and regulatory approval, and for as long as
i is prescribed by physicians.
P? fizer scientists use information i.eportecl
hy physicians, patients and caregivers, as
as peer-reviewed journais and medical
li.terature, tu detect heaith risks as early in a
ihedicine's lifecycle as scientificaily possible.
In partnership with outside experts and
lkalth authorities, we thoroughly evaluate
dil reported potential safety concerns
and communicate risks to physicians and
patients in the most timely way possible.
1
STRENOTHÈNING PATIENT SAPITY
Strengthening Pfizer
Medical Governance
In response to new chalienges and
siakeholder concerns aboul the safety
of medicines, we have estabIished a new
medical governance process that strengthens
coordination and accountability among
the medical and safety organizations
responsible for the benefitlrisk profiles of our
investigati.onal and approved medicines.
These procedures refiect Pfizer's i.ncreased
- scale, the critical importance of reaching
clear medical decisions on a timely basis,
and Lhe need for transparency in Pfizer's
medical decision-making process, both
internally and externally.
This new process is comprised of a
three-tiered Medical Review Comniittee
structure:
t
The Executivo Medical Review
Committee is chaired by the
Chief Medical 0ff cor and senior
managernent. This ccmrnittee providés
oversight, direction and resolution of
conflicts arising from the legitimate
diversity of medical opinion that can
otten exist.
t
The Therapeutic Moa Medical
Review Committees are composed of
senhor therapeutic arca medical, safety,
regulatory and legal management.
These committees provide prirnary
oversight and support of the Product
Medical Review Cornmittees, as
needed.
e
I
N
The Product Medical Review
Committees are composed of
our product teams, as well as
medical, safety, regulatory and legal
representativos. These committees
oversee lhe development and
maintenance of the benefit/risk profile
of specific compounds.
STRENOTIIENING PATIENT SAPETY
Pfi:er 2007 tarpnr&v Rc.ponsibilkv Repor:
53
'e
Communicating About Safety to Key
Stakeholders
In addition to assuring besl practices internally, Pfizer is taking
steps to broaden safety awareness and contlnuously improve
safety comrnunications. These include:
• Makirig information on our medicines' labeling easier
to understand
• Developing and continuatly updating brochuras for doctors
and patients that explain the appropriate use of our
medicines
• Producing safety trainlng materiais for physicians who
conduct clinical triais
• Providing clearer safety inforniation on our product
websites to help patients understand the safety issues
invoived with lhe medicinas they are taking.
Working with Regulators
We wanl to make sure lhe medicinas we develop and produce
are approved and monitored by strong, effective and rigorou
regulatory agencies. We support a drug regulatory framework
that is well funded and effeclively managed, bolh pre- and
post-approval. We are committed to working with regulalory
agencies, governments and olher stakehoiders to address
concerns about drug safety.
Regulatory guidelmnes provide a checks and balances
system for safety reporting. We niusl notify the FDA in lhe
(iS, for exampie, of adversa fmndings within seven days of
becoming aware of an unexpected life-lhrealening safety
issue and within 15 days for a serious unexpected health risk.
Non-serious events are aggregated and reported periodically.
Meanwhiie, in the US, we support proposais that will
slrengthen the FDA's ability to conduct regular surveiliance,
identify new safety signais and hypotheses, and comrnunicale
risks to patients and heaith professionais. We also beijava
the FDA should have access to safety data from large sludy
popuiations so that risks and benefits can be evaivated
with the rnost rigorous statislical methods. And we strongly
support proposais that require niandatory risk rnanagement
plans, which we aiready include in our drug applicalion
submissions.
54
J'fueryOO7Qn-rnW RtgponsilnljtyRepi,rt
Conducting Post-Marketing Studies
Oür safety research and assessment continues throughout lhe
life of a drug because additionai risks ar benefits can become
aparenl after a medicine is approved for markeling and
raches a broader and larger patient popuialion. in this poslmarkeiing effort, Pfizer spends miiiions of doilars and employs
ataff of medical professionais around the world who work
with outside experts to evaluate potentiai concerns, using lhe
bst scientific methods at our disposai; including lechniques
tiiàt look at real-world, post-approvai patient experiences with
our medicines. We empioy new technologies to gather patient
eperiences with our medicines as quickly and accurateiy as
p!ossibie.
, increasingiy, regulators are requiring a plan to monitor
patient safety posl-approvai. As part of our commitment
t6 patients and regulators, Pfizer proactively proposes
comprehensive medicine safety pians before they become
aequiremenl. Working with regulators, we develop longlemi studies of large patient popuiations in real-world clinicai
pactice environrnenls to help further ensure patienl safety
dnce a medicina is availabie. For exampie:
Our clinicai program for Exubera, inhaied insulin, inciudes
studies evaluating ils long-term safety. The studies are
run by an independent governance structure and are
designed to further evaluate lhe effects of iong-terrn
exposure to Exubera' on the lungs. independent physician
investigators wili continue to sludy lhe effects of lhe
medicina in thousands of patients in severai countries,
in real-world settings, over the long term.
Our medicina for arthritis pain, Ceiebrex, is being
reviewed in an independenl sludy conducted by the
Cleveland Ciinic. We have invested $300 million in
lhe study, which is overseen by an independent Data
Monitoring Board, and compares cardiovascular effects
of Celebrex' against ibuprofen and naproxen in a doubieblinded, rwidomized program that wili invoive more than
20,000 patients.
STRENGTHENING PATIENT SAFETY
W
Transparency 7.
11`11
ti SCE -
fdr more
nonlhe
ãafQty dfmédicines
ihe maiketp1ace. T
took:j1rnportant €
pübhcacéàiintabihi
May 2007 of our dn
.A
31,
tliis, we
.cling
uzich In
g
•
1
Thi'ir
heips.d
•.•;r.
-
10
ted after a
as a requir
regiIatoïapproVai
or continued marke
•arüd,Tgned to pro
medicinas safety; e
ffrsf&f itá kind for a
website pro
FDA post-marketinç
IistedPfizer PMCs,
process. It is avaiial
a medica]
r
deeIbpment, aná'I
medicines;undegõ
ahd evaluation in cc
Afie worlq," said Pfi
Eeczko. "Thís kincí
tne status of our tJS .• .
keting comrniÏmonls
edicine receives
ent for approval i
ias. Thd st ias
nlitioh abdLjt lhe•
.
Tile
A
•.
FDA first posted a database of aI[ the inc
ng commtrnents on its public wBte in
zer site expands the informationavailabi
approval date
update the sie
1
ENT 8Á
jo
j4
-
-
•.
treatrnE
th3$ Ç
pr.
thev- of
d
Deterring Medicine Couriterfeiting
to Protect Patient Safety
Pharmaceuticai counterfeitíng is on Lhe risc
around Lhe giobe, potentially putting at i.i.sk
inillions of patients Mio take for granted
that Lhe prescription medicines they buy
are safe and effective. Counterfeit drugs
are dangerous by their very nature—they
are not produced uncler safe manufacturing
practices and they are not inspected by the
regulatory authorities. Many are producçd
by criminais with sophisticated equiprnent
capable of duplicating near-perfect copies of
the medicines and their packaging.
-
Because counterfeiters are frequently more concerned with
lhe appearance than the effucacy of their counlerfeits, it is
impossible for palienls to know whal ingredienls lhese fake
medicines actually contam. Some may conlain norte of lhe
active pharmaceutical ingredient, depriving palients of lhe
therapeutic benefil they expected from the product. Others
may contain lethal ingrediente, mncluding heavy metal, arsenic,
boric acid, Ieaded paint and floor polish.
To address this issue, Pfizer Iaunched a focused anticounterfeiling program in 1998 to delecl and disrupt major
counlerfeíling operations, in response to the detection of
counlerfeil Vlagra. Since their, counterfeit Pfizer medicines
have been found in at Ieast 73 counlries, with more than
25 million counlerfeit lablets seized by authorilies in the past
three years alone. In response to this growing prõblem, lhe
staif devoted to combaling counlerfeiting has increased
to 17 fuli-time coileagues, most of whom have prior Iaw
enforcemenl experience.
We have partnered with Iaw enforcement around lhe world,
developing Ieads, providing those Ieads to Iaw enforcemenl
and regulatory agencies, and then assisting in those
investigations as requested. We have siso lnvesled
56
Pfieer 2007 Crparo trprn,sih,Ti&v Reprrl
irS slate-of-lhe-art forensic facilities to support lhese efforts.
Supporting these agencies includes lhe tesling of suspected
counlerfeit products to determine their aulhenlicity, and
entering resulte in a dalabase, which nas; helped to trace
the flow of counlerfeit producls. In addition, Pfizer has
rovided 40 training programs for enforcernent and regulatory
aijlhorilies in 17 counlries.
Our partnerships with those agencies have conlributed
to the dismantling of counlerfeiting operations in more lhan
20 counlries, lncluding Belgium, Bulgarla, Canada, China,
Colombia, Costa Rica, Egypt, India, Israel, Jordan, Mexico,
lhe Netherlands, Paraguay, Peru, Poland, Catar, Russia,
Taiwan, Thailand, Turkey, Ukraine, the United Kingdom and
lhe Uniled Stales.
.
Pfizer partrrera with Iaw enlorcement agencies around lhe world
and has invested in slate-of-lhe-arl forensic facilities and Iraining programe.
lhese partnerships have helped te dismãnlle counterteitlng operatiohs
in more than 20 countnes.
STRENGTHENING PATIENT SAFETY
Using New Tocis and Techniques
In addition to investigating and prosecuting counterfeiters,
we also review the integrity 01 the suppiy chain and have
consequently introduced new high-security measures to
differentiate between genuine and counterfeit products.
In high-risk markets, such as the UK, we have changed the
way our medicines are distributed, opting to move away
from lhe Iess-secure wholesahng modei to supply directiy to
pharmacies. On rnany of our products, we have introduced
color-shifting ink logos and tamper-evident packaging as
authentication bois for pharrnacists, doctors and patienls.
e
Using Radio Frequency ID to Combat
Counterfeiting
I-low do you know lf you've purchased a counterfelt medicina? In some
cases, patients latem identified counterfeita as having a different lasle, odor,
conslslency or appeàrance. Patients may siso have a diffe,ent reaction to die
counterfeil drug.
In our latest initiative to combat pharmaceutical counterfeiting,
we have begun a pilot program to ship a medicine containing
radio frequency identification (RFID) tags to custoniers in the
United Stales.
RFID technology is being added to ali Viagra tablets
sold in the US 50 pharmacies and wholesaiers can verify
the unique eleclroníc product code, or EPC, on Viagra®
packaging. We are lhe firsl pharniaceulical company to put in
place a program of this type, focused on EPC authentication
as a means of deteriing counterfeiting.
Pfizer lias invested several million dollars to date in the
technology, which discourages counterfeiting because itis
bolh difficult and expensive to duplicate. Pharmacists and
wholesalers use specially-designed electronic scanners that
communicate lhe code over the Internet to a secure Pfuzér
website.
The companys app!ication ai RFID is not yel capabie of
"tracking and tracing" medicines lhrough lhe distribution:
system. "Track and trace" requires lhal ali parIs of the suppiy
chain invesl in compatibie technology and agreo to capture
and share informalion about producl movernent. Pfizer wili
continue to explore lhe uses of this technology—inciuding
"track and trace" in 2007 and beyond.
Pfizer's apphcalion 01 RFID does not allow for lhe
coliection of any palient information. We are also working
cooperaliveiy with standards-selting bodies, stale
governnients, the FIDA, industry groups and customers
to estabhsh policies for lhe widespread application of
RFID in lhe futuro.
STRENGTHENINO PATIENT SAFETY
Pfirer 2007 Corporuh' Eepon,ihi1ity Rvpoti
57
OPUE
Improving Safety in the Drüg
Distribution Chain
Eveiy yearÀmericans flul more than three
biHion prescriptions through reputable
pharmacies. The vast majority of these
medicines are disti'ibuted through
top-quahty wholesalers. But in the last
few years, counterfeit drugs have entered
the nation's supply chain.
ti
e
This probtem is exacert,ated by the split jurisdiction of
drug sal ety. While the US FIDA oversees the approval and
manufacture of drugs, each of the 50 states is in chaie of
licensing and inspecting the wholesalers who distribute and
dispense them. And now the Internet complicates matters
even more.
To help prevent counterfeit medicines from entering the
pharmaceutical distribution system, Pfizer has helped
shape model legislation that imposes criminal background
checks and criminal penalties for counterfeiting. It also
establishes licensing requirements for secondary wholesalers,
and requires "change of ownership" documentation if
medicines leave the traditional distribution chain.
Working with iaw enforcement agencies and many other
stakeholders since 2004, anti-counterfeiting legislation has
passed in 25 states, with the remaining 25 states either
considering or introducing similar laws. Stakeholders
working with Pfizer on this legislation include the Hcalthcare
Distribution Management Association (HDMA), the National
Association ci Chain Drug Stores (NACDS) and the National
Association cl Boards cl Pharmacy (NABP).
One change spurred by the legislation is a significant
reduction in the number of transactions (the number cl times
a medicine changes hands) in the distribution process,
from 15 to 20 transactions to three or four. And when a
medicine leaves the normal distribution chain, it would
require a "pedigree"—a document or electronic file that
would include defined data elements that established
the medicine's change cl ownership. By 2010, Pfizer expects
to implement "e-pedigrees" for ali our medicines, and
those most susceptible te counterfeiting may also carry
a unique serial number.
58
Pua, 2007 Gnrporate Rrsponsih,Iitj' Report
DS AND RECOGNITION
•received, in 2007, an Internationai
;iation of Business Communicator's
Quili Award for communication materiais
oped for the Coaiítion Against Fake
izer was chosen by CIO (Chief information
ficer) magazine to receive its CIO 100 award
2007, for using information technoiogy
rectively to create value.
lood & Drug Packaging magazine named
Ifizer's Amboise, France, manufacturing
facility a 2006 Piant of the Year for its RFID
pilot program used for \flagra' packaging.
STRENGTHENINO PATIENT SAFETY
sfi!N DSAYÍI
49E/4>
9€
_1•
Advancing good health ocjcurs not only through
the discovery, developmerit and distribution
of medicines, but also by Dreserving and creating
a healthy environment. Pfier is dedicated to
addressing environmént, IeaIth and safety
(EHS) issues rõlevant to our industry and our
stakeholders through !inn4vative policies and
programs.
2006/2007 KEY ACTIONS
.Endorsed lhe UN Global Compact's
"Caring for Clímate: The Business Leadership
Platform" in May 2007 to advance climate
change solutions.
Reduced greenhouse gas (GHG) emissions
in 2006 by about 179,400 tCO2eq from
the previous year; on track to achieve longterm goal of reducing carbon dioxide
(CO2) emissions per milhon doltars of saies
by 35 percent in 2008.
Mel Volatile Organic Compounds (VOC)
emission reduction goal twa years in advance
of our 2008 target.
lmpiemented more than 400 energy
conservatian measures in 2006 resulting in
an improvement in energy efficiency and
reduction of 69,000 metric tons of COz
emissions.
ENVrR0NMENT, HEALTH AND SAFETY
•Decreased water usage in 2006 by over
21 million cubic meters.
Achieved ISO 14001 certification for
34 facilities, OHSAS 18001 certification
for 21 facilities, and OSHA VPP status
o for three facilities.
Participated in the US EPA National
Envirorimental Performance Track at eight
facilities.
Partnered with the Alliance to Conserve
the Maya Forest to promote sustainabie
growth and conservation in the second largest
rainforest in lhe Americas.
Completed our second year using 30 percent
post-consumer content recycled paper as the
preferred paper for ali US-based operations.
Pfi.-er2007Gorporafekeapõrsibétity R,port
61
E
TO DATE WE HAVE EsTABUSaED
FIVE COMPANYWIDE GOALS:
* Climate Change To reduce carbon
dioxide emissions by 35 percent per mililon
dollars of saies by 2007 from our baseline
year 2000.
* Clean Energy To meet 35 percent of our
global electricity needs by 2010 through
"clean" energy sources
C
* Ozone Depieting Compounds (ODCs)
Te phase out the use of Class 1 ODCs
ri large heating, ventilation and air
conditioning (HVAC) and industrial process
eq u i pment
* Ozone Depletion Potential (ODP)
Te reduce our ODP from ODC releases by
the end of 2007 by 80 percent from our
2002 baseline
* Volatile Organic Compounds (V0CS)
Te reduce our releases of VOOs by
40 percent on an absolute bagis from the
baseline year of 2002 by the end of 2008
62
fizer 2007 Ck'rporai. Rapon.ihility Repert
Climate Change: Reducing Greenhouse Gases
and Using Energy Wisely
The weight of scientific evidence indicates that global climate
cFange is prirnarily caused by emissions related to burning
fossil fuels—cornmonly referred to as greenhouse gases
(GHG). Because this significant global environmental problem
wUl have potential impact on the health of millions of people,
Pflzer is not waiting for mandatory programs and has been
pràactive in reducirig its emissions.
Pfizer's Climate Change
and Energy Prograni seeks
CLI MATE
minimize the cost and
LEADERSÁÂUQ to
operational restrictions ansing
is. E,wfronrn,ni.ipyci.ctionAgancy
from a carbon-constrained
environrnent, reduce Pfizer's contribution to GHG emissions,
and assess the risk presented to Pfizer's operations from the
potential physical dhanges resulting from a warming global
climate.
Pfizer has had a company standard requiring the
conservation of energy and the reduction of GHG since 1996.
19 2002, we became a charter member of the us EPA Climate
Leaders Program, a government-industry partnership that
works with companies to develop long-term, comprehensive
climate change strategies.
As a Climate Leader, we established a companywide goal
of reducing carbon dioxide (CO2) emissions by 35 percent per
nillion doliars of saies by the end o! 2007 from the baseline
year of 2000. In 2003, we expanded our goal te include a
cFmnhitment te meet 35 percent of our eiectricity needs by
2010 through the use of clean energy technologies such as
wind power, solar power, and cogeneration.
In addition to reducing GHG emissions fiem our facihties,
Fizer is working to better understand the impact of our nearly
38,000 vehicies worldwide. In this regard, we are conducting
apiIot program in 2007 to field-test hybrid vehicles to help
increase fuel economy and reduce potential GHG emissions.
We are siso entering into a partnership with fuel providers to
sLipport clean energy projects that would offset the carbon
emissions from our fieet.
ENVIRONMENT, HEALTH AND SAFETY
Absolute GHG Ernissionsmst.,,
3.0
—
me-
Diroot
Ind iria
• Actual U AdJusted
• Actual E Adjusted
• Actual • A4ustS
From bssolin. 2000 to 2006, Pfizer reduced 0H13 enlissions by 32.7 percemt por
milton doliars cri saies. Ouring lhe sarne time peried, our absoluta CO. ernissions
decreased approximately 11 percent. TIre company ia on track to meel cur goal of
reducing CO. emissiens 35 p.rcert por nillion dcliars ef saies by the ind ei 2007
trem the baselino year 2000.
o
Data Scop.
a Pfizer calcijations of 0H13 emisalons we.a comploted referenclnç the WRl 0H13
Pretecol. using file Opersllonal Cont,ol 0TanizationaJ Boundasy method and a
materlalily threshold ol 5 percent.
b lhe data is based àn facity-specific utihty invoices for purctiaaed quanfihies ei
eleclricity, fuel ou, natural gas and aleani.
o Direct CO, omiasioria—emisalons reaultirig from flue combustion ol fossil fuels ai
our faculities te provide ates.,, for manutacturing processes, hiesting and cooling.
d indirect CO; emissions—emisaiens resulting primarily trem lhe cembustion ei
foaail tueta for purchased oiectrtcity and steam.
o Fleel orniesiens—emissions resulting from the oparation ei our global saies iloel.
En4ronmantai performance data included in this report haa bem deveioped using practices that ahgn witi, te World Resources Institute Ri) protocol for 13H13 erniasiona.
Principaily, data tuas bean atandardtzed and baaeline adjusted te more aocurateiy accounl for changes in ou, environmentai footprint duo te alt. ciosures, divestitures, and
acquisitiens. The double bar graphs lncluded for lhe envlrenmentai p&ennance data róresent lhe originei data sot reported and aubsequent baseline adjustments. Satety
performance data in tia report, which is rate-based, is tíne actual data set at lhe time ei coilection.
ENVIRONMENT. HEALTII AND SAPETY
P/i:er2007C'orporolvRe.pon,bililyRepor1
63
DPOE
Planning for Change
Effectively managing the financial implications and
opportunities associated with reducing climate impact is
another Irnportant componont of our program. We are piloting
projects to secure and preserve carbon credits (e.g., Energy
Efficiency Credits, Renowable Energy Credits) in preparation
for emissions trading programs. In 2006, we were ano of the
first companies to successfuily trade energy officiency credits
generated in the State of Connecticut.
In lhe longer temi, we are striving to identify operating risks
and business opportunities prosented by a changing global
climate, such as pianning for severo stornis and restricted
wator availability, and evaluating our response as à leader in
healthcare to changing disease pattorns. We will report on
these risks and opportunities in more dotail in future years.
O
Pfizer's Green Building Program
Pfizer owns ar operates over
70 million square foot of faciiity space
worldwide—and with it comes a significant
environmental responsibility.
We have mede a commitment to
BUILDINGS
develop environmentaily responsible
facilitios through a program called
"Green Buildings: Local Action, Global
Results." Tho goal is to promoto the best alternativos to
standard building materiais and office interiors that support
heaithior, moro oco-friondly business onvironmonts in
addition to conserving natural resources and reducing energy
consumption.
Our Green Buildings Tear is also showcasing best
practices across Pfizer to help coileaguos make inforrned
green and lifocycle cost docisions.
GREEN
Tho team has:
•
•
•
•
64
Deveioped lifecycle cost analysis tools
Created a Green Buildings evaluation process
Publiclzed caso studios
lntroducod a rocognition program.
fizer 2007trporate Rcspone,h,Iity Report
AI tie end of 2006, Pfizer obtined llpercent of its ,egy neds frorn dean
energy aources, wÍth an eatlmated 7 percent contribulion froin Mure cogenoratron.
lhe company Is on track co mel te goal of 35 perceni afta eneiy consuniption
from clean energy sources by 2010 but continues to be cha!Ienged by facility
clàsures, energy purchase considerations, capital inveslnieni decisions, and the
operatlng costa and technical Iln,itations associated with running cogeneration unite
1'
ENvIRONMENT, HEALTH AND SAFETY
Ma
Conserving Water
The availability of clean potable water is one of the rnost
important health issues of our time—and one that may be
further exacerbated in coming years by clirnate change.
Our commitment is not only to advance good health through
our medicines, but siso to advance good health in the
communities in which we operate by conserving water and
protecting water quality.
While Pfizer's use of water in its research and manufacturing
facilities is relatively small compareci to some other industries,
our responsibe management of water is an important element
of our global EHS program. Our EHS Guideline on Water
Gonservation requires facilities worldwide to:
• Review and quantify their water use
• ldentify and prioritize water conservation measures
• Develop, implement and report on water conservation
action plans and targets
• Support cornmunity efforts during drought conditions.
Although Pfizer's overali water use continues to decrease,
the consumption (net use) has remained fairly constant over
the past four years, annually at approxirnately 30 million cubic
meters. We see this as an area to improve and are working
to better understand our global water use— needs, demand,
potential impact—and will subsequently focus appropriate
water conservation measures in these areas.
OsisJteWeU.
Offsfte Water
• Actual • 4usted
• Actual U A4usted
Onalte surlace Water Not VisIble on Chart
On average. Pfizer obtaina Ita water equally from offsite and anSI, resources.
welis are the primary source onsite wlth only a few thousand galiona taken htm
onsite surface water. With plant conalderations and production changes, total water
use should continue to decine, resulting Ina relativa change to source.
ÔO:
100'.
reo
NRé
'101H
MMIR.E
Rq
40
20
W!..
1
W.
Noncontact 000ling water
Consumptlon nei use)
• Actual E Adjusted
0 Actual U Adjusted
Pfizer's total water use continues to decline, showing an overali reduction
0133 percent from 2003 to 2006.01 dia total water used in 2006, approxlmat&y
57 percent was r,turned to ha original soube subsequent to lia use as one-pesa,
nonoontact coollng water. In general, nonconlact cooling water impacta water
resource availability rninirnelly, sovas energy and reducea COa emisaions.
ENVIBONMENT, HEALTH AND SAFETY
i'fi?er2OO7C:orporoteRolonsibiüfyRepart
65
CPDE
Continuing to Reduce our Footprint:
Reducing Air and Waste Emissioris
Pfizer's commitment to reduce the environmental impact of
our operations inciudes reducing our emissions to the air,
rninimizing the waste we produce and nlaxirnizing our use
of recycled materiais. We are also committed to effectively
nianaging any waste we generate to elirninate its potentiai
impact on human heaith and the envirõnment.
Eliminating Ozone Depieting Compounds (ODCs) and
Volatile Organio Compounds (VOCs)
To help protect the Earth's ozone iayer, we are committed to
eliminating 000 releases from Pfizer operations woildwide.
Once released into the atmosphere, ODCs riso into the
stratosphere where they prornote reactions that destroy the
Earth's protective ozone layer, allowing more harmfui solar
radiation (primarily ultraviolet radiation) to reach the Earth's
surf ace. Class 1 ODCs are known to be more harmful to the
ozone iayer than Class II compounds.
Pfizer's use of Class 1 ODCs is sornewhat hrnitedprincipally found in chillers and refrigeration units (CFCs) and
in flre-suppression systems (Halons).
We met our 2005 goal to phase out the use of Class 1 ODCs
in large HVAC and industrial process equipment for specific
faciliities with the exception of those sites pending closure or
those with major production changes, which would trigger
taking Class 1 equipment out of service. Pfizer is working to
meet its 2007 goal in which we pledged to phase out the
remaining use of Class 1 ODC equipment.
Pfizer is not oniy committed to the phase-out of 000s,
the company set a public goal to reduce the ozone depletior
potential (ODP) by 80 percent at the end of 2007 from baseline
year 2002. We are pleased to report that through various
measures which include 000 substitution and an aggressive
maintenance and repair program, Pfizer has met the ODP goal
a year in advance and is poised to retain lts target.
66
Iii "ir 2007 Go'por4k Rspón.iMiitr Rcporl
Pfizer uses VOCs primarily as soivents in our manufacturing
processes. We have a long-standing strategy for reducing
loses of VOCs to the environn,ent through process
inprovements, in-line controis, and end-of-!ine devices.
To realize further reductions, Pfizer set a public goal to
further control VOO emissions by committing to reduce
oir11 relesses by 40 percent on an absoluto basis from the
baseline year o! 2002 by the end of 2008. We are pleased to
re°port the company has met its absolute goal o! a 40 percent
VPC ernission reduction, two years in advance of its target
date 2008. Efforts attributed to this achievement include an
aãgressive solvent reduction program, production changes
ahd installation of additionai thermal oxidizer units.
Reducing our Waste
We classify our waste as either special waste or non-special
w'este. Special waste is defined as waste that could adversely
impact public health or the environment if mismanaged,
and includes such waste strearns as biomedical waste, solvent
and hazardous chemical wastes, returned pharmaceutical
poducts and heavy metais. Non-special waste includes
papar, cafetaria waste, and recyclabies such as giass, metal
ahd plastic.
A]though there is a trend toward decreasing our total
waste footprint (a 24 precent reduction from 2003 to 2006),
our recycling rates remain consistent at 26 percent. Compared
with others in our industry, there is opportunity to improve.
To help drive improvement in our waste and recycling
performance, we continue to critically examine our global
program and performance data associated with waste
generation, as well as our onsite and offsite recychng programs.
Fdr example, Pfizer teams are focused on reducing solvent
Waste and promoting solvent recovery and recycling. At the
site levei, many facilities have found smart ways to reduce
total waste generated, reuse material and recycle
on- and offsite.
ENVIRONMENT. HEALTH AND SAFETY
L
Goa]:
Total Ozone Depieting Potential dcflogrtma R li eq
vs
soco
7,000
.
6.000
4.000
•.'
1
NI
'i
3.000
ii
toco
:T402
02
Froin Production
HCFC Loas
Primrny 000 Loas
• Actual E A4usted
• Actual S Aousted
• Actual U AdJusIed
AI lhe end of 2006, we reduced our ODP (tom ralasses of ODGa by 82 percent
againat our baseline year of 2002, me.tir,g ou' public goaJ one year in advance.
A 57 percent reducllon was acheved (tom 2005 to 2006, as a result of 000
substitulion, an aggresslve rnainlenanàe and repair plogram, and plant
considerations.
Non-special Waste Generated
60
Air
Pfizer achieved the VOO pubtic goal twa yeass in advance afta targetour woddwide relesses (lo air and watar) were reducad by 43 percent troo, our
baseline year 2002 102006.
pecataStLFSled
alto
200 M
uft
'30 ~i4iiiJ
em
15 0
,100 v-
20
IM
10
03
Recycled
Oflslle
1.
• Actual • Adjusted
j;
015
04
:1:!
• Actual • Adiusted
S Actual U MjuSted
[
-
03 04
J Ii IT 7T
0
06
Dispoaed
Recyoled Otfsite
Dlsposed
• Actual • Adusted
• Actual U Adjuated
• Actual E A4usted
Pfizer reduced lhe generation ol non- apaclal waste by approximately 16 percent
(tom 2003 to 2006, with a alight increasi, of 4 percant (tom 2005 to 2006 — attçibuted
loa mole compreheflaive data acope (te., data cotacted (mm mofa oflicea). Oftaite
recyctng ratas inctoased 49 percent in 2006 (mm 33 parcent In 2003.
ENVIRONMENT. HEALTH AND SAFETY
Pfizer reduced lhe generailon of speclal waate by approxlmately 27 percent trorn
2003 lo 2006 and 12 pircant (tom 2005 to 2005. lhe offaita racycling rata, however
remains conalatent over Iha paat lour yean at an sverage of 22 percenl. Sino* our
onsite racycling eftofls am aignhtioant, there is a focus on retining data collectiort of
tNs meftic to advance lhe aolvent recovezy and reoycling program further.
Pfi2vr 2007 fl'rporofe Reaponsibitih' Repori
67
Understanding the Impact of Pharmaceuticats
in the Environment
o
Pharmaceuticais and their by-products have found their way
into lhe environment by way of patient use for as long as
medicines have been used to treat disease. However, our
awareness ai this issue has increased with lhe developnient
of new anaiytical teóhnoiogies that detect minute traces
of pharniaceuticais and other organic chemicais in the
environment.
Patienl use ai prescription and over-lhe-counter
niedicalions is the most significant palhway by which trace
amounts ai pharmaceuticais enter lhe environment. Because
peopie excrete medicines that are not fuily metabolized or
absorbed by lhe body, and because sewage treatmenl planta
are generaliy nol equipped to remove these conslituents,
trace amounts of medicines are present in rivers, streams and
other surface waters. A small quantily of pharrnaceuticals may
be introduced into the environment when patients dispose
ai unused prescriplion and OTG medications in iandfffls and
sewage systems, bul disposal is not believed to be a major
pathway.
Severa] studies to date indicate that lhe presence of trace
concentralions of pharrnaceuticais in surface water and
drinking waler present no appreciabie risk to human heaith,
but scientific knowledge on the cumuiative ar long-term
impact of these trace leveis on both human heallh and aquatic
ecosystems is in the earliest stages of development.
Because Pfizer is cornmitted to adhering to principies of
responsible environmental stewardship, we are working in
dose cooperation with the scientific community, reguiatory
agencies, patient groups and NGOs to develop and advance
the body of knowiedge reiated to pharmaceuticais in the
environment and their potentiai lmpacts. For instance, Pfizer
was an aclive participanl in lhe pharmaceuticai industry's
development of lhe PhATE model, a scientific boi that can
be used to more reahsticavy estimate the concentration and
distribution of active pharmaceulicai ingrediente discharged
into US surface waters.
Pfizer aiso participates in producl take-back programs
in countries that have iniliated them. We are committed to
minimizing lhe disposai ai pharmaceuticais frorn palients and
to investigating unused medicine disposai ailernatives.
Realizing the Promise of Green Chemistry
Pfizer has been at the forefronl of developing and
rranufacluring drugs using environmentafly-friendiy Green
Chemistry (GC) praclices. By appiying GC principies,
Pfizer has improved lhe way it produces many products,
sibslàntia!ly reducing waste, saving moncy, and winning
reàognilion for ils environmentai efforts.
For exampie, Lyrica, which lreats
neuropathic pain associated with diabetes
or shingles, is being manufactured using a
lhird-generation synthesis ai lhe producl
that eiiminates five muiihon gaflons of waste
per year. Similarly, a green chemislry
GREENCHEMISTRY
modification for lhe manufacture of Vfend',
an antifungal medication, 15 years in lhe
màking, ied to a reduction of 25,000 tons of waste per year.
In arder to share knowiedge within our organization,
c'oileagues meel monthly to produce cornmon education
naleriais for chemists and engineers. The tiraI of these
materiais—a guide in lhe seleclion of environmenlaDy-friendly
saivents—has been rofled oul to chemists throughout Pfizer's
R&D organization and is subsequenlly used by chemists
and engineers in lhe manufacluring organization. Similariy,
reagenls guide has been deveioped and is expected to be
dislributed over the next few months.
Pfizer teams aiso actively coVaborate to promote lhe
principies of Green Cheniislry lhrough a number of community
dutreach activities, inciuding workshops, conferences and
6urricuia for mlddie schooi, hlgh schooi and universities.
fl
Recognized as a Green Chemistry Leader
1,
jOL
in 2002,Pfizr reçeived the US Environmentai
Pdlection gency Presidential Green Chemistry Award
for appiying Gren Chemistry lo lhe nianufacturing
ol ZoIoft. Pfizer doubied lhe producl yieid and
significantly reduced EHS impact in the process.
Pfizer's efforts lo enhance lhe EHS profiie of
Viaga were honored in 2903 'Wibhthe receipt of the
UK iriélilúle ai Chemict Enginers (iChemE MCryslal
1
1,Farabay Award for Gree'p Chernicai Technoiogy?
Pfizer reducedthiamounl of organlc process wastes
generafed from4,30d tons per year lo oniy 300 tons 41
par yearr
in Otober 2006, 1 hmE once again recagnized
Pfizer fâr Green Chemislry practièes for Lyrica'
and Vfep&. Lyrlca° won lhe top European Green
Ghemistry award—theExcetience in Green Chemistry
'and Englneering Award —and Vfend' was a finabat for
lhe Faraday Award.
-
68
Pjiccr 2007 Q'rporate Rcspon,ilility Rezw,rt
ENVIRONMENT, HEALTH AND SAFE??
7
Workplace Safety: Enhancing Strong Safety
Performance Across the Business
Attaining workplace safety across a business as diverso
as Pfizer's is a chailonge. With offices, laboratories,
manutacturing facilities, warehouses, and other working
environments, ensuring safety exceDence requires the focus
and attention 01 the entire business.
"Workplace safety" includes:
• Providing a workptace where chemical and physical
hazards are appropriately rnanaged
• Establishing a culture where ali coileagues prioritize safety
and constantiy demonstrate caro and safe behavior
• Ensuring the medical well-being of our cofleagues In the
workplace
• Making cortam that our operations are not at risk of an
accidental chemical release, firo, explosion or any other
unexpected process upset
• Safeguarding those In the workpiace from adverso
exposure to chemical hazards and
• Protecting the safety of our drivers and those who share
lhe roads with our drivers.
Pfizer is committed to ensuring lhe safety of its coiloagues
and others and promoting a safety cultura in ali our areas of
operalions.
o 1.
ENVIRONM ENT, HEALTH AND SAFETY
fi
i'fier 2007 £'rnporoteRprrnibititv Report
69
e
Reducing Injuries and Promoting
a Culture of Safety
guidelines that establish baseline performance criteria.
Fé,r example, each Pfizer facility is required to establish
ahd implement a safety managemenl system that includes
workplace risk identification and control, management and
coileague safety cornmillees, safety training, incident reporting
and invesligation systems, safety procedure implementation
apd docurnenlalion, managernenl system review, and
p:erformance expectations.
Every person who works at or visits a Pfizer site expects to
cave lhe work environrnent unharmed by their activities. This
simpló tenet is the goal of Pfizer's coileague safety program,
and underlying this goal are two priniary objectives —to
continuously improve our safety performance and to maintain
a strong safety cultura throughoul lhe company.
To further improve our safety performance, Pfizer has
developed and implemenled a comprehensive seI of safety
1ttJ*
:
MI ø1
1 õW
'h.p
Poij IÍr!ib t
0
:1.
ENVIRONMENT, HEALTH AND SAFETY
4Ç1E147\
As.
t
icR
DP'X
ases and Injuries
II
'4uryratay
a
7É
ml02
ti
K1
11
04 OS
Coe ar our prinary lnjury and Ilineas mesaures is tire Leal Tinia lnury and Iiinew
rata (LTIR), me number of iniuries and moesses Incidente par 100 colleagues) mal
result lo one ornara leal work days par 100,000 hoursworked. From 2003 to
2006, we reduced our leal tine lnjury and ilmneas rata by 21 percenl. However, trem
2005 to 2006 lhere was an approxinale decrease 01 onty 5 percent. We recognize
0w LTIR Ia abova lhe 2006 pharmaceutical lnduat.y average o! 0.47. We continue
to avstuate lhe reasona behind lhe rale and In parailel, have mnplemented several
programa In 2007 te advanca cor aalely cultura.
e
ENVIRONMKNT, HEALTH AND SAFETY
As-rother coe ei our key netries to hetp determine lhe adequacy ei our satety
programs is me Total lnJury Rale (TIR). conmonly reterred to as lhe 051-IA
recordatile rale. II is expressed as lhe nunber 0f racordable injurias ffiat occur
par 100 enployees par year. We Irack lbis information ln addition te lhe LTIR
bacause lI captures nora lntornation on injwies, enabllng us to baIlar ldentity
and locus on aram lo naad o! k'nprovsnent. Pfizer successlully reduced tis
TIR by 43 percent trem 2003 to 2006, and 20 parcent Irem 2005 te 2006, although
wa still remain above lhe 2006 phannaceutical industry avarage o! 1.04. As wilh
lhe LTIR, lheie are signiticant afforta underway to bring this rale lowa, decraaslnú
the 051-IA recordables.
ifiter 2007 €.'orporrjfe Rewon uihilify R,'pori
71
OPDE
Process Safety
Fieet Safety
The production of Pfizer's medicines requires the uso ai
complex R&D and manufacturing processes and techniques
that have certain inherent risks. To address these risks
and ensure the safety of our conimunities, coileagues and
others, Pfizer lias a niature and sophisticated process safety
prõgram designed to maintain safe and environnientaily sound
operations worldwide. This moans taking the necessary steps
to prevent the risk aí an accidentai cheniicai relesse, tire,
explosion ar any other unexpected process upset.
In addition to tuli cornp!iance with ali laws and reguIation,
we use te EHS Guideline on Process Safety to make sure
R&D and manufacturing facilities worldwide implement
programs to protect our coileaguos and conimunities from
the threat of an accident. Those operations must develap and
maintain a management system that, at a minimum, addresses
process and equipment operating practices and controis
together with site and community emergency preparedness
and responso.
Mono ai the world's loaders devoted to healthcare, our
saies fome íleet is among the largest in the world. With
aiestimated fleet of 38,000 veludos worldwide and and
11
etimated 910 milhon mitos traveled last year, driving is
rdbognized as a significant risk, and safety continues to
be a focus for the organization.
accident rate (accidents por miltion miles) is
dose to—but above—the pharmaceutical industry average.
This is not where we would like it to be and we aro
c&mmitted to doing better. Performance improvement
iritiatives include efforts to standardize practices, increase
diver safety awareness, conduct mandatory motor vehicle
record reviews, and imprave driver training. Safeguading
olir drivers and thoso who share the roads with them is
paramount to our program.
Greenng Pfizer's FIeet"—The Us fleet is piloting the 2007 Toyota camry
Hybrid this year. a vehicle alternativo that meets our safety selection criteria and
cnsiders envirorunental and economic benetits.
72
flzer 20)7Gorporote Rtspon..;hz?ityRc'p'jrt
ENVIRONMENT, HEALTU AND SAFETY
íris.
j\
\
AWAROS ANO RECOGNITION
Received our third successive Missouri
Water Environmental Association "GoId Star
Certificate" for pretreatment achievements
by our St. Louis R&D facility.
For more information
bout Pfizer's Environment,
fr
HeaIth and Safety Program,
p!ease visit www.pfizer.com/
! respõnsibility.
Honored with the National Award from
the Irish National Safety Organization to our
Ireland-based manufacturing sites.
Achieved program recertification for
the Kalamazoo, Michigan site from the
Wi!dlife Habitat Council.
Recognized by the "Labs for the
21 st Century," a coilaborative partnership
between the US EPA and US DOE, the
Ann Arbor B520 Renovation Project was
first in its class for Pfizer.
r
Earning the first
Silver-rated award in
Leadership in Energy
and Enviromental
Design in Connecticut
our Clinical Research
Unit Iocated in New Haveri was also the
first industry project to receive three (out
of four) Green Globe certifications.
ENVIRONMBNT, HEALTH AND SAFETY
J'fi:er 2007 (Joiporat Repon,ihilily R.'port
73
o)
Fb
Over the iast few years, thS business community
has been revamping its côrporate governance
procedures in response to shareholder demands
for increased transparenc,. In 1992 we became
the first major com pany td form a department
devoted exciusiveiy to co orate governance.
We have worked steadily buiid a solid
foundation of Jeadership 1 Board effectiveness
and accountabiiity to sha hoiders and ali
stakeholders. This year, ' took new actions to
buiid on that iegacy.
2006/2007 KEY. ACTIONS
The lmpact of Culture and Values
Elected Jeff Kindier as Chairman and CEO.
improvements in corporate governance alone will not
generate trust ar restore invostor confidence. Good corporate
governance must be rooted in lhe culture and values of the
organization and lhe way we do business every day. Our
coueagues understand that these values apply to everyone,
everywhere around the globo.
Our ability to be viewed as a trusted nieniber aí society
begins with lhe Pfizer Policies on Business conduct. In
addition, Pfizer Directors are required to comply wilh a cade
of Business conducl and Elhics designed specifically to cover
ali areas aí professionai conduct relaling to service on our
Board. These policies and cade, as well as athers menlioned
In this seclion, can be found at www.pfizer.com/carpgav.
Elected Constance J. Horner as Lead
Independent Director.
Strengthened the link between executive
comperisation and Pfizer's financial
performance through several actions by the
Board of Directors.
lnitiated face-to-face meetings between
institutional investors and the Board.
Adopted a new international procedure
to improve our implementation of the
US Foreign Corrupt Practices Act and local
anti-bribery laws.
GOVERNANCE & COMPLIANCE
ii!
Pfi:er 2007 Co,porub' )?ponihiIiiy J*port
75
DPOE
Ensuring Board Independence
The Board is comprised of a rnajority of independent directors,
and has elected a nonmanagement director to serve in a iead
capacity. The current Lead independent Director, Constance J.
Horner, presides at executive sessioris, functions as principal
liaison on Board-wide issues between the independent
directors and the Chairman, assures an appropriate agenda
and flow of information to the Board, and recommends lhe
retention of outside advisors and consultaria who report
directly to the Board. If requested by shareholders, the Lead
Independent Director will be available, as appropriate, for
consultation and direct communication.
The Board of Directors adopted a formal set of Director
Qualification Standards, which outline guidelines for director
independence that either meet or exceed the independence
requirements of the NewYork Stock Exchange. Strict
guidelines for Directors and their immediate families must be
followed with respect to past employment or affiliation with
Pfizer or lts independent registered public accounting firrn.
Ali of our Directors are independent, with the exception of our
Chairman, Jeff Kindier and our Chairman Erneritus, William
C. Steere, Jr.
The Board foliows a defined set of Corporate Governance
Principies and conducts an annual evaluation to assure
that the guidelines are timely, effective, and best represent
lhe Board's oversight and accountability on behalf of
shareholders. Each Board committee has a charter outlining
its responsibilities, and a checklist of oversight responsibilities
to be covered throughout lhe year.
As part of the annual nornination process for directors, the
Corporate Governance Committee reviews the qualifications
of each director, evaluatirig skilis and talents to assure a
balance of expertise in various disciplines and perspectives.
Encouraging Shareholder and
Stakeholder Participation
Pfizer's Corporate Governance Committee Charter requires
directors to "maintain an informed status on Cornpany issues
related to corporate social responsibility and the Cornpany's
participation and visibility as a global corporate citizen." To
assure effective communication, Pfizer was among the first
companies to expand communication via the Internet, $0
shareholders and ali stakeholders can contact members of the
Board directly.
Relevant communications are distributed to the Board
or Individual directors, and the Board receives a quarterly
summary of ali shareholder and stakeholder communications.
This practice serves as an early warning system, $0 the Board
can identify and respond to shareholder and stakehoider
concerns.
76
I''ieer 2,90, Qirparate Rcspon.fh,lisy Rcpert
Pfizer is the flrst company to initiate a regular meeting
between its Board and institutionai investors on governance.
The Board wilI invite representatives who evaluate governance
ractices and who vote the proxies of the company's largest
institutional investors. These representatives wiv have an
opportunity to provide comments and perspective on Pfizer's
governance policies and practices including executive
c,ompensation. They own in aggregate approximately
35 perceni of Pfizer's shares. The initial meeting is pianned
for the fali of 2007.
Pfizer has been in the forefront of corporate governance
for over two decades. it has taken the lead in the elimination
its poison pio; the declassification of the Board, 50 that
ali directors are elected at each annual meeting; the adoption
df majority voting pohcy; and expanded disclosures on
executive compensation well ahead of new SEO regulations.
The company was siso among the first to use SEC "Piam
Enghsh" rules to make disclosures more understandabie to
investors.
GOVERNANCE & COMPLIANCE
Fis
Prevenling Bribery and Corniption
The Foreign Corrupt Practices Act (FCPA), which became 1.15
iaw in 1977, conlains lhree key provisions that pertain to our
business:
Complying•with Ali Laws, Committed
to the Highest Ethical Standards
Pfizer's Board of Directors established our Corporate
Compliance Program to support the company's unyielding
con,niilmenl to high standards of legal and ethical conduct.
Our corporate ethics and compliance officer and staif provida
oversight and guidance to ensure compliance with applicable
laws, regulations and company policies, and foster a positive,
ethical work environment for ali employees.
Colleagues worldwide siso receive the Suffimary of Pfizer
Policies on Business Conduct, orthe Blue Book" as it is
known, and must sign a statement acknowledging that they
have read it and will abide by it. The Blue Book has been
translated into 45 languages.
Our commitment to operate with inlegrlty is supported
by comprehensive and coordinated processes, policies,
communications and training, which enable coileagues
to act lawfutly, meet internai expectations and promote
transparency. Our compliance program cascades frorn our
Chief Compliance Officer to Depuly Compliance Otficers and
a network 01 compliance liaisons aI each site worldwide, with
24-hour toII-free hotlines. For a detailed overview of Pfizer's
corporate governance policies, procedures, managemenl
structure and staff, please visil www.pfizer.com/corpgov.
,.
Ai, anll-brlbery provislon, which maRes it uniawfui to bribe
foreign governmenl officials direclly ar indireclly to oblain
ar relain business
• The books and records provislon, which Imposes
requiremenls on pubiic companies to maintain accurate
s and records, and to implement stringent accounting
b
and financial contrais and
,. The system of internal contrais provision, which imposes
requiremenls on public companies to impiemenl stringenl
accountíng and financial contrais.
To continually improve on our ability to adhere to ali provisions
of lhe FCPA, we implemented, in Apr'd 2007, the International
Mti-Bribery and Anti-Corruption Corporate Procedure. This
procedure estabiishes anli-bribery standards and processes
designed to support compliance with the FCPA, as weil as
local anti-bribery laws.
Pfizer siso deveioped an impiementalion piatform to
help local leams train coDeagues and adopl local procedures.
This platform is divided into 12 separale sections, which
covers such lhings as third-party Iransaclions and
consultancy agreements to gifts, hospitahly, inlernalional
meeling support and sile visits, to educational grants,
invesligalor-initiated research grants, charilabie contributions
'and poiilicai contributions.
To support compliance even furlher, lhe company has also
established lhe foliowing bois and systems:
Advancing Coileague Underslanding: Pfizer Compliance
Education Center
The legal environment is becoming more complicated with
each passing year, so we addressed the need for additionai
coileague education by creating the Pfizer Compliance
Education Center. The Center offers a series of interactive'
programs, delivered through the web and other available
means, which are customized to meet individual needs in
lhe areas of greater risk. For exampie, saies representatives
lhroughout lhe Uniled States receive annuai training in the
varlous healthcare laws and Pfizer policies which affect their
interactions with healthcare professionals These programs
cover topics of corporate compliance, as well as ethical
and legal responsibility, primarily complemenling the many
programs already in place within the organizalion. The goal
is to give coVeagues access to compliance information aI ali
times and to make sure, to lhe exlent possibie, that they are
appropriateiy grounded in lhe key compliance issues that
affect service to patienls and customers
Every year we ask Pfizer coileagues, including the
company's senior Ieadership, to lake the Pfizer integrity
Piedge and certify that they understand and are abiding by
lhe standards described in the "Blue Book". Online guidance
and 24-hour support are available to any colteagues with
questions ar concerns in their area of lhe business.
E. A compFance hotline in 70 countries
Global compliance liaisons In ali n,arkets
• Trainlng for ali coDeagues, with materiais available
in 45 languages
• Auditing procedures for ali saies and marketlng programs.
Evaivating Corporate Regulatory Compliance
To maintain and enhance lhe value of our internai audit
aclivities—and to make sure lhe company is able to identify
and evaluale any potenlial galos in lhe overali status of
Pfizer's compliance systems—lhe Legal Division broughl
four Regulatory Compliance Audil funclions logelher under
a singie umbreila and redesigned the audil process. The
new organization, called Corporate Regulatory Compliance,
identifies audil targets and deploys audil resources based on
risk analysis, and assesses systems that support compliance.
The funclionai audit groups that comprise Corporate
Regulatory Compliance are Environmenl, Health and Safety
Compliance Assurance, Corporate Quality Assurance,
Research and Developmenl Oversight, and Research Quality
Assurance.
[
COvERNANCE & COMPLIANCE
I,er 2007 ()o,porot' R,t31,on.ihilitt Report
7
1P
4:
lês
(iII
- Si
y
e
a0
*Jifli
FIt!! IWI a2=üz
Jo
e
Fui
1kTJ
-
PXiIØ tvJ$n
10
,
SEI
jo
mum
EADDFPEMDNTmRFCTOt
iÇI
1
Iip
78
fl&zw &O7Lrppmce !rsponsrtiilttyfkvorL
GW
PO
lj
$
GOVERNA
:*PLIAN C Er
am
c
DPDE
AWARDS ANO RECOGNITION
FflOMLEFTTORJÇHT:
FSTROW
•
Dennis & Ausielio, MD. çk
Michaci S. Bwn, M.D.
Dis*ngutsf$,d ebair, BiorneaSaisices,
flegntai rofeso, Unft'erftg oL1ess
So'tithw4strfl elictil Ceri
!Rated the top company in our peer group
by Governance Metrics International, a
New York-bâsed research firm that provides
corporàte governance ratings for almost 4,000
publie companies worldwide (April 2007).
M. MthonyBums
h,irman Lmentu&
ydorSysirnlhc,
SECONDROW
1
Robert N. Burt
1eIIred Chairman and CEO
MCCopor oq
W DoriCorriwell
Chaimian Md CEO,
Gronite Btoa Içat'ng Coporson
Im
»dilliarn H Gray III
Chalrtnan
MiarGroup
41,
pilo
THIRD R0W
William R. Howell
Chainnan EmeMus,
J O. enney Company n"
.InffrAvR
'-
kip
'
JwK
Windlpr
George Lorch,JL
Oh
Çeus
tro
WI!*
ÀlIp
-
FOURTH 110W
MI* 4 , P$
DanaGMeadhD
Oj,aIrmi
Cotóti
rr
r
WiIiiaib. SeerejTr2i.,.
cSj& the
o
i:
ii
•4•.
'9
!110
J
GOVERNXNCE
&
COMPLÏÁ
i,er 2007 C'o,porale Re*;'ontíbiIiIy Report
79
[Fia -
Pfizer is cornmitted to res onsible Sales and
Marketing practices that Jdress physician and
patient needs by próvidin fuli and accurate
information about our mei icines. Sales and
Marketing practices were tt the forefront of
the change proõess at Pfi rjaIiEIIIErlI[s
2007. Changes that were iplemented include
endorsing and implement g guidelines for
prescription medicine adxj rtising, committing
to and rolling out a global ode of conduct on
interactions with healthca professionais, and
reducing staff to better aiin with physician need.
We reinforce our comrnitrïfient with ongoing
training, monitoring and cêmpliance with ali
healthcare ethics, law arcÇ regLlation.
2006/2007 KEY ACTIONS
Ranked Number One overail in the US industry
in 2007 by physicians and customers for an
unprecedented 12th consecutive year.
Rolled out a code of conduct on interactions
withhealthcare professionais in 45 languages
in more than 100 countries.
SALES AND MARKETING
lmplemented guidelines for more beneficial
'prescription medicine advértising.
Launched PfizerPro website, a one-stop
resource information site for healthcare
professionais on Pfizer's products ranging
from pipeline to post-marketing studies.
J'fier2fiOiCoJporafrRceponsibiIityRdpofl
81
vE/
IFI3
Advancing a Track Record in Training
Ranking Number One for
12 Consecutive Years
For an unprecedented 1 2th consecutive year, physicians
and customers in 2007 ranked Pfizer's US saies force
Number One overaV in the industry, according te an
annual survey conducted by Verispan, a pharmaceuticai
research firm.
Pfizer's US seles force was named the best by 10
specialties and by nurse-practitioners and physicians
assistants. Categorias included quahty, faniiharity and
physician speciaity. Speciaities giving top scores to Pfizer's
fieid force inciuded Uroiogy, internai Medicine, General
Practitioners, Cardioiogy and Orthopedic Surgery. The
company was arnong the top three in 15 specialties—the best
in the industry.
This recognition reflects Pfizer's commitnent to its
customers and heaithcare providers, and to consistentiy
dehver against our goai to provide disease and product
knowiedge and support the vaiue of our current medicines
and newiy avaiiabie therapies.
t=fll iwat.
Cw
Si
'LL.I
=-
z
d'ur abihty to consistentiy rank Number One is rooted in our
ijng track record in professional deveiopment throughout
eãch seles coiieague's career. We focus our training on
poduct knowiedge, different diseases, heaithcare ethics and
law, and fieid ieader coaching. A primary objective of our
sâies force isto provide physicians with accurate medicai and
product information, inciuding ali avaiiabie data on benefits
and risks, so physicians can make more informed treatment
d'ecisions. Ali rnembers of the seles force are expected to
know the medica] foundation of diseases and treatments as
dell as the iatest research findings on Pfizer and competitors'
pkducts.
Self-study, instructor-Ied, classroom style and on-the-job
courses are offered. Speciflc heaithcare iaw compliance,
irciuding effective documentation, is a major part of the
tiaining for every seles colieague and seles manager around
tle world at Pfizer. Colieagues are required to take an onhne
training course and pass a test on ethics and compliance
every year.
1
1ooking for new ways to interact with US
Falthcare professionais, Pfizer set out to totalty
revarnp its web-based approach for healthcare
providers. Pfizer for Professionals (PfizerPro),
Pfizer's new one-stop shop for heaithcare
9rofessionals, is an innovative online resource
tiat not only communicates to providers about
inline products and patient education but also
about the company's pipeline, post-marketirig
studies and more.
Www.pfizerpro.com/content/home.jsp
82
Jker 2007 Cr.rp.,ratc tksp,,n,ihilitv Jtep'irl
SALES AND MAREETINO
P1,
lmplementing a Global Marketing
Code of Conduct
In 2006 we rolled out the Pfizer Global Policy on Interactions
with Healthcare Prol essionais throughout Pfizer. This poiicy
incorporates comrnon legal and ethical standards from many
of Pfizer's major markets, inciuding the US and Europe,
and applies them to every country in which we operate.
The pohcy, written in 45 languages, provides specific
guidelines on appropriate behavior for Pfizer coHeagues who
have direct contact with physioians and other healthcare
.professionals. It covers such topics as the guidelines for
Pfizer-hosted educationai or prornotional meetings, medical
communications, marketing activities, confidentiality of patient
data, and use of giveaway items.
Seles professionais, in particular, are required to complete
and pass a self-study course oh the poiicy. In Sales, the pohcy
was roiled out through a process coordinated by the Seles
Leadership and Compliance Senior Seles Management which
was responsibie for completion of the training and monitoring.
Restructuring the Sales Force
In 2006, we reduced the size of our seles torce in the (iS by
20 percent, and management by up to 30 percent, with similar
cuts in Europe and other parts of the world. The restructuring
was undertaken to better aiign Pfizer with physician needs
and other changes in the marketplace—changing products
and services, and changing stakehoider expectations-to.
become a better partner with heaithcare professionais.
The saies force was reorganized into four operating units
focused on products, with a fifth focused on customers.
The saies force became more entrepreneudal; increased
its speed of decision-making in the fieid, and coordinated
better with the Pfizer leadership team. As a result, physicians
said they feit they had been heard and that their patients
could be better served. in addition, we improved our internei
efficiencies.
SALES AND MARKETING
E
Pfi:er 2ÜO7Yn,porue Rta;'on,tbiütyR'port
83
1
(,
1,7M
W
é
M
1
LJNITEDSTATES
Deflvering Beneficial Prescription Medicina Advertisin
impienienting New Prescdptioi Med;cine Consumar
We beijava that responsible consumar advertising educates
Advertising Guidelines
patients and is a critical conversation starter that results
in life-changing diagnosis and troa rnent decislons. Dataj 4
we comrnitted to change some of our consumar
dá
supports that consumers value the information pro'ded by
avertislÁgprctices in the liS by:
advertising that alerts them about potential health conditions
• Educating physicians about our new medicinas for
and available treatment options. Not ali advertising is relevant
a mirjimum of at ieast six rnonths prior to beginning
to ali people,but It is of critical interest to those who suffer or
consumer television and print advertising
are at risk for an advertised condition. lmportantly, advertising
• Subniltting ali new television ads to the FOA for comment
motivates patients to seek additional inforniation and to taik
in ávaAce of airing
to their doctors, and it is only through consultation with a ,
• lncreasing advertisirig efforts behind disease awareness
physician that a treatment can be evaluated and prescribedJ
and Pfizer Helpful Answers to provido more information
We recognize that this type of communication reaches a
on access to medicina (see pagas 39, 48). i
broad audience and thus requires a responsible approach.
Jr
To continuously improve the usefulness of this form of
communication, we embarked on a serias of changes over
'in 2007 wemade the foliowing changes:
1
the past two years to make sura our prescription medicine
i
Lipitor advertising now reinforces the role of alternativa
1— 1 1
advertising encourages patients to have appropriate
treatments for high cholesterol, such as exercise and diet,
conversations with their doctors, heips consumers understand
and advises patients that physicians rnay recornmend other
ithe risks and benefits of prescription medicines, and motivates
l treatment options
peopletoovercomesigni
•
.
Pnnt campa gnsfor Lyr ca', Lpitors, Zyrtec' and others
include eay-to-read facts aboutsks, and ali print ads
include Pfiíer Helpful .Answers inforrnation
OuFdvàtising now prornotés disease awareness,
nciuding awareríess of heart health, overactive bladder and
chronic obstructi,e puimonary disease (COPO)
• Ournewest Celebrex commercial, pèeviewed by the FDA,
01
provides a broad context of the risk-benefit profiies of
URROU
0910
various prescription pain rnedications.
r
.
1
-
EUROPE
1
)
The AC (Allgnjng O stomer Exeelience) P%qgram in Euçppe, is Pfizerinitiativtdestgned tá alfgn Pfizer Europe to
9
IV
.-
m
i~tíw
.piqI, 4Iii' 11 i:.1jjj$jj
• 8empowenrig physicians-and patients se costs apot the oniy fac(or in défermlningjie9jth doais
the burden oldisease.
-1
4
-
SE
Through AOL we )lave reailocated jesourcs in Éurope so wà can jnteract more flexibly with a range ai ata ehoiders
WhaErovide direct eedbacilthat heps,N suddres th& concer siand interests. Patidht g?oups, the pubiic at iare,payers,
governrnent and haltiofficiais and ph siõians' ari ti rses' group are'all increasrngjy
i organ zed to advise us in
thiscapacity
.
.
-
WW
i
-
84
Jj#r2QoO?Ç'nprat,Re.ypot4qjüiRq,a
1
-
iIr,
w. 11
rk
ffiN
4
SALES ANO MARKETING
.
1.
ÁRINI
41
-
1 no
\;4~
%o
We believe that effective pthblic policies can
help create an environrnenf in which innovative
medicines are more effectitiely brought to
market, and natients are aMe to receive the
medicines they need. For 1 s reason, we believe
it's our responsibility to en ge in public policy
discussions. This includes sues that affect
regulatory guidelines, mec me safety, and a
range of business practice around the world.
We engage in ways that ar transparent and
consistent with our value.sj
2006/2007 KEV ACTIONS
Worked with the Health Coverage Coalition for
the Uninsured to develop recommendations
to address the uninsured in the US healthcare
system.
ER
Worked around the world to strengthen
healthcare policies, increase patient access
to care and protect against counterfeit
medicines.
Requested US trade associations to disclose
any portion of our dues used for political
purposes.
86
J'fizer 2007 Gorp,rutq Rrspo,,,íhility Rcpor
Éxpanded the Pfizer Europe Advisory Council,
Vvhich includes a range of stakeholders who
advise Pfizer on healthcare issues.
Supported proposed legislation with the
çampaign for Smokefree Air to help make
Michigan the 30th US state to protect citizens
from exposure to secondhand smoke.
Supported increased access to medicines
and safety monitoring in the US through policy
ádvocacy.
PUBLIC POLICY
Contributing to the
Political Debate
Publie policies—on such issues as access
to medicine, Lhe futuro of Medicare, iliegal
importation and inteilectual pi.operty
proteciions—have enormous impact ali
our ability to ineet patient need.s and
create shareholder value. For this reason
we actively participate in public policy
discussions, sharing our knowledge about
healthcare, global public health, dísease
prevention and health education, and
contributing ideas about improving efficiency
and effectiveness.
Public Policy in the United States
Different parts of the world face different public policy issues
based on their healthcare systems, mailets and economic
• strengths.
In the US, for exanipie, we participate in one of the most
•
heavily regulated industries, and comply with ali federal
and state lobbying registration and disclosure laws. We
demonstrate transparency by publicly disclosing on our
website our corporate political contributions and employee
Political Action Committee contributions. In addition, we have
agreed to disciose any portion of our trade association dues
that are used for political purposes.
To access Pfizer's Political Action Report, visit www.pfizer.
comlresponsibiiity/lobbying_and_political_contributions.jsp.
We strongly believe in contributing to
public policy activities in ways that are
appropriate, ethical and trai.isparent.
This approach is applied giobaily, wherever
we engage with governrnents, private ar
public institutions.
PUBLIC POLICY
Pfi:er 2007 (Ja,poro!e Rej'onjhliSy Report
87
vE/
Supporting Healtti Reform
Pfizer is part of a larger healthcare system in the US. We ara
working along with other companies to heip make policy
reforme that strengthen the current system, Improve quaiity
and stabilize esoalating healthcare costs. Here are some
primary exemplos:
FDA Revitalization Act (FDARA)
This legislation is an expansion of the reauthorization of the
Prescription Drug User Fee Act (PDUFA), a Iaw requiring
lhe lndustry to pay fees tolhe FDA in return for predictable
regulatory review limes and processes. With this special
funding, the FDA has been able to double its review staif and
bring median review times for new drug applications down by
about haif—to aliow for a 10-rnonth review cycle (six rnonths
for priority applications). Usar fees were first estabiished in
1992, then re-enacted everyfive years.
User fees make up 42.5 percent of the FDA's Center
for Drug Evaluation and Research budget—with Congress
appropriating $298 million and lhe VOA collecting $220 million
from industry. The user fee system has been criticized for two
reasons: the potential or perceived impact of user fees on the
FDA's impartiality, and the fact that the fees are earmarked for
new drug apphcation reviews rather than for general activities
ar post-marketing safety work. FOARA, however, siso
includes provisions for drug safety legislation and pediatrics,
specifically lhe Best Pharmaceuticals for Children Act and the
Pediatria Research Improvement Act.
Based on recent negotiations with lhe pharniaceutical
industry, Congress will increase usar fees for new drug
applications, to keep drug review largels at 10 months. The
FDA can use a substantial part of the fees for post-marketing
drug safety and pharmacovigiiance efforts, as well as research
on new drug safety tools. This is the most comprehensive
reform 01 the FDA in the past decade and Pfizer is actively
supportive of this important legislation.
Medicara
In December 2003, the US Congress passed, and President
George W. Bush signed into iaw, the Medicare Modernization
Act (MMA) which, for lhe first time, provided prescription
drug coverage for American seniors and peopie with
disabilities, called Medicam Part D. Pfizer appiauds the
Federal government for recognizing that a heaithier society is
achievabie by addressing disease and sickness prevention.
Medicare Part D is a significant step towards ensuring that
lhe country's senior and disabled patient populalions have
affordabie access tolhe medicinas they need to hve longer
healthy rather than tive longer sick. Without medicine, they pay
more for hospitahzations and end-stage disease treatment.
88
J'fi4er 2007 Co'porate Rpon,iluIitv Report
is considerable evidence that lhe program is working
even better than initially expected, by giving Medicare
recipients access to innovative medications at reasonable
phces. Recent estimates show that beneficiarias will sáve an
a'verage aI $1200 a year, whiie millions of iow-income and
s&iousiy iii patients will each save thousands more. One of
the reasons for this success is competition. The different
pians offered by different insurance companies compete on
prerniums and on access to the best, most-commoniy-used
medicines.
With this successful impiemenlation, Pfizer continues to
suppart the roU-oul of lhe Part O benefil. Over 90 percent of
America's senior cilizens and younger peaple with disabilities
ndw have prescription drug coverage due tolhe new Medicare
pescription drug program. We partner with both government
a'nd community groups to provide education and assistance
and heip improve access to medicines for seniors.
Drug importation
Prescription drug importation occurs when foreign pharmacies
and traders ship medicines, which may or may not be
aproved for use in other countries, into lhe US for sele to
4 nerican consumers. Over the past severai years, there have
been a number of legislative proposais to amend current
l'ealth and safety laws so distributors can import prescription
V!dic1nes from other countries Into the US, ar aUow
individuais to purchase medications directiy from phannacies
in other countries. Aithough importation may sound appealing,
itpresents real risks to patients and there is no guarantee that
the imported phamiaceuticals would be safe. Federal law an
pSscription drug imports reI lects welI-documented concerns
aboul the safety of imporbed medicines, and the risk that many
of these drugs will be unapproved, adulterated, conlaminated,
ar counterfeil (see page 56 for more on counterfeit medicines).
Many drugs that consumers befleve are coming from
Canadian pharmacies actuaily come from other countries,
where lhe supply chain may not be secure. lI lhe US
government were to aUow iarge-scale, systematic importation,
several federal agencies believe that safety problems would
only get worse.
lmpórtation not only creales safety risks, II does so
without any guarantee of meaningful off-setting cost savings.
Italso lhreatens innovation and lhe future deveiopment of
dew medicines. Because foreign governments mandale
cscounled drug prices, the US market bears more of lhe
costs of biomedical research. If markets are unwilling to pay
f?r innovation, the flow aI new, innovative medicines will
be affected. To heip solve this problem, Pfizer is working
hard to find long-term, sustainable solutions to irnprove lhe
affordabihty of medicines in lhe US without requiring patients
lo incur safety risks from importation.
o
1
PUBLIc POLIOY
O
Supporting Legislation for Smokefree Air
Pfizer supports legisiation to eliminate the hazards 01
secondhand smoke from lhe workplace, and other public
places. We joined the Campaign for Smokefree Air (CSA),
a grassroots coalition, to advance lhis cause for prevention
and wellness.
Our partnership with the CSA aims to help make Michigan
the 3O' state to protect its workers from deadly exposure
to secondhand smoke. As a member of the CSA's Steering
Commiltee, we are aso the first and only pharmaceutical
company actively participating in tinis effort.
Secondhand smoke causes severe health repercussions.
Michigan absorbs approximately $3.4 billion a year in related
productivity losses and spends. through Medicaid, 11.04
billion to cover heaith costs associated with smoking. These
are some of lhe reasons why 63 percent of Michigan's
registered voters support a new state Iaw to ensure srnokefree
workplaces, restaurants and bars. With such support, CSA
is aggresslvely pushlng for the passage of Senate BilIs 109
and 110 and House BilI 4163 to secure these smokefree
environments.
Partners in the 60-member CSA, along with Pfizer, Include
lhe American Cancer Sociely, the Nnerican Heart Association,
the Arnerican Lung Association of Michigan, lhe Michigan
Stale Medical Sociely, lhe Michigan Health and Hospital
Association, among other medical provider organizations and
health advocacy groups.
' Jldng toExpand Health Insu/ance Goverage The probiàt of the uninsured plagues the American
healthcare sysfem, with ppiodrnateiy 47 milllon -.
•M1ericnlaçking heeIhcovwage. Progrese on
the issué, however, has'been stymied,by lhe vastly
d,fferent approaches of vjrioàs stakeholders. But now
lhere is a changé.
'
F6r lhe past
years, Pfizer has participate in a
d'verse coalltion of 16 groupa irciudihg heãltháara
providers, Irada asociationsand activist groupa
determined lo rethink lhe issue and lay out a path for progreas. Together the gsoups devaloped consensus.
reconimendatíons for coveririg a significant number
o! thõ uninsured and formed lhe Heallh Coverage
Coalition for the Unlrisured (HCCIJ) tb rnoe lhese
98
reconjijiendations lorward. On January 18, 2007, lhe
ion released sri agreement which alI the partias
endorsed. e HCCU agreed to certain key principies:
Making coverage vàilabi&tc those who could
ReI jdng\ipon incentives and voiuntary approaches
Buildln'gon t)e'employer-based system and.,':
not weakenlng IncentIves for employers lo provlde
coverage
4 Using a comblnation o! pãbiic and
approaches to expand covejiTgè - -.
5 Recognizing lhe budgõt challsngè facing most
states and .
6 Recognizing the imoorta"of consumar outreach
td education on health óoverage options.
f
R
TIie HCCU's recommii,àations advooMe coverage
expansion for lhe uninsured Qccurring iri two phases.
In Phasé 1, lhe focus would be on children. In Phase
li, Die key recommendatíons are teliminate farnily -.
status as an éligibility ruirement, and to give
states an option to expard coverage lo alI adulta
w,th Incomes u
l
he fed l poveesrteynle eI. In bcoet ho
h es,lhe ranodnemendauoenras repr
t av balan
f
£ ubc-ad112r
opbons.
We are also working with the Coalition to Advence
Heaith Retorm.
PUBLIC POL1CY
Pfi:er 2007 Corpo,&e Respon.U,iüty Repon
89
E
.1
EA
Strengthening Inteilectual Property Protection
We believe that appropriate incentives for biornedicai
innovation fuel the discovery and development of new cures
and treatments. That's what the track record shows.
The research-based pharmaceutical industry depends
oi patent rights because they provide needed Incentives
to make expensive, high-risk investnients in biomedical
discovery and development. This is where new medicines
come from. It costs on average about $800 tnillidn to discover,
develop and manufacture one approved medicine bef ore it
enters the market, with no guarantee of success. Patents
guarantee a lirnited period of exclusive marketing rights for
approved medicines in order to earn a fair return on such a
largo investment. In short, patent protection is the only proven
systen, of bringing new medicines to soclety in a timely
manner.
This is why we are helping emerging markets strengthen
their regulatory systems, including inteliectual property rights
protection. We believe that strong patent laws, when balanced
with reasonable times of exclusive marketing rights, lead to
more medicines and, ultimately, less disease.
There is a view that patent rights limit access to medicines
because they prohibit the unauthorized manufacture and
saie of a patented medicine. We disagree that patents are a
primary cause of hmited access to medicines. The fact is,
90 percent of the World Flealth Organization's List of Essential
Medicines are no longer patented and stili do not reach
the people who need them. Further, these medicines were
criginally discovered and developed by private industry.
As noted in this report, we're working actively to form publicprivate partnerships to improve access to medicines around
the world.
90
flar 2007 Qwporate ItcaponsiMitv Repor!
Right to Privacy for Patient Information and Physicians
The right to privacy is fundamental, but it's being challenged
as our society becomes more reliant on electronic forms of
cèmmunication and information technology.
That's why electronic prescribing, when physicians use
electronic rnethods to send prescriptions to pharmacies and
hospitais, Is being scrutinized so carefully. We believe that
electronic prescribing, cone with proper safeguards, is an
inHcreasingiy valuable and important tooi for protecting patient
s&fety, enhancing patient treatment and improving overall
efficiency. We believe the following guidelines should apply:
• Patient and physician needs should drive the deslgn of
e-prescribing tools that willl be used at the point of caro.
A market-driven approach will best assure the adoption of
• systems aligned with the provision of quabty care.
• E-prescribing should be provlded through a neutral and
open piatforrn and conform to prevailing quality and
technicai standards. it should not be designed te advance
the commercial interest of any particular participant to the
potential detrinient of patient care.
Patlent privacy must be protected.
•, Ali messages transmitted to physicians and their staffs
through e-presiibing systems must be sourced, accurate,
and fact-based.
E-prescribing technologles should support greater access
to data for better clinicai decision-making, including alerts
1 to adverse events and access to formulary information.
Such information should not be selectively or competitiveiy
pushed to the physician, and the distribution of such
information must not diminish the patient's right to appeai.
• E-prescribing must not subvert the protections offered to
patients in other areas of Medicare.
PUBLIC POLIcY
Public PoIicy in Europe
Healthy Ageing
Pfizer Europe has established a 'Healthy Ageing" Platforni to
guide "partnering and comrnunicating differently" that aligns
with the public's acknowledged desire for staying well. Active
work with the EU Commission on a Resolution of "Active and
Healthy Ageing" resulted In a partnership toward Healthcare
Systems Reform programs. For example:
New Approaches to Healthcare
In Europe we are changing how we embed the neecis of our
stakeholders into the value Pfizer provides them—not only
through medical and scientific value, but by siso integrating
social value.
In practical terrns, we are achieving this by changing how
we communicate and partner with our stakehoiders, which,
in turn, affects how we operate. We call this "customer
facing." For a description of how we implement this in Saies
and Marketing through ACE (Aligning Custonier Excollence),
please soe page 84.
Our transformation is supported by hiring a far more
diverso colleague base that comes from the array of social
interests in healthcare: patients, pharrnacists, payers,
government decision-makers, policyn,akers, economista
and NOOs. By allocating our resources to hiring people with
these backgrounds, we are embedding the thinking, cuiture
and needs of the groups from which they come. Below, and
elsewhere in this report, are some results of our Stakehold&
Model approach (see pages 10-11):
• rhe Luxembourg Sustainable Health Financing StudiesTho Cox Report (named for former President of lhe
EU Parilament, Pat Cox)—have been received by lhe EU
Health Commission
Tho Alliance for Health and The Future works in lhe EU
to facilitate rei orms on Health as an lnvestment to keep
peopie as productive mombõrs of society.
1
A Pfizer Germany coileague was awarded
the Patient Rights Award 2007 by PMI,
publisher of several pharmaceutical
periodicais, for outstanding work with patient
groups to strengthen patient participation
and patients' rights.
Pfizer Europe Advisory Council
Pfizer Europe expanded the Europe Advisory Council, which
meets regularly with our management on conimercial goals.
To better serve patients, we included diverse social and
economic interests, in addition to the medical and scientific
lnterests, associated with particular medicines. For example,
for Champix, our smoking cessation medicine, we included
diverse experts from international organizations, Ministries
of Health, patients, tradé unions and others, in addition
to medical and scientific experts. Our understanding of
how Champlx would serve patients better was enhanced,
shilting us from an insular approach to a stakeholder-focused
approach.
PU DLI C P0 LI CY
AWARDS AND RECOGNITION
E
l'firvr 2007 ( opporu fr Reepr,nibiti!y Rpor
91
E
F?3.
Public Policy Around the World
We are working hard to address public policy chalienges
and opportunities around the world. In partnering with
governments, communities and many other stakeholders
we're cornmitted to working towards policies and prograrns
that will help to bring more medicinas to more patients
more quickly.
92
Pfiar 9007 Üorporcte Respnnvh.liLv Report
PUBLIC POLICY
"bEl
F13
DPOE
PUBLIC POLICY
2007 Cwporate Rospon.nbihty Report
93
PfIzer!sLApproacl$o Sustaii
;e Study in China
aw.jt 1
In our view,"sustainability" in the
b pharmaceütical sector cj6esbeyond:aíuE
Yt1 r
and enviionmental renéÂfáI. AtPfiz
"How can we help meet thehealth
of people today, withàutôohipràrh
ability tomeet the healtKneeds of
t1r
tomorrow9"
b
We beijava the most workable answer lias fri our dtYI
approach:
• Sustainabie enterprise—investing in the büsineés
• Sustainabie development—investing In the cõrnmunity
Sustainabie enterprise includes estabiishinq research
partnership agreements local manufacturing capabditles and
R&D centers to discover and develop new m&diciti.
It aiso means supporting inteliectual property háhis só we ãnd
other innovators can help meet the health needs of peopie
tornorrow
Sustainable development includes working With local
government to understand their health priorities a,d then ii
forming partnerships to met those needs by rmproving
disease awareness, providing needed treaf
fZid biiilding
..heaithcarecapacity.
Pfizer China is a good exarnple o how our approach to
sustainability works. After.entering the rnarket in 1984, We no
ee
have a presence in more than 50 cities with2,100 employsr
We have introduced over 40 medicinas to China and have
four state-of the art manufactunng facilities inDaiian Suzhouzi
and Wuxi. in 2005 we opened an R&D cantar lnShanghal,
and today we have public heaith programs ín six disease
areas ranging from 1-11V/AIOS to hypertension. In 2006, Pfizer
China was ranked byFottes magazine as one of the niost
£}»iT
4
"The dose partnership between
Pfizer and our City has truly blossomed
in he past deCade, Over this period,
of how Pfizer China exemplifies
oür partnership has Contributed both
to Shanghás de')eIoment and to the
health of our Citizens. Looking ahead,
we see our association growing
strongeç and deeper."
ZI-JENG, MAVOR OF SHANGHAI
4;
1
94
P/icr 2cO? C,rporaAc Rn.porictbiWi_v ftçporf
1
--
C POLIGY
0,12lá,PM
m1
Sustainable Development
Irivesting in the Community
:
1.
Sustainable Enterprise
:
..Investinq:in
theBusrness
j:
••
• JLí•
À,
> :; iot .
E•1
HIV/AiDs PfizeçÇhina has responded to the AIDS epidemic
Manutacturing Pfizer Suzhouour arnniai heaíth products
inChina bycommittiíT itself to a siate of H1V/AIDS initiatives,
facihty, is expariding to become an advanced large scale
from training heaithcare professionais tojçomoting ncreased
internationai manufactunng and distributuon centeRit empioys
!I awareness and education about HiV/AIDS prevention and j
advanced rnanufacturing equipment and testing techriotogy
treatnient prograíns Pfizer also becarne the first muitinational
to produce a vanety of vetennary and agricuitural antubiotic
pharmaceutical company in China te issue an H1V/AIOS
formuiationsWhen complete manufacturing capacity will
i~lkiplace Policy that ensures a work environment free from
increase from 800 to 7 000 tons, and producte manufactured
j harassment and discrimination for employees living with HIV/
in Suzhou will be exported t55 countried around the world
LJL}AlS
AI
r
crN h
t
T
Research & Deveiopment in 2005 Pfizer opened a state-of
'"qpF
the-art Research and Development Center in Shanghai The
1Hypertension in November 2006 Pfizer began working with
1 Shanghai s Center for Disease Prevention and Control to help
Center provides drug developrnent support capabilities and
biometnc expertise to China and the Asian region The Center
manage and reverse hypertension and related cardiovascular
supports study design data management and statistical
nsk factors Cardiovascular disease is the leading cause of
f tI
analysis for global clinical tnals while also training local
?jideath rand disease burden in urban centers in China The
Pfizer coileagues in internationally recognized Good Clinical
Çfgoal isto fuily utilize the resources and infrastructure of local
Practice standards
hospitais to irriprove diagnosis and disease management
as well as proÃdeducatin and traininá to improve skillat
Supply Chain Responsibihty Pfizer sources a number
selected hospitais
E
of raw materiais and active pharniaceuticai ingredients
1
r
from suppliers in Chinad this business is growing
Stress Management In March 2006 Pfizer China and Song
To assure responsibie practices with regard to safety and
Jiang University Town launched a joint effort called the Mental
the environment we have an active suppher review program11
? Heaith and &&es Managernent Traning Project The project
In 2006 reviews were cone at 22 suppiier facilities in China
1 is designed to rase awareness about mental disorders among
Reviews involve onsite visits by Pfizer environmental and
university faculty so they can heip recognize and prevent
safety experts typically for two days In addition Pfizer has
such disordera among their students The project also offers
provided training and coaching to key supphers regarding
free psychological counseling to the tens of thousands of
environment and safety management Effortsincluded
students at the eight coileges within the university
a five-day training program in November 2006 given tol q
30 managers and engineers from six suppliers on industnal 9 E
Smoking Cessation Chin&with approximately 350 niillion
hygiene and process safety.
smokers, rdudes and consumes more cigarettes than any
other country in the world Pfizer China hopes to chalienge
Anti-Counterfeiting - in March 2007 Pfizer iaunched a new
this trend by conducting a series of community awareness
anti-counterfeiting color changing logo for1 viagra® in Chinai
and education programs including a three year smoking
jEEçE
on Consumer Rights Protection Day with planá to repiac
cessation initiative at Peking University called Staying Away
the current laser anti counterfeiting label globaily This effortgfi [froY Tobadco fora Healthy Life
reflects Pfizer 's commitment to patient safety through the4
application of new technoiogies
Cataracts Cataracts are one of the leading causes of
bhndness in China Pfizer provides support to Lifeline Express
E
Working with Government In October 2006 the Mayor of
a unique traveiing eye hospital train that has provided more
Shanghai Han Zheng reaffirmed the city s strong partn&rship
than 60,000 free operations to cataract patients in frontier
with Pfizer during the first Pfizer Board of Directors meetuigiP
and povïrty stricken areas In 2003 Pfizer China donated
heid in Shanghai "The dose partnership between Pfizer and
neariy 1 100 artificial lenses to heip more than 1,300 cataract
our city has truly blossomed in the past decade the Major
patients r`e g'en their sight Pfizer China also heiped Lifeline
said Over this penod our partnership has contributed both
Express host aoadeniic exchanges in rural China to train local
to Shanghai $ development and to the heaith of our citizens
ophthalniologists and to bring local doctors to Hong Kong
Looking ahead we see our association growing stronger and
and Guangdong for formal training
deeper
1jb1Ib
j
1 III
PUBLIC POLICY
I1L½r007Ga,or41eÉçion9íhftilvR.pci-t
95
Fia
1
r
OPDE
Making Pfizer a great plaqe to work is a key
strategic priority in 2007. Engaged emplõyees
are essential: to discoverinp and developing
new medicines, and servipg the needs of ali
our stakehoiders. They are essential to our
success. That's why w&r4 developing a company
culture that drives busineSs performance and
e innovation through a broaJ diversity of talent and
views—where colleagues 6uild their careers, are
empowered to make deci ons, have an impact,
and are rewarded for achi ving business results.
hi
200612007 KEY ACTIONS
Managed significant organizational changes
with transparency and emphasis on affected
coileagues.
.e
Expanded CEO and senior.management
engagement with coileagues, including a
global CEO-Colleague Advisory Committee
to improve the flow of ideas.
Developed a strategic plan endorsed
by the Board of Directors to expand Pfizer's
global diversity and inclusion.
Eliminated dozens of management
committeesto push decision-making down
into the organization.
Expanded Pfizer's employee healthimprovement program, which is based
on prevention, early diagnosis and
timely treatment.
EMPLOYE ES
1
l'firer
, 2007 Gorpnrafe Rc*pon,ibitity R.pofl
97
'4
'mnE/4
w
Devetoping Talent and Employee Engagement
Meaningfui work, an inclusive environment and effective
leadership—these are some of the primary drivers of
..colleague engagement," the commitment of eniployees to
give their best efforts, stay with Pfizer and say they are proud
to do se.
We assessed colleague engagement within certain
divisions in 2006 and ídentífied a number of key chalienges
and opportunities.
These included the need for:
• Regular, clear and more direct communications during
a time of change
• Support from managers through change
• Focus on retaining and developing commltted employees
• Performance-based incentives and career development.
riá
We addressed some of these chalienges quickly with new
solutions. Other challenges we addressed by building on
established programs as described throughout this section.
In Iate 2007, we will begin an annual ali-colleague survey of
colleague engagement using the Gallup survey to assess our
progress going forward,
Managing Pfizer's Transformation
Pfizer currently has 89,000 employees worldwide; In Iate
2006 and early 2007, the company cornrnitted to reducing
its workforce by approximately 10 percent of Pfizer's
worldwide employee base in fine with evolving changes in
the marketplace.
Planning for Pfizer's transformation began in early 2005
with teams of colleagues in each division analyzing issues
and priorities. As the pace increased in 2006 the chailenges
of leading change were met through a robust set of strategies
including senior-level communications, colleague focus
groups, and providing managers and colleagues; with useful
toois to help them deal with the unprecedented pace of
change across the company. During this period, we launched
several initiatives focused on strengthening supervisors'
skills in leading change, colleague retention and building
colleague resilience.
98
J'fivir 2007 G;rpt,rate &spon*ihiFity Reptrt
Leadership Education and Development
Fizer invests in the developrnent of programs to educate
and prepare those who supervise others, ensuring a pipeline
di "ready now" leaders. The company providas core,
coi-nmon and critical leadership development resources for
Pizer leaders with a focus on behaviors such as sustaining
Arformance, creating an inclusive environment, encouraging
oMpen discussion and debate, managing change, developing
eople, and aligning across Pfizer. Prorams are based on a
three-pronged development strategy that includes coaching,
or-the-job experiences, and varlous leaming opportunities.
Bátween 2004 and 2006, 2,290 managers across the business
graduated from these programs.
Olvislonal and Location Education and Training
Most of the education and training at Pfizer is conducted
a the business levei, where specific quality, technical and
research skills are required. For example, our global R&D
orànizatioh condúcted more than 50,000 instructor-led
fraining classes and nearly 200,000 seif-study events during
2006.
Another example is Pfizer's partnership with the University
of Michigan, where 160 high-potential R&D colleagues
received executive leadership education in 2006. This program
complernented a broad curriculum of personal, manager and
EM PL OY E ES
aM4try
ívk1
ffiá
r
rijM
clusion
Striving for Enterpnse
1
4
GHML
Ji!h
1
sProcesses
Diversity and Inclusion is anather key pilíar c
engagement Over the past few years mie h
nipraved progress in attracting diverse taler
campany—particulariy at entry leveis acroas
In additian to attracting diversa colleagues
is being focused on their deelpment and
talented cofleágues ádvanõe to sinior leels
Pfizer mindset" ar success profile is being
This rneans certain jabs dan t have ta be do
have always dane thern ir the past We are
af environment in which ali types af calleagL
and their ideas and contributions are valued
In 2006 Pfizer's Baard ai Director; ando;
caniprehensive strategic pian ta expand the
culture ai diversity and inclusion gIabaiiyTh
designed to attraot, retain and dévelóp the ti
talent in the world by creatinâ andhürtüri,i
that respects diversity and where ali employ
respected and engaged The pIar revolves a
foliowing piatf arma
1 examine select HP? pmctices and
ire that neither bias nor blacks to pra gress
an ta cr4ate progress on ,nclus,an and
env,ronment which is percetved as fair
comlng
s a(nalyzing identifying and addressing
ofapportunity acrass Pfizer such as
agernent talent planning cornpensatian
>es that can be enhanced ta create and
iva enviroiiment urrently being evaivated for efficacy is aur
which permita any cai eague to present
uesansbiems,
a
ar suggestians directly
dership with
n
w
ut fear of
ess Maxumization and Groth
Leader Education and Accountability
We viiii praduce infrmed and engaged Pfiz€
the world who actively deve Diversity & Indo
progress and plana in their organiza bons Th
ultima tely be responsible for deliverrng speci
resulta
Senior leader Engagernent and Educatiaftis
the Pfizer Diversity & inçiusian strategic frarr
the Worldwide DM 0ff ice DIO) began dev,
curriculum for Pfizers tolaseniar business la
ar the critical rale they play in ereating and
inclusive enviranment that optirniz&s índIvdL
pertarmance across the entire arganizatiaF
ieaders wili be expected ta embrace new be
attitudes and cammunicate messages that
Pfizer 's arganizatianal culture
Pfizer business leaders are each cammitti
resaurces ta suppart and suceessfuily rrnplei
pians Each business unit lhas identified repri
the DM Worldwide Leadership Cammittee
meets regularly to pravide executive levei av
and gavernance for the campany s DM strati
serves an advusary bady ta the Pfizer Execut
Tearn and the Worldwide Diversity & Inclusia
works in caHaboratuan with the Pfizer Baard
Divisions are alsa each identifying DM Busin
individuais charged with partnering with iead
to crive D&l pians throughout theirghniiaI
'(2
DM Worldwide Leadership Committee will work
iusiness leadeit t&idéntifj/ and lead efforts that
nstmte Um bus,ness value af creating a d'verse and
iva enviranrnent Me wdl seek ia partner with key
la! organizations ia share aw D&l visson enhance Pfszers
tsotíand support our business goa/a
©.
uccess dernand that aúr business units retlect the
.L ....
variety ai perspectives ta respand ta the acceierated
;és in the marketplace and tbe needs af the diverse
mera and patients mie serve The Ü&i Worldwide
rship Cammittee wiir wark to utilize the D&i pracess ta
rt Pfizersbusiness success
ir external facus on D&i also apphes to or suppliers,
ssspartnersccrnrnunities, and key externai
izatians ta hlp drive our business results and share
mmitment and progress in the D&l pracess
kwLi
ti
1
1
EMPLOVEES
1 z,,r2(jó7 ( ry0r4i
li
i(Pj'( n'nt,i
Repod,
99
Diversity and Inclusion Initiatives
for Specific Groups or Communities
We have programs and initiatves for specific groups or
communities who have been historically underrepresented
in lhe US.
Sorte examples include:
Ml
100
PJL-cr 2007 Gorporate fÇcponeihrU&v Report
E MP LOTE ES
4E
Improving Wellness
One way we are striving to hve the heaith principies we
promote as a company is through Healthy Pfizer, an
integrated, comprehensive heaith-iniprovernent program.
Launched to our US colleagues and their farniiies in June
2005 and in Puerto Rico ii, September 2006, the Healthy
Pfizer program is designed to increaso heaith awareness
and support positivo change based on the principies of
prevention, eariy diagnosis and timeiy treatment.
Healthy Pfizer's personalized, easy-to-use toois,
programrriing and services include a confidentiai, personahzed
web portai, onsite health screenings, a heaith risk assessment
tooi which inciudes a detailed report on individual risk factors
and overali heaith, telephonic and onsite coaching programs
designed to help participants reduce risk factor; and rnanage
chronic conditions, a 24/7 nursehne, and a physicai activity
program.
To date:
• 22,991 colleagues have conipieted hea]th screenings
conducted onsite at Pfizer faciiities throughout the US and
Puerto Rico
• 84 percent of colleagues and 52 percent of dependents
have conipieted the heaith risk assessment tool, the Health
Questionnaire
• 41 percent of eligible colleagues and 28 percent of eilglbie
dependents are enroiied in coaching programs to reduce
heaith risk factors and
• 20 percent of ehgibie colleagues and dependents are
enrolled in programs to heip them betier manage chronic
conditions.
The program seeks to set a new standard in empioyersponsored heaith programs that is best-in-ciass in usability,
customer satisfaction and measurabie heaith outcomes.
EMPLOYEES
•
Communicating Openly
\_ CR
Open dialogue between colleagues and senior management
Ibuiids trust and improves performance, especiafly duringperiõds of change.
This is why our CEO and senior rnanagers have iaunched
a variety of ways to engago colleagues in interactive
communication. in one program, called "On the Road,"
,ieaders have been visiting and touring various Pfizer sites,
8hosting town hali meetings and conducting informal iunches
with colleagues. Leaders have "gotten out of the office" and
are spending significant time with the saies torce and meeting
community and state ieaders. As a foliow-up to these events,
Reports from frio Road" are posted on our intranet site.
These are webcam dispatches in which the CEO shares his
informal views on his trips around the company.
Two-way communications between senior management
and colleagues recentiy improved with the redesign of
PfizerWorld, fim company's Intranet-based magazine. The
sito now features The Exchange, a forum through which
members of the Executivo Leadership Team speak about
criticai issues affecting the company—from the canceDation
of the torcetrapib clinicai trials (soe pago 27) to Pfizer's
reorganization.
The Exchange ser-vos as a portai for Pfizer ieaders and
colleagues to comniunicate with one another. CoDeagues can
siso submit ideas directiy to Chairman and CEO Jeff Kindler.
He has received thousands of recommendations, questions
and feedback on a range of issues.
As another example of new ways of communicating,in
2007, Mr. Kindier created the first Pfizer Coileague Advisory
Committee. This global panei of 15 empioyees, from ali leveis
and divisions, wiili serve as a sounding board for the CEO
and provide input and suggestions from our colleagues who
interact directly with customers.
In September 2007, every Pfizer colieague in the
world wiili participate in the Pfizer Colleague Engagement
Survey and action planning. Pfizer utilizes the Galiup G2'
survey that measures the most significant drivers of
coileague engagenient and inciusion, which directiy relate
to productivity, retention and shareholder vaiue. This process
inciudes a confidentiai survey with the resuits provided at the
supervisor levei which tom, the basis for specific action plans
to iitiprove the work environment. it wili siso crive coiieague
engagement and a greater sense of inciusion and merit-based
icareer advancernent and rewards.
ler 2007 t'orporcsh' R,sponsíbüiry R.'port
101
1
Eliminating Bureaucracy
AWARDS AND RECOGNITION
Making Pfizer a great piace to work includes creating a more
agile, flexible and empowered organization to speed decisionmaking. Coileagues kke to get things dono. To that end, we
have begun efforts to unieash the talent and potential of our
coileagues by:
Wrking Mother named Pfizer one of the
100 Best Companies of 2006—the eighth time
Pfizer was so honored.
• Eliminating bureaucracy and reducing rnanagement
Iayers so that leaders are closer to their Pfizer teams and
custorners. We are in the midst of reducing the number
of Iayers between the top and bottom of the organization
from fourteen to eight. This reduction in layers is intended
to not oniy bring leaders dosar to customers and patients
but will push decision-making down to increase speed and
customer focus.
• Giving Pfizer coileagues more freedom to make decisions,
be more creative, and have clearer accountability. As an
exampie, we are in the process of extending the span
of control of supervisors with the intent of empowering
coileagues and allowing managers to focus on leading and
developing their staffs.
We are also building a stronger performance-based cultura
by reviewing our compensation syètems at ali leveis of the
organization in 2007, so there is a more direct hnk betweon
rewards, performance and total shareholder roturn. This wilil
require improvod performance planning and evaluation, as
well as building talent at every levei of the organization. Pfizer
is bui?ding on its 2005 succoss of making conipensation
more transparent to coileagues by increasing the emphasis
on business performance and increasing the differentiation of
rewards relative to individual and team performance.
:er is ano of 30 companies named to
National Association of Female Executivos
FE) Top Companies for Executive Women
for 2007.
Nfikkei Womanin Japan ranked Pfizer as
ajnong the top 100 companies for women
in 2006.
9fizer earned a perfect score on the Human
9ights Campaign Corporate Equity Index for
tI'!e third year in a row.
Urban League's New Yark Chapter named
fizer a 2007 "Champion of Diversity" for
deating and sustaining an environment of
inclusion.
..2
o
1
102 flzcr 2007 Corporate Rpo,níbUitr Report
F
EMPLOYEES
457
(Fia. _
-
4L4
Pfizer is committed to ãssting quality, safety
and consistency in the manufacture of our human
and animal heaith produçt, while making sure
the actions of individuais ad organizations within
our supply chain are cçnsi$tent with the highest
ersonal ethics.
standards of business
2006/2007 KEY ACTIONS
Conducted more than 100 onsite reviews
at the facilities of contract manufacturers
and researchers, key supphers, and
outsourced logistic centers in 2006 to
assure environment, heaith and safety (EHS)
responsibihty of our suppiy chain.
Continued to buiida supplier base that reflectis
the changing demographics of the consumer
marketpiace through a comprehensive
Supplier Diversity program.
Expanded our Responsibie Contracting
initiative across ali Pfizer divisions in the US.
C-5
104
JWcer 2007 Gorporcte Repo,nih,/i&v Report
improving Quality
Quality In everything we do is criticai because our products
help people lead healthier lives. Today, every major country or
region lias legal requirements that apply to Pfizer products,
ircluding sophisticated standards of Good Manufacturing
Pactices (GMP) against which regulatory agencies examine ali
pharmaceutical companies. These efforts are supported by a
number of corporate functions within our Legal Division.
Our Corporate Reguiatory Compliance (CRC) organization,
ith experts across the globe, verifies compliance through
11
Ariodic audits of Pfizer and selected contractor sites, as well
as through measures of quality performance. A risk-based
a"naiysis of each site, which considers products, activities,
t&chnoiogy, and compliance history, determines the frequency
aid duration of audits. Quality performance measures inciude
such things as number of recalis and compliance incidents
and everits.
-h These measures and audit resuits are reviewed by
business unit management and rnay be shared with our Chief
C,omphance Officer or raised for discussion at our Corporate
Compilance Cornmittee meetings.
Our Right First Time strategy for manufacturing is
màkin a signiflcant contribution to quality assurance and
rik mitigation, and reflects our commitment to quality in
1 1erything we do. Right First Time promotes the use of
ipnovative technoiogies and a set of toois that wUli improve
process understanding and reduce variabihty in manufacturing
operations. Manufacturing and CRC coileagues around the
world are extensiveiy trained in the use of Right First lime
technology and tools and have mede significant improvement
in the quality of our processes and products.
MANUPACTURING 1 SUPPLY CHAIN
Another essential factor in niaintainlng GMP compliance
is understanding and infiuencing ever-changing regulatory
expectations. Our regulatory monitoring functions gather,
evaluate and disseminate emerging regulations and guidance
to the Pfizer comrnunity. We have also taken an industryleading role in interacting with the LiS FDA and lhe European
Medicines Agency (EMEA) to communicate lhe value of
recasting GMP regulations based on scientific and risk
nianagement principies.
Reducing Costs
Pfizer has initiated a Technology and Innovation strategy for its
manufacturing facilities to reduce costa by $5 billion avariO
years. As part of this strategy we are expioring manufacturing
methods foi traditionally found in the pharrnaceutical industry,
especially continuous manufacturing processes, and the
development of new material options designed to reduce lhe
cost of active pharmaceutical ingredients.
Improving EHS Performance of Contract
Manufacturers and Key Suppliers
Our commitment to responsible environrnent, health and
safety (EHS) rnanagement goes far beyond our facilities'
boundaries. We use stringent environmental performance
criteria in assessing and selecting contract manufacturers
and key Active Pharrnaceutical Ingredient (API) suppliers
We are also committed to heiping our contract manufacturers
and key suppliers in the developing world improve their EHS
competency. By helping to elevate the EHS performance
of these contract manufacturers and suppliers, thair
workers and communities benefil, and we protect ourselves
against business interniption that could irtipact contractual
obligations.
To assure EHS responsibility in our suppiy chain, our EHS
professionals in 2006 conducted more than 100 onsite reviews
at the facilities of contract manufacturers and researchers, key
suppliers, and outsourced logistic centers. Reviews were dono
in ali regions of the world, with a focus on China and India.
The results are communicated to our procurement groups and
considered in suppher decisions.
Our suppher EHS review program is a key part of our
supplier selection criteria. We use a two-tier approach. The top
tier includes contract manufacturers and researchers for APIs
or finished drug products that contain potent compounds. It
also includes key suppliers of drug products and chemicals
that are critical tolhe supply chain, such as high-value,
unique chemical entity or single source suppliers. The second
tier includes contract manufacturers that do not use potent
compounds, do not make APIs and are considered Iess
critical.
MANUFACTURINO 1 SUPPLY CHAIN
If suppliers are rated as acceptable with qualifications,
the qualifications are shared with lhe suppiier and an action
plan is requested to address the arcas of cancern. If a
potential new supplier is found to be unacceptable, we will
not do business with the entity until the concerns are
addressed. If an existing supplier is rated as not acceptable,
we typically work with the supplier to improve perforrnance,
or we may also and lhe relationship.
Pfizer also actively supports EHS management
iniprovement at hany suppliers. In November 2006, for
example, we sponsored a onc-week intensivo EHS training
course in Shanghai, China, focusing on occupational
hygiene and process safety. The training was conducted
by internationally recognized consuitants, with Pfizer
• facilitating discussions. Sixty participants representing six
• key suppliers attended lhe course.
Integrating EHS Criteria in the Purchase
of Goods and Services
lntegrating EHS criteria into our purchasing decisions for
goods and services can reduce our cosi, improve lhe quality
of the product ar service, reduce risks to our business, and
reduce environmental degradation. For these reasons we have
• been examining categorias of goods and services, identifying
opportunities and risks in these purchases, working to develop
EHS specifications and defining lhe methods by which we can
measure the benefits of such purchases.
One example of how such "groen purchasing" benefits
Pfizer and the environment is in lhe use of office papar.
Sixty-eight percent of the printer and copier paper we
purchascd in lhe US in 2005 was recycled papar. The foresting
practices used to produce the raw material for
the paperwe bought were certified as sustainable under
the Sustainable Forestry Initiative. In making this choice
we helped save 8,068 trees, 1,645,587 kilowatt hours of
energy (enough to power 61 homes for one year), and
321 metric tons of related carbon dioxide (CO2) and olhar
atmospheric greenhouse gas emissions (equal to lhe amount
of CO2 from lhe operation of 64 cars par year). We are
currently purchasing printer and copiar papar with 30 percent
post-consurner waste recycied content.
Pfizer 2007 (orporate Re,per.,ihititv Rport
105
/%E Ilj
(r
Ft ...
Increasing Supplier Diversity
Responsíble Contracting
The objective of our Supplier Diversity program isto build a
supplier base that reflects the changing dernographics of the
consumer marketplace while helping Pfizer increase market
share and shareholder valuo. In arder to do this, we have
implemented a three-part strategy:
To years ego, we iniplemented a Responsible Contracting
initiativo in the US for use on ali major capital projecis,
sito services and sõMce contracts. Pfizer was the first
pharrnaceuticai company to do so. Under the initiative,
contractors and ser-vice providers may bid to Pfizer provided
tF'ey compiy with "responsibie contracting" prequahfication
cltteria that include paying appropriate wages, providing family
health insurance and job training, compiying with empioyment
laws, and not using independent contractors. The company
receives services frorn a broad spectrum of contractors
v)ith both union and non-union affihations. Over the past
decade, more than $1.2 biiiion, ar approximately 85 percent,
our construction doiiars have gane to union contractors.
Responsibie Contracting has helpod to expand and diversify
Pfizer's servico provider iist, attracting new contractors to our
sites and new workers to our communitios.
• Creste opportunities through our sourcing process to
increase our spending with minority and women-owned
businesses. Over the last several years, we have increased
such spending by 10 percent a year, well above the
pharmaceutical industry average. SmaII businesses,
service-disabled veterans and veterans are inciuded in our
Supplier Diversity Program.
• Provido executive educational prograrns for our diversity
suppliers and diversity education training and developmeht
for interna! coileagues. For exarnple, over the past three
years, we have provided scholarships for minority and
women-owned businesses to attend the Tuck Schooi
of Business Minority Executive Education Program at
Dartmouth Coliege. This program heips entrepreneurs with
such issues as buiiding strategic alliances, marketing and
organizational development. lnternally, we focus on goal
setting and techniques to identify minority and women
suppliers.
• AIIgn with advocacy organizations, such as the National
Minority Supplier Development Council (NMSDC) and the
Women's Business Enterprise National Council BENC).
Theso leading advocacy and certification organizations
provido certification and business development
opportunities for minority and women-owned businesses
We support these organizations through local and national
board memberships and sponsorships of conferences and
workshops.
106
JYÜCT
2007 Cvrporafç flrspon,,h,li:v Rpejrt
of
MANUFACTURINO 1 SUPPLY CHAIN
4oEi
Fb
AWARDS AND RECOGNITION
The Women's Business Enterprihe National
Council (WBENC) has recognized Pfizer asone
of the 2006 Top Corporations for Wornen's
Business Enterprises. This marks the thírd
consecutive year Pfizer has received this
honor.
•
.
For the fourth consecutive year,[ Pfizer has
beenrecognized as the Best Cqrporàtion
for Multicultural Business Oppõrtunitiesby
DiversityBusiness.com. The online survey of
minority and women business énterprises
considered such factors as extérnal oútreach,
mentoring, and seniormanagement
1
commitment to diversity.
M
Pfizer's Thane, India manufacturing fadllity von
the Sfty, Hlth & Environment Award from
the Confederation of Indian-Industries for its
education and awareness initiatives
1
:1
MANUFACTURING / SUPPLY CHAIN
Pfizer 2007 ('o'poruf Rnponibihtv &pQrL 107
'••!
-
-
OPDE
Looking Ahead
f
We are looking for sustaina!ile.ways to neel
healthcare needs aroúnd thé wófld,
tomorrow. We help people get••needed treatn
and services, while fostering a cliniãtè '6fini
thatensures steady progress inbiomediàaI
tion
Certainly, our work ii.. reserch and dêVélp
prevention and wellness, and healthcâre rei
helps empower people in their ownheãltha
Bút gien the cotnplexities ôf global héalthc
issues, we cannot solve problems alone.
t,
So, we will hsten. learn and change; and 70
hard with responsible business practices; ifl
pai tnei ship with our stakeholders to1 hep c
a healthier, wealthier world
That is our conirnitment.
108
1
Jiw !OO7 Gorporote RcsponeihiTity Report
o
Global Reporting Initiative (GRI)In4ex
The GRI Sustainability Reporting Guidelines provido a framework for organizations to report on thoír social, environmental and ecoromic
perfomianco. For more Information, please soe www.globalreporting.org.
'/JJerLflht.o porair noporao,t& w n.'poflIu
Explanation
f.
ot me affecls cl anyrestaternent O!
atlonplded In earlier reporls.
3.10
1
J
tnviitfln,ent, neann fina atety
-
CI
S~evious
1
rabio Identlf4ng the localion cl lhe Standard
J9losuresin the mort
z.
3.12
Policy and currant practice wilh regard o seeking
3.13
[Jalusuranforlhé report
][0aestt00fte0r9anhzat0n
aaewIaa weaa
r
-T
About the Report
Ir
aarn,ain
{
CorporateResponsibility and me Board ofblrectors
taaca,r - -e.r iIttir
Governance and Cornpliance
Indicate whether lhe Chair aI lhe highest govemance
bodylsalsoan executiva officer
4.2
-
.....
GRI Index
....
J
4.3
1
Members of lhe highest governance body that are
independent and/or non-execut've member 4
4.4
naisa
Ertcouraging Sharehoider and Stakehoider Participatior
jlte*#lnett'
4.5
,jtneçeetr .ta,a
Linkage between compensation and the organizations
perlorniance
.1u._Jli.
LI.
41 is.— 4
4.6
J
LS-
Corporate Responsibility and the Board 01 Directora
Mechanisms for'shareholders and omp1ayes to
provida recomniendations or directio lo the highest
governance
%
Ensuring Soard Independence
Processes in placa for lhe highest govemanco body to
ensure conflicts of interest are resoived 1
,..,,r
.-,---
r lnstltuling Greater .Accountabitity in
Executiva Compensation
,
Compiylng with PJI Laws, Committed to lhe Highest
Ethical Standards
cess for deternhining lhe quahflcatlons and expertise l Ensuring Board Independence
themember ofthehighestgovernancebodyfor
uiding the organization's strategyon econonlic
vlronmental and social performance
IL
IO9,1
t 'tpa. qptert
In
III
4.8
lnternally dev&oped statement of mission ovalues,L
Complying willi Ali Laws, Committed tolhe Highesl
codes cl conduct. and principies relavant to eccnomic,
Ethical Standards
en~mental, and social performance and the status
of their irnplementation
1a414s...
4.9
1•
—
4.10
k
4.11
lhe hlghest goveranco bodyfor
e organizatuon a identifioalion and
ang.V
-~rn~i o! econonIc, envlron!nentland socla
L
Corporate Responsibility and the Board 01 Directors
Complying with Ali ws Ccmmitted lo the
21 tHlghest Ethical S{anddds
r'
-------Processes for ovaluating me highest governance
bodys cwn performance, particularly with respect to
ecanornic, environmental and social perforrnance
Ensuring Board Independonce
rrr'r
r
~pnation cl whether and how lhe precautionary
achorprincJple a addressed by tho organtzation
Understanding the lnipact of Pharniaceuticals
In thEnvlronme
Realizlng lhe Proniiseof Greon Chemlstry
n.,
o,
a,
w,waa,.,aa,,aurat.
4.12
Externally developod economic, environrnental, and
social charlers, principies, o' olhar initialives to wtch
lhe organization subscnbes or whrch it oridorses
91
2
--
1
4
iáN
,
1'
110
JWcrr 20Õ7 Cerp,rate fltspnrn;h.tity Report
Our Colleclive Actions
1 Our Corporate Responsibility Standards
1 and Evaluation Partne,s
lncreasrng Scíentufic Coltaborations and Partnerships
lnvestinglnHealthi
1Envlronmerit. Health and Safety
1 Sales and Matleting
-
EU
cai INDEX
\jr7
r
S'gniflcant mirmbershipínoganzaons 1
413
ifl ttirn 1
4.l4W: jL ..
kíSt4SLwaiw
415
IOurCoiloctiveAction
CborationsandPa,1norshjp
r77pwnfl ,r1
Wst 01 stakehoIderrupiengaged bythe organMIjjperatingwith a Now Stakehotder Módel
'"
F
r
t
tP
rMtnwtrnnrTrnn rt!:
Basis for identification and selectuon of stakehoIders4tflL øperating w'th a Now Stakeholder Model
r---.srtt-&et
416
4.17
Operating w'th a New Stakoboldor Modal
Approaches to stakeholder
ncluding frequency of engagement by type and
b
hIHr%i
by stakeholder group
....
Keytopics and concems that have beon raised through, Changing Ilow We Intograte StakehoIde!Needs2
stakeholder engagernent anã how the oianization has
ii $ r
responded to those key topics and concerns IncIudin r
throughitsreporting
<1kincIuding rovenuesoperatir
iflconpensation, donations ar
retained earnir
,
jJjProidersànd goveminents
EC2
EC3
CS
$4SE j
Operàng wh a N w Stakeholdet M&
NÉ, J.
- ex
Expenses
Consolidated Finanbtal StàSiiiénts
i[rinanciai iniplicatuons ando
for lhe organizations activiti
for
'tc
:
obligations
Change
4qÇ4
r4
ans
-
EC6
(Partially Càvered)
ersity
EC7
(Partlalfy Covered)
Vide Diversily and Incluslo,
Rrfl
EC8
1;;---
O RI INDEX
Development
and services
throughcomr
benefit
ídndersandin
1
H ecdhomlc irii
i'fi,er 2007 (.'orprir&v Respon,ibüitv Report
111
Disciosur es -
-
h.
rr
------'
-
1
--,Continuing ta Reduce our Footprint: Reducing Por and
~te Ernissions
E
Materiais used by welght ar volume
EN1
:-----1----1 Percentage of materiais used that are recycied input
materiais
-
EN2
r.EN3
(Partially Covered)
(
Cantinwng to Reduce our Footprint: Reducng Por andP.
ÁA
Waste Emissions
.
-e—
Planning for Change
J Dprect energyconsumption by prlmary energy source
J
r
L EN4
ÉM lndurect energy consumption by pnmary source k
-
Energy saved dueto
improvernents -
EN5
EN6
- -
11-Pus
and efflcincy
9
1 Initiatives to provido energy-oflicient ar ranewable
energy based products and serices and reductions
energy requlrements as a resuil of these initlatives1
Carbon Disclosure
ri
et—r—r
lnitiatives lo reduce tndirect energy consumption and
reductions achieved
EN7
Planning for ChangeJj
Total waterwittidrawalbysource rrsSSamaeasaafla
- - aInu!r4e—aSa
Water saurces slgn,flcantly affected by wlthdrawai
Jlofwater
ENB
-
[
íE
EN1O
-
Water Use and Conservatian
MEN 15fl4
..-
I
.o
Percentage and total volume of water rocycied
andreused;
Ls
____
EN1?
-
--
-
Chmate Change: Reducung Greenhouse Gases and
ng Energy W&y
Et
Using EnergyWiseiy
Ï
Er,issions af ozone-depleting subsiances by woight
EN20
-
NO SO and other significant ak emissions by type
and welght
iL
-
_____
— _________
EN27
(Partlally Covered)
—,
—-
Totai water discharge byguality and destinatlon
-0
Total weight of waste by type and disposai method
-
r—
awn.nw_a
'r-- -- --------a -
initiatives to miligate environrnental impacts oS
f products and services, and oxtent ai lmpact mitlgatlon
Percentage o! products sald and their packaging
materiais that are reclaimed by category
-
--«-----11 Understanding tho impact ai Pharmaceuticais in
the Environment
--
fines and totalthumber
-
ConseMng Water
mec..erno4a
Saaneaenae—anzwaasassavnan
mrsc
Contlnuing to Reduce our Footprint: Reducing Por and
Waste Ernissions
3 --
-
,,JLan,síLaean
o! non-monelary sanctions for non-campliarice with
Understanding the lmpact o! Pharmaceuticais in
the ESronme2 0j
h
environmental iaws and regulations
Sigcantenvironrnental impacts ai transporting producs and other goods and matertals used for the
woMo
organízations
operations and transporting members 01
1
Continuing to Reduce our Footprint: Reducing Por and
Waste Emissions
a
EN21
—
Conl(nulng to Reduce our Footprint: Reduclng Por and
flEmissIons
EN26
--
rr
—
rr.
Cther reievant lndirect greenhousa 955 emissions
Chmate Change. Reducing Greenhouse Gases and
r
EN1O
Ln_.
- -
«-
Total direct and lndírect greenhouse gas emissions
by weight
•
_____________
r EN22
-.
-
Conserving Water
_SS_
ENIO
1
jconservingwater
San
tasJ eSas
j ENB
u----
-
Plannlng for Change
j
EHS
E
J
lã
-
1 Ciimate Change: Reduclng Greenh
Uslng Energy Wsoiy
"
-L
i
112
Pfizer 2007 Corporal, íksponsihriitv Report
CRI INDEX
E
e
CRI IND gx
Pfirer 2007 Co,w.eo ReApÚn.IihitUy &'pofl
113
$
Pá
114
I'jier 2007 (..p,rote &spirneíh.Jity Report
O RI INDEX
e
1
Index
A
Allempo 40
Academic Ailiance Fotindation 43,48
Academy for EducationaJ Deveiopment 36
Active pl,annaceutical ingrediente (API) 8.55,105
Alhcan trypanosomlasis 21
Agency for l-lealthcare Mminislration (Ai-lCA,
Florida 47
Age-relaled macular degeneratioà 42
AIOS service organizations (ASOs) 36
Aiignlng Cu~ Excelience Pro9ram (ACE)
12.84.91
Ailergy & respiratory discasse 4
AJIlance for a Healthy Bordar 37
AJliance for Health and lhe Futuro 91
Ailiance to Conserve the Maya Foresl 61
Arnerican Academy of Family Phyaicians 48
Nuerican Cancer Soolety ID, 40,89
M,erlcan Heart Assoclation 10, 89
Mnerican lung Association of Michigan 89
Ajnorican Medical Assoclation 10
Ajmericans with Dlsabilities Aol 100
Amigos en Salud 47
MCHOR 42
Animais in research 29
Animal welfare p0110)' 29
Mn Ajtor B520 Renovation Project 73
Argentino Congress of Clinical Oncology 40
4ornasin° 4
Association o? Businees Communicalors 58
Association of Clinical Oncology 22
Association of tiro Brlllsh Pharrnaceutical
Industry 12
Ausielio, MD, Dennis A. (Director) 78. 79
Mitinib° 24
5-2
Balance Ir Oul: Arkansas 46
Biomadcers Consortium, The 30
Biomedical innovalion 21
Blue Book, lhe (Summary o? Pfizer Policies on
Buslness Conduct) 77
Boston University School 01 Public l-fealth 9
Brookings lnslitution, lhe 9, 34
Interna Ilonal Volunfeerisrn iniciativa 34
Brown, MD, MichaS S. (Director) 78,79
Bums, Anthony M. (Director) 78,79
Burt, Robeil N. (Director) 78, 79
Buslness Etblcs Conter of Jerjsalem 92
Businesa fora Healthy Society Task Force 45
Busineso Roundlable, lhe 7
IND EX
o
Caduel° 4
Campalgn for Srnokefree Ar 86, 89
Campaign for Tobacco Free Kids 10
Camptosav° 4
Cance,s 19, 22, 24, 29, 30.40.41
•
(aJso soe 'oncology
Candidemia 20
Caphri Research Instituto of lhe University
of Maastricht 45
Cardiomobile, The 44
Cardiovascular, metaboto and endocrine disoaso
4, 22, 24
Care-A-Van, The 44
Cwing for CIlmale, lhe Business
Leadership Platforni 61
Celebrex 4, 54, 84
CEO-Coileague Advisory CoMn,ittee 97, 101
Chagas' disease2l
Chantlx (siso Champix°) 4,9,19, 91
Chetnicals in lhe workplace 69
Childhood obesity 41,42,47
Chloroqulne 21,24
Chronic diseases 46
Chronic Obstructive Pulmonar Dlsease (COPD) 45
Chronicle o! Philenthropy, Tire 49
CIO magazine 58
Cleveland Clinic 54
Climate change 62
Clinicai Research Unit, New Haven, CT 73
Clinicai trata 25-26
developing world 26
disclosurw policy 25
ofhical25
phases o! 25
piogress on cornrnitrnenfs 8
quality assura rico 25, 26, 52! 54
trsnsparency 26, 27
Clinton Global Initialive 35
Coalition Aalnst Falte Medicinas 58
Coalition to Advance Health Refonu 89
Commiltee for Medicinal Producls for
Human Use 20
Confederalion 01 Indian Industries Safety,
Health and Enmnment Aw&d 107
ConnectHlV 34
Connectlon to Cara 48
Conserving waler 65
Conlract manutacturers 105
Cornelia Vlieg ,Association 41
Comwell, Don W. (Director) 78, 79
Corporate ethics and compliarice 77
Corporate Govemance P,inclles 76
Corporate Regulatory Compliance 77,104
Corporate rosponsibllity 5
abouf Lhe report 5
Board o! Okecton' Corporate Governance
Cornmitfes 5
integm?Ion o! 5
sfandards and ova luation partners 7
Cox Report 91
CP-945-598 24
D
Data and Satety Monitoring 8oard 27
De.mentia 40
Delrol°/Detrol LA 4
Developing lalent 98
Diabetes 18,19,22,24,30,31,38,40.43,
47, 48, 70
Diflucan Partnership Program 36,49
Disabilily Nelworldrig Group IDO
Diseases 01 lhe developing world, research for 21
verSty and Inclusion 99
DlversllyBusiness.coni 107
Dow Jones Sustainable Asset Managemeni
(DJSAM) 7
Dnig counlerfeiting 56. 92, 95
Drug distribution chain 58
Dmg iniportalion 88
Easter Seals 10,88
Edna McConnell Clark Foundalion 49
Educaling for Inteilectual Property
Rights Progran, 92
Educational Grant Disclosure Plan 12
Egypt Health Minialer 93
EHS Critõria for Purchasing Goods and SeMces 105
EHS Guldeline on Proceas Safety 72
Electronic producl code (EPC) 57
Elirninaling bureaucracy 102
Employee education and training 82, 98
Employee engagement 98,99
Employees with disab8ties 100
Energy efllciency credits (or renewable
energy credita) 64
Environrnent, heallh and safely (EHS) 61
EPA Climale Leaders 62
EPA Envlronmental Performance Track 61
EPA Presidential Green Chemlstry Award 68
e-prescribing 90
Eraxis° 4,20
Ernst & Yourig 9
EU Health Coqnmission 91
European Medicineb Aency (EM EA) 105
Exceilence in Green Chemistry and
Engineering Award 68
l'ftrer 200T Unrporule Reepon,ibiiity Report
115
Ar
zrz
Executivo compensation 76
Executivo Leadership 'ream (ELO 101
Executivo Medical Review Commlttee 53
Exubera° 4,9.19,31,54
Exxon Mobil 43
F
Family I-tealth International 49
FDA Center for Drug Evaluation and Research 88
FDA Critica] Palh Inhtiative 30
FDA Revitajization Ad (FDARA) 88
Feczko, .Joseph (Chio! Medical Olficer) 55
-Fibromyalgia 20
Fleot safety 72
Florida; A Heallhy State 47
Food & Onjg Packaging magazine 58
Foites magazine 94
Foralgn Conupi Practices MI (FCPA) 75.77
Foundation for the National Institutos
of Health 30.31
FTSE4Good 7
a
Gailup survay 98, 101
Gastrointestinal 24
Gastrointestinal siromel tumor (GIST) 19
Gay, lesbian, bisexual and transgender
(GLBT) community 1 00
Genetic Aaaoclatlon lnformalion Network (GAIN) 31
Genitourinary 4,24
Genõtropin° 4
Geodon°/Zeldot 4
Cetfluit 19
Gllead Sciences 43
Glaucoma 42
Global Accountabillty Project (GAR) 7
Global Envonmental Management
Initiative (GEMI) 13
Global Health Partners 34, 40
Global lIA Nova 49
Global Manufacturing Active Pharmaceutical
Ingrediente 105
Global Reporting lnitiativé (CRI) 5, S. 109
Global Summit o! Women 1 00
Good Clinical Practices (GCP) Guidelines 26
Good Manufacturtng Practices (GMP) 104,105
Governance Metrics lnlen,ational 78
Cray, III, William H. (Directo.) 78, 79
Green buildinga 64
Green chemislry 68
"Green" purchaslng 105
Greon Ribbon Health 46
Greenhousa gases 61.62.63
116
P&er 2r7O C',p,nate Rcspon.ih,lity Reporl
H
K
Han Zheng, Mayor o! Shanghaj 94, 95
Hazardous waste 66
Health Coverage for lhe üninsured
(-ICCU) 13,86.89
Health disparities 92
Health Volunteers Inlemational 49
Healthcare Distribution Managenient Association
(HDMA) 58
Healthy agoing 91
Healthy Pfier 101
1-11V/AIOS prevention 36
HiV/,AJOS workpIace policy 100
Hong Kong Social Weltare Departnient 49
Honor, Constance J. ead Direaor) 75, 76,78
Hospital Partnership Program 48
Howell, Witiam R. (Director) 78, 79
Human RightsCanipaign 102
Humana Inc. 46
Hungarian Socloly 01 Hypertension 39
Hyporlension 23, 39, 94, 95
Kenya Msoclallon ol lhe Pham,aceutical lndustry 92
Kindlor, Jeff (Chairman, CEO) 2-3, 75, 78, 78, 101
Korean Reaearch Instituto o! Biosolonco
and Biolechnology 93
Ibuprofen 54
Improvac 29
In Vitro Testing industrial Plattorm (IVTIP) 29
incubator' at La JolIa 31
Industry strengths and weaknesses 6
lnfectious Disease instituto QDQ 43,48
lnfectious diseases 4, 21.23.24 ,
lnfectious Diseases Society o! knerica 43,48
lnflammation 4, 24
Instituto for Supply Chain Managehient (ISM) 7
Instituto of Chemical Engineers (iChem ) 68
Crystal Faraday Award for Green Chemlca/
7âchrológig, UK6S
lntellectual prope,ly protectiàn 90,92
International Alllanoo o! Pathents' Organizations 10
Inlemational Mti-Bribery and Mti-Con-uption
Corporate Procedure 77
k
International Conterence o! Harmonization (10H) 26
International Federalion ol Pharmaceutloal
Manufactu,ers and Associations (IFPMA) 26
International LHe Sciences lnslittites/Health
and ErMronmental Sciences Instituto 29
International Rescuo Comniittee 49
International Trachoma Initiative (171)36.49
lrlsh National Satety Qrganizatlon 73
L
Labs for the 21 st Centu' coliaboralive
partnership 73
Lalcec (Argentino League Against Canoer) 40
Latino community 1 00
Leadership in Energy and Environmental Design
(LEED) 73
L&shmanlasis 21
Lifeline Expresa 95
Lipilor 4, 84
London School ot Hygiene and Tropical Medicino 35
Lorch, George A. (Director) 78, 79
Lost Time lnjury and lllness Rale 71
Low income radical soheme, South Africa 92
Luxernbourg Sustainable Health
Rnanclng Studies 91
Lynca° 4, 20, 23, 68, 84
M
Makerere Universily 43,48
Mataria 21,24,36
~
manta 21
Manufactu.tng/supply chain 103-106
Mead, Dana G. (Director) 78. 79
Medicam Health Support Program (MEIS) 46
Medicam Modernizalion Act (MMA) or
Medicam Par: O 46, 88
Medicines Australia 93
Memory Bus 40
Meningitis 26
Monta] Heaith and Stress Managemeni
Training Project 95
Mexlcan Diabetes Assoclalion 39
Michigan Health and Hospital Assoclation 89
Michigan Stale Medical Soolety 89
Missouri Waler Environmental Association
aold Star Ceitificate' 73
Mobilize A9ainat Mataria 34-35
Monja Mi.nal Foundation 29
Mulago Hospital 48
J
Johns Hopkins Bloomberg Sohool 01
PubIic Health 36
IND EX
N
Q
NMCP 48
Naproxe., 54
Nailonal Ailiance for Hispanic HeaIih 48
National Aihance for the Mentally 111 10
National Association of Boards of Phamiacy 58
National Association o? Chain Drug
Stores (NACOS) 58
National Association of Community
Health Cantora 48
National Association of Fernale
Executivos (NAF E) 102
National Business Disability Council 100
National Cancer Instituto (NCI) 29
National Governors Association 48
National Human Genome Advisory Council 31
National Institutos o? Heslth )NIH) 18.30,31
National Minority Supplier Development
Council MSDC) 106
National Urban Leaguo 48
Neuropathic pain 20
Neuroscience 4, 23, 24
New stakeholder modal -li
Nigeria, Kano 26
Nikkel Woman, Japan 102
Norvasc 4
lo
Onchocerciasis 21
Oncology 4,22,24,40
(siso se. cancers
Ophthamology 4.24
Organlzation for Economic and Cooperatlon
Development (OECD) 10
OSHA VPP 61
OSHAS 14001 and 1800161
Oxfani 10
Ozone depieting con,pounds (ODC) 62, 68, 67
Ozone depletion potential (ODP) 62. 87
P
Pain 4, 24
Partners lii Cara Solutions (PICASSO) 45
Pantnorship for Prescription Assistance (PPA) 39, 48
Pantnership for Quality Medicai Oonatlons
(POMO) 13
Patient and medical group transparency 12
Patlant pnivacy, night to 90
PEPFAfl 49
Pfizer Mimei Health 4, 29
Pfizer Board cl Diroctors 5,75-79
Pfizer Australia 93
Pfizer Canada 42
Pfizer Canina Tumor Biospeciman Bank 29
Pfizer China 94
lI2J] 4:1
Pfizer Compliance Eduoation Center 77
Pfizer Corporate Connpliance Program 77
Pfizer Europe Msory Council 86,91
Pfizer Foundation 36,40
Pfizer Germany4l
Pfizer Global Health Felows 8, 37, 43, 44, Pfizer Global Policy on Interactions
with Heallhcare Professionais 83
Pfizer Health Solutions 46, 47
Pfizer Helpful Mswers 9, 39, 48, 84
Pfizer Hong Kong 49
Pfizer Indonesla 42
Pfizer Israel 92
Pfizer Japan 43, 93
Pfizer medical governance 52
Pfizer Policies on Business Conduct 75,77
Pfizer Pra 81, 82
Pfizer SpaIn 42
Pfizer Suzhou 95
Pfizer 'Thailand 92
Pfizer values 3
Pfizer Wornen Summit IDO
Pfizer World 101
lhe Exchange 101
Pfizer's Corporate Govemance Commlttee 76
Pfizer's leadlng medicines; 4
Pfizer's PoliUcal Milo,, Report 87
Pfizer's transiormation 98
Phanma Futuros 1112
Pharmaceutical and Medicai ~cos; Ageccy
(PM0A), Japen 93
Pharmaceutical Benefits Scheme P85) 93
Pharmaceu cal lndustry Labog
Management Association ID
Phermacetjtical Research and Manufacturem
Association (PhRMA) 26, 30,
Pham,aceoticajs in the e,Mronment 68
PhATE Model 68
Philippine Association of Diabetes Educators 43
Photovallalc solar panela 64
PhRMA Discoverers Award 31
Posl-traumatic stress disorder (PTSD) 42
Past-madçeling 53.55
1
commitments 55
swdles 53
fransparency 55
PowderMed Ltd. 21
Prescription Drug Usar Fee Act (PDtJfA) 88
Prescription medicine advertislng 84
Product Medical Review Comrniltee 53
Progresso an 2006 commitments 8-9
Project Hope 49
Project Leonardo 39
Publlc pollcy 85
Around fite World 92
Europe9l
United States 87
Publlc-private partnershlps 21,30
QEII Health Sciences Centre Foundation 42
Qua)ity, imprang 104
R
Radia frequency identification (1FID) 57
Rebif 4
Reducing casta 104
Reduclng wasto 66, 67
Relpax 4
'Reporta froni the Road 101
Responsible Contracting Initiative 104, 106
Revaflo 4
Right Flrst Time training 98, 104
Research and development 16, 18, 22-24
pipo/iria 22
pipeline transparency 24
Ridley, Or. Rabert 21
S
Safety cultura 70
Salas force 81
global coce o! conduct 83
number one mnking 82
ràsfnictuüng 83
San Francisco AIOS Foundalion,/Pangaea
Global Foundation 48
Schistosorniasis 21
Scnipps Research Instituto, The 30
S.E.E. Change/Climate Resolve 7
Selzentryi/Celsentni (maravlroc) 18, 20,23
Shanghai Center for Disease Prevention
and Control 95
Shanghal Research & Develapment Conter 94,95
Shasing the Caro 48
Sheet Metal Ykrkers Intemational Association 10
Simmons Leadorship Conference 100
Slovenlan Diabetics Assoclation 44
Slovenian Heart Foundation 44
Smoking cessation 19,91,95
Song Jiang Llniversity Town 95
Southem HIV/AIOS Prevention Inlilative 40
Steere, Jr, Wililam C. (Director) 76.78.79
Stenn ceIl 'pclicy 28
Supplier Diversily Program 104,106
Sustainable development 94, 95
Sustainable enterprise 94, 05
Sustainable Forestry Initiative 105
Sutent 4,19,24,31
Pft:er 2007 C orporufe Reeponsibilitv .k.'pofl
117
HSÇ
TEM Projeot 41
Tochnology and Innovation Strategy 8
Tho AIOS Subort Organlzation (1'ASO) 48
Therapeutic Arca Medical Revlew Comrniltee 53
Thorapeutic areas (iAs) 24
Torcotrapib 27
Total Injury and Illness Rato 71
Tranzparency International (11)7
Sfeodng Con,miftee on Business Principies
for Countering Driber, 7
Troat, Teach, Build, Serve 35-45
Trovan 26
Tuck School 01 Business Minority Executivo
Education Program 106
Tufts Conter for the Study o? DnJg Dev&opment 27
Tnisly, Juanita 44
WalerAid 45
Way2Go. For a Healthier Vou 41
llness 101,àWoAse4
Wildlitê Habitat Council 73
Womon Impacting Publlc PIicy 10
Womenin Loadership 100
Woryten's Buslness Enterpdso National Counci
(INBENC) 106,107
Worldng Mctlior magazine 102
Workplace safety 69
Wo,ld Health Organization 18, 20,49
Hóafth Evidente No? work 10
11sf of essentiai medioin 90 -
•1,
1
-
SAFE 35
Special Prog,sm for Reseamh and Training
In Tmpiãai DLõses *WHOITDR) 21
World Resources Instituto (MO 63
u
linited Nations Global Compact 7, 61
United States ErA Climate Leadors 7, 62
tinited Way o? Micros 48
University o? Michigan 98
Unlversily of Pennsylvania 42
Unlversity of Texas-Pan American 37
I.Jrban League's Charnpion of Diversity Award 102
1!A
Vorsipan 82
Vfen& 4, 68
Magra- 4, 56, 57, 95
VcIatLle organic ?ornpounds (VOC) 61, 66, 67
118
Jccr 2007 Q'rpnrate Rcsponaihility Reor!
x
XaIatanaIao o m 4
-]
...................
-
- Zilhromax 21, 36;9
Zilhkomíx°/chIo8uid 21, 24
Zmax4
ZoIofr 4, 68
ZonMW45
Zy*leo 84
ZyVOX° 4, 31
INDEX
A
t
A
s
:4•
9
t
!Wx!:r:H.s GLOBAL LE AI) ERSIÍIP POSJTIQNÇ
t
L
-
-
Largest_Selling Biotechnoloy
B
grami
Enbrel®
ir
-
Number One Antidepressant: Effexor XR®
WoHdLead:ng Vaccine
-
Top.Ranked I.V A
Best SeIIing Adult Vitamin: Centrum®
:
Leading_áIciurn• Supplement Càltrate®
•
j
*by revenue 2007
2 On the Cover
-'
L
Today, children in emerging
markets like Mexico and
in dozens of other countries
around the world are
benefiting from the extraor
dinary advances in disease
prevention that have come
from Wyeth Vaccines. Now
Wyeth is hard ar work
developing next-generation
vÍccines to protect both
children and adults.
r
Contents
1
Ãeport to Stockholdors
7
Wyeths øipeline
for Innovation
8
MU
Highlights from NCR í,
Wyeth's Lato-Stage
Drug Developnient
10 WyethVaccines:
A World to Protect
32 Financial Review •1fl
34 ljirectors and .Officers
3. Wyéth Worldwide
36 Corporate Data
IBC Selected Products
from Wyeth
Wyeth at a Glance
Wyeth is one of the world's largest research-based
pharmaceuucal and health care produccs companies
Ir a leadé} rn the disco?y, developrnent,
marketing of pharinaceuticals,
manufáãüriáÈ
bfotechnology products, vaccines, non-prescription
medicines and animal health care products that
irnprove the quality of life for people worldwide
The Company's major divisions include Wyeth
Pharmacedticals, Wyeth Coi'isumcr Healthcare and
Fort Dodge Animal Mealth,
4ÕEi
Eis
REPORT TO STOCKHOLDERS
16
LW
w
th delivered a very strong financial performance ii 2007,
mainly driven by the fast growth of our biotechhology prodJcts Enbrel
and Prevnar. We introduced new products - Torisel and Lybrel - and
continued our rapid expansion into China, the Middle East and Latin
America. We also expanded our aggressive cost-management efforts. As
a result, we were able to produce record saies and earnings in 2007 and
also were abie to increase our dividend to stockholders. in addition, we
implemented important Ieadership changes, effective in janukry 2008,
that were well-pianned and efficientiy executed.
While we did not secure ali expected new drug approvaIin 2007, the
recent approval of Pristiq for major depressive disorder and of Xyntha
for hemophilia A points to our abiiity to execute on this fronè. To achieve
sustained success, Wyeth Research is undertaking a number of breakthrough initiatives - strategies to address the chalienges posed by an
ever-changing regulatory and public health environment aropnd the
world. A key outcome of this project isto establish the differntiation of
our product candidates to ensure a greater value propositioI,to key
stakehoiders: patients, physicians, payors and regulators.
The at-risk launch by a generic manufacturer of a generic version
ofWyeth's proton pump inhibitor, Protonix, iate in 2007 iii4strates one
of the importam chalienges façed by innovation-driven companies like
our own. In response to loss of Protonix saies, ia 2008 we irtroduced
Project Impact, a corporate-wide initiative to adjust down our infrastructure and reduce our operating costs.
Our goai remains to protect and sustain our important ipvestrnents
in rcsearch - well illustrated by Wycth's current projects in is fight against
/ Aliheimer's disease. Research and deveiopment is the engine, that drives
our Company and poises us for great possibihty - the oppottunity
to make an important difference in the health and well-bein of people
around the world.
L1
Robert Essncr, Chairinai, of the }oard,
and Bernard I'oussnt, Presidenc and
Chief Exccicive Officer
e
1
Financial H ig h Iig hts
Voar Ended Decémber 31,
In thousands except per share amounts
Net Revenue
Net Income
Diluted Earnings per Share
Dividends per Comm!n Share
Total Assets
Stockholders' Equity
1
2007
2006
$22,399,798
$20.350.655
4,615,960
4,196,706
3.38
3.08
1.06
1.01
42,717,282
36,478,715
18.210,535
14,652,755
Financial Highlights
jtions about the emergence of gene
(fexor XR and Zosyn in our plans
ur operating resuits for 2007 helpe
strong foundation on which to bui.
ing a company-wide effort in 2008 to
Wyeth's worldwide net revenue for the 'y
)st structure, reduce expenses and
Euctivity opportunities. Among other
10 percent to $22.4 billion. This was led
ive wiii heip guide our Company in
growth in Pharmaceuticais, with seven ç
force by as mueh as 10 percent over
chises each achieving more than $1 biiiii
rs.
multibiilion-doilar biotechnoiogy produ
i1ient organization, with a proven
and Prevuar— demonstrated especially s
iercoming chalienges. As you will see
growth, positioning Wyeth as the world
Lnnual Review, our people, our
biotech company by revenue. Biotechno
resources, our products and our
represented more than 35 percent of
new
product pipeiine provide
our 2007 pharmaceuticai revenue,
us
with
a strong base from which to
up from 17 percent in 2002.
continue building our Company.
Consumer Heaithcare revenue
- grew 8 percent, and Port Dodge
oftransitionan dçrogre
Wyeth Pharmaceuticals
-' Animal Heaith revenue increased 11
for
our
Company,
as
we
percent, surpassing $1 billion in saies
2007, Enbrel, marketed for both
for the first time in its history.
ri ri ,n nrnvwth•1 UfSUO
Inrheumatoid arthritis and psoriasis,
Wyeth's reported ner income and
diiuted earnings per share for 2007
innovation a fl(i ntinue to generated $5 billion in global saies,
making ir the industry's largest
were $4.6 billion and $3.38, respeco
further
look
for
way
selling biotechnology brand. Net
tiveiy. Before certain significam:
saies
in North America - where we
items, ner income was $4.8 billion,
erformance.
imprové our
co-promote the brand with Amgen
with pro forma diiuted earnings
Inc. - exceeded $3 billion. Sales
per share up 12 percent to $352, a
in
internationai
markets
- where we have exclusive rights
third consecutive year of double-digit pro forma earnings
to the product - grew to more than $2 billion, an
growth. An in-depth review of our 2007 financial perin'rease of 36 percent over 2006.
formance can be found in the Wyeth 2007 Financial
Sales of Effexor, marketed for anxiety and depresReport, which accompanies this Annuai Review.
sion, grew to aimost $3.8 billion in 2007, increasing
2 percent over the previous year and maintaining the
Outlook for 2008
bdnd's position as the world's iargest seliing antidepressat. This was achieved despite a wide range of
view 2008 as a year of transition and progress
chiienges,
inciuding emerging generic competition to
VV for our Company, as we drive growth, pursue
th product in some markets.
innovation and continue to iook for ways to further
In February 2008, we received U.S. Food and Drug
improve our performance.
Administration
(MA) approval to market Pristiq, a
A near-term chalienge for the Company is the impact
once-daiiy
serotonin-norepinephrine
reuptake inhibitor,
of generic competition for several of our major products,
fof
the
treatment
of
adult
patients
with
major depressive
including Protonix, Effexor XR and Zosyn. For Protonix,
we believe our patent, which runs through 2010, is strong. diorder, a serious medical condition that affects more
proConfronted with a generic manufacwrer's "at-risk" iaunch th6 120 million adults around the world. Pr!stiq
vides
efficacy
at
a
simpie,
once-daiiy
dosage
without
the
of a generic form of Protonix, we decided in January to
néed
for
titration,
providing
most
patients
the
appropriiaunch our own generic through a designated distributor.
We also are vigorousiy pursuing patent iitigation to protect ate thcrapeutic dose right from the start of treatmcnt.
We also received approvai for Xyntha, an improved
our rights to this importam: product. In addition, we
recombinant factor VIII formulation, both for the control
atd prevéntion of bleeding episodes and for surgicai proplyiaxis in patients with hemophilia A.
O
C
E
frIA
:ii
Our irnpact on human heaith around the world consaies of $430 miilion, a decrease of 5 percent for
tinues to be defined by innovative products iike Prevnar
In May, Wyeth received U.S. market clearance for Lybrel,
(Prevenar outside the United States), a first-in-ciass vaçthefirst and oniy FDA-approved low-dose combination
cine to help prevent invasive pneurnococcai disease in
oral contraceptive with unique 365-day dosing, which
infantis and chiidren. Globaiiy, Prevnar achieved net saies rnakes it possibie for some wornen to be period-free.
1
of $2.4 biiiion, ao increase of 24 percent. Much of this
Torisel was approved in the United States during the
growth carne frorn inciusion in national irnrnunization
second quarter of 2007 for the treatrnent of advanced
prograrns around the world, volume growth in the U.S.
renal celi carcinoma. li is the first targeted therapy with a
private market and continued geographic expansion.
prcven overali survival bdneflt in patients suffering frorn
This past year, we produced more
this cancer. Torisel uptake in its first
than 45 miHion doses of Prevnar.
few rnonths has been strong, with
The vaccine is availabie in 86 coun$27 rpiihon in 2007 saies. European
Qur impact on human
tries, 19 of which have inciuded ir
Medicines Agency approvai was
health around the world
received in Novernber, and saies in
in their nationai irnrnunization
the European Union (EU) have begun.
prograrns. In 2007, reguiatory fihings continues to be defined
seeicing approvai for Preamar were
byinnovative products
submitted in China, Russia and
Wyeth Nutrition
Japan, which, combined, account
like Prevnar, a
for about 19 rniiiion new births each
nTyeth Nutrition is a woridwide
help
year. In deveioping countries, we
In-c!ass vacc me
ieader in the deveiopment
are working cioseiy with the internaof scientificaiiy advanced nutritionai
prevent inva ve
tionai health communiry to help
products for infants and young chil---4
chiidren gain access to this impordren. A comrnitrnent to research
pneumococc / disease
tant pubiic heaith intervention.
has enabled the Cornpany to achieve
r
Ifllnf.8fltS8Th chilidren.
Wyeth vaccines, inciuding Preamar,
numerous annovations, rnost recently
are the subject of a speciai report
with the first-to-market addition
that begins on page 10.
of lutein to the prerniurn Go!d product une. In 2007,
In 2007, saies of Zosyn, a broad-spectrurn intravenous global saies increased 20 percent to $1.4 biiiiion, with the
antibiotic, grew 17 percent to becorne oniy the second
G&!d hne accounting for the rnajority of saies. Doubleproduct in its ciass to exceed the Si biilion rnark in
digit growth was recorded in each of the three regions in
annuai saies. During the year, the Company cornpieted, in which Wyeth Nutrition competes. A key driver for
rnost markets around the world, the introduction of a
Wteth Nurrition's growth has been its focus on growing
new and irnproved Zosyn formuiation designed to rneet
markets in Asia, Latin America and the Middie East. To
current speciflcations for particuiate matter for injectable
met the increasing dernand for high-quaiity formulas, the
drugs. Compound patent protection for Zosyn in the
Crnpany recently cornpieted nutritionai manufacturing
United States and Europe expired ira 2097, and the prodfaciity expansions in Mexico, and íurther expansions are
uct is facing generic competition in a number of markets
under way in the Philippines and Singapore. A new faciuity
in Europe and eisewhere around thc world.
aiso is planned in China, which, with growth of 38 percent
Tygacil, oijr newest entry in the I.V. antibiotic market, in 12007, becarne the iargest Wyeth Nutrition market.
continued its growth, particuiariy for use against drugresistant strains of bacteria. Sales for Tygacil nearly
er Healthcare
doubied in 2007 to $138 miiiion, and ir now is approved
in 66 rnarkets. Regulatory fihings were made during
"oral global net saies rose to $2.7 biiiion in 2007,
the year for use of Tygacil in cornrnunity-acquired pneuan increase of 8 percent, with international net saies
monia, which currentiy accounts for 20 percent of ali!
16
percent. Wyeth Consurner i-Ieaithcare executed
in-hospital, I.V.-adrninistered antibiotic usage.
ortant brand extensions during the year with the
In women's heaith care, 2007 global saies of the
roduction of Advil Liqui-Geis on a global basis,
Pren,arin farniiy were consistent with the prior year ar jut
atrunz Cardio in the United States and Centrum food
over $1 biilion. Wyeth contraceptive products dehvered
de in China. Overali, key growth drivers inciuded
the Advil franchise, which grew 11 percent, in pari: as a
result of significant growth in Advil PM;, Centrum viranuns, which grew 7 percent; and the Caltrate brand of
calcium suppiements, which saw 16 percent growth. Also
driving growth were strong performances in a number
of internationai markets, inciuding Brazii, which grew
40 percent; Canada, up neariy 13 percent; and italy,
with saies up more thah19 percent. As a result, Wyeth
Consumer Heaithcare remains among the top five overthe-counter (OTC) companies in the world, with Advil
and Centrum t*o of the top five global OTC brands.
b
We have outlined a number of late-stage devei
meiit highiights in the chart on pages 8 and 9. These
incude three novel oncology agents, a monocional
antibody to fight Aizheimer's disease, a next-generation
vaccine, an antipsychotic, an oral therapy for opioidincuced constipation and a new therapy for river
b1idness. We also have programs progressing throiigh
deeiornent that seek to expand existing products with
ne*iy identified uses and indications. We are hopefui
forU.S. approvai in 2008 for Relistor in subcutaneous
forkh to treat opioid-induced constipation in patients
iri jalliative care settings. We expect that Viviant, being
de'eloped for the prevention and treatment of osteoAnimal HealthCare
poosis, wili be reviewed ar an FDA advisory committee
1
me
Aprela, under investigãtion for postmenopausai
ales in 2007 grew 11 percent over 2006, to exceed
vaomotor
syrnptorns and the treatment of postS $1 bilhon for the first time. Port Dodge significantiy
menopausai
osteoporosis, is targeted for regutatory
enhanced its leadership position in the iúdustry through
fiuig in the flrst haif of 2009.
the U.S. and European introductions of ProMeris, a new
In addition, we are pressing forward on many fronts
une of fica and rick products for cats and dogs.
in
new
product deveiopment. For exampie, we have nine
lis hvestock product business experienced 12 percent
projects in active development for
global growth, led by strong saies of
improved symptomatic treatments
cattie products in the United States
or disease modifiers for Aizheimer's
and Europe and a fuli year of saies of
We are sha rply focused
disease, using smali moleçuies,
Suvaxyn PCV2, a new swine vaccine.
bioiogics and vaccines. We also are
onbiologic
s.
As
a
result,
Aiso achieving signiflcant saies was
expioring
a wide range of unique
the poultry product hne, up 13 pernearly one-thirá of
compounds
with novel mechanisms
cent, with a broadening portfoiio of
ofaction for schizophrenia, bipolar
is
our current
vaccines, inciuding an avian influenza
disorder, major depressive disorder,
vaccine to address the potentiatiy
com poied of
other
cognitive disorders and chronic
pandemic Asian HSNI strain. Port
pain.
Though
stiii eariy, these comDodge also remained the overali
late
nology ca
pounds potentialiy offer significam:
leader in the U.S. companion animal
products and vaccines.
improvements compared with
biological vaccine market. During the
currènt
standards of care. In the caryear, an irnportant new registration
diovascular
arca, we are deveioping
was approved for the prevention of a
nw
compounds
that
focus
on
reducing
cardiovascular
particuiariy virulent strain of cahcivirus in cats. To accomnõrtaiity and the complications of diabetes. In addition,
modate future growth, Fort Dodge is epanding its
we
are investigating innovative therapies in gastrointestiresearch facilities in the Kansas City metropoiitan arca.
nal disease and asthma.
To address the chalienges of getting new drugs
Research and Development
approved in an increasingly difficuit environment, Wyeth
Rsearch is undertaking a breakthrough initiative. lis
yeth's research and deveiopment organization
s8ope
inciudes ensuring that new product track candidates
draws upon expertise in muitipie discovery piatci,
ariy
demonstrate a vaiue proposition ; deveioping preforms. This means that, in addition to traditionai smàil
dictive
safety and efíicacy modeis that are the best in the
moiecules, we are sharpiy focused on biologics. As a
industry;
and improving the process for assessing benefitresult, neariy one-third of our current pipehne is composed
risk during development. This breakthrough project buiids
of biotechnoiogy candidate products and vaccines.
on Wyeth's existing R&D productivity initiatives and is
intended to formuiate strategies for sustainable success in
tie years to come.
W
E'
Social Responsibility Initiatives
n everything we do, our goal is to act responsibly - not
only for the sake of our stakeho!ders but for the world
at !arge.
Two examp!es are prominent. The flrst is the ro!lout
Prevnar
of
in the poorest of countries to make this
!ife-saving vaccine more accessible over time to mi!!ions
01 chi!dren. In addition, since 1996, we have been
working with the World Hea!th Organization to develop
moxidectin, a fixst-in-c!ass agem for te treatment - and
potentia! eradication - of onchocerciasis or river b!indncss, a disease that is endemic in sub-Saharan Africa as
well as in parts of Centra! America and the Midd!e East.
More than 125 miltion peop!e worldwide are at risk with
more than 17 mil!ion people infected with the disease.
In 2007, we contributed approximately $12 million
- in products to deve!oping countries, inc!uding about
700,000 doses of Meningitcc vaccine to prevent
meningitis C and 25,000 doses of Prevnar to arcas of
Peru hard hit by an earthquake earlier in the year. What's
more, our U.S. patient assistance programs continue to
provide Wyeth products at no charge to those unable
to pay. More than 145,000 patients benefited from the
program in 2007, with product donations va!ued at
over $143 mi!Iion.
I
Ô
BERNARD
11
PoussoT, WYETI-I'S
WEW 0W
In !ate September 2007, Bernard Poussot was e!ected
President and Chief Executive Officer of Wyeth,
ffectiveJanuary 1, 2008. Fie succeeds Robert Essner,
who announced his plans to retire from the Company.
v1r. Essner wi!l continue as Chairman of the Board
of Directors for a period of transition.
Poussot began bis career at Wyeth in 1986
»s President of Wyeth France. In 1996, he was
appointed President of Wyeth-Ayerst lnternational
and a year later became President of the worldwide
business. In 2002, while continuing
President of Wyeth Pharmaceutica!s, he became
ecutive Vice Presidem of Wyeth, assuming
ditionai responsibiity for Wyeth R&D. In 2006,
r. PouSot was promoted to President and Vice
iairman of Wyeth and, in january 2007, to the
sition of President, Chief Operating Officer and
Chairman of te Company.
Management Changes
n the sidebar to this lene; you can read more abour
Iour CEO transition announced during 2007. In addition, we have other changes to report. We're pleased
that Robert M. Amen, Chairman and Chief Executive
Officer of International Flavors & Fragrances Inc., has
joined the Company's Board of Directors, bringing us
bis wide-ranging expertise in consumer products. At the
same time, we offer our thanks to Wa!ter V. Ship!ey, who
stepped down from te Board in 2007 in compliance
with te Company's mandatory retirement po!icy, for bis
years of devoted service. We also want to express our
appreciation to Ivan G. Seidenberg, who afrer bis years
aí dedicated service, resigned from the Board.
We have made a number of corporate management
!eadership changes to prepare Wyeth for continued
growth and to capitalize on te executive ta!ent within
the Company. Gregory Norden became Senior Vice
President and Chief Financial Officer. Fie has been
with the Company since 1989 and previously was
In announcing this succession, Mr. Essner noted,
"Bernard is exceptiona!ly we!l-qualified for this
!role, and we have built a wor!d-c!ass management
team to support him and te Company. Mis election
is a result of the Company's ongoing succession
planning process - an important focus ofWyeth's
Board of Directors and managernent."
Mr. Essner's !eadership helped prope! Wyeth to
the top der of the global pharmaceutical industry.
During bis tenure as CEO, revenue increased from
$14 billion in 2001 co more than $22 bi!lion in 2007,
accornpanied by significant increases in earnings
per share. Mr. Essner was responsib!e for initiating
a transformation of the Company's research and
drug dávelopment process, advancing a new model
for pharmaceucicat saies in the United States
and successfully navigating the Company through
significam litigation chailenges.
O
CFO of Wyeth Pharmaceuticals. Denise M. Peppard was
codntries, the lives of hundreds of thousands of children
promoted to Senior Vice President, Hunan Resources,
evehtuany will be saved. We know that Enbrel aiready
with the retirement of Renê R. Le*in, who was instruhasmade an extraordinary difference in the lives of peomental in deveioping a performance-based culture during pie!who have benefited from its use.
his 13 years with the Company. Mary Katherine Wo1d
To continue and expand this record of achievement,
was promoted to Senior Vice President, Finance. The
we1 will remam fiexible and resihent in seeking berter ways
Board eiected Andrew E Davidson as Vice President,
to deliver accessibie and affordabie hea!th care.
Internal Audit. Final!)', in February 2008, Timothy P.
As *é do aii this, we will be guided by five principies
Our vaiues. Science and innovation. Leadership. Sound
Cost joined the Company as Senior Vice President,
flnhnciai decisions. And belief in our nobie cause Corporate Affairs, bringing to Wyeth many years of
imroving the lives of peopie through mediëal advances
experience in communications and investor reiations.
Mr. Cost repiaces Marily H. Rhudy, who has announced and putting the patient ar the center of everything we do.
We thank our coileagues ar Wyeth for their innumerpians to retire. We thahk Ms. Rhudy for her many
abie contributions - and for their dedication to reshaping
contriburions to our business.
There also were a nurnber of organizational changes
ourl Company in order to make it stronger. As we iook
to the future, we believe that the support and hard work
within our business operations. Joseph M. Mahady was
of our peopie will help us to grow, to prosper and to
promoted to Presidem, Wyeth Pharmaceuticals, and
lea'd as we buiid the most trusted and respected health
remains Senior Vice Presidem, Wyeth, Geno J. Germano
care company in the world.
became President, U.S. Pharmaceuticais and Womén's
Heaith Care. U!f Wiinberg was promoted to President,
EMEA/Canada and BioPharma, and remains Senior Vice Sincereiy,
President, Wyeth. Ia the animal heatth division, Richard
R. DeLuca, Jr., was named President of Fort Dodge
Animal Heaith with the re;mf E. Thomas
contributions to Wyeth. Cavan M. Redmond was promoted
Bernard Poussot
Robert Essner
to President, Wyeth Consumer Heaithcare, while
Presidem and
Chairman aí the Board
Douglas A. Rogers became President of U.S. and Global
Chief Executive Officer
New Business for the division.
Wyeth's abi!ity to develop talent, as well as to attract
February 29, 2008
new leaders, high!ights the continuity aí cuiture and depth
of experience that is critical for our future. We wish ali!
those with new responsibi!ities great success and wiil give
them our fuil support, and we thank those retiring from
the Company for their many contributions over the years.
The outstanding ieadership, expertise and experience that:
1
our entire managenlent team brings to Wyeth shouid continue to transiate into successful solutions to importar
heaith probiems worldwide.
I
The RoadAhead
e are immensely proud of aii wé have accomplished during the past year and the past decade.
The capabilities we have built in R&D and across the
Company are de!ivering innovative products to save and
improve lives. We hope our work on Alzheimer's disease
will rnake a difference for the patients and families who
suffer. We believe that as Prevnar is intrp duced in more
W
6
Wyeth's PipeÍine for Innovàtiõh
During 2007, Wyeth filed four New Drug Apícations (NDA) in
the lJnited States, including two that represented new molecular
entities. Sincó 2004, Wyeth has delivered on its goal offiling
two NDAs each year for new molecular entities. In addition,
over the past seven years, 91 new candidate medicines were
placed into development, with 72 advancing to human clinical
trials.The majority of these have the potential to be first- ar
bdt-in-class therapies.Thia chart prescrita a snapshot, as of
February 2008, of new drugs ar potential new indications/
fonnulations firam Wyeth the: are in advanced human trials ar
uri-der review by regulatory agencies.
Wornen's Nealth and fone
es and Jnfectious Disease
Lybrel/AnyC (levouiorgestrel/EE)
Continuous contíaception (EU)
(tiúóàyciine)
Diabetic foot infections
Prernenstrual dysphoric disorder
Hspital-acquired pneumonia
Pristiq (desvenlafexine succinate)
Vasornotor syniptoms of menopausa
Puivear 13
Prvention of pneumococcal disease in
íinfants and cliildren Mc monfits to fuve years
Viviant" (bazedoxifene)
Postinenopausal osteoporosis prevention
Prevention ci pneumococcal disease in
high-risk individuais and adults> age 50
Postmenopausal osteoporosis treatment
AprelC (bazedoxifene/cgnjugated estrogens)
Posimenopausal osteoporosis
occel B vaccifle
i of meningococcal disease in
ents
VasomotorsyTmptoms of menopausa
Neuroscience
(river blindness),
withWHO
Bapineuzumab (AAB-001)
Alzheimer's disease
ACC-001
Alzheimer's diüase
Idflaninatorv Disease
Pristiq" (desvenlalaxine succinate)
Neuropathic pairo
Aamkinzumab (IMA-638)
Athma
Fibromyalgia
Oncology/lnirnunotogylHetnophilia
SAM-531
Alzheimer's disease
lrotuzuniab ozoúamicin (CMC-544).
F6lIicular non-Hodgkin's lymphoriia
Vabicaserin (SCA-136)
Schizophrenia
D!iffuse lare B-cell lyniphoma
Gastrointestinal
inversion in Tiver transplant
Relistor (methylnaluexone)
Subcutaheous for opioid-induced
constipation in advanced medical illness
iFact& AF (antihemophilic factorrecombinani)
I.V. for post-operative ileus
Oral for opioid-induced constipation
Mande celI lymphoma (EU)
'
Bosutinib (SKl-606)
dhroníc myeloid leukomia
Breast cancer
Neratinib (HKl-212)
Rraast rnotar
Phase 2 - Oeter,nirtation aI safo and ettectivo dosage for an
experimental medicina, goneraily conducted is hundreds 61 patients
Pinas. 3 - Oeterrniration si overali berietu/risk ratio for an
experimental medicina, generaily conducced is tousands ad patienta
Regulatory Revlew - Evaluation ai oafeuy and el5cacy data
by govemmental regulitory agencies
-
«4
~-
Wyeth's development pipeline of new
(
therapies continues to grow in breadth, depth
innovation Eleven potential newtherapies or uses tor ,
sigriifiàant existing drugs are in Phase 3 devàlàpment,
and another eight currently are awaiting approval in
Highlights lrõm Wyeth's
Late-Stage Druõ Developmetit
Candidate
Stage
Prevnar 13
Bapinounlmab(AAB_OQI)
For infants, childieú
and adulta
Coilaboration wirh
Elan Corporation, plc
Phase 3 — Infants
and children
Phàse>3
Phase 3— first-tine CML
Phase 2£ breast cancer
Phase 2
Current thera,ies for
Alzheimer's disease
provide some symptomatic relief but do
nor alter the underlyin
disease pathology.
Thereís a need for safêr
and more tolerable therapies capableof inducing
tapid and long-lasting
remissions in newly diagnosed CML patients.
Opioid anatgesics ofiS
produce constipation as a
sitie effect, which can he
a barrier to effective pain
management. Currently,
chere are no approved
medicatidns rhar specifically target OIC's cause.
By biiding to ali f rms of
beta-amyioid in the brairi,
Bosurinih is an orly
icvive inhibitor of src and
abi kinases, proteins
involved in tumor celI
growth and níetastasis.
Relistor is a selecrive itisiopióid receptor ancagonist
that blocks the péripheral
side effects of opioid analgesics without interfering
with pain relief.
This compouud potentia11
offd] ia excellent sitie
effect proflie in conparison
uiithimarinib and ocher
.second-generarion abl
kinase inhib itors. In
imatinib-resistanrlintolerant
patients, hosutinib exhibits
response rates comparabte
with or hetter than
li is designed to rapidly
Phase 3
Unmet
Medical Need
-
Mechanism
;( otAction
Whats
Diffurent
For infants ahd children,
Frevnar 13 expands protec-
The vaccine is designed to
induce functonal antibody
responses to ali 13 vaccine
serotypes, thus prornoting
clearârice of the bacteria
by antibodies binding to
piemüococca1 capsular
polysaccharides.
For infants and children, ir
is expected to be the mostcomplete Wccine for the
globa l prevention ofserious
pneui'nococcal disease and
active otitis media. For adulta,
ir is the first conjugate vaccine
for adult pneumococcal
disease, including pneurnococcal pneumonia, with the
potential for long-term
protectioi through boosting.
8
Sosutinib (51(1-606)
Reuno,
Oral forniulation
Collahoratkn with Progenics
Pharmaceuticals, Inc.
Adults
tion agaifist aix additionab
pneurnococcal diseasecausing serotypes, including
19A. For adulta, ir may
provide substantially
greater efficacy against
pneúrnococcal disease tban
current srandards of cate.
e
f
hapineuzuifiàb is thought
to help clear dam aging ;
beta-amyloid plaques fr?m
the brain and also neutralize neuro-tócic forrosof
beta-arnyloid, thereby havT
ing a fundamental inipact
on the disease process.
rheipy for A1zheirner'
disease thaEiay kàlt 01
modify its course.
other second-generation
abl kinase inhihitors.
reverse OIC without
reversing analgesic effects.
FtG(W
lhe Lhiitéd States orthe European Union. Most
important, 75 percent of lhe projects inWyeth's o'erali deveiopment portfoiio, inbiuding those in eariier
stages of development are new molecular entities
dí NMEs.These represent novel or innovati*
cbnipoun
and socie
drugs or
irom Wye
.under re
that offersignificantvaiueto pótients
This chart presents á snapshot of new
,ificaiit new indications/formuiations
that are in advanced human triais or
v by regulatory aginciü.
Vabicaserin (SCA-136)
lnotuiúmab ozogarnicin
(CMC -544)
CoIiaboti&i wirh
Coliaboration wirh
UCB Group
Folticuiar non-Flodgkin's
iymphoma (EL NHL)
and diffuse large li-deli
iymphoma (DL BCL)
HER-2 positive
meiastatic breast cancer
(initiai indication)
Phase 3 - EL NUL
I'hase2—DLBCL
Phase 2
Phase 2
Phase 2
Current treatments couid
benefir from reduced
toxicities and from
improvements in durajion
of remission, d,sease-free
survivai and quaiity of life
as weli as from reduced
supportive care costs.
In paúents whose nimors
recur after treatment wtth
trastuzumab (Hercepun)
there is a significant need
for alternative therapies,
shat can hait the concinued
growth of the tumor and
progression of cancer.
Riveriindiess is a devastating parasitic disease
predom,nantiy found in
Africa thats the secgnd
leading infdcrious cause
of blindnesk.
Current antipsychotics
for schizophrenia offer
adequate symptdin relief
but often have significam
side efíects, indàding
weight gain and cardiovascular and merabolic problems. The relief of negative
- sympcoms and a reduction
of cognitive defects remam
iinportaiit unmet needs.
This anti-Cb22 antibody
calicheamicin conjugate
binds to thêCD22 receptor expressed by li iyrnphocytës ir' the body. The
compiex then is internalized by the ccii, reieasing
calicheamicin into the
ccli nucleus and inducing
celi death.
Ir potentially Is an irreversible inhibitor of erbli
tyrosine kinass, including
HER-2 and EGFR, which
are implicat&l in cancer
ce11 growth and division.
xidectiA ads 5h the
BA-A receptor chioride
mel cdiinlpidx to disccii niembranes ir' the
isite, ultixhateiy leadto às paralysis
Inotuzumab ozogimicin,
combined with rituximab,
has the potential to be the
first completeiy targeted
treatnient for nonHodgkin's lymphoma,
resulting ir' increased
efficacy and bettê? safety.
Through ar' irreversible
inhibition of erbli kinases,
use of neratinib tnay
resuit in the sustained qppression of associated
pathways, thts inhibiting
cancer ccii prouiferation.
Unlike currenr çreatments
thariiãy i4ave serious side
cífeas or &n oniy doútroi
the ciiseasd', ir has a unique
mechanisrh of adián that
may resuitjn complete
¶ ehmrntíà, bf the paras ite ,
ir' endcmiè arcas over tirjie.
t,
1
5-HT2C agonists impact
iliè activity of serotonin
receptors in the btain and
differentially moduiate
dopaiine reieaè ir' seve key pathways relevam:
to schizophrenia.
Vabicaserin potentialiy
trcats symptomswithout
the significant side effects
assõbiated with currendy
avaiiabie antipsychotics.
9
1
,,'
ç ~ -~
E
A Legacy ofAchievement
in Preventing Disease
T
he significam: impact of Wyeth's vaccines - and those of
its predecessor companies Lederle Laboratories and Praxis
Biologics - dates back more than a century. In theearly
1900s, the Company was involved in the commercial production
of smallpox vaccine. Ir later launched Dryvax, a highly advanced
version of the vaccine, and revolutionized smallpox vaccine
delivery with the introduction of the bifurcated needle. These
contributions helped lead to the worldwide eradication o f this
11
devastating disease. In 1906, Lederle became a major supplier of
the diphtheria antitoxin and later introduced the first coi1ibined
vaccine for preventing diphtheria, pertussis and tetanus. Lederle
also produced more than 600 million doses of the firse liye
trivalent oral poliovirus vaccine, substantially contributing to
the 1994 eradication of polio in the Americas.
As vaccine research and development took exciting new direcdons through emerging knowledge about viral and bacterial
diseases, Wyeth continued to press forward. Even as many others
abandoned vaccine research, Wyeth remained on the Ieaèling
edge in vaccine development. In fact, says Jim Connolly, who
heads the Company's Global Vaccines business unir, "Wyeth has
played a leading role in the introduction of some of the iost
significam: vaccine advances over the last century, and otr
commitment and excitement about vaccines today are stronger
than ever."
"One of rny tirst jobs after coming
here from Russia was with tire pneumococcal program at Praxis Biologics,
whicb later became part of Lederle
and then Wyeth. Our goal was tu
create a vaccine that woutd work in
infants by boosting their immune
response. Applying our knowledge tu
create such a complex vaccine and
malte it effective - that was the cttailenge. Not many people are lucky
enough to work on such a project, tu
actually set what a vaccine like this
can do and then help bring it te
the populations that need it most.
Tbat's very special7
Maya Koster, Principal Research Scientist,
Pharma R&D,Vaccines, and recipiani.
National Modal of Tnçhnølogy tor P,ovnar
Streptococcus pneumonias, bacteria,
magnified 25,000 times, is the
pathogen responsible for infections
such as bacteremia, sepsis and
meningitis as well as middle ear infections and pneumonia. Most at risk
are young infants and older adults.
EW
Greating ConjugateVaccines
-
In 1989, Wyeth's use of novel conjugation technologies lcd
co the introduction of groundbreaking vaccines, ones tiat were
effective in young children, ofíered longer protection aüd
reduced the rates of disease transmission. In many bacterial
diseases, the bacterium expresses a surface coat composed of
characreristic polysaccharides, which are long-Iinked súgar
molecules. Using conjugation technology, Wyeth scientists linked
these polysaccharides to a specific protein called CRM97 a non-toxic variant of diphtheria toxin. Doing so produced
vaccines that boosted the body's immune response and in-imune
memory, even in very young infants. Three innovative Wyeth
conjugate vaccines resulted from this technological breakthrough. The first conjugate vaccine, HibTITER, targeted a
bacterium called Haemophilus infiuenzae rype b (Hib), thus
he!ping to protect young infants from resulting infectipns that
cou!d Iead co severe meningitis, an inflarnmation of the membranes surrounding the brain and spinal cord. A seco rtd vaccine,
Meningitec, targers the meningococcal group C bacteiium.
This vaccine made a significant contribution to pub1icheaIth
in the Iate 1990s, when the United Kingdom experiened an
Wyeth's Meningitec, a vaccine against
meningitis C, was introduced in the
United Kinydom when the country saw
an alarming spike in cases, especially
in adolescents and young adulta.
"Wyeth has played a
leading role in the introduction of some of the
most significant vaccine
advances over the last
cenrury, and our commitment and excitement
about vaccines today
are strongcr than ever."
13
-J4
F
alarming increase in group C meningitis. After its 1999 introduction in the United Kingdom, Meningitec, along with follow-on
vaccines from other producers, led to the virtual eliminatjon of
the disease in that counrry.
The third vaccine - Preunar— was launched in 2000 in theUnited
States and now is avaílable in 86 countrjes. Prevnar is the first
and only pneumococcal polysaccharide-protein conjugate vaccine
approved for routine use in infants and young children. As»a result
11
of the extraordinary heakh benefits ir provides, Prevnar has
become the global standard in pneumococcal disease prevntion.
The vaccine focuses on the seven most prevalent pneumococcal
serotypes that cause the majority of disease worldwide. These
bacteria can cause severe invasive disease, including baderemia,
sepsis and meningitis as well as middle ear infections anã
pneumonia. Infants, children under the age of two and older
adults are ar highest risk because their immune systems are
less capable of fighting the disease.
In recognition of the pioneering sciénce employed!by Wyeth
in the development of Prevnar as well as its broad publiè health
impact, a team of Wyeth scientists was awarded the 2OIJS
National Medal ofTechnology - the highest honor the United
States can bestow for technological achievement.
PrevnarMakes a Significant Impa
on Pubtic Health
alter Orenstein, M.D., is a world-class infectious
disease specialist who today is Associate Director of
the Emory Vaccine Center. During bis leaderhip of
the Centers for Disease Control and Prevention (CDC) National
Immunization Program, Dr. Orenstein was pivotal in dcommending that Prevnar be included in the U.S. national
immunization schedule.
W
'Tracking of epiderniological trend
data predicted a peak in incidente of
meningitis C in lhe United Kingdom.
In 1992 lhe British govemment had
asked ali vaccine suppliers to accelerate development of new vaccines,
By November 1999, a national immunization campaign hegan with
Menlngltec,the only vaccine available
for lhe disease during the critical
winter peak months. Meníngitec
reduced infections by 76 percent, with
an efficacy of 97 percent in adotescents.Today, thanks to ar; effective
imrnunization program, meningitis C
infections have been reduced dramaticaiIy in lhe United Kingdom7
JufleWiflingharn,Vaccines Groop Product
Manager.Wyeth U,K.
"The health burden in the United States from pneumosoccal
disease in children was substantial ar the time," Dr. Orenstein
says. "You had bacteremia, meningitis and pneumonia1i li also
was clear that there was a substantial risk for young ch'ildren and
that the current pneumococcal polysaccharide vaccine 'as not
effective in that group. We looked to pneumococcal cohjugate
vaccine for a new answer."
Jerome Klein, M.D., now professor of pediatrics ar Boston
University School of Medicine, was on the Data Safety Monitor
Committee for the Phase 3 trials of Prevnar conducted by
Northern California Kaiser Permanente. "The committe broke
14
Thanks toWyeth's Prevnar, mililons
of children are protected from the
potentiatly devastating effects of serious
pneumococcal disease.
3
Fia.
the code when 17 cases of invasive pneumococcal disease were
identified among children in the triais. Ir was exrraordinar, to
recognize within seconds that every child who had received
Prcvnar had been protected and that the illness was conflred only
to those children who were not vaccinated." At the time of irs
approval, Dr. Klein deemed the vaccine "a big win for kid."
He recalis, "As soon as Preunar was available, pediatricians enthusiastically grabbed it. lis profile of efficacy and safery was very
advantageous. Universal irnmunization soon was recommended."
e
DPOE
Optimally, the vaccine is given in four doses. Dr. Klein explains:
"You want to starr as early as possible to capture disease in the
very young. After the first dose at two months, you get a minimal
1
anribody rise; at four months, an amplified rise; at six months,
a great rise because the infanr's immune system is more çapable
ar this time. Ar 12-15 months, a booster is adminisrered— to get
another substantial rise of antibodies. This takes you rhiough
the period of major vulnerability."
David Peristein, M.D., is Associate Medical Director and
Ambulatory Pediatric Director ar St. Barnabas Hospitaiin the
Bronx, New York. The hospital, located in a neighborhod with
explosive pediatric growth, receives more than 75,000 éediatric
visirs a year and has 45 pediatricians on staif. Dr. Perlstin
remembers what his work was like before the vaccine.
Navajo children in lhe southwestern
United States, at greater risk of invasiva pneumococcal disease than most
of the U.S. population, participated
in the clirtical trials that lcd to the
introduction of Prevnar.
"Before Prevnar, we erred on the sidè of doing everything possible
ar the moment - including administering every kind of tesi and
giving advanced antibiotics - because we knew the damaje that
invasive disease could do to our younger patients. Now oijir whqle
practice has been revolutionized. We watch and follow, e4ecially
when we know a child has received Prevnar. 1 can't remerhber
the last time we had a positive finding of invasive disease tiue to
Streptococcus pneumoniae."
The CDC recently reported that in 2005 there was a 98 perent
reduction in invasive pneumococcal disease caused by the seven
serotypes contained in Prevnar and a 77 percent reduction in
overali invasive pneumococcal disease in chiidren under ai tive
in the United States. "A great deal of the history of infectiôus
disease is tied to pneumococcal disease," says William Gruber,
M.D., Vice President, Wyeth Vaccines Clinica! Research. 7Being
in a position to see such a dramatic reduction in this disease is a
wonderfui history to be living."
Unexpected Benefit for Adults
What's more, there has been an unexpected benfit. "The kicker
carne from CDC and Kaiser Permanente data showing that
invasive disease among non-imrnunized individuais alsjhad been
reduced," Dr. Klein notes. A reservoir of immunity led to the
decreased spread of those diseases from infants to olde?siblings,
parents and grandparents."
So adults are being protected as well. The CDC observed a
76 percent reduction in the incidence of vaccine serotye disease
- especially pneumonia - among unvaccinated aduits over age
50. With fewer cases of pneumococcal disease in the overail
population, there are fewer chances of transmitting thedisease
to those over age 50 and especia11 to those over age 6 whose
immune systems becorne less efficient. This remarkableíphenom
non, known as "herd immunity," underscores the broad public
health impact of the vaccine.
i
"What's unique about vaccines is that they have both apri individual and a societal effect," says Peter Paradiso, Ph.D., had of
Scientific Affairs for Wyeth Vaccines and a scientist wh1b has
worked on Prevnar for many years. "Vaccines don't jut prevent
disease in the individual, they also protcct society. We hw
their power years ago when mass polio vaccinations pSvented
an epidemic.
"One of the nicest aspects ei vaccine
devIopment is 11w almost immediate
gratification that follows.Vou have
a disease hurden in a poputation,you
introduce an efiective vaccine and,
in a few years, the disease burden is
reduçed substantially.You can seo the
lnipact very quickly.The concept ei
reducing ar even eliminating seiious
iltness and death in infected kids in
onty a few years is incredibte."
Emilio Ernini, Ph.D.. ExecutiveVice Presidem,
vaccine Research and oeveloprnent,
Wyeth Pharrnaceuticals
"Today," he continues, "Prevnar is the clearest example of a
vaccine that has targeted and immunized a population1 that gers a
disease and, ar the sarne time, helps stop the spread of thar disease to other cohorts. Indeed, in many ways, the societal benefit
of Prevnar is bigger than its direct benetit."
17
4'.
Mexico: An Emerging Market Mpdt
1
t is estimatèd that in Latin America, two children die ofinvasive
pneumococcai disease every hour. In 2001, Mexico was
among the first countries in Látin America - and the first
emerging market in the world - to introduce Prevnar. Mexico
wili serve as an importam model as the vaccine is introduced
in other emerging markets.
J
Today, nearly 50 percent of ali children in Mexico who 7hould
be vaccinated with Prevnar are receiving ir - either ar n9 cost
through government hospitais and clinics or through the private
sector. By the end of 2008, ir is expected that coverage
reach neariy 100 percent. "Ali children born in 2008 wili have
the right co be taken to a government hospital and receive the
vaccine," says Carlos Fabian Abeiieyra, General Manager
for Wyeth in Mexico. "This is a major achievernent for Wyeth
and a great benefit for the children of our country."
With the addition of Prevnar co Mexico's nationai jmmunization
schedule in February 2008, the vaccine has forced a change in the
paradigm of how vaccines are viewed. "Basicaliy, chis has éaused the
government co take a fresh look ar how ir aliocates its hea1h care
doiiars," Abelleyra says. "As you can imagine, in Mexico,1 s it
many ocher councries, resources are iimited, and the goverriment
must carefully choose its pubiic health prioricies. By including
Premiar in its nationai immunization program, the Mexican government has ensured that children wili be protected from a dangerous
and potentially deadiy disease. Ir also has affirmed the importance
and cost-effectiveness of prevention as a critical component of its
national health strategy, as advanced vaccines like Preunar beqefit
children and society - today and weli into the future."
..c
Early on, the Mexican government created its own co
analyses for Prevnar and, as a result, decided to move
initial coverage in only the most at-risk popuiations children in rural areas of the country - to universal co
Feeling of Hope Emerges
Demóstenes Gómez Barrem, M.D., has been a pediatrfdan in
Mexico City for the past 30 years. 9 saw many cases of severe
pneumonia, bacteremia and meningitis in my practice!So ali
of us who treated children understood the need for a vaccine
like Prevnar," he says.
"We were very happy when ir first was introduced in private
practice because we finaily could protect some of our wn
patients. But we were even happier," he adds, "when the
government started its own vaccination program in grkips
of high-risk children."
20
To raise the profile of pneumococcal
disease and the benefits of immunizatloatWyeth worked with the Mexican
govemment on a mass media
campaign, the first ever in Mexico for
a vaccine.That allowed us te foster
awareness and creste an environment
that would facilitate the introduction
of Prevnar on a universal basis7
Carlos Faban Abelleyra, General Manager,
Wyeth Mexico
Ei
1*-
Today, Dr. Gómez Barreto believes Preunar is covering most of
the serotypes that can cause disease in the country and iJshowing
a strong efficacy rate.
"Our hope," he says, "is that the most positive impact 111 be
seen in villages around the country, where a campaign to vaccinare
every chíid is taking piace to reduce mortaliry rates in thse rural
areas that have limited access to health care services."
AVaccine for the Developing World 7
Today, even with ali the advances that Prcvnar has made, pneumococcal disease still kilis more chiidren than any otheriillness more than AIDS, maIana and measies combined. Yet only a smafl
percentage of children in the world ar greatest risk of ding from
the disease are getting the vaccine. Starting this year, that picture
is expected to begin to change.
Wyeth's goal is to work with the internationai heaith community
to make Prevnar available to the poorest countries in th'e world
as quickly as possible. Thirty-four countries with per capita
incomes under $ 1,000 already have indicated an intere 11t in introducing pneumococcai vaccines by 2010. These coufitries account
for more than a third of ali the childhood pneumococdl deaths
worldwide. The most interest has come from Africa, wl4ich has
the highest incidence of pneumococcal disease.
Global Impact
•
Countries whore Prevnarcunontly
is available
•
Çountries whe,e Prevnar also
Is on their national immunization
schedule
C11
21
Orin Levine, Ph.D., au associate professor ar The Johns Hopkins
University Bloomberg School of Public Health, leads theeffort
to create a bridge to the developing world for pneumococal
vaccines. As Executive Director of PneumoADTP, a projet
supported by the GAVI Alliance - a unique public/privare partnership of which Wyeth is a member - he is focused ou getting
these vaccines to every child who can benefit.
DPO
Dr. Levine says, "Even though many peoplehaven't heard of ir,
pneumococcal disease is the leading vaccine-preventab1 cause
of death worldwide. More than 90 percent of those deaths occur
in developing countries. So if we want to change the wokd - as
we do - then we need to use these vaccines in the countries where
children need them the most."
In addition to GAVI, a novel funding mechanism cailed the
Advance Market Commitments (AMC) is seeking to help ensure
that needed vaccines will be taken up by developing cojntries.
Designed to create predictable markets in poorer counti4es for
future vaccines, the AMC was launched in February 2007,
with donors pledging $1.5 billion to support ncxt-genetation
pneumococcal vaccines. The AMC goal isto guarantee market
for vaccines from producers ar steeply discounted prices and
then get those vaccines to countries in need.
"We expect pneumococcal vaccines to begin saving líves in
developing countries in 2008," Dr. Levine concludés. "?we also
expect the impact of Prevnar to be substantial. We should get
on with using ir now and have that experience serve as a base for
an expanded vaccine. If we can show good results early, we can
sustain political support and financing. Success requireS that
industry and the public sector demonstrate they can come
togecher, deliver the vaccine and measure its health imact."
1 bdiave that raugh roads lead to
thelop and tbatthere is no substituta
for hard wodcThat's why l'ni proud
ta he part ai the Pearl River team that
helps produce Prevnar. What a great
feeling to know the vaccine we're
producing helps san the ligas ei
babies around the world."
Ernie M, Skinner, Aseplic Set-up Worker,
otbVaccines, Peari Rivei. New 'íork
Manutacturing One of the
:Most Cornplex Bioteçh Products Ever
mil the advent of vaccineslike Prevnar, vaccinçproduction often involved growing bacteria, adding certain
components to either kill or weaken those bacteria,
then filtering and packaging the result. Advanced conjugate vaccines like Prevnar are changing ali that. "Now we're using
more biotechnology," says David Zisa, Vice President,Vaccines
Product Supply. "We're expressing components of baceria,
then performing biochemical rearrangemenis or restrt&turing
to actually make the vaccine work."
U
The result, ar least for Prevnar and for a next-generation
Wyeth vaccine that will cover 13 different pneumococ'ai strains,
22
Among other complex production
processes, the carrier protein that gives
Prevnar some ai its special characteristics is grown atWyeth's Santord,
North Carolina, manufacturing facility,
where the key focus is quality contraI,
increased productivity and efficiency.
P13
is increased complexity, longer cycle times and higher costs.
"Prcvnar is among the most complex biotech or bioiogid
products ever made," says Michael Kamarck, Ph.D., Executive
Vice President, Wyeth Technical Operations and Product Supply.
"It's a combination vaccine that contains seven giycocorijugates or seven different vaccines in one. li combines, or conjuates, the
seven different polysaccharides or sugars found on the cèll coats
of each of seven different bacterial strains in the vaccine with a
ft
carrier protein that enhances their effect."
Dr. Kamarck furrher expiains: "At a modern faciliry in Pearl
Rivei New York, in a series of fermentation tanks (with separate
tanks for each different strain), we start by growing bac&ria
using a mixture of nutrients, ali of which support the baUcterial
growth. Then we kill the bacteria by adding chemicais that disrupt the celis. After that, we take the ceil coatings that irgeiy are
polysaccharides and separate them from other bacterialdebris."
Õ A series of steps in a rigorous purification process follows to
isolate the poiysaccharide intermediates.
Canier Protein Is Key
The carrier protein that gives Preunar irs special ability td be identified by an infant's immature immune system and that enhances
immune memory also must be grown, a process that takes place
ar the Company's Sanford, North Carolina, faciiity. Thdproteiri CRM197— is isolated from the Coryncbacteriunz dipht/nriae
bacterium, grown in large quantities, then separated from the
bacterium and purified.
The purified polysaccharides for each strain in Prevnarare
chemically activated and then linked with the carrier pfotein
through another biochemical process. Each of the seven
resulting glycoconjugates is purified. Ali along the wa4 quality
control tests are used to make sure batches are consistent and
remain sterile.
Finaily, the seven glycoconjugates are combined using !iluminum
phosphate to complete the formulation. The final formulated
bulk vaccine is fihled into syringes and packaged ata nmber of
sites in the United States and Europe for distribution around the
World. There are some 1,000 controls in place to ensu#e quality
and safety during production. The manufacturing conplexity
is unprecedented because 15 individual components de required
for Prevnar.
To ensure that production facilities can meet the growing demand
for Prevnar, Wyeth has invested hundreds of millions of dollars in
new facihties and capital improvements.
Creating the next-generation pneumococcal vaccine —a 13-valent
formulation - will require even more resources, including a new
24
"Our peopte are using their technical
skilIs to Iricrease output at our
facilities se that we get Prevnarto
more and more kids.What reativ
motivates people is that they're
delivering a lite-saving product.
Evorywhere you go in Pead River,
Coliegevitie and Santord, you see
pictures ei babies - the babies
we're trying to save.Actuatly, it*s
almost too easy te be a manager
in an environment where you're
working te cave kids' lives. It just
doesn't get any better than this
David Zisa,Vice Presiclent,
Vaccines Product Supply,Wyeth
"Preunar is among the
most complex biotech
or biologic products
ever made. It's a
combination vaccine
that contains seven
glycoconjugates or seven different
vaccines in one."
process deveiopment facility in Sanford costing $200 miIon as
well as investment of near!y $1 biilion ar other Wyeth sités in
Andover, Massachusetts; Pear! River, New York; and Gdnge
Castie, Ireland.
DPCE
"We'!1 almost be doubling the compiexiry of the vaccine,"
Dr. Karnarck says. "There will be 27 discrete steps for analytical
assessments. Our job is to manufacture ir perfectly."
No wonder employees ar ali the Wyeth facilities invoivedare
"absolutely inspired by ir," Dr. Kamarck says. Process irhprovemenes have tripled the output of existing p!ants in the pat four
years. And, over the next decade, Wyeth is looking for further
increases in manufacturing capacity.
Creating a New Generation ofVaccnes
toAddress Global Concerns
T
oday, Wyeth R&D is focusing on the next generation of
significant vaccine advances - both to prevene disease
and to be used therapeutically to trear ilinesses.
The Company's pipeline includes: Prcvnar 13, a 13-valËnt vaccine to prevenr pneumococcal disease in infants and children as
Aboriginal children and adults in
Australia are arnong the higher-risk
groups expected to benetit greatly
from Prevnar 13, Wyeth's nextgeneration 13-valent pneun,ococcal
conjugate vaccine.
well as adults; a vaccine that targets a bacterium that causes
significant numbers of meningitis and bloodstream infecions for
which no vaccine currently exists; a first-in-class vaccine- being
developed in coilaboration with Elan Corporation - to halt the
progression of Alzheimer's disease; a vaccine for strep t14-oat; and
a vaccine for the staphylococcal infections that have incrased
significantly in both hospital and community settings.
DPDS
Provnar 13 Pediatric
The Company has a 13-valent pneumococcal conjugate vaccine
in late-stage clinical development for use in infantis and children.
This vaccine - called Prevuar 13 - adds protection for sx additional serotypes to the seven already present in Prevna;thus
covering approximately 60 percent of the bacterial strains
responsible for the remaining pneumococcal disease.
Included among those are serotype 19A infections, which have
li
been on the rise and are responsible for an increasing pr
of antibiotic-resistant disease. In addition, the vaccine iiicludes
serotypes prevalent in developing countries in Africa and Asia as
well as in certain other high-risk populations, includingrNative
Americans, Native Alaskans and aborigines in Australi.
Targeting serotypes that have begun to repace the sevei original
strains, sooner rather than late; is an important part ofthe
Prevnar 13 Pediatric vaccine strategy. "The CDC is on recor
that 19A is the rnost important emerging serotype in th postPrevnar era in the United States," says Wyeth½ Dr. Gruber.
"Two triais - one in Israel and the other in Alaska - are designed
to make the case that our vaccine works to protect against
11
this serotype."
The deveiopment program for
Prsvnar 13 Pediatflc Is crie of the
most compiex and chaiienging ever
attémpted since, in principie, you're
dealing with 13 separata vaccinesAs
a result, dia unprecederited efforts by
our intenial teams are nothing si1ort
of heroic. For exam pie, hundreds
ofthousands of tests are expected to
be compieted over the nem year
alone to assess protectiva lmmuno
responses as weli as to demonstrate
that this vaccine doesn't interfere
with other childhood vaccines7
Kathrin Jansen, Ph.D., SeniorVke Presideni,
Early Phase Pl-oyrarn5, 'Wyeth Vaccino
Rasearch
The trial in Israel will examine how the six additional íerotypes
in the 13-valent vaccine will affect colonization by emerging
pneumococcal serotypes. With regard to Alaska, Dr. Guber says:
"19A has emerged as a very important cause of invasite pneumococcal disease in Native Alaskan infantis and children and may
serve as a sentinei for what we might expect to see ove4 time in
the population ar large," Dr. Gruber says. "So, in addiion to
potentially improving protection in this vulçierable poulation as
part of the trial there, we will be better able to predict the global
impact of the 13-valent vaccine in reducing disease."
"The objective of our 13-valent pediatric pneumococcl conjugate vaccine program is to develop the most complete laccine
available for the global prevention of pneumococcal disease and
pneumococcal otitis media," says Wyeth's Emilio EmiiÇi, Ph.D.,
Executive Vice President, Vaccine Research and Develpment.
Planned for regulatory submission in 2009, the progdm now is
in Phase 3 clinical development.
Oposito pago: Chiidren in Kenya
wiii be aniong the many who wili
benetit as rniliions of doses of
Pra vnar are provided to countries in
Latin Arnerica, Africa and Asia.
27
e'
P13.
Prevnar 13Adúlt
While Preunar has provided herd irnrnunity to older aduits in
many countries by reducing the reservoir of cornmunicable
disease that can be spread, pneumococcal disease in adults stili
remains a major health burden. Death rates from pneunococc
disease in adults between age 50 and age 64 are 10 times
higher chan those for one-year-old infants. And for adults over
age 65, death rates increase to 27 times greater than for
one-year-olds.
"CtÍrrentiy, there is a 23-valent, free-poiysaccharide pneuinococcal
vaccine available for adults ages 65 and older," Dr. Erninisays.
"However," he expiains, "within tive years of administration, the
efflcacy of this vaccine declines. And the vaccine cannotbe used
to substantiaily boost the irnmune response once an initial dose
is administered.
Dr. Gruber says: "We expect that Wyeth's Prevnar 13 Adult will
provide immunologic memory to permit boosting to maintain
protective leveis of antibody throughout adult life. These features
of Prevnar 13 Aduit couid extend the age of protection ragainst
pneumococcal disease and provide ionger-term protectiôn with
repeated dosing or boosters.
"Another important objective for the vaccine is to protect the
elderly against community-acquired pneumococcal pneumonia, a
leading kiiier of older adults," Dr. Gruber adds.
Notes Wyeth's Connoily, "The adult vaccine has the opportuniry
to transform and reshape the adult pneumococcal areal
sarne way Preunar continues to transform pediatric pne'urnococcal disease." The adult clinical program is in Phase 3 trals 'vith
regulatory filings expected to begin early in 2010.
o
Meningococcal BVaccine
Next in Wyeth's pipeline is a vaccine targeting meningdcoccus
group B, which is an irnportant cause of meningitis and
bloodstream infections in very young children and adolescents
and for which no vaccine currently is avaiiable. In the United
States, a third of ali meningitis cases caused by meningococci
are the result of meningococcus group B; in Europe, ailnost
rwo-thirds of the iilness is caused by group B.
The disease is devastating and has rnortality rates of 10 percent,
with 20 percent of those who survive often suffering seere consequences of the disease, including limb ioss and brain damage.
"Parents and physicians alike are frightened by this disd'ase. Ir can
kill in just 24 to 48 hours,"says Kathrin Jansen, Ph.D., Senior Vice
President, Early Phase Programs, Wyeth Vacciqe Research.
28
The development o! conjugate
vaccines is a tremendous story about
medical as well as public heatth
advances. After ali, woildwide, the
death rato for pneumococcal disease
is about 1 miltion children a year.
With hrnader.application of a
13-valent conjugate pneumococcal
vaccine, there is the posslbility of
preventing up to 750,000 deaths a
year. The opportunity is reaU'
WIIorn Gruber, M.O.,Vice Presidem.
WyethVaccinej Clinical Research
Currently in Phase 1 and Phase 2 clinical triais, Wyeth's vaccine
works by targeting a surface protein that covers almost ali 'the
meningococcus group B strains, eliciting antibodies that kill the
bacteria. "Our researchers were hunting for a cross-proteçtive
antibody response and discovered a lipoprotein that showd the
desired traits," Dr. Jansen adds. "More than 1,000 differekt
strains were evaluated to make sure there was enough lipoprotein
target on the surface of the ceil so that antibodies made b the
vaccine could efficiently kill the bacteria. The bacterium sçeins
to actually need this protein so we believe we have found the
right target."
Alzheimer'sVaccine
O
Alzheimer's disease affects some IS inillion people worldwide.
Wyeth and its partner, Elan Corporation, are engaged in Phase 3
triais for a so-called "passive immunization" approach to attack
Alzheimer's disease, based on providing monoclonal antibodies
to a patient.
In addition, an "active immunization" approach - based on the
body's production of antibodies in response to the presence of an
antigen - also is being developed.
This Wyeth and Elan vaccine - ACC-101 - uses peptid
fragments of the beta-amyloid protein conjugated to a protein
carrier to elicit an immune response against beta-amyldid
plaques presem in the brains of Alzheimer's patients. It!is hoped
that the immune response will clear the plaques, thereby stopping
progression of the disease or preventing the plaques' iniia1
deposit. The vaccine currently is in Phase 2 triais after demonstrating in mouse modeis that immunization using the vaccine
could prevent memory loss. "This would be one of the firsr
examples of a therapeutic rather than a preventtive vacine,"
Dr. Jansen observes.
Staphylococcus Aureus Vaccine
Staphylococcus aureus is the leading cause of hospital-hcquired
"As we have seen an increase in the
ove reli pubhc health impact of
Prevna,, the cost-effeetiveness of this
compex vaccine bécomes even
clearer.The need now isto broaden
into emerging markets like Mexico
and other countries with about
70 million new births each year and
to implement mi affordablo and
sustainable plan for the vaccine's
use in the developing world."
Jim Connoily. ExeCutivo Vke P,esider,t and
Gene,aI Manager. WyethVaccines
infections - more than a haif million cases annually - in the
United States. In addition, there has been an alarming ncrease
of methicillin-resistant S. aureus or MSRA. S. aureus can
cause large boil-like lesions, pneumonia, bloodstream infecrions
and even death.
A vaccine to address these infectipns is in developrneJ ar Wyeth.
This vaccine:includes a bacterial surface component. "jWhile the
antibodies generated from the immune system in response to the
vaccine can't kill the bacteria directly, they coar the ba'cteria and
act in concert with immune components in the blood io gobble
up these complexes and destroy the bacteria in the .pràcess,"
Dr. Jansen says.
29
EI
Group A Strep Vaccine
While the major burden of group A streptococcus (GAS) infection
is strep throat, with more than 600 million cases a year, uitreated
or unrecognized GAS infection can result in acute rheurrnhic
fever, a disease that is the most common cause of acquirei heart
disease in children and adults worldwide. A multi-compdkient
vaccine that seeks to prevent GAS infections in young children is
in earty development.
A large team of scientists at Wyeth works ou the Company's
vaccine R&D projects. "We ask a lot from our scientiststhese
days, but our people are willing to work more and go the extra
mile," Dr. Jansen says proudly. "There is incredible enth'usiasm
to bring these programs to the finish tine."
L
lí
Redetining the Possible
As head of Wyeth's commercial vaccine business, Jim Connotly
spends a good part of bis time looking at new opportunties for
what already is one of the ompany's main drivers ofgbwth
while also planning for the introduction of new vaccines. j-Ie knows
that "the market will pay for innovation but not for mediperity."
"It's at the heart of
Wyeth's mission to lead the way to a
healthier world - and
we take that mission
very seriously."
Says Connolly, "1 believe the success we have achieved ith
Prevnar is a direct reflection of the extraordinary va1ueand
public health impact of the vaccine. Prevnar has redefirèd the
possible when ir comes to meeting significam: unmet m&Iical
needs on a large scale. As we look ahead, we will have other
assets - advanced vaccines - that could make a drarnatic impact
in parts of the world where most of the deaths from invasive
disease are occurring. We will do ali we can to make these
vaccines available and to do ir in a sustainable and affddab1e
way. The key is finding the narrow pathway that meed the
needs of our stockholders and the needs of the countries - and
the people - who can benefit most. 1 know we will be dble to
do that. We simply must. It's at the heart of Wyeth's mssion
1
to lead the way to a healthier world - and we take that mission
very seriously."
•
1
Wyeth's new 13-valent vaccine Prevnar 13— now is being developed
to more tully address invasivo
pneumococcal disease in vuinerable
populations, including infants and
children as well as older adults.
30
H
SELECTED FINANCIAL DATA
(boilar amounts in thousands except per share arWountst
.YeárEndédDeceznber3l,
Net revenue
Research and develàpnient expenses
Net income
Diluted earnings per share
Dividends per commonshare
Capital expenditures
Total assets
Number of employees ar year end
Wages and sálaries
o
2006
2005
2004
),655
$22,399,798
3,255,785
,109,060
3
4,615,960
4,196,706
3 08
338
1.06
1.01
/J
1,289,784
1 390 668
$42.717.282
$36,478,715
50,060
50.527
$ 3,488,510
$ 3,765,604
$18,755,790
2,749,390
3,656,298
270
0.94
1,081,291
$35,841,126
49,732
$ .3,434,476
$ 17,358,028
2,460,610
1,233,997
091
0.92
1,255 275
$33,629,704
51,401
$ 3,280,328
2007
COMPANY DATA BY RÉPORTABLESEG.MENt
(In millibns)
Net Revenue from Cusú,niers
Pharmaceuticals
Consumer Healthcare
Animal Health
Consolidated total
$18,622.0
2,736.1
1,040
$223998
Income (Loss) before Iricome Taxes
Pharmaceuticals
Consumer Healthcare
Animal Health
.,
Corporate
Consolidated total
$ 6,164.5
519.2
194.1
(421.1)
$64567 r
Depreciation and Amoruzation hxptnsc
Pharmaceuticals
Consumer Healthcare
Animal Health
Corporate
Consolidated total
$
$
800.5
35.1
32.6
50.5
918.7
ëípenditures for Long-Lived Assets
Pharmaceuticals
ConsumerHSlthcare
Animal Heakh
Corporate
Consolidated total
$ 1,4106
72.2
42.4
g4.i
1
6
$ _
,2
Total Assets at December3 1,
Pharmaceuticals
Consumer Healthcare
Animal Health
.
Corporate
Consolidated total
$18,814.9
1,833.4
1,569.4
20,499.6
$42.717.3
32
2005
2004
$16,884.2
2,530.2
936.3
$20,350.7
$15,321.1
2,553.9
880.8
$18,7558
$13,964.1
2,557.4
836.5
$17,3580
$ 5,186À
516.2
163.7
(436.4)
$ 5,4299
$ 4,544.9
574.3
139.4
(478.0)
$ -4,780.6
$ 4,040.1
578.6
134.8
(4,883.3
$ (129.8
2006
2007
Vear Ended December 31
1
,.
-
11
]
,
$
719.9
20.0
32.7
$
$
803.0
$
1
682.0
40.8
30.3
33.8
786.9
$
$
529.5
45.7
29.9
17.3
622.4
$ 1,228 3
15.3
37.2
72.0
1,3728
L_
$ 1,0779
28.4
45.0
47.1
$ 111984
$ 1,226.5
33.2
40.0
83,4
$ 1,3831
$17,171.6
1,492.9
1,430.0.
16,384.2
$36,478.7
$15,770.2
1,463.2
1,326.7
17,281.0
$3s,841.1
$15,771.2
1,701.4
1,340.9
14,816.2
$33,629.7
jn
//
WORLDWIDE NET REVENUE BY PRODUCt
(In miltions)
Pharmaceucicals
Effexor
Prevnar
Enbrel
Frotonix
Nutricion
ZosynfTazàcin
Premarin famll$'
Oral contraceptives
I3enevix
Raparnune
rhBMP-2
ReFacto
Tygatil
Zoton
Tortsêl
Alliance revenue
Ocher
Total Pharmaceuticals
Consumer Healtbcare
Centru,n
Advil
Caltrate
Robitussin
ChapStick
Preparation H
AdvilCo!d&Sinus
Ditnetapp
Alavert
Other
Total Consumer Healthcare
Animal Health
Livescockproducts
Companion animal products
Equineproducts
Poúltryproducts
Total Animal Health
2007
2006
2005
2004
$ 3,793.9
2,439.1
2,044.6
1,911.2
1,443.0
1.137.2
1.055.3
433.9
432.6
364.8
358.9
334.9
137.9
93.3
26.6
1,294.2
1,320.6
$18,622.0
$ 3,722.1
1,9613
1,499,6
1,795.0
1,200.8
972.0
1,050.9
454.9
357.6
336.9
308.0
305.6
71.5
130.8
0.0
1,339.2
1,378.0
$16,884.2
$ 3,458.8
1,508.3
1,083.7
1,684.9
1,040.9
891.6
908.9
525.3
343.3
300.2
236.3
268.4
10.0
3752
0.0
1,146.5
1,538.3
$15,321.1
$ 3,347.4
1,053.6
680.0
1,590.6
943.3
760.3
880.2
590.1
301.5
259.0
165.3
249.4
0.0
447.7
0.0
789.9
1,905.8
$13,964.1
704.9
684.1
225.9
220.3
139.7
109.7
73.7
72.6
56.0
449.2
$ 2.736.1
$
$
634.0
514.0
189.2
253.2
134.4
104.8
122.4
80.4
49.5
472.0
$ 2,553.9
616.6
490.4
179.0
237.9
123.2
102.3
129.7
87.8
56.0
534.5
$ 2,557.4
$
452.4
317.9
145.3
126.1
$ 1,041.7
$
,
657.1
620.2
19..Ï
225.5
127.9
103.1
61.0
81.7
i
49.8
408.8
- $ 2,530.2
$
$
405.5
283.9
135.5
111.4
936.3
$
$
377.2
257.8
138.2
107.6
880.8
$
$
$
351.0
252.6
138.2
94.7
836.5
33
DJRECT9RS AND OFFIcERS
Principal Division a
Board of Dlrectors
Principal Corporate Officers
Robert Essner
Chairman
Robert Essner
Chairman
&rnard Poussot'
Presidem and
Chief Executivo Officer
Bernard Poussor 7,1,9,1411
Presidem and
Chief Executivo Officer
Robert M. Amen 2,112
Chairrnan and
Chief Executivo Officer
International Elavors
& Fragrances Inc.
John D. Feerick 2,3
Professor of Law
Fordham Univeraity School
aí Law
Timothy P. Cost "a"
Senior Vice Presidem,
Corporate Affairs
Frances D. Fergússon,
Ph.D. 4.5,1
President Emeritus
Vassar Coilege
Victor F. Ganzi 1.1,3,12
Presidem and
Chiei Executivo Officer
The Hearat Corporation
Robert Langer, Sc.D.
Instituto Professor
Massacbusetts Instituce
ofTechnology
John P. Mascotte 1.2, '3,12
Retired Presidem and
Chief Execudve Officer
Elue Cross and Blue Shield
of Kansas City, Inc.
Raymond J. McGuire "
Co'Head, Global
lnvesrment Banking
Citi
Mary Lake Polan, MD.,
Ph.D., M.P.H. a'
Professor and Chair Enieritus
Deparenient of Obsterrics
and Gynecology
Scanford Universicy School
of Medicine
Gary L. Rogers 2,3
Former Vice Chairman
General Electric Company
Thomas Hofstaetter,
Ph.D. "
Senior Vice President Corporate business
Development
Joseph M. Mahady 7,
Senior Vice President
Gregory Norden 7,0,9,10,11
Senior Vice President and
Chieí Financial Officer
Denise M. Peppard
Senior Vice Presidem Human Resources
Marily H. Rhudy
Senior Vice Presidem Public Affairs
Robert R. Ruffolo, Jr.,
Ph.D.
Senoor Vice Presidem
Lawrence V. Stein
Senior Vice President and
General Counsel
UlfWiinberg "
Senior Vice President
Mary Katherine Wold "°"
Senior Vice President Finance
Subsidiary Officers
Andrew E. Davidson
Vice Presidem liiternal Atidit
Wyeth Pharmaceuticals
Joseph M. Mahady
Presidem
Douglas A. Dworkin'
Vice President and
Deputy General Counsel
Wyeth Pharmaceuticals Asia/Pacific and
Nutritionals
Mark M. Larsen'
President
0'
leo C. Jardot
Vice President Government Relationa
Paul J. Jones •.
Vice Presidem and
Controlier
Jeffrey E. Keisling
Vice Presidem Corporate Information
Services and
Chiei Information Officer
Wyeth Pharmaceuticals Latin America
Eduardo G. Nieto'
President:
E'
John C. Kelly
Vice Presidem Finance Operations
11
Eileen M. Lach'
Vice Presidem,
Corporate Secretary and
Associate General Counsel
bavici A. Manspeizer
vice Presidem Intellectual Property and
Associate General Counsel
11
JamesJ. Pohlman
.ice Presidem 1Corporate Strategic Initiatives
Steven A. Tasher a
Vice Presidem and
Associate General Counsel
in R. Victoria 8.9
President lar Relations
erv E. Landry, Jr.
Wyeth Pharmaceuticals
Teci-mica! Operations and
Product Supply
Charles A. Portwood
President
Wyeth Pharmaceuticals U.S. Pharmaceuticals and
Women's Health Care
GenoJ. Germano'
Presidem
Wyeth Research
Robert R. Ruffolo, Jr., Ph.D.'°"°
Presidem
Port Dodge Animal Health
Richard R. DeLuca, Jr. . lJ
Presidem
Wyeth Consumer
Healthcare
Cavan M. Redmond 2,1,9.10
President
Wyeth Consumer
Healthcare - United States and Global New Business
Douglas A. Rogers'
President
Wyeth Consumer
Healthcare - Internacional
Etienne N. Actar'
Presidem
Johfo R. Toreli lI1
Parmer
Core Capital Group, LLC
1 Execuçive Comoniittt
2 Audit Comaoittee
3 Compenaaaion and Bendita
Conaanittee
4 Corporate Isoun Conmitue
Nominating and Governonce
Conmittee
6 Scienct and Tec}nology Committee
7 Managemen e Co,nn'ttee
5
34
Wyeth Pharmaceuticals EMEA/Canada and
BioPharma
UlfWiinberg '
Presidem
t.aw/Regulatory Review
Conmictce
9 Operaeinna Conninee
O lluaianResonrces.nd
Benefiti Conaninte
Renrenleni Committee
Ia Deiignated cobe a FinanciaI
Expert' ai defined in
applicable sec noMa
'8
WYETH WORLDWIDE
Pharmaceuticals
Consumer Healthcãre
Animal Health
Affihiate & General Manager
AfSliate & General Manager
Regional Managers
John Wyeth and
Brother Ltd.
(United Kingdom)
Palie H. Chrisrensen
Wyeth Consumer
Healthcare Inc.
(Canada)
Suneer Varma
Wyeth Industria
Farmaceutica Ltda.
(Brazil)
Carlos Cesar Sampaio
&ent A. Standridge
Senior Vice President North America Sales and
Marketing
Wyeth Pharma GmbH
(Germany)
Andreas Krebs
Wyeth Consumer
Healthcare S.p.A.
Iltaly)
Massimo GalIo
Wyeth Taiwan
Corporation
(Taiwan)
Jessica Yeh
Whitehall-Much GmbH
(Germany)
Frank Kube
Wyeth Consumer
Healthcare Ltd.
(Puerto Rico Branch)
(Puerto Rico/Caribbean)
Alberto R. Fernandez-Comas
o
yeth South Africa
(Proprietary) Ltd.
ksouth Africa)
Luciano dePortu
Luis E Andrade
Senior Vice Presidem
and Managing Director,
Lârin America, Japan,
and Global Poultry
Wyeth Pharmaceuticals
France
(France)
Emmanuelle Quiles
Wyeth Lederle S.p.A.
(Italy)
Mathieu W. Simon, M.D.
Wyeth Farma S.A.
(Spain/Portugal)
Elvira Sana
Wyeth K.K.
Uapan Region)
Susumu Kurata
Wyeth AB
(Nordic Region)
Vacant
Wyeth S.A. de C.V.
(Mexico)
Carlos Fabian Abelleyra
Wyeth Pharinaceutical
Co., Ltd.
(China/1-Iong Kong)
Dr. Xiaobing Wu
Wyeth Australia Pty.
Limited
(AustralialNew Zealand)
Erica Mann
Wyeth Pharinaceutical
Co., Ltd.
(China)
John Choü
Wyeth Consumer
Healthcare
(Eastern and Central Europe/
Commonwealth of
Independent States/Middle
East/Africa/Balkans)
Luciano dePortu
Rob Barclay
Senior Vice President
and Managing Directo;
Asia/Pacific
Ugo Cosentino
Vice President and
Managing Director,
Euiope and
Emerging Markets
Whitehal! Laboratories
Limited
(England/lreland)
John R. Smith
Wyeth Consumer
Healthcare Pty. Ltd.
(Australia)
Alian R. Franz
Wyeth S.A. de C.V.
(Mexico)
Arturo Sanchez
Wyeth Canada
(Canada)
Arnour Ploos vais Ajustei
Wyeth Consumer
Healthcare Ltd.
(Colombia Rranch)
(Colombia)
Camilo Tedde
Wyeth Philippines, Inc.
(Philippines)
Andrew Ericson L. Santos
Wyeth Sagre Familiale
(France)
Faissal Tahiri
Wyeth Pharmaceuticals
FZ-LLC
(Middle East/North Africa)
Joseph 1-lenein
Wyeth Philippines, Ind.
(Philippines)
Edgardo B. Meridoza
Wyeth Pharmaceuticals
B.V.
(Netherlands)
Edward Lysen
Wyeth-Lederle Pharma
GmbH
(Austria/CLE Region)
Mark Heseiton
35
CORPORATE DATA
Executiva Offices
Wyeth
Five Giralda Farms
Madison, NJ 07940
(973) 660-5000
www.wyech.com
StockTrading Information
Wyeth stock is listed on the New York
Stock Exchange (ticker symbol: WYE).
Independent Registered Publie
Accounting Piaui
PricewaterhouseCoopers LLP
400 Campus Drive
Fiorham Park, NJ 07932
Annual Mõeting
The Annual Mecting of Stockholdets
will be bebi on Thursday, April 24, 2008
ar the Hyatt Morriscown in Morristown,
New Jersey.
StockbolderAccount Information
The Banir of New York Melion is the
transfer agent, registra; dividend disbursing agent and dividend reinvestxnent
agent for the Companjr. Stockholders of
record with questions about lost
certificares, lost or missing dividend
checks, or notification of change of
address should contact:
Wyeth
elo INY Melion Shareowner Services
P0 Box 358015
Pittsburgh, PA 15252-8015
(800) 565-2067
(Inside the United States and Canada)
(201) 680-6578
(Outside the United States and Canada)
For the hearing impaired:
(200) 231-5469 (TDD)
Internet address:
www.bnymellon.com/shareowner/isd
BuyDIRECT Stocic Purchase and
Safe Plan
The BuyDIRECT plan provides stockholders of recordand n&w investors with
a convenient way to make cash purchases of theCompàny' common stock
and to automatically re?nvest dividends
inquiries should be directed to The Bank
of New York Melion.
ReportsAvailable
ft
The Company's 2007 Annual Report
on Form 10-K and ali Company fihings
with the Secuiities and Exchange
Commission canbe accssed on our Web
site ar www.wyeth.çom Alternarively,
a printed copy of the Cornpany's 2007
Annual Report on Forn 10-K and other
Company hlings rnay be obtained by
any stockholder without charge through
Wyeth by caliing (877) 552-4744.
Equal Employnient Opportunity
Our established affirmtive action and
equal ernpioyment prograins demonstrate our long-standini commitment to
provide job and promotional opportunities for ali qualifled persons regardiess
of age, coto; disability/national origin,
race, religion, sex, sexual orientation
or status as a vete±an.
Environment, Health and Safety
Information on the Corbpany's
environrnentai, health and safety
(EI-IS) performance and its EI-IS
Policy is available on the Web ar
http://www.wyeth.con-Jaboutwyethl
cicizenship/ehs. EHS inÍbrmatión
also is included in Corp'orato
Citizenship 2006— Living Our Values,
which is available on the Web ar
http://www.wyeth.comaboutwyeth/
cirizenship. A copy of the EI-IS
Poiicy may be obtainedtpon written
request to:
Wyeth
Deparcinent of Environment,
Health and Sáfety
Five Giralda Farms
Madison, NJ 07940
This papa is FSC (Foresr Stewardship Councit)
certified from weIl-managed foresta, contro!ted
sources and recycted wood offiber.
36
Coiporate Citizenship
Ccnporate Citizenship 2006 Living
0w' Values, a report describing the
Company's efforts in the arcas
of governance, empioyee development,
support for our communities, and
protection of the environment and the
health and safety of our employees,
is availabie on the Web ar
http://www.wyeth.com/ahoutwyethcitizenship or via written request to:
Wyeth
Pubiic Affairs
Five Giralda Farms
Madison, NJ 07940
Tradein aiics
Product designations appearing in
diíferentiated type are vradernarks.
Trademarks for products that have not
received final regulatory approval are
subject to change.
Cautionary Statement
The information in this Annual Revi~ is
a summary and does not provide complete information; ir should be considered
along with the information contained in
the Company's 2007 Financial Report,
2007 Annual Report on Form 1 0-K and
oth& periodic fiuings with the Securities
and Exchange Commission.
This Annual Review inciudes
forward-iooking statements. Ali statements that are not historical facts are
forward-iooking statements. Ali forwardlooking statements address macters
invoiving numerous assumptions, risks
and uncertainties that could cause actual
resulrs to differ materially frõm those
expressed or implied by those statements.
In particular, the Company encourages
the reader co review che risks and uncer
tainties described under the heading
"Item IA. RISK FACTORS" in the Company's 2007 Annual Report on Form
10-1<. The forward-looking statements in
this Annual Review are qualified by these
risl< factors. Accordingly, the Company
cautions the reader not to place undue
reliance on these forward-looking statements, which speak oniy as of the date on
which they were made, and the Company
undertakes no obligation to update or
revise any of these statements, whether as
a result of new information, future deveiopments or otherwise.
SEIECttD PRÕiCTS
,0
5
t
Wyeth
Phamiaceuticals
1
Consumer
ØQ
Fort Dodge
Animal Health
thcare
ft
Nutntionals
Cardiovascular and
Gastrointestinal
o
Nursoy
v, Progresa
Protonix
Protonix,,l.V,
Zoton
!romise
Promise Gold
5-26
5-26 Gold'
Hesnophilia
BcneHX
ReFacto
Xyntha
PM
-X
Vaccgnes
Immunology
and Oncolóiy
Çold & Sirfús
p,
Meningitc
Prevnar/Prevenar
Mylotarg
Neumega
Rapamune,
Torisd4
i
-
Néd
Nutritional Supplements
-
Caitrate
Centrum
Çentrurn Cardio
Centrum Select
Centruin Silver
o ase
Vitasprint S12
Women's Health Care
7
lnfecticuá Disoase
Tygacil
Zosyn/1a?ocin
Inflamrnatory Diseass
Enbrel
Dimetapp
Robitiissin
Loecte
Lybrel
:
Minesse
rrernarin
Premarin Vaginal Cream
Premphase
Prempro/Premetie
Totetie
Other Products
Anhesol
erCon"
Néuroscience.,
.1
EffexõrlEfexor
Effexor XR
Co.rornoted wicF. Amgen mc:
Me
fle bove produc; areidcntifi,d as rrade:na,k u;ed byysth and ics'shiidtariea.
ti:
JI
Broifëhi-ShieId
Bursine 4
: ÇaJid
Cydectixf
Duramune
Fe!0:Vauf1entofe1
.Fluãd
,.LymeVíx'
Nolvan
"Polyfle3f"
Poulvac,
ProHeartiGuardian
ProMeris
Pyritnid
Quest/Equest
1Rabarri i
lII iij
S uvaxyn
Synovex
Tela zoi
TODAY
TOIÇIORRQW
Tobugesic[rorbutroI
Triangie
West Nile-Innovator
Wyeth
Five Giralda Farms
Madison, NJ 07940
UR
XUP
/
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE (DIREITO ECONÔMICO
OFICIO N°
Q /2009/SDE/GAB
Brasília, 16 de fevereiro de 2009.
fl
A Sua Senhoria o Senhor
ARTHUR BADIN
Presidente do Conselho Administrativo de Defesa Econômica
Ministério da Justiça
Brasília - DF
Senhor Presidente,
De ordem, encaminho a V-,', Sa., nos termos do § 41 do art. 54 da Lei n°
8.884/94, a documentação, inclusive confidencial, referente ao Ato de Concentração no
08012.001157/2009-71, de interesse das requ&entes PFZIER, INC. ("PFIZER") e WYETH
VEDO
MINISTERIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
,l't)
OFICIO N° [Z; ) 12009/SDE/GAB
Brasília, 16 de fevereiro de 2009.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO SIL
Secretário de Acompanhmento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3° andar, sala 324
70048-900 - BRASÍLIA/DF
Senhor Secretário,
De ordem, encaminho a V! Sa., nos termos do § 4° do art. 54 da Lei-n"
8.884/94, a documentação, inclusive confidencial, referente ao Ato de Concentração n°
08012.001157/2009-71, de interesse das requerentes PFZIER, INC. ("PFIZER") e WYETH
("WYETH").
Atenciosamente,
REGINA
Chefe
MINISTÉRIO DÃ JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE
Em
11
de fevereiro de 2009
. Determino a divulgação dos seguintes atos de concentração econômica protocolados
N°
nos termos do art. 54, da Lei n°8.884/94 e do art. 13, da Portaria n° 5/96/SDE:
ft
AC n° 08012.001157/2009-71. Rqtes: PFIZER, INC. ("PFIZER") e WYETH ("WYETH").
Operação: aquisição, pela PFZIER, da WYETH. setor de atividade envolvido na operação é o
1,
de Indústria Farmacêutica - Produtos Farmacêutics e Veterinários.
Á S OVN
Chefe de Gabi
ENVIADO Á PUBLICAÇÃO
MPLC/OABNETE/DESPACHOS/ACs 17022009
1;
MINISTÉRIO DA! JUSTIÇA SECRETARIA DE! DIREITO ECONOMICO
GABINETE
DESPACHO DO CHEFE DE GABINETE
h
Em-IV de fevereiro de 2009
N° Q ? . Ref.: Ato de! Concentração n° 0012.001157/2009-71. De ordem da Senhora
Secretária de Direito Econômico, ao Departamento de Proteção e Defesa Econômica - DPDE,
para que se manifeste, preliminarmente à .autüação, sobre o pedido das! reuerehtes de
tratamentõ confidencial dó parte da doúmèhtaãoque instrui a prdente notificação.
hN4S
Chefe de abinet 513 stituto
4
-17
( OZ f
F.
ft
28
ISSIV /677-7012
Diário Oficial da União - seção
1
SECRETARIA NACIONAL DE JUSTIÇA
DEPARTAMENTO DE ESTRANGEIROS
DIVISÃO DE PERMANÊNCIA DE ESTRANGEIROS
DESPACHOS DO DIRETOR
.cooitri,iirào Mitistio do Tnbalbo
Dispute di mia'
- o_____. e.......4 • uti.a..i. . ..r,, ib os..noasiur ,
N 34, quina-feira. IS de fevatim de 2009
Tmdo os vista goto ficou demormtndii efetiva eecasídide
di maswbasçio do aEitgefro si Oi.peaa. rorasdairodo que o p.
sate Oe owsofl.Ie imbuido na forros di lei e. drisre da
isfeomiio do Mirdsrtio do Trt.IIso e Essupteto. DEFIRO o Pedido
de PonosogaÇio de Estada no Pais - 24/09/2010.. Poocaoo 0°
09000.0I223I/2-33 - Olivia tive Bourely
Tosdo os - que ficou dososndia dEIrva nidade
da miouleuiclo do aovraein na mirpoma. cosa.ldcnndo que o pego.
& Psusopçao de Emd. rIo Pus .54 14/08)2010.. Processo n°
080I24I7ç2008-92 - Autuo Rodolfo Afta Creia
Tardo ao viola que ficou dosoeotrala 1 efetiva neccoaladi
à
o do aüarSm na mosos. aS&aado cato o eec-
Eocaasbshe-uc o feito no Dfretoi do Dqsrtumo.lo de Esmr,gàoo pan ddboaclo. atolado que soja m.nOido o tIo is&faiotno de fis. 40, lado no voas. isto.rpasivid.de do pedido.Pro
t E8000.012728'2008-3l 3iana. Huaiag e W. lUto
-
LUCIANO PESTANA BARDOSA
Ii
DESPACHOS DO CHEFE
i -
MARIANA TAVARES DE ARAUJO
DESPACHO DO CHEFE DE GABINETE
Eu lide fevereiro de 1
.109
74° 86 - DaSo i dMoçk dimo ~ .do co.EotaçIo
emitira petoocoisdos mc lassa do itt 54. di 04 ? L88Q94 e
do itt II. à Paisana 0° SI9SSDEi
AC 0° 01012001157/2009-71. Rqtea: PFIZEB, INC. rPFlZER°) e WYETH (WYETH1. Opaiçio: .quiuiçleh pela PFEIER.
da WYETH. O neste de ilividade owolvido ou eçuaaçlet o de
Irãiaia Fasssractustca - Prodiooea Ftomacbulicoe e t/dasuina
NELSON CAMPOS
DEPARTAMENTO DE PROTEÇÃO
E DEFESA DO CONSUMIDOR
DECISÀO N° II, DE li DE FEVEREIRO DE 2009
Processo Aóskujsostivo o 040l2.00413512002-97. Rqiee- Assodaçio Denileisa dia Peodidoem de Cii. Repaimotado(s): Miiaaç,io Mfnego Lak Asamvooc Coloe.Çio no morado de
produlo Snprdçeio ao conom.o.
Em ir000in.moeo as raSa tic cabataridada - Nom
Tderdc. mupta. .dotiodo-a meto rnoouv.çio e. dose modo. coceidoando . goavidide e e eutemlo da IM. oss.da . milhirar de
mmtuvide.ss mli iodo o pais. • v.ntisn. .asfaida. bar, meto •
mndiçao atedmie. à eTasa. nos lama do rsjgo 37 do 14a
tOltAlO e da not
23. II e III e 2& III e VI do Deaao,
1181)97. splieo à repoamitaS • n'oçio de mula. no vila de ES
82.800.00 (oitaoo. e dois mil e oitocona nos), de'urdo o vilce
defiosovo ser dquaitude as fava do Fundo de ~ de Direitos
D'Suom neo truta à Raoluçio MD n. 16. de (8 de miTço de
2005. ceaoiote delcusiso. o noflo 29 do basto .2.181/97.
RICARDO MORISPOITA WADA
Direter
DESPACHOS DO DIRETOR
Em li de faicreasu de 2009
P4' 19 -. Trago a público u decido de arquivar o Procano Adm&tsEauvo de ouúmao 08012.004128/2002-95. mm iisnd.reto sri
Noqa e. M. CGAJ/DPDl que ee oicorba pulidi aos
pecava ia
74° 20 - ltoio a público i decido de arquivar o Pto Admadvo de sõrnero 080I1084I3412002-41. mm ftradommto a
Noou a 47. CGAJIDPDC/1®9, que ar mmsra joda um
po_vei
P4' 21 - Processo Admlelsuallvo .0° 08012004147/2002-I1. Regreimitaste: Aisociaçio Boanleisu dei Produtora de Cal. Repeoatsdar
Lindasalva Almeida D. & C. AannsOo: Propinas de Q.
Itd.dedoCutH,&ila.
Ceirçiolasdo os aula. vosSos qoir o .anon apostando
pela eepesteasdo é soepativo. assa no e4amv.do o peito asbcleeido pelo capa do misto 49 do Deasto a° 118097. boa cine
- situo 39 do Là .° Ç7$4/99
toonlda.nIo que o on'uss iotposoo on' as. sou bojo os
rolamos asgosnlo.00s já aprceindoo e redoádos a decido pisfroide
mmc Peocauo Adouinisfritiv, rito vgo rato para eecoaidai-Ie.
Dossio do aposto e - que maio doo iodos rasou, recebo
o matoso no efeto nasatoeo os edicto is ascOen inopoalsa, nos
larram do ciSmes» no prigosfo fatia do aoL 61 da Lá u. 9784/99
edo tiL 49 do Dwmo 1881)97. ccrsido. que bá receio de
poçrulro de dificil ou mata. eqsasçlo à rqarso.tad. ato a dedelo
leis refoomai..
RICARDO MORISHITA WADA
Tardo «ri vista que ficou dosoatidi efelivi noEooidode
0 POsà mtoçio do onnrãro las empema. osmidoando
en
a.se honda a teia di IS e. diaaooe di
miamaçao no uuilsosaw no 'mono e otgo. urnonu o pauto
do Proerog.Çio do Estada a Pois itt l0to3,20I11.-Po
.0°
OSao.012163t201l-00 - Momin lan Z.jic
Tado os vista que Som dossooauadn a efetiva necessidade
do anulado do obSo nu oiuprno, comidaoodo que o pien'te poocaso anota-se isisoisuldo a tossa di lã e. diva di
teamaçio do Misisofaio do Tuteslbo e Esgorego. DEFIRO o pedido
de Pieeroesçto de Estada no Pus itt DVD7,201t- Procoso ot
011rtuO.011(06i.200847 - Sa.niolsw Mordia
Diante doo nova etosota connta. ao asile e. coosiderando i ir,fcemaçio do Mininotio do Teatulho e EmpeEgo. mono
husabsbooale o aio irodefoildoio publicado os Dufio Ohicial de
28/12,2008. pan DEFERIR o pedido de Recomidauçlo concederodo
• Franzido de Prezo do estada .04 0105r200t- Proemno ro°
(8000/011995/2088-10 rabio ESta Fano.da ~j~ Deda Maria Ba,sojo
MteaaoePsbloFossssdaBamojo O
To.do em
do viola que Soou dosoaoads a efetiva necasitisde
àmaasaasçio
muaegao na arsçuma. coraidaindo que o pieomito peocano eoscoosua-se imwutdo 015 forma da lei e. disite à
àofoemaçlo do Ministdrio do Trabulho e Emprego. DEFIRO o Podido
de Trirafoomaçio de \/OsOo lar' V pan Pormrerroa- Precioso 0°
c8303.o2382Q1®t-a9 - iahs ADoto CSny Posso, e Miou Dei
Pilar Acevolo Cruz
Tmde os vista que ficou doc000ulnda a efetiva ,itde
do manhorçio do aorgdeo na o.ravma, misdondo que o pieiate precato crceuoa..e SOtaldo a tossa do IS e. disst do
ofoemaçlo do Minosotio do Taubsllas e Enrprcga DEFIRO o Pedido
de Proorogoçio do Estado no Pais até 12)18/2010.- Processo ef
0t.0I30S4/200849 - Bapisrd Wicling, Fito Wieling. Heidras
sc.esaoura WloIürg Diolulroff e Mito Whel.eg
Tardo as vista que ficou dosoatada i efeolvi neonoidade
di manançio do atuorgeiro na osgoemi, cosõdetiodo que o pisommc pat
ossonba.e t.toddo a fossa de iit e. baste de
iofasmçio do Mirmisttsio do Tsabaftio e Enspeego. DEFIRO o Pedido
de Pmemsaçio de Estada no PS sf4 03/11/2010.- Procoso n°
0t0l&%5377,2008-% - Gerando Primitivo Rasando Omaoa
Tardo ais vista que ficou domomenda n efetiva roecosidade
do us.mçlo do ae.ngaro Sri empossa. cosoidorsndo que o pIelote peteato oieoistw iiIa.oldo na fosso. do lei e. discute da
iofecmaçlo do Mioistdrio do Trabalho e Enspreao. DEFIRO o Pedido
de Preorogaçio de Estado no Pais - 09/IMola- Processo t
0110I2.®5533/2008-26 - Dhot Goodirlr lo
Tel no visa. que ficeni doso_rada n efetiva ncocoiàde
da usarataçio do osEsngoto ti amplmi considerando qone o posososie phocano arestos-se Imbuido ira domas di lei e, diarte à
isfamnçio de Minisotio do Trabalho. Eosspr000u DEFIRO o Pedido
de Proerogoçio de Estuda no Pias itt 29/10/2009.- Processo n'
08.0l305G'201lS-24 - feio Rioloard Bladley
To.do no vso que ficou derocrorreda a efetiva oidide
di m.çio do aea. na oaa. co.aidoiodo qie O 88nosle pa
aoconfl-se mentido na tesas da lo e. drinte da
infoossaçio do Minfsodoio do TsbsIlro e Esrpsto. DEFIRO o Pedido
do Proorogaçio do Estada no Pais alt 03/01/2011.- Ptocoso V
0O0l3032/200O-l3 . Minonu 1)0.0 e Tomoko Uo.o
Toado osi vista que ficou das000asonda e efeiiv. oeeatdsde
da masusooçio do anssgáso na empoa aaidaasdo que o
n..e toauuido ri forma da lei e. diante da
- pe
afetomiçio do Mao do Trabalho e Easporgo. DEFIRO o Podido
do Ptoorogaçio de Esteda no Pata itt 28/11/2010. - Pmenoo t
t8tl&009034'2008-48 - flooea Paul time Baia Ccile Ddeootb
Male Douret. Claroat J.eqoaa Mede DoereI No.oIsit LasSo Amea.e
Mede 000,6 Ntuhis e Saoduisc Catamooa DoureI Noubin
Tardo co visa. que fies.. ~trela. efetiva necessidade
do isiroteoçlo do ataogelm 5. osspomt considerando que o pieaote aoeoss o.eoofra-ae hiat.ldo ri bossa da lei e, dnoOe da
Sfausraçio do Mirisodijo do Trabalho e Emprego. DEFIRO o Pedido
de Prereogaçio de Estada no Pais .58 22/01/0011. - Ps
a°
080111.03337V2008.31 - Cbada CaoS Dwioo e tassoe MaS Bo.tlota
-E
-
08a0u264'2008-76 Peter Paula. Cliadin
daik Pouna e Lotos P000ser
Outrossim. iiotosssso que a mhiogdroi
poe stgfr o disposto no AoL '23, XVI di Lá
do Denodo 86.715/81.
48
Tando os vista que Soto.. dosoemuada
da mastoaçio do coossipoiro na oroao. ao
ocioso processo encosta-se irsualdo ri temi
Introroaçio do Miointãio do Tesbilho e Empre1
do Prorropçlo de Estada os Pilo iii 07/01
08008/012723i2008-29 Rudiga Wostwoa e
--G~ ~que a aoaogeira dovos na.jtades
por irditargiro disposto a AoL 123, XVI da Lei 6.815/80 e/e Aat 6Z
§13- do Decrat 86.715/81.
Tardo ao vista que já deeaisos opino nqaaler ao da atada
nohlcitsda, ~imo. ARQUIVAMENTO do Pedido de Pleerogiçlo
do Estada no Pula-Procaso 0° 03097.002772)2008-lI - Estoban
Mastro de Fruia
?
-
FERNANDA t SALDANILA DE AZEVEDO
INDEFIRO o praias pedido de pamnanfeisa para o mil
cicio! chiada QOAN 11), por tio la sido localizado no adoeço
fresecido na turco.
0,55500 a oiciooil ttias HUANC Y1JXIN. deoassioo o
ARQUIVAMENTU rendo ao vasta a perda do objeto.. Precato 0°
(8503011191)2%4-lI . Qian lo
Detamano o snpuivnmento do(s) praote(o) procasE(o). ia.
do os vem o falecior.00qn de(s) rmpaamote(n).
Procnoo P4' 08260.00095G'2006-89 . SsJv.dor Musa (3ailego
MARIA ol.MA !I, DE MIRANDA ALVES
Subilitoli
Fia de diliginein procodida pelo Dqrato do Policia
Fedaal. DEFIRO o proaute pedido de pa~ no que rouca.
prendo pie o(s) atungeto(s) 'oras 5 poole benoleima rb ia
guria e dqsadb.oa mcerãmica. nostúrdo-s social e aeeabrsaoe.
Procoso N° 08241.35,2007-0l . C.nvo Sotia
la
Processo 74' 011387080289/0038-47- Hino Viooeim Rossatd
FoosliS
Precato P4' 08433.001739/2008-16. Matias tgroaclo Fiemira BInoiIb
Poceato P4' 0S491007194fl007-76- Diata Cabulei FIleOcn
FIielIa e Crus Boisia Coret Fossa
Pro P4' 0R503009646)2H38-49 - Maio Piloy Ayala,
Alma Doniela Ba.. Beta. Laia. alisto Wlardo
Proc000 N° 0E303010838)2001-o6 - Felix Maio Mimaai
Ana)m e I0rin. Soledad Rojuo Raia
Procato N°08503.010844/20(8-35 - Evaisto R. Ceadai
Tarmpsi e Baoolict Trqse
Nocero 74° 05u503.01087D208843 - licitei Ramt Pioa
Processo P4' u8505,010954)2001-17 - Ditoso Mas..i Orlia, Priroiuva Mimosa de Mitsui e Victor Mamas MamaS
- - Processo P4' 08505.010989/2008-56- Alce Osigwe e lvlus,
Eluwe Dikr
P000ecio P4' 08305.013239/0088-36 - Robalo Cororul Fiorota e Horoetirida Cavala Pera
Proonoo N5 0t305.0I333a/2-I9 - Ovidio Diet.a Sitia
Zctrslloa e Eta MiaraS Samnioio
Promo 10 083030108 14,2008.37 - Vieste 00050 Mmmii
Qulsose, Alvaiso ~ii Mmmi Mamsni e relia taise MimaS
Qumçe
Procoso 14' 0003.02Ol2088-60 - 1.1 11 leso Poste.
Clara Adelino Soarys Porte e Sylvie AndaS Rlaad Po.00e
Potaso 740 oa303.02l0002008-a4 - Jnomiurg Hong e
Ymgza 01
Procaso N° 08505024 103,2008-13 - AsaS lCsOla Condool.
Fr
Pralina Quo.alisoa PnDI e iowa! Eotnaa KalIa Queoullata
Psoceauo N5 09503.023703t200a-26 - Y.00borg Ztom e
Quaoyiog flis
Precate P4' 08505026670/20011-42 - Rouasudo Hareru iran
e Ssià Romolo Oretisa Flora
Proavo 14' 08305.026742/2088-51 - listo!. Wang e S.
'is.
0P1
!
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA
COORDENAÇÃO-GERAL DE CONTROLE DE MERCADO
Nota sobre Pedido de Tratamento Confidencial
Ato de Concentração n° 08012.00115712009-71
Requerentes: - PFIZER, INC. ("PFIZER")
- WYETH (-WYETH")
Consta dos autos pedido de tratamento confidencial de informações e/ou documentos.
Em conformidade com os artigos 26 a 30 da Pbrtaria MJ no 4/2006, sugiro:
r
___________(i) (X) o deferimento do pedido, com a aütuação em apartado confidencial dos seguintes
dãüiüëiifdC `
- Versão confidencial do formulário Anexo 1, em relação aos itens 1.9, 111.1 e VI.!;
- Cópia do Agreement and Plan ofMerger —item III.1 do formulário Anexo 1.
documentos e informações descritos abaixo. As
(ii) (X) o indeferiniento do pedido, referente
05 (cinco) dias, nova versão pública do Anexo 1
,requerentes devem ser intimadas a apresentar
da Resolução 15/98 do CADE. A versão púbi de informações percentuais deve ser apresentada
em intervalos de 10 pontos percentuais.
- Versão confidencial do formulário Anexo em relação ao item IV. 3;
- Relação dos produtos comercializados pc PFIZER e pela WYETH no Brasil - item IV.3
do formulário Anexo 1 - Anexos 1 e II.
À consideração superior.
Brãsília4 de
de 2009.
PICCOLI L. CAVALCANTI
Asses1ora Técnica
M
De acordo. Após a certificação nos autos, comunique-se às requerentes, à SEAE e ao CADE.
Publique-se.
1
1
Brasília,
de
de 2009.
RAYVI KUUSTQ1)E ABREU C. MADRUGA
11
Cooid6ador Geral
MINISTERIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA
DESPACHO DA COORDÉNADORA
Em 20 de fvereiro de 2009
N°. 067. Ref. Ato de Concentração n°08012.001157/2009-71. Requerentes: Pfizer, Inc e Wyeth.
Advs: José Inácio Gonzaga Franceschini e O?tros. Em conformidade com a Lei n° 8.884/94 e o
Capítulo VIII da Portaria/Mi n°. 4, de 06 de janeiro de 2006, defiro, parcialmente, o pedido de
tratamento confidencial solicitado. Intimen-se as Requerentes a cumprirem à diligência
solicitada, no prazo de 05 (cinco) dias, nos )termos da nota técnica de fis. Dê-se ciência ao
Conselho Administrativo de Defesa Econômica - CADE e a Secretaria de Acompanhamento
Econômico - SEAE. Publique-se.
VERA LÚCIA 11
Coordenadora Geral de
S NARITA NUNES
de de Mercado, Substituta
RomiIdajt67SIClLO-DIL-PÇIZER X WYETH . 200209
ENVIADO A PUBLICAÇÃO
r
t-.
iy
0
o
MIN
'SECRETAR
DEPARTAMENTO D
Êsplanada dós Mnitérios Fone: 61.3223-3909/3.
Oficio n`
(116:1
STÉRIO DA JUSTIÇA
A DE DIRLIT(.) FCO\Ô\IICO
PRO FEÇÃO E DEFESA EC ONÔMJCA
d. Sede -- 5° andar - Sala 552 - Cep: 70064-900
23-8916/3429-3396 - Fax: 6,1 3226-5772
L'UAB
-
:
Brasília,
de fevereiro de 2009
.Ao Senhor
.ANTQNIO IIENRIQL 'E PINHEiRO SILVEIRA
£
1
,Secretario de Acornpinharnento Lconõrnico do \linistério da Fazenda-SEÁE, Interino
Ed. Sede. Bloco E. 3' andar - sala 324
70048-900 --Brasília,DF
Assunto: Comunica Confidencialidat
xl
Senhor Secretário,
JÁ
Comunico a\10ss3 Sen oriao d Ç' ferirnento do pedido de tratamento confidencial
referente ao Ato de Concentração n° 8012.001157/2009-71 em que figuramcorno requerentes
asempresas Pfiier, Inc e Wveth. coni rme notd técnica em anexo.
Atenciosamente,,
VERA LUC
NARITANtINES
de Mercado, Substituta
SEAE-SIGILO
:
- -c
MIN 1Sf
USTIÇA
SECRETARIA DE Dl tEITO ECONÔMICO
DEPARTAMENTO DE PROTE ;ÃO E DEFESA ECONÔMICA
Esplanada dos Ministérios - Ed. Sede 5° andar — Sala 552— Cep: 70064-900
Fone: 61.3223-3909/3223-891 3429-3396 — Fax: 61.226-5772
Oficio n°
17 Z'c'
/2009/CGCM/DPDEIGAB
Brasília, c ') de fevereiro de 2009
Ao Senhor
ARTHUR BADIN - Presidente do Conselho
Setor Comercial Norte - Q. lfl - Projeção C
Brasília/DF
strativo de Defesa Econômica - CADE
Assunto: Comunica Confidencialidade.
Senhor Presidente,
Comunico a Vossa Senhoria o dferimento do pedido de tratamento confidencial
referente ao Ato de Concentração n° 08012.001157/2009-71, em que figuram como requerentes
as empresas Pfizer, Inc e Wyeth, conforme notd'técnica em anexo.
Atenciosamente,
VERÁ LÚCIA PkgÍtÀS NARITA NUNES
Coordenadora Geral de donkol
e de Mercado, Substituta
CADE-SIGIW
36
-
Diário Oficial da
1ssx1677-704r2
SECRETARIA DE DIREITO ECONÓMICO
DFSPACHOS DA SEM FÁRIA
E. 19 do leveraro de 2000
P4' 97-Ato de Concentração 5' 080l2.037/2009-57. Requeretua:
BHP liilhios Pio, Rio tinto Pie e Richardi Da7 Minerais e bise Ilorisce Innessrcenca 41 Limiled. Mvi: Dimane Lima Cominho e Ouimt
Pelos principias da economia processual e da rflcilncis da Adminianaçio Publica. nos Iremos do (1' do antigo 50 da Lei 9.784/90, e
lendo em viola o Teimo de Coopenaçio Técnrco-Openacional firmado
entre a Psncwadoria do Cooaelina Adminiatisuivo de Defesa Ecotsimia es Secretina de Direito Ecoodoico e publicado no DOU, em
20 de aoslo de 2007. concordo com olmedo parecer da Secrelazuidc
Acnnsponhienenro Económico, do Mpnlnitno da Fazenda. cujos termos
pemaan. irma,rear essa decido, conto sua molivaçio. Opino, come-
r
Ii
Seção 1
2003-ló. Ri~leirasMagathaese
noma do Deaula Mtmee,
sina razoes à
es visa
à oedem ecoE em sede dc
Nt 104- Ptocmsinseoto Aàsiniitvioivs a' O
presesnie: Unilever Bona ii Lida. Represesi
dustiusleComercial Lide. Mvogadcs: Cano
ouna Acolho alloeaTdcssicador fia., apre
panainesno de ProteçIo e Defesa Ecoodanioi
secos futcrono(I'doaet50,da Lei9.714/
presente dec~ iriclinin, como usa mooiv'
denuncia em indEne nazi. indicio. minimo
nimica, e com vistas a garantir o ano ema
inclino de oficio, determino. lnat.aaraçlo e
nos termos do artigo ilda Lei tI. 1.584/94.
fundamentos e'poueo. na Moo Técnica eia
Proocçio e Defesa Ecoodmira. emendo que
dlcioadc irifraçini ordem económica toifitil
Processe Adminialralívo. Por esse motivo.
da presaste Aterigliaçio Preliminar, recortes
Na 37, quanla-fcinu. 25
de fevereiro de 2009
SECRETARIA NACIONAL DE JUSTIÇA
DEPARTAMENTO DE ESTRANGEIROS
DIVISÃO DE PERMANÊNCIA DE ESTRANGEIROS
DESPAChOS DO CHEFE
•
Tendo em 'sua que ficou dononiirsda efetiva necessidade da
ntmulettçao do etasalgeiro na empina.. considerando qosopeesensa
P0 I03-A.eslgas o? v'siiarit04OI2,0l0849r1005-i7. Repesnasiuuier
MisSiuoPúUiendoEstedodeidfrasGaaklepe,meudo General Moina
do lhiI Lida. Ata,: Lesoado Pausa da Roda e Silva e
id C
Ri-
mos planam a in.ewn nua isentas, 500W asIa riintsvaçso. Up.Im
coloeqiosleniente,
sprovsçlo do pio, denSo mie processo na
encaminhado ao Ceitelbo Admininleadvo de Defesa EconômicaCADE, em cumprimento ao disposto ao 5 6' do M. 54 da Lei
5,884/94.
-
P4' 100. Aio de Concentraçio 5' 0801201161/2001-73. Roque'
fl: Bexosvoobil Marina LimltM e Esse Brasileira de Peorolso
Limitada. Ata: loS Alexandre Doais Neto e Outros. Pelei peincipina da economia punocenual e da eficiência da Adasslnislnçao Pú.
bIses, na lermos do Ir do aedgo SOda Lei 9.7141* e lendo em
vista o lhano de Cooperado Técnico-Operacioral rimado mire.
Procsndteia do Conselho Adminisarsflvo de Defesa Econômica e a
Sectotaoia de Direito Económico e publicado no D.aU. em 20 de
igeno de 2007. concordo com o imr do parecer da Secretatta de
Aconçuebamessio Ecenérnico, do Miniauério da Fasenda, cujos terusa pintam a nsse
asa decido,
ma motins opino.
coas
lamente,
alurovaçio do ano, devendo _
encaresabado ao Conaelho Adminiasraeivo dc Defesae
CADE, um esaispiunento ao dlaposao no 5 6' do L 54 da IS
-
r,ner
-
P0 101 Ato da Cooceoaraclo nu 0i012.00006112004-16. RemsaresIna: Lubeizol Advancrd Material,, Inc e lhe Doar Chemical Cotapanyd.
tIo Aacaat de Antiasde e On/0os, Pelos pri~ da
ecoeicmla processual e da eficidocia da Adoniniutraçao Pública, nos
lermos do
5' do amigo 50 da Lei 9.784/99, e tendo em vista o
Termo de Cooperas Tdcstico-Opeoacional firmado ente a Pato.'
ratais do Conselho Admlniaurativo de Defesa econõmica e a secrelarla de Direito Econômico e publicado no D'O_o, em 10 de
agonio de 2007, cnocoido com o teor do patecer da Secretsrii de
Acompasbansenio leondirico, do Ministério da Fs,xsda. csajna termoa passam a integrar esta decisão. conto sua moliveçao. Opino.
conaseqaenlesnmsr, pela nprosnaç5o do sto, devendo este processo ter
escanhado ao Conselho Administrativo de Defesa Eeooõn,ica
CADE, em cuntproasserito ao disposto no * 6' do aro. 54 da i.ei
5884/94.
-
P4' 102' Ato de Conceuirsçiã n' OiOIl.000231,2009-32. Roquenotar Desusuult Avigion SÃ, Alcaaet.Lsaceio e Tbaleu S.A. Advu:
elMo Ei
Plol. Regia. PenomietIo Pugtiene Amar.l de
Pelos princlsioe da ecascosia processual e da efi.
cidnciasAdmiuütaçaoPúb)ica,noalennoadolrdoauigosoda
Lei 9.784/99, e senda ens vises o Termo de Coepesaçio Técnico.
Opmacionul firmado asic. a Pnocusadooia do Conselho Adousuiuuadvo de Defesa Econdessica e a Seana.ia de Direito bcenãn,ico
publicado ao IXO.U. as 20 de agosto de 2007. «ffiOrd0 cm o t.
do parecer da Secretas de A ipasbamenlo Econômico, do Mininsério da Fazenxis, estio. aeemoa
us a ir.tegn-tr essa decido,
conto atas moslvts Opino,
aIo, devendo esie processe ser encaminhado ao
tatuo da Defesa Lcondmica CADE, em cumprisnsenio ao disposto
no IS' do art. 54 da Lei 8.084°94.
.
co0ae0Ientaseoie.rdo
-
-
N' 103 Ano de Concrmtrsçio a' 0I0I2.000799/1009.53. Reqiie'
rentes: Flore.nsl 26 de Novembro' Flnoestnmento e Reflorestamento
Ltd... Florestal ltupirattge Fliresurmenlo, e Reflorestar.tenio Lida, e
Muita SÃ , Adva: Tão AmaraS do Andrsde e Outrou. Pelos pote'
clpiia de economis processual e da eficiência da Admmninorruçlo Pibltes, no. ta.. do * P do artigo 50 da Lei 9.784/99. e tendo em
vista o Termo do Coopençeo Tecniro-Operacional formado cena a
Procuradoria do co.lho Adminuauaiivn de Defesa Econômica es
Seesuiria de Direito Ececismico r publicado no DOU, em 20 de
agosto de 2007, ceescoedo com o leor do parecer da Secresaoia de
Acomspaslsmessto Econdenico, do Minioiério da Fazenda, cujna ter,
atos psa.ams a isíegrar nau. decido como sua moeivaçio. Opino,
cnnneqiossenamoe, pela aprovado do aio, devendo este poscaro ser
encaminhado ao Conselho Adrnisian.tivo de Defesa Econômica CADE, em cunweimmmo ao disposto no5 V do agi. 34 da Lei
1.584'94,
-
MARIANA TAVARES DE ARAWO
1
DESPACHO DO CHEFE DE GABINETE
Em 2/Ide faveoeiro de 2000
-
N'IS Determlnoa divulgaçio doaae8iuinueaatea dc concenuriçioeconómica prneocoladoa nos teimo. do ato. 5414 Lei t5.814/04e do sri.
3 da poep,e3p e' 5/p'JSDE:
AÇ a' 010t2,001236/2000.12. Rqla: EVIALIS DO BRASIL NUTRIÇAO ANIMAL LTDA. ('EVIALIS') e MALTA CLrnON DO ORASIL SÃ. ('MALTA'). Operaçao: aquiniçio,
EVIALIS, de parte do
capalal ,ocial da MALTA. O setor de atividade envolvido na operaçiol
Psoãkia e Ptoduçao Aniul Raçom.r
-
-
•
AC 01o12.no1321/2009.41. Rqtean COMPANHIA DE PARtiCIPA'
ÇÕES EM CONCESSÕES ('CPCl, BRISA, PARTICIPAÇÕES E EMPREENDIMEN7tS LTDA.CBRlSA' CARLOS SEABRA SUAREZ,
ABIGAILSILVASUAREZ,ISABELASILVASUAREZ,Ai4APAULA
SUAREZ e GABRIEL SILVA SUABEZ, Operação: aquisiçio,
'CPC'CBRISA'de, ieapedivaanenie.50%dasaçãaadinisiasr 100%
dnsçtesprefaenclaSdocsesãaisocsldamNlROLkts.&rContro-
-
é°nç°'is
DIEGO FALECE
DEPARTAMENTO DE PROTEÇÃO
E DEFESA ECONÓMICA
COORDENAÇÃO-GERAL
DE CONTROLE DE MERCADO
DESPACOtOS DA COoRDrNDORA-cERAL
Em 19 de fevereiro do 2009
ti,
1,064- Alo de Conceniraçio a' 001I2.091079/2®9.13. Requennleu
Proteger Brasil S.A Tnnsponadors de Velame Segurança. Prosegsr
Siaiernas de Segurança Lada, Ccniúns Sinsenusu de Segurança Ilda e
Cmir/u-ia Coendrrio e Serniçm Ltd. Advt: liso Amsrul da Andrade e
(Miou. Em conformidade roma Lei nf 8.884/94 e o Capliulo VIII da
Ponarl&Wt4.de%dajaneirodaltoô,defwoopedtdodeníaínrstoconfldcttcialaolicilsdo.
-
-
-
P65' Ato de Caacenlraçto ir 00012.07I020/2009-17. Raquertuler
Prosegor Tecnologia em Sistema, do Segursnçs Eletrônica. Iscindio
Lidae SeiS Indústria Eleutaica Lida Ad,,: lua Mninsl da Psadrade a
Outros. Etas conformidade com a Lei a' 5184/04 ao Capltsalo VIII da
PooiarMi5'4,de00dejanekodo20Q&defkoopedldodev.w
confidmeal aolicitado.
es
P66' Ato de Corsotauraçio ir 00012.00106/2009-40. Requerentes:
Uniln Brasil Lida e Mucolo Broehers Limitará. Ad,,: José Inicio
Oottzaga Franaschimi e Outros. Em coaifomiidade coes a Lei nt
1.814,94 ao Capitulo VIII da Poeaaoialsej n. 4. do 06 de Janeiro de
2006, defirso pedidode tratamento coalidencial nolicitada,
Em 20 de fevereiro de 2009
ti
P067- Ato de Concentração n' 08012.001157/2009-71. Requerenter
PArir, Inc. Wyeüt. Advs: José Inicio Gonaga Fmncerchini e Outros,
Em conformidada com a Lei a' 8.884/94 e o Capitulo VIII da Portariw3liít4,daoidejaneirodell0ó, defino, psrcsaknenie,npcdidode
lrstansenno confidencial solicitado. lnlimsm-ie si Requerentes a cumprirem à diligdscta totícttida, no peno da 05 (cinco) dias, nos latinos da
nota técnica de A.
VERA LÚCIA PRI'flASNARITANUNFS
Subslil.uis
-_
pçao na EMana no raia alt UjRflt2iflY.' moo
0461000742/200-8. Miolsel Senos Boftgtoan
Tendo em tinia que ficou dasaonasrade a efetiva caem
.unaiéetnçio do estrangeiro na empeca, coauidcoando qsm o
processo encontra-se inatruldo na faina da lei e.diante da tal
do Miniaidolo do Trabalho e Empren DEFIRO o Pedido 4
gaçio de Estada no Pais alI 22104'20t1.- Pron
OIala,000843/200I-94 Teodnlo Drilon Ajanre
TeSoemvj.'j que ficou demssdaaefaiva
manntentçao do eaintogcÍro na empresa, considerando que o
processo ot,conln-,e instwdo na foenia dalei e, diante de liii
do Ministério do Trabalho e Emprego, DEHRO o Pedido 4
gaçlo de Estada no Pais ind 30/06/2009.' Pato
I1000.009443/200842 Tom Seque Dela Cruz
Tendo em vlsi. que ficou demosaimdaaefetiva necea
InSiulenÇiO do estrangeiro na empresa, considerando que o
processo encontra-se n'traido na forma da lei e, diante da mi
do Ministério do Trabalho e Emprego. DEFIRO o Pedido do
gado de Estada no Pais and 09/1012010.. Pron
000l5.005469/2008'13 -GeoegeTurntbull
'bem vias. pie ficou demonstrada a efetiva meca
manutenção do eltrnagrno na empresa, conaiderando nua, o
processo enconline innstsuldona ranina da lei e, dianseda iii
do Mit/elO do Trabalho e Emprego. DEFIRO o Pedido do
gafe de Estada co Pais até 05/10/2010.- Pino
01000.0126l91200a.34 Mauayisid Fulosenara
Tendo em viela que Sena demoesiradaaefellva ueca
marnoleraçio do esbangeieo na empresa, considerando que o
processo meantes-se ivalnsaldo na forma da lei e, diaasse da IS
do Ministério do Trabalho e Emprego, DEFIRO o Pedido di
gaçio de Estada no Psiu até 20/11/2010,- Prec'
01018.009115/2001-48 Jsoatbsn CortezSuganob
Tendo em vista que flceudcmooniradaaefetivanecar
ssanuurmçlo do estrangeiro na empeesa, muulderarsio que o
processo erscnolra-ae intimido na forma da lei e, dias. da mi
do Mhuisnétlo do Trabalho e Emprego. DEFIRO o Pedido di
g,çb° de Esísda no Pata sol 13/03/2010.- Pino
08000.01485/2001-34 Brian Frsncis Donohoe
Tendo em viola que ficou demcoslrtdaaefctiva neces
manutençio do estrangeiro na empresa, coanldarando que o
procesaoenconhrn.eetnuuwdonaformsdalele,dianledainl
M Ministério do Trabalho e Emprego, DEFIRO o Pedido di
Estada no Pala até 26/09/2009.- Pino
g•fe
o8000.006247/2008.I5- Cari Flensing Slefan leigos
Tendo em viste que ficou demonstrada a efetiva necas
menuiençio do estrangeiro na empaasa, considerando que o
processo encontra-se insizuldo na fama da lei e, dinnte da ml
doMininnésiodoTrabalboeEmprego,DEFtROoPedldodi
gsçao de rasada no Pais ali 26/98/2009.- Fruo
0l0lS.009.03/200&13. DssyIl Buemavidez Viatavilia
Temdoemvistaquc rídoiandaaernivaonca
ma.esençao do easasgesuo na empinas. considetando que o
pIocaloIts-te mesozsaldo Isa faina da lei, diaaíe da lã
do Misiatdgio do Trab.sho e Emprego, DEFIRO o Pedido da
gaflo de Essas no Pala and 18/024011.. Pesca
01013.005467/2008-24 - Jeeom Harmen Modernas
Temdoemvssia que ficou demoosuada .cfetivn linces
maniateoçao do essosaigetro na empress, corelderando que o
processoencoutia-te mnsuruldo na foomada lei e, diante da iii
do Ministério de Trabalho e Emprego, DEFIRO o Pedido do
gaç5o de Estada no Pala até 28/11/2009.' Feto
01280.02915I02007.37'RamonNooaioAnoyaveciraldo
Tendo em viam que ficou doncatttsada a efetiva meca
manuienfo do esarangelro na em
considerando que o
processo rncastra.ae lmtnaldi na
da lei e, diante da lei
do Ministério do Trabalho e Empregn, DEFIRO o Pedido do
gaçao de estada no Pele ind 26/11/2010.- I'mnn
08011.009693/2001-84 - Gerbard Clemens Devenier
.
.
-
-
FRANCËSCHINI
e MIRANDA
Advogados
1
José Inácio Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo F. Ferreira
-Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Moita
Giannl Nunes 08 Araujo
Ana Carolina Pinto Couri
Paulo Messias Pedrassoli
Waiter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Gomes Esteves
Maria Eu gênia Dei Nero Poietti
Camila Pimentei Porto Dona
Fiávia Maria Peiliciari
Cristhiane Helena Lopes Ferrero
André Pissolito Campos
Clâudla Nastari Capanema
MarcosPaulo Amorim
Patricia Bandouk Carvalho
Av Brig. Feia Lima, 1451-13° anda- São Paulo. SP -01.
Tal. + 5511 3095-2566-Fax: • 5511 3813.9693
sv-ftne*n-advoqadosn.&
-
-
SECRETARIA DE DEFESA ECONÔMICA SDE
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECO
- DPDE-
--
---
SDEJGAB/CAPRO
Coordensçlo de Apele Processual
MikIlCTrPlfl
flA II ITIflA
' '''
• '
IIIIIlIIIIlIIIlIlIIIttIIIIIIIIIIIIIIII
11111
III Iliflulil UlI 11111111 IIIUIlII 1111 b
08012.001360/2009-48 !
Ato de Concentração n°08012.001157/200971
1.
WYETH, empresa devidamente qualificada nos
Ato de Concentração em referência, er que também é Requerente PFIZER,
vem, respeitosamente, por seus advogados, requerer a retificação e conseqüente
substituição das informações constante°s dos itens 1.1 B e 1.4 do Anexo 1, de 13 de
fevereiro de 2009, nos termos que segdem:
lnformase1i em relação ao item 1.1, que o
Representante Legâldá WYETH é o se!nhor Aryeh Friedman.
e
No tocante à informação prestada no item 14, informase que a--WYETH tem suas ações negociadas na Bolsã de Valores de Nova lorque
e encontram-se pulverizadas, não sendo controlada, em última instância, por
qualquer pessoa jurídica ou indivíduo. E
Por fim, protesta-se pela posterior juntada do
A Procesisual
instrumento de mandato, para os devidos fins de direito.
Junb3-e.
SS8,jjc)2/dr
Termos em que,
Pede beferimento,
De São Paulo para Brasília, 20 de fevereiro de 20
Pp._
José
OAB/SP n° 28.711
coordenador
CGSIIDPDEISDEJMJ
Camila Castanho Girardi
OAB/SP n° 175.500
9,2
OAB/bF n° 26.634
)
li
FRANGESÇHINI
e MIRANDA
Advogados
José Inácio Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo F. Ferreira
Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Motta
Gianni Nunes de Araujo
Ana Carolina Pinto Couri
Paulo Messias Podrassoli
Walter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Gomos Esteves
Maria Eugênia Dei Neto Poletti
Camila Pimentel Porto Dona
Flávia Maria Pelilciari
Cristhiane Helena Lopes Ferreno
André Pissohto Campos
Cláudia Nastari Capanema
Marcos Paulo Amonim
Patricia Bandouk Carvalho
/
SECRETARIA DE
Av, Brig. Faria Lima, 1461-13' andar- São Paulo - SP - 01480-900
're11L + 5511 3095-2566 - Fax + 5511 3613-9693
adv-!meh1l-ad'oQadoS. com .br
ECONÔMICA - SDE
II
-.
DEPARTAMENTO DE PROTEÇAO E DEFESA ECONOMICA
1VL7CAPRJ
- DPDE
Coardrn.çto de Apoio Procenu.l
MINISTÉRIO DA /UsTIÇA - MJ
08C12.001561/2009.45
Ato de Concentração n° 08012.001157I2009-71 Recebido em_c 3__Vlas
Servidor
/
PFIZER, INC. e WYETH, devidamente qualificadas
nos autos do Ato de Concentração em referência, por seus advogados, vêm,
respeitosamente, em 3 (três) vis, requerer a juntada das anexas cópias dos
instrumentos de mandato por elàs outorgados, bem como o envio de uma via
11
para
o
CADE
e
outra
para
a
SEAE,
para os devidos fins de direito.
,-% jai
fl9
a
/Termos em que,
•Pedem Deferimento,
De São Pauto para Brasília, 02 de Março de 2009.
ga
pwjÂiigustoA.C.
/
CGSUDPDE!SDEIM.J
PFIZER, INC.
WYETH
II
II
Pp._ —
José Inácio
OAB/SP ne 28.711 /
Pp.
Camila Castanho Girardi
OABISP n° 175.500
dia Nastari Capanema
OABIDF n° 26.634
E:
PROCURAÇÃO
POWER OF ATÜORNEY
• meio do presente instrumento particular, a
presa PFIZER, INC., (doravante designada
torgante), constituída e existente conforme as
de Delaware, com escritôrio-sede em 235
KNOW ALL MEN B"( THESE PRESENTS that
PFIZER, INC., a corporation duly organlsed and
validly existing under the laws of Delaware and
having its principal place of buslness in 235 East
t 42 Street, Nova iorque (NY) 10017, EUA,
rieia e constitui seus bastantes procuradores
Srs.:
42 Street, New York (NY) 10017, EUA, hereby
appoints and constitutes its attomeys:
0
José Inácio Gonzaga Franceschlni,
Custodio da Piedade U. Miranda,
Camila Pimentel Porto Dona
Giannl Nunes de Araujo,
Càmila Castanho Girardi,
Cristhlane Helena Lopes Ferrero
CPFIMF 160.105.278-21,
CPFÍMF 254.527.028-81,
CPF!MF 221.923.918-70,
28.711,
22.122,
OABISP
OAB/SP 172.50013,
OABISP 130.569,
OABISP 175.500,
OABISP 252.787,
Marcos Paulo Amorim
Claudia Nastari Cananema
Patrícia Bandouk Carvalho
CPF)MF 038.713.756-40.
CPF!MF 296.416.146-86.
CPFIMF 329.289.728-97
OAB/SP
OAB/SP
OAB/SP
ali Brazilian citizens, attomeys-at-law, members
of the iàw firm FRANCESCHINI E MIRANDA-ADVOGADOS, registered witfl Brazilian Bar
Association, Seccion São Paulo, under no 2143,
with offices aí Av. Brigadeiro Faria Lima, 1461,
1 Sth. floor, São Paulo, State of São Paulo, Brazil,
Zip Code 01451-904, granting the forenanied
Grantees, on behalf and stead of me Grantor,
joint and severally, regardless of the appointment
order, ali spedal powers to represent me
Grantor's interests in ali and any administrativa
proceedings, inciuding acts of concentratiori,
before the Brazilian Secretariat of Economic
Controi (Secretaria de Acompanhamento
Econômico - SEAE), of me Ministiy of Finance,
me Secretariat of Economic Law (Secretaria de
Direito Econômico - SDE) and its Department of
Economic
Protection
and
Deferice
(Departamento de Proteção e Defesa Econômica
- DPDE), of the Ministry of Justice, and the
Administrativa Council for Economic Defence
(Conselho Administrativo de Defesa Econômica CADE), the Grantees beíng further empowered to
CPFÍMF 197426.148-49,
CPF(MF 346.147.538-68,
CPFIMF 277.153.008-29,
OABISP
202.543,
26.634.
281.994
brasileiros, todos advogados e integrantes do
escritório FRANCESCHINI E MIRANDA ADVOGADOS, sociedade inscrita na Ordem dos
Advogados do Brasil, Secção de São Paulo, sob
2143, com escritório à Av. Brigadeiro Faria
Lima, no 1461, 130 andar - Torre Sul, CEP 01451904, São Paulo, Capital, outorgando-lhes todos
os poderes contidos na Cláusula Ad Judicia et
Extra, para o fim de, em conjunto ou
separadamente, independentemente da ordem de
nomeação, defenderem os direitos e interesses
da OUTORGANTE em qualquer Procedimento,
Processo
Sindicância,
Averiguação,
ir
' Administrativo ou Ato de Concentração perante a
Secretaria de Acompanhamento Económico SEAE, do Ministério da Fazenda, Secretaria de
Direito Econômico - SDE ou seu Departamento
de Proteção e Defesa Econômica (DPDE), do
Ministério da Justiça, e o Egrégio Conselho
Administrativo de Defesa Econômica . CADE;
podendo, ainda, tomar ciência de despachos,
prestar declarações, receber contatos e
notificações e todos os demais atos judiciais ou
4- '
1"
jJ\
conipromise and to receive notifications, to follow
up said procÕedings, to cornply wlth requests of
and to subi information to such cornpefltion
euthorities, to acknowledge opinions of the
mentioned proceeding, and decisions of and
orders from CADE, to have access to the
relevant records, to subgrant powers and, in
general, to do ali acts necessary to the fulfilment
of the present and specially to represei Lhe
Grantor on the submission of the transaction
which involves PFIZER and WYETH through
Administrative Council of Economic Defence CADE.
São Paulo, Februa 20',2009
Marc Brotman
PFIZER, INC.
extrajudiciais que se fizerem necessários para o
firme e valioso cumprimento deste instrumento
realizar
o
particular
de
mandato,
acompanhamento processual dos mencionados
inclusive
Administrativos;
e
Frocessos
substabelecer, no todo ou em parte,
especificando no respectivo Instrumento os
poderes substabelecidos, e, especialmente, para
representar a OUTORGANTE na submissão ao
Conselho Administrativo de Direito da
Concorrência - CADE do Ato de Concentração
nvolendo a PFIZER, INC., e a empresa
ãoO de Fevefeiro
Marc Brotrnan
PFIZER, INC.
4,.
"0.
PROCURAÇÃO
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS that
WYETH, a corporation duly organised and Validly
existing under the laws of DELAWARE and
•
Por meio do presente instrumento particular, a
mprésa WYETH, (doravante designada
Outorgante), constituída e existente conforme as
11
having its principal place of business in NEW
eis DELAWARE, possuindo seu escritório-sede
11
pm NEW JERSEY, nomeia e constitui seus
JERSEY, hereby appoints and constitutes its
bastantes procuradores os Srs.:
attorneys:
José Inácio Gonzaga Franceschini,
Custodio da Piedade U. Miranda,
Camila Pimentel Porto Dona
CPF/MF 197.426.148-49, OAB/SP 28.711,
CPFMF 346.147.538-68, OAB/SP 22.122,
CPFMF 277.153.008-29, OAB/SP 172.50013,
Glannl Nunes de Araujo,
CPFIMF 160.105.278-21, OAB/SP 130.569,
Camila Castanho Girardi,
OAB/SP 175.500,
ÔPF!MF 221.923.918-70, OAB/SP 252.787,
Crlsthlane Helena Lopes Ferrero
Marcos Paulo Amorim
Claudia Nastani Capanema
Patrícia Bandouk Carvalho
CPF/MF 254.527.028-81,
CPF)'MF 038.713.756-40, OAB/SP 202.543.
CPFIMF 296.416.148-86. OAB/SP 26.634.
CPF/MF 329.289.728-97 OAB/SP 281.994
ali Brazilian citizens, attorneys-at-law, mernbers
brasileiros, todos advogados e integrantes do
of the law firm FRANCESCHJNI E MIRANDA--
Lcritório FRANCESCHINI E MIRANDA.
ADVOGADOS, registered with Brazilian Bar
ADVOGADOS, sociedade inscrita na Ordem dos
Association, Seccion São Paulo, under n° 2143,
Advogados do Brasil, Secção de São Paulo, sob
with offices ai Av. Brigadeiro Faria Lima, 1461,
I nO 2143, com escritório à Av. Brigadeiro Faria
1 3th. floor, São Paulo, State of São Paulo, Brazil,
Zip Code 01451-904, granting the forenamed
Lima, n°1461, 13° andar - Torre Sul, CEP 01451904, São Paulo, Capital, outorgando-lhes todos
os poderes contidos na Cláusula Ad Judicia et
Grantees, on behalf and stead of the Grantor,
joint and severally, regardless of the appointment
Extra, para o fim de, em conjunto ou
order, ali special powers to represent file
:separadamente, independentemente da ordem de
Grantor's interests in ali and any administrative
nomeação, defenderem os direitos e interesses
proceedings, inciuding acts of concentration,
da OUTORGANTE em qualquer Procedimento,
Sindicância,
Averiguação,
Processo
Administrativo ou Ato de Concentração perante a
Secretaria de Acompanhamento Econômico -
before the Brazilian Secretariat of Economic
Control (Secretaria de Acompanhamento
Econômico - SEAE), of the Ministry of Finance,
the Secretariat of Economic Law (Secretaria de
ÉAE, do Ministério da Fazenda, Secretaria de
Direito Econõmico - SDE) and its Department of
Protection
Economic
and
Deíence
Direito Econômico - SDE ou seu Departamento
(Departamento de Proteção e Defesa Econômica
- DPDE), of the Ministry of Justice, and the
Adrninistrative Councfl for Economic Defence
(Conselho Administrativo de Defesa Econômica CADE), lhe Grantees being further ernpowered to
e Proteção e Defesa Econômica (DPDE), do
Ministério da Justiça, e o Egrégio Conselho
Administrativo de Defesa Econômica - CADE;
podendo, ainda, tomar ciência de despachos,
prestar declarações, receber contatos e
notificações e todos os demais atos judiciais ou
•-
------
J•
ÇC
;
ir
compromise and to receive notifications. to follow
etrajudiciais que se fizerem necessários para o
up said proceedings, to comply with requesta of
and to submit information to such cornpetition
authorities, to ackno'Medge opinions of the
mentioned proceedirig, and decisions of and
firme e valioso cumprimento deste instrumento
particular
mandato,
realizar
o
yocessos Administrativos; e inclusive
substabelecer, no todo ou em parte,
especificando no respectivo instrumento os
general, to do ali acts necessary to Lhe futfilment
doderes substabelecidos, e, especialmente, para
of Lhe present and specially to rõpresent Lhe
Grantor on Lhe submission of Lhe transaction
which involves PLEASE INFORM and PLEASE
epresentar a OUTORGANTE na submissão ao
Economic Defence - CADE.
Conselho Administrativo de Direito da
Concorrência - CADE do Ato de Concentração
envolvendo a FAVOR INFORMAR e a empresa
FAVOR INFORMAR
1
,aJ.4-a
h
de
acompanhamento processual dos mencionados
orders trom CADE, to have access to lhe
relevant records, to subgrant powers and, in
INFORM through Administrativa Council ai
-
.
Location and Date
e Data
Coilegeville, PA, USA
February 20, 2009
/
i
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N*3?5 /2009/SDE/GAB
Brasília, 03 de março de 2009.
A Sua Senhoria o Senhor
ARTLIURBADIN
Presidente do Conselho Administrativo de Defesa Econômica
Ministério da Justiça
Brasília — DF
4
- -.
Senhor Presidente,
De ordem, encaminho a V. Sa. doc..a1en ção de interesse da empresa
PFIZER, INC rPFIZER" E WYETH ("W7VETH"), referente ao Ato de Concentração n°
08012.001157/2009-71.
Atenciosamente,
REGINA Ct
Chefe do
AZEVEDO
- Ministério da Justiça -Bloco T - 50 andar -sala 538 -0
Fone: 613321-780013321!'8195 - e-mail: sdeíhnj.ov.br
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N°
W
AR
3R 6 /2009ISDE/GAB
Brasília, 03 de março de 2009.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO SILVEIRA
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3 ° andar, sala 324
70048-900 - BRASÍLIAJDF
RECEBIDO
às(érdOhr
Em 03
: O)) 05
Senhor Secretário
De ordem, encaminho a
PFIZER, INC ("PFIZER") E WYETH (
08012.001157/2009-71.
Sa. documentação de interesse da empresa
'ETH"), referente ao Ato de Concentração n°
Atenciosamente,
REGINA CÉLIA
AZEVEDO
Chefe do Prol
as Ministério dá
Fone: 61 3321
0TU 50 andar ~ sala 538— Cep: 70064-900 - Brasília-DF
195—e-mail: sde)mi.ov.br
SOE
FRANCESÇHINI
e MIRANDA
José Inâclo Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo E. Ferreira
Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Moita
Gianni Nunes de Araujo
Ana Carolina Pinto Couri
Paulo Messias Pedrassoli
Walter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Comes Esteves
Maria Eugênia Dei Nero Poletti
Camila Pirnentel Porto Dona
Flávia Maria Pelliciari
Cristhiane Helena Lopes Ferreiro
André Pissolito Campos
Cláudia Nastari Capanema
Marcos Paulo Amorim
Patricia Bandouk Carvalho
Av, Brig. Faria Lima, 1461-13' andar- São Paulo SP - 01480-900
Tal: + 5511 3095-2566 - Fax: + 5511 3813-9693
adv-fmefm-aôooãdOs.c1, br
ECONÔMICA - SDE
SECRETARIA DE
DEPARTAMENTO
- DPDE
o
PROTEÇÃO E DEFESA ECONÔMICA
VGIRO
CoordeniçiO de Apoio Procr,suai
MINISTÉRIO DA JU
ID HI tINI 11111 WIfl 11111 I I I
08012.001562/2009.90
Ato de Concentração n°08012.001
ri
Recebido en,.._-21.—'
Servidor
PFIZER, INC. [e WYETH, devidamente qualificadas
nos autos do Ato de Concentração em referência, por seus advogados, vêm,
respeitosamente, em atenção ao Despacho n° 67, publicado no Diário Oficial da
União, de 25 de fevereiro de 2009, informar que deixa de submeter nova versão
pública do Anexo 1, diante do indeferimento parcial do pedido de
confidencialidade formulado na Inicial, tendo em vista que o conteúdo do item
-lV.3 encontra-se disponível versão públiáa já apresentada e os Anexos 1 e II são
documentos independentes, de sorte que igualmente poderão ser utilizados para
compor o volume público dos autos.
A
Termos em que,
Pedem Deferimento
tz
888,
°"cc), g'52
De São Paulo para Brasília, 2 de março de 2009.
Coordenador /7
CGSWDPDEIs{Jfr'
-1'52' —yPFIZER, INC.
Pp.
_—,
Jqs-IuâioGonz_a'í Franceschini
OAB/SP n° 28.711
Camila Castanho Girard
OAB/SP n° 175.500
1
MINISTÉRIO, DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO W
j
/2009/SDE/GAB
Brasília, 03 de março de 2009.
A Sua Senhoria o Senhor
ARTHUR BADIN
Presidente do Conselho Administrativo de
Ministério da Justiça
Brasília - DF
Econômica
- -a-',-
-
CADE/MJ
08700.000814/2009_1 3
Senhor Presidente,
De ordem, encaminho a Vli Sa. documentação de interesse da empresa
PFIZER, INC ("PFIZER") E WYETH ("WYETH"), referente ao Ato de Concentração n°
08012.001157/2009-71.
Atenciosamente,
REGINA Cf
Chefe do
AZEVEDO
Esplanada dos Ministérios -'- Ministério da Justiça - Bloco T _5° andar— sala 538— Ccp: 70064-900 - Brasília-DF
Fone; 61 3321-7800/3321-8195 - e-mail: sde(ámi.2ov.br
!lt
1
Ma.
Jf
L ai?
e
MINtStÉR1) DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE 6o SECRETÁRIO
OFÍCIO N-293 12009/SDE/GAB
Brasília, 03 de março de 2009.
o,
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO SILVEIRA
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3 ° andar, sala 324
70048-900 - BRASÍLIA/DF
RECESIDO
às /tdhr
Em&/jjO9
Senhor Secretário
Fone: 61 3321-7800/3321-8195 - e-mail: sdecmj.govbr
- 7
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DÓ SECRETÁRIO
51- /2009ISDE/GAB
OFICIO N°J ? ¶
A Sua Senhoria o Senhor
Arthur Badin
Presidente do Conselho Administrativo de
Ministério da Justiça
Brasília - DF
Brasília, 12 de março de 2009.
;sa Econômica
CADE/MJ
08700.00100012009-98
Senhor Presidente,
De ordem, encaminho a V. Sa. documentação de interesse das empresas.
PFIZER, INC. ("PFIZER"), referente ao Ato' de Concentração n°08012.001157/2009-71.
Atenciosamente,
69
La
FRANCECHINI
eMIRA'4DA
dvogados
José Inácio Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo F. Ferreira
Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Motta
Gianni Nunes de Araujo
Ana Carolina Pinto Couri
Paulo Messias Pedrassoli
Walter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Gomes Esteves
Maria Eugênia Dei Nero Poletti
Camila Pimentel Porto Dona
Flávia Maria Pelliciari
Cristhiane Helena Lopes Ferrero
André Pissolito Campos
Ciãudia Nastari Capanema
Marcos Paulo Amorim
Patricia Bandouk Carvalho
4
Av, Bnig. Faria Lima. 1461-13' andâr- São Paulo -5
TaL: + 5511 3095-2568 - Fax: + 5511 381:
sdv4mhn-advooados. com br
SECRETARIA DE DEFESA ECONÔMICA - SDE
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONOMICA
- DPDE
Vias
Recebido
MINISTÉRIO DA JUSTIÇA - MJ
Ser clor
YW
Ato de Concentração! n° 08012.001157/2009-71
-SDvG/cAPRo
-
coordenaçto da Apoio Proceooual
lfl Uli lUI I I lI I Jli fllHI I IlI
08012,001800/2009-67
PFIZER, INC.,' devidamente7jDliticada nos autoso
Ato de Concentração em referência, em que também é interessada WYETH, por
seus advogados, vem, respeitosamentJ, em 3 (três) vias, requerer, para os
devidos fins de direito, a juntada de 01 (uma) via original e 02 (duas) vias
autenticadas do comprovante de reáolhimentõ da Taxa Processual de
Apresentação de Ato de Concentração, nos termos da Lei n.° 9.781, de 19 de
janeiro de 1999.
Termos em que, requerendo dessa d. SDE o envio da
via autenticada à d. SEAE e a original aoE. CADE.
Pede Juntada e Deferimento,
De São Paulo pára Brasília, 11 de março de 2009.
INC.
aga Franceschini
n°28.711
n
Camila Castanho Girardi
OAB/SP n° 175.500
-
A Procesgaj
Claudia NastiriCapanema
RavvtAilwío A. C. Madruga
coordenador
CGSUDPDE!SDW 1
Ii
e
4,
i
C6digo de Recolhimento
-
MINISTÉRIO DA FAZENDA
14500-9
Ndmero de Referência
1
SECRETARIADO TESOURO NACIONAL
Competência
Guia de Recolhimento da União - GRU
0212009
Vencimento
12/0212009
Nome do Contribuinte / Recolhedor:
Francoschini e Miranda Advogados
CNPJ ou CPF do Contribuinte
Nome da Unidade Favorecida:
CONSELHO ADMINISTRATIVO DE DEFESA ECONOMICA
UG (Gestão
68.314.343(0001-54
303001 /30211
Valor do Principal
Instruções: As informações inseridas nessa guia são de exclusiva
responsabilidade do contribuinte, que deverá, em caso de
dúvidas, consultar a Unidade Favorecida dos recursos.
45.000,00
(-) Desconto/Abatimento
(-)Outras deduções
Mora / Multa
GRU SIMPLES
Pagamento exclusivo no Banco do Brasil S.A.
[STNFFD7144BB5CE4D4B5BEFB7FC1 2816AB0]
(+5 Juros/Encargos
(5 Outros Acréscimos
-
Valor Total
-
-.,&
45.000
89990000450-9 00000001 01 0-3 955231 61 450-5 00453523008-0
111111111111111111 1111111
1-
1
j/02/2009
-
D'ANGU DO
BRASII\ -
\
14:58:38
0450
- '-
COMPROVANTE DE PAGAMENTOS COM COO BARRA
-
Convento GRU-CUIA RECOLHhI UMIAO
899900004509 00000001010-3
Codiqo de Barras
00453523008-0
95523ib1450-5
t
10/02/2009
Data do pagamento
1
NRO de Referencia
02/2009
Competencia MM/AAAA
12/02/2009
Bata de Vencimento
68314343/0001-64:- .&
'
ÇNPJ
45 000,00
Valor Principal
45000,00 "
Valor Total
NR AIJTEIITICACÃO
O F5A 487 275 F71 F9E
-J----
001
FRANCESCHINI
e ML
Av. Bng Faria Lima 1461 - 13o andar- São Paulo. SP -01
Tal.. • 5511 3095.2566. Fax: • 5511 3613-9693
adv-fntfrn-advoaados cornbr
José Inácio Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo F Ferreira
Thays R Martins Fontes Moreira
José Alberto Gonçalves da Motia
Ana Carolina Pinto Couri
Paulo Messias Pedrassoli
Walier Basilio Bacco Júnior
Camila Castanho Girardi
Maria Eugénia Dei Nero Polelti
Camila Pimentel Porto Corja
Flávia Mana Pelticiari
Crislhiane Helena Lopes Ferrero
André Pissolito Campos
Cláudia Nastari Capanema
Marcos Paulo Amorim
Patricia Bandouk Carvalho
SECRETARIA DE DEFESA ECONÓMICA - SDE
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA
1
SDEJGAB:CÁPRO
- DPDE
Coordeniçio de Apoio Proce,rtal
J
MINISTÉRIO DA JUSTIÇA - MJ
08012001990/200912
APENASVERSAO PUBLICA
Ato de Concentração n° 08012.00115712009-71
Recebid
mG? Vias
ar!
WYETH, devidamente qualificada nos autos do Ato
de Concentração em referência, em que também é Requerente PFIZER, INC,
por seus advogados, vem, respeitosamjnte, em 3 (três) vias, requerer, para os
devidos fins de direito, a juntada da cópia autenticada do instrumento de
mandato por ela outorgado.
§
Termos em que, requerendo dessa d. SDE o envio de
1 (uma) via à d. SEAE e 1 (uma) ao E. COIDE.
Pede Juntada e Deferimento,
De São Paulo para Brasília, 16 de março de 2009.
_—t7
WYETH
Pp.
Joseinacio Gopzaga Franceschini
C..
OAB/SP n° 28.711
L. IL.y
Cristhiane Helena Lopes Ferrero
OAB/SP n° 252.787-SP
Camila Castanho Girardi
OAB/SP 175.500
P.p.________________________
1
Claudiã Nastari Capnema
OAB/DF n° 26.634
A Prcc*nt jrt 4
Jt!!
it3t.4
o
Auiusto4. C. mmga
cá
a23
o:--
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS
WYETH, a corporation duly organised and validly
Por meio do presente instrumento partictitaa
empresa WYETH, (doravante designada
existing under the laws of DELAWARE and
Outorgante), constituída e existente conforme as
leis DELAWARE, possuindo seu escritório-sede
having its principal place of business in NEW
em NEW JERSEY, nomeia e constitui seus
JERSEY, hereby appoints and constitutes its
bastantes procuradores os Srs.:
attorneys:
José Inácio Gonzaga Franceschini,
Custodio da Piedade U. Miranda,
CPF/MF 197.426.148-49,
CPF/MF 346.147.538-68,
OAB/SP
28.711,
OABISP
22,122,
Camila Pimentel Porto Dona
CPFJMF 277.153.008-29,
OAB/SP 172.500B,
Cianni Nunes do Araujo,
CPF/MF 160.105.278-21,
OABISP
130.569,
Camila Castanho Girardi,
CPF/MF 254.527,028-81,
OAB/SP
175.500,
Cristhiane Helena Lopes Ferrero
CPF/MF 221.923.918-70,
OABISP
252.787,
Marcos Paulo Amorim
CPF/MF 038.713.756-40.
OAB/SP
202.543.
Claudia Nastari Cananema
CPF/MF 296.416.148-86.
OABISP
26.634.
Patrícia Bandouk Carvalho
CPF/MF 329.289.728-97
OABISP
281.994
ali Brazilian citizens, attorneys-at-law, diembers
of the law firm FRANCESCHINI E MIRANDA -
brasileiros, todos advogados e integrantes do
escritório FRANCESCHINI E MIRANDA -
ADVOGADOS, registered with Brazilian Bar
ADVOGADOS, sociedade inscrita na Ordem dos
Association, Seccion São Paulo, under n° 2143,
with offices at Av. Brigadeiro Faria Lima, 1461,
Advogados do Brasil, Secção de São Paulo, sob
ri0 2143, com escritório à Av. Brigadeiro Faria
Lima, n°1461, 130 andar - Torre Sul, CEP 01451-
1 3th. floor, São Paulo, State of São Paulo, Brazil,
Zip Code 01451-904, granting the forenarned
Grantees, on behalf and stead of the Grantor,
joint and severally, regardless of the appointm&nt
904, São Paulo, Capital, outorgando-lhes todos
os poderes contidos na Cláusula Ad Judicia et
Extra, para o fim de, em conjunto ou
order, ali special powers to represent the
Grantors interests in ali and any administrative
separadamente, independentemente da ordem de
proceedings, including acts of concentration,
da OUTORGANTE em qualquer Procedimento,
Sindicância,
Averiguação,
Processo
Administrativo ou Ato de Concentração perante a
before the Brazilian Secretariat of Econo4ilc
Control (Secretaria de AcompanhameÇto
Econômico - SEAE), of the Ministry of Finan6,
the Secretarial: of Economic Law (Secretaria de
Direito Econômico - SDE) and its Departmenof
Economic
Protection
and
Defence
(Departamento de Proteção e Defesa Econômca
- DPDE), of the Ministry of Justice, and the
Administrativa Council for Economic Defence
nomeação, defenderem os direitos e interesses
Secretaria de Acompanhamento Econômico SEAE, do Ministério da Fazenda, Secretaria de
Direito Econômico - SDE ou seu Departamento
de Proteção e Defesa Econômica (DPDE), do
Ministério da Justiça, e o Egrégio Conselho
Administrativo de Defesa Econômica - CADE;
(Conselho Administrativo de Defesa Econômija -
podendo, ainda, tomar ciência de despachos,
prestar declarações, receber contatos e
CADE), the Grantees being further empowered to
notificqcãep todos os demais atos judiciais ou
esta
rs,vj
jÇQÃo/0l) 3817700
compromise and to receive notifications, to foflow
extrajudiciais que se fizerem necessárksra
up said proceedings, to comply with requests of
firme e valioso cumprimento deste insiruti3''
and to submit information to such competition
particular
mandato,
realizar
—ÔIO
authorities, to acknowiedge opinions of the
acompanhamento processual dos mencionados
mentioned proceeding, and decisions of and
Processos
Administrativos;
e
inclusive
orders from CADE, to have access to the
substabelecer, no todo ou em parte,
relevant records, to subgrant powers and, in
especificando no respectivo instrumento os
general, to do ali acts necessary to the fulfilnent
poderes substabelecidos, e, especialmente, para
of lhe present and specially to represent the
representar a OUTORGANTE na submissão ao
Grantor on lhe submission of the transaction
Conselho Administrativo de Direito da
whjch invoives PLEASE INFORM and PLEASE
Concorrência - CADE do Ato de Concentração
INFORM lhrough Adminir""'
Economic Defence - CADE.
Location and Date
Coliegeville, PA, USA
February 20, 2009
ÇÁ
-
de
AR e a empresa
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DÍRÉITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N°
2/67
/2009/SDE/GAB
Brasília, 18 de março de 2009.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO SILVEIRA
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco 'P", 30 andar, sala 324
70048-900 - BRASÍLIA/DF
MF/SEAE
ASS
RECEBI O ORIGINAL
hs
Em/ti os
aí
Senhor Secretário
De ordem, encaminho a V. Sa. documentação de interesse das empresas,
=TH. ("~TH"), referente ao Ato de Concentração n°08012.001157/2009-71.
Atenciosamentc
REGINA
Chefe
Esplanada dos Ministérios - Ministério da Justiça - Bloco T —5° andar - sala 538— Cep: 70064-900 - Brasília-DF
Fone: 613321-790013321-8195 - e-mail: sde(mj.2ov,bT
a
a
087
CAD
00001
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N°'1
/2009/SDE/GAB
Brasffia, 18 de março de 2009.
r..
A Sua Senhoria o Senhor
Arthur Badin
Presidente do Conselho Administrativo de
Ministério da Justiça
Brasília - DF
o
Econômica
LI
Senhor Presidente,
De ordem, encaminho a V.
WYETH. ("WYETH"), referente ao Ato de C
documentação de interesse das empresas,
rntração n°08012.001157/2009-71.
Atenciosamente,
REGINA CÉL DE OLIVEIRA AZEVEDO
Chefe do
Esplanada dos
Ministério da Justiça —Bloco T— 50 andar— sala 538— Ccp: 70064-900 -Brasília-DF
Fone: 61 3321-7800/3321-8195 - e-mail: sdeami.2ov.br
FIs.j
JUSTIÇA
[O ECONÔMICO
MINISTÉRIO
SECRETARIA DE
E DEFESA ECONÔMICA
DEPARTAMENTO DE
o
Referência n"
oOS-0eJ153 /o- 7i
Partes:
[INFOR)%AR A ARTE QUE REPRESENTA, SE APLICÁVEL]
11
Solicitante:
[NOME / DOCUMENTO DE IDENTIFICAÇÃO]
Volume dos autos:
..F&iJJflA_o
ti ǀtt}fltl2
[N° DO VOLUME FLS.]
Brasília (DF), em
&93
de
1
[ASSINATURA]
_de 2009
M00P/Pf10TO
AUÇADt) NO
MtLS
FRANCESCHINI
e MIRAt4DA
Advogados
José Inácio Gonzaga Franceschinl
Custodio da Piedade U. Miranda
Fernando Eduardo F. Ferreira
Thays R. Marfins Fontes Moreira
José Alberto Gonçalves da Moita
Gianni Nunes de Araujo
Ana Carolina Pinto Couri
Paulo Messias Pedrassoli
Walter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Comes Esteves
Maria Eugênia Dei Nero Poletti
Camila Pimenlel Porto Dona
Flávia Maria Petticiari
Cristhiane Helena Lopes Ferrero
André Pissolito Campos
Cláudia Nastani Capanema
Marcos Paulo Amonim
Patricia Bandoulç Carvalho
Av. Brig, Faria Lima, 1461— 13' andar- São Pa11- SP:
Tal.: +5511 3095-2566-Fax: +5511 31 C
SECRETARIA DE DEFESA ECONOMICA - SDE
DEPARTAMENTO DE PROTEÇÃO E DEFESA ECONÔMICA
-DPbÉ
MINIStÉRIO DA JUSTIÇA - MJ
AProcSY"
APENAS VERSAO.PÚBUCm
o) /
a
Râvvi usIoA.0
Coordénador-Geral
DPDEJ$DEIMJ
Í!
1
Ato de Concentração n° 0801200115712009-71
9
SDOAB/CAPRO
-
E)
O
A0
-ja:
.0
oordlfltÇ110 de Apoto ?rOCtlIUhl
o801 2.00223012009-22
1
451
PFIZER, INC (doravante designada "?FIZER"),
devidamente qualificada nos autos do Ato de Concentração em referência, em
que também é Requerente WYETH, porseus advogados que esta subscrevem,
vem, respeitosamente, para os devidos fins de direito, em 3 (três) vias, requerer
a juntada dos seguintes documentos:
(1)
tradução para o vernáculo do CONTRATO E
PLANO DE INCORPORAÇÃO ("Merger
Agreehient"), bem como do respectivo
Termo de Responsabilidade firmado pela
tradutora; e
1
Protesta-se pela posterior juntada da tradução juramentada, caso entendam os órgãos do
SBDC ser esta necessária.
s
- —--rC-
SZ
flÀNèEscrnNI
eMIRANDA
Advnoadti
(ii) cópia jautenticâda do instrumento de mandato
outorgádo pelaPFlZER;
Termos em que; requerendo dessa d. SDE o envio de
.1 (urna) viaà d. SEAE é 1(úma) ao ECADE.
Pede Juntada 4D?ferimento,
be Sãõ Pàulo para Brasília, 26 de março de 2009.
IZERJ; INC.
WYETH
P.
José Inácio Gonzaga Franceschini
OAB/SP n° 28.711
Pp.—
Cristhiane Helena topes Ferrero
OAB/SP n° 252.787-SP
•
P..
Camila Castanho Girardi
OAB/SP 175.500
aets
Claudia Nastari Capanema
OAB/DF no 26.634
2
--
—:
L
FIs,,..3
PROCURAÇÃO
POWER OF ATFORNEY
KNOW ALL MEN 6V THESE PRESENTS that
PFIZER, INC., a corporation duly organised and
validly existing under the laws of Delaware and
having its principal place of business in 235 East
Por meio do presente instrumento particuIar,'a.
empresa PFIZER, INC., (doravante designada
Outorgante), constituída e existente conforme as
leis de Delaware, com escritório-sede em 235
42 Street, New York (NY) 10017, EUA, hereby
East 42 Street, Nova lorque (NY) 10017, EUA,
nomeia e constitui seus bastantes procuradores
appoints and constitutes its attorneys:
os Srs.:
José Inácio Gonzaga Franceschini,
Custodio da Piedade U. Miranda,
Camila.Pimentel Porto Dona
Gianni Nunes de Araujo,
Camila Castanho Girardi,
Cristhiane Helena Lopes Ferrero
CPF/MF 197.426.148-49,
CPF/MF 346.147.538-68,
CPF/MF 277.153.008-29,
CPF/MF 160.105.278-21,
CPF/MF 254.527.028-81,
CPF/MF 221.923.918-70,
OAB/SP 28.711,
OABISP 22.122,
OAB/SP 172.500121,
OAB/SP 130.569,
OAB/SP 175.500,
OAB/SP 252.787,
Marcos Paulo Amorim
Claudia Nastari Cananema
Patrícia Bandouk Carvalho
CPF/MF 038.713.756-40.
CPF/MF 296.416.148-86.
CPF/MF 329.289.728-97
OAB/SP
OAB/SP
OAB/SP
202.543.
26.634.
281.994
ali Brazilian citizens, attorneys-at-law, members
of the law firm FRANCESCHINI E MIRANDA -
brasileiros, todos advogados e integrantes do
escritório FRANCESCHINI E MIRANDA -
ADVOGADOS, registered with Brazilian Bar
ADVOGADOS, sociedade inscrita na Ordem dos
Association, Seccion São Paulo, under n° 2143,
Advogados do Brasil, Secção de São Paulo, sob
with offices aí Av. Brigadeiro Faria Lima, 1461,
n° 2143, com escritório à Av. Brigadeiro Fária
13th. floor, São Paulo, State of São Paulo, Brazil,
Lima, n° 1461, 130 andar - Torre Sul, CEP 01451904, São Paulo, Capital, outorgando-lhes todos
Zip Code 01451-904, granting the forenamed
Grantees, on behalf and stead of the Grantor,
joint and severally, regardless of the appointment
os poderes contidos na Cláusula Ad Judicia et
order, ali special powers to represent the
separadamente, independentemente da ordem de
Grantor's interests in ali and any administrative
nomeação, defendérem os direitos e interesses
proceedings, ihcluding acts of concentration,
da OUTORGANTE em qualquer Procedimento,
before the Brazilian Secretariat of Economic
Control (Secretaria de Acompanhamento
Sindicância,
Econômico - SEAE), of the Ministry of Financé,
the Secretariat of Economic Law (Secretaria de
Direito Econômico - SDE) and its Department of
Economic
Protection
LDeTnc
t ' and
(Departamento de Proteção e DeMsaEèonômica
- DPDE), o! the Ministry o! Justice, and the
Administrativa Council for Economic Defence
(Conselho Administrativo de Defesa Econômica CADE)[the Grantees being further empowered to
Extra, para o fim de, em conjunto ou
Averiguação,
Processo
Administrativo ou Ato dê Concentração perante a
Secretaria de Acompanhamento Econômico SEAE, do Ministério da Fazenda, Secretaria de
Direito Econômico - SDE ou seu Departamento
de Proteção e Defesa Econômica (DPDE), do
c
compromise and to receive notifications, to follow
extrajudiciais que se fizerem necessários para
up said proceedings, to comply with requests of
firme e valioso cumprimento deste inshentl
mandato,
realizar '—e
de
particular
and to submit information to such competition
authorities, to acknowIedge opinions of the
mentioned proceeding, and decisions of and
acompanhamento processual dos mencionados
inclusive
Administrativos;
e
Processos
orders from CADE, to have access to the
retevant records, to subgrant powers and, in
substabelecer, no todo ou em parte,
general, to do ali acts necessary to the fulfilment
of the present and specially to represent the
poderes substabelecidos, e, especialmente, para
Grantor on the submission of the transadtion
Conselho Administrativo de Direito da
which involves PFIZER and WYETH through
Administrative Council of Economic Defence —
Concorrência — CADE do Ato de Concentração
envolvendo a PFIZER, INC., e a empresa
CADE.
WYETH.
São Pauto,
ua
2O
9
especificando no respectivo instrumento os
representar a OUTORGANTE na submissão ao
São Pgujg,Q0 de Fev iro de 009
-.
Marc Brotman
Marc Brotman
PFIZER, INC.
MADÂ[h:A. PINHEIROS
urna. 7' pio, (II) 3816.7700
IlTEflçAç,
Esa cópia expedida P0I
- dite com o crginai. Dou M.
MAR 2009
por
-e
(EL. O24í
Termo de'Responsabilidade
Nara Maria Salomão Ribeiro, portadora de cédula de
identidade e 5.880.888-7, inscritd no CPF sob o n" 029.221.548-74,
residente e domiciliada na cidade de São Paulo, estado de São Paulo,
atesta, para fins de comprovação 'perante o Conselho Administrativo
de Defesa Econômica - CADE, qdè a presente tradução, de sua lavra,
reproduz, na sua integridade e com total fidelidade, o conteúdo de
documento original que a acompanha, concebido em idioma
estrangeiro.
Reconhece, ademais, estar plenamente ciente das conseqüências
deste ato, inclusive quanto às sanções aplicáveis, sejam de caráter
administrativo, sejam de índole criminal.
São Paulo, 19 dè março de 2009
Nara Maná Sâlomão Ribeiro
Nome e assinatura do résponsável pela tradução
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DÓ SECRETÁRIO
OFÍCIO N0335L4 /2009/SDE/GAB
Brasília, 27 de março de 2009.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO SIL
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3' andar, sala 324
70048-900 - BRASÍLIA!DF
Senhor Secretário
De ordem, encaminho a V. Sa. documentação de interesse da empresa,
PFIZER, INC ("PFIZER"), referente ao Ato Concentração n°08012.001157/2009-71.
Atenciosamente,
REGINA CË
Chefe do
AZEVEDO
RECEBI O C
4bL
Em
j-03—
Esplanada dos Ministérios - Ministério da Justiça - Bloco T — 50 andar -sala 538 — Ci
Fone: 613321-7800/3321-8195 - e-mail: sdemi.eov.br
Brasília-DF
t
CADE/MJ
1p
SECRETARIA DE
78.
P3700.001193/2
,j..._.
DAJUSTIÇZ.
tEITO ECONÔMICO
SECRETÁRIO
OFICIO N°S65 /2009/SDEIGAE
Brasília, 27 de março de 2009.
A Sua Senhoria o Senhor
ARTIIURBADIN
Presidente do Conselho Administrativo de Defesa Econômica
Ministério da Justiça
Brasília DF
-
Senhor Presidente,
De ordem, encaminho a V. USa. documentação de interesse da empr
PFIZER, INC ("PFIZER"), referente ao Ato de Concentração n°08012.001157/2009-71.
Atenciosamente,
REGINA CÉL4I$tËVOLIVEIRA AZEVEDO
Chefe do PT'otocololProcessual/SDE
Esplanada dos Ministérios - Ministério da Justiça~ Bloco 9-5° andar -sala 538— Cep: 70064-900 - Brasília-DF
Fone: 61 3321-7800/3321-8195 - e-mail: sdeCrni.gov.br
r
-Y
MINISTERIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE 1*) SECRETÁRIO
2
OFÍCIO N',9(-,
Brasília, 25 de fevereiro de 2009.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO SILVEIRA
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3 ° andar, sala 324
70048-900 - BRASÍLIA/DF
Senhor Secretário
De ordem, encaminho a V. Sa. documentação de interesse das empresas
WYETH e PFIZER, INC., referente ao Ato de Concentração n°08012.001157/2009-71.
Atenciosamente,
AZEVEDO
•
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DÏREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N° 3 ((j /2009ISDE/GAB
Brasilia, 25 de fevereiro de 2009.
A Sua Senhoria o Senhor
ARTIIUR BADIN
Presidente do Conselho Administrativo de Defesa Econômica
Ministério da Justiça
Brasília - DF
Senhor Presidente,
De ordem, encaminho a V. Sa. documentação de interesse das empresas
- WYETH e PFIZER, INC., referente ao Ato de Concentração n9 08012.001157/2009-71.
Atenciosament(
REGINA CEUA DE OLIVEIRA AZEVEDO
.Chefe do Protocolo/Processual/SOE
Esplanada dos Ministérios -Ministério da Justiça -Bloco T -5' andar— sala 538— Cep: 70064-900 - Brasília-DF
FRANCESCHIN]I
e MIRANDA
Advcados
José inácio Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo F. Ferreira
Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Motia
Paulo Messias Pedrassoli
Walter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Gomes Estoves
Maria Eugênia Dei Nem Poietti
Camila Pimentel Porto Daria
Flávia Maria Pelliciari
Cristhiane Helena Lopes Ferrero
André Pissolito Campos
Dávio Antonio Prado Zarzana
Renata S. Tormim
Av. Biig.Fana Una 1461 _j3'asar.Toq Sul . São Paulo .$P-01451-9O4
Tel.: + 5511 3095-2566 - Fax: + 5511 3613-9693
adv-fnefm-advad.nbr
COORDENAÇÃO-GERAL DE CONTROLE DE ESTRUTURA
DE MERCADOS COGCE
p
SECRETARIA DE ACOMPANHAMENTO ECONÔMICO SEAE
A p,JU1t9ÉRIO DAFAZENDA - MF
Jun3-se
s
RawiAugusto& C.
Coordeirador-Gerl da
SDVGABIC*pRo
Ato de ConcentraçaEi78O12.001157I2
Coordeniçio de Apoio Proce,sg.j
I I11111111111111111111111
08012.005I3958
PFIZER, INC. e
autos do Ato de Coticentração em E
advogados, requerer a juntada do anexo
direito, requerendo-se, ademais, o envic
apresentados à d. SDE e ao E. CADE.
ETH, devidamente qualificadas nos
vêm, respeitosamente, por seus
belecimento, para os devidos fins de
J
rmos em que,
dem DeferimE
De São
.\1 /
o Rio e Janeiro, 02
Camila
ho Girardi
175.500
julho de 2009.
-_
-
-
FRANCESCEINI
fi
MIRANDA
Advogados
José Inácio Gonzaga Franceschini
Custodio da Piedade U. Miranda
Fernando Eduardo F. Ferreira
Thays R. Mal-Uns Fontes Moreira
José Alberto Gonçalves da Motia
Paulo Messias Pedrassoli
Walter Basilio Bacco Júnior
Camila Castanho Girardi
Sandra Comes Esteves
Maria Eugênia Dei Nero Polelti
Camila Pimenlel Porto Daria
Flávia Maria Peiliciari
Cristhiane Helena Lopes Ferrero
André Pissolito Campos
Dávio Antonio Prado Zarzana
Renata S. Tormim
andar-Tcfte Sul - São Paulo - SP - 01451-904
Ai. B,ig. Feia Lina 1461.13Tel.: + 5511 3095-2566 - Fax. +5511 3813-9693
adv-frS5fm-advodOSm.br
-
COORDENAÇÃO-GERAL DE CONTROLE DE ESTRUTURA
Ir
DE MERCADOS - COGCE
-
SECRETARIA DE ACOMPANHAMENTO ECONOMICO SEAE
II
~ÈÜO DA FAZENDA - MF
A Fiffi
§ '
t-
Jufl -Se.
___
ENASVERSAO PUBLICA1
re
RawtAugustokC.Mad
Coordenador-Geral da
Z'G/CRO
Ato de Concentraç&tRflO8O12.001157i2OO9-7l
Coord.nçja de Apoia Procosuti
IøhII lihItiI I I I Ii itifti i (I I
li!
0801 1005130/200958
PFIZER, INC. ei WYETH, devidamente qualificadas nos
autos. do Ato de Concentração em epígrafe, vêm, respeitosamente, por seus
advogados, requerer a juntada do anexo S!jbstabelecimento, para os devidos fins de
direito, requerendo-se, ademais, o en'
apresentados à d. SDE e ao E. CAbE.
irmos em que,
em DefõrimE
De São Pàulo/para o'Rio
02
n
Camila
iho Girardi
175.500
julho de 2009.
Cl
SUBSTAB ..ECIMENTO
ti
Substabeleço, com reserva de iguai para mim, na pessoa da advogada
RENATA SEMIN TÕRMIN, CPF/MF 25.894.668-97, OAB/SP n.° 235.664,
integrante do escritório FRANCESI HINI E MIRANDA - ADVOGADOS,
sociedade inscrita na Ordem dos / Ivogados do Brasil, Secção de São
Paulo, sob n° 2143, com escritório li calizado na cidade de São Paulo/SP,
Av. Brigadeiro Faria Lima no 1461, 13 andar - Torre Sul, os poderes que me
foram conferidos por PFIZER, INC e WYETH, nos autos do Ato de
Concentração n° 08012.001157/200 -71, em, trâmite perante o Sistema
Brasileiro de Defesa da Concorrênc a - SBDC, para os devidos fins de
direito.
De São FauIo para o Rio de
CamiI Castánho Gira
OA/SP h° 175.500
a.
de julho de 2009.
MINISTERIO DA JUSTIÇA
SECREAR1A DE MRZrrO ECONÓMICO
li
DEPAILTAMINTO DE PROTEÇÃO E DEFESA ECONÓMICA
s 1P9J
a.
A PARTE QUE REPRESENTA SE APLICÁVEL]
(NOME / DOCUMENTO DE
Volume dos amos:
x
JjfrM.O
ti
[N DO VOLUME / ÉL
S.]
1
Bmsfluz (DF), em
de
[ASSINATURA]
De ordem, defiro conforme
Em;
•
MINISTÉRIO DA JUSTIÇA
-
—
Leiie de Fur
da CGPj
- SECRETARIA DE DIREITO ECONÔMICO
--
De ordem, defiro conforme
solicitado.
Em, -1f
2009
e
MINISTÉRIO DA JUSTIÇA
11
SECRETARIA DE DIREITO ECONÔMICO
Secretaria de Direito Econômico DPDE
Ministério da Justiça
Referência - 08012.001157/2009-71
Requerentá: Akzo
por seu representante legal abaixo assinado, vérn a presençâde Voêsa Ser
requerer. Cópia das flsts
nn4q.
(preenchimento obrigatórIo)
Nestes termos pede Deferimento
Procuração:
Brasltiá-DF,
14 de
Julho
2009
José Alberto Gonçalves da Motta
(Nome do representante legal por xtenso e de forma legível)
Fone: 3327-65-41
OAB: II4DF
1:
(Assinatura)
PARA O
- Justificativa:
Vafoc-R$
Deferido
N° de Folhas:
Requerente:
N° de
•Wtor. R$
2009
RECIBO
gkrO DE PROTEÇÂÕ E DEFESA ECONÔMICA DA SECRETARIA DE DIREITO ECONÔMICO
o cÓPIAnoSaUTo5
E] CARGA DOS AUTOS
Brasllla-DP
07
de 2009
de __
(Assinatura)
ATENÇÃO: O prazo de carga dos processos é de 24 (vinte e quatro)
De ordem, defiro conforme
solicitado.
- - - -
1
à
MINISTÉRIO DA JUSTIÇA
li
SECRETARIA DE DIREITO ECONÔMICO
Secretaria de Direito Econômico DPDE
Ministério da Justiça
08012.00115712009-71
Referência
Requerente: Akzo
por seu representante legal abaixo assinado, vem a presença de Vossa Senhoria requerer: Cópia das
-
-
--
r03L(
C
(preenchimento obrigatório)
Nestes termos pede Deferimento
Procuração:
Brasília-DF,
14 de
Julho
de i 2009
José Alberto Gonçalves da Motta
(Nome do representante legal por extenso e de forma legivel)
Fone: 3327-65-41
OAB: I14DF
-
(Assinatura)
INFORMAÇÕES PARA O RECOLHIMENTO DA GRU
Deferido
N° de Folhas:
Jütificativa:
Valor R$
ROVANT,EDE\RECOLHIMENTO DO VALOR RELATIVO À EXTRAÇÃO DE
Requerente:
No de'
T
VÁ ~R
o r: $
Vt
RECIBO
id:2OO9
"TO DE PROTEÇÃO E DEFESA ECONÔMICA DA SECRETARIA DE DIREITO ECONÔMICO
E] COPIAS-DOS AUTOS
D CARGA DOS AUTOS
Brasllia-DF
L
5 de
__
de 2009
(Assinatura)
ATENÇÃO: O prazo de carga doa processos é de 24 (vinte e quatro)
De ordem, defiro conforme
solicitado.
E
. Q
2009
, //a4JgjduedeF0fl;
MINISTÉRIO DA JUSTIÇA
da COM
SECRETARIA DE DIREITO ECONÔMICO
Secretaria de Direito Econômico DPDE
Ministério da Justiça
-
(
Referência - 08012.1157/2009-71
U
Requerente: André Alencar Porto
por seu representante legal abaixo assinado, vem a presença de Vossa Senhoria requerer: cópia integral da versão pública dO4n/
4
(preenchimento obrigatório)
Nestes termos pede Deferimento 1
Procuração:
Brasllia-DF,
24 de
2009
Setembro dei
André Alencar Porto
(Nome do representante legal por lextenso e de forma legível)
Fone: 32022825
OAB: DF 25103
(Assihatura)
INFORMAÇÕES PARA O RECOLHIMENTO DA CRU
Deferido
N° de Folhas:
Justificativa:
Valor. R$
COMPROVANTE DE RECOLHIMENTO DO VALOR RELATIVO À EXTRAÇÃO DE CÓPIAS
Ç
Requerente:
________ Valor. R$
fr 1 /f 4
Servidor
RECI DO
E] COPIAS
TOS
o CARGA
AUTOS
Brasllia-DF,
ATENÇÃO:
\
t2 O(
Bsb, em
b
/
de 2009
RTAMENTO DE PROTEÇÃO E DEFESA ECONóMICA DA SECRETARIA DE DIREITO ECONóMICO
cot
de ___________ de 2009
O prazo de carga dos processos é de 24 (vi j te e quatro)
MN1STÉffltYDkJ1JSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
DEPARTAMENTO DE PROTEÇÂÓ E DEFESA ECONÔMICA
REGISTRO DE VISTA DÉ AUTOS PÚBLICOS
Referência n°
Partes:
A PARTE QUE
A, SE APLICÁVEL)
DE
Volume dos autos:. 10
(N° DO VOLUME/FLS)
;rí1iC@F),ern
2
de
5
ALSSINATUIRA)
de 2010
FRANCESCHINI
e MIRANDÃ
José inácio Gonzaga Franceschini
Custodio da Piedade li. Miranda
Fernando Eduardo F. Ferreira
Thays R. Martins Fontes Moreira
José Alberto Gonçalves da Motta
Paulo Messias Pedrassoli
Walter Basilio Bacco Júnior
Sandra Gomes Esteves
Maria Eugênia Dei Nero Poletti
Flávia Maria Pelilciari
Cristhiane Helena Lopes Ferrero
André Pissoiito Campos
Renata S. Torn,in
Hannali Manuela Galvão Pereira Regis Coppini Meireles de Lima
Av. Brig. Fada Lima, 1461 -lYandw
TeL .5511 3095-2566
sctamefm.advQoados wm br
Jj
DE
DEPARTAMENTO
ECONÔMICA DPDE
PROTEÇÃO E DEFESA
-
SECRETARIA DE DIREITO ECONÔMICO SDE
Recebido em--&
-
MINISTÉRIO DAJUSTIÇA—MJ
L
PENASVERSÂO PÚBLICR
-
SDE/GAB/CAPRO
CoordtniÇtO de Apoio Proce,iUtI
Ato de Concentração n.° 08012.001157/2009-71
08012.002663/2011-01
Pfizer, Inc. por seus advogados que esta subscrevem,
devidamente qualificada nos autos do Ato de Concentração em epígrafe, vem,
respeitosamente, requerer a juntada dos inclusos Instrumentos de Renúncias, para
os devidos fins de direito.
Requer-se sejam' as respectivas vias remetidas à d.
Secrõtaria de Acompanhamento Econômico
Administrativo de Defesa Econômica CADE.
-
SEAE e ao E. Conselho
-
A Processual.
Junte-se
BSB_LLJ.JJL
Termos em que,
Pede juntada e deferimento.
Luis CLaditIma Pinhelryj
Subsbhjto
De São Paulo para Brasília; 15 de fevereiro de
INC.
Pp.
José Inácio Gonzaga Franceschini
OAB/SP 28.711
PP-
AU-A IA J4Q~Mo
Hannah Manuela Galvão Pereira
OAB/SP 297.613
e
RENUNCIA
Eu, CAMILA PIMENTEL PORTO DORIA, inscrita na Ordem dos
Advogados da Brasil sob o n.° 172.500 e no CPF/MF sob o n.°
277.153.008-29, por intermédio do presente ato venho apresentar
RENUNCIA, nós termos do artigo 45 do Código de Processo Civil,
aos poderes que me foram outorgados pela empresa Pfizer, Inc
para atuar em seu nome perante o Sistema Brasileiro de Defesa da
Concorrência - SBDC, em especiàl no Ato de Concentração n°
08012.001157/2009-71.
Em face da existência de outros
procuradores, faz-se desnecessár a notificação da mandante,
bem como a continuidade da repre ntação pelo prazo de dez dias,
previstos no artigo 45 do Código de kocesso Civil.
Sãà Paulo, 14 de janeiro de 2011.
a
Camila PimentelPorto Dona
OAB/SP n.° 172.500
RENUNCIA
0
Eu, CAMILA CASTANHO GIRARDI, inscrita na Ordem dos
Advogados do Brasil sob o n;° 175.500 e no CPF/MF sob o n.°
254.527.028-81, por intermédio do presente ato venho apresentar
RENUNCIA, nos termos do artigo 45 do Código de Processo Civil,
aos poderes que me foram outorgpdos pela empresa Pfizer, Inc.
para atuar em seu nome perante o Sistema Brasileiro de Defesa da
Concorrência - SBDC, em especiàl no Ato de Concentração n°
08012.001157/2009-71.
Em face
procuradores, faz-se desne
bem como a continuidade da
previstos no artig
da existência de outros
i a notificação da mandante,
ntãção pelo prazo de dez dias,
MINISTERIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N°
)si 1_
/2011/SDE/GAB
Brasília, 04 de março de 2011.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO
o
MA D) Íf41
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3 ° andar, sala 324
70048-900 - BRASILLAJDF
SE.AJM
Senhor Secretário
De ordem, encaminho a V
versão pública, de interesse da empresa
08012.001157/2009-71.
gh
Documentação de n° 08012.002663/2011-01,
R, INC. referente ao Ato de Concentração n°
Atenciosamente,
JONAS IYELNIÃN BIS1tO]Y OTJ
Chefe do Pr4oc6IoIProcessuaI/SDE
MINISTÉRIO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N°
/2011/SDE/GAB
Brasília, 04 de março de 2011.
A Sua Senhoria o Senhor
ANTÔNIO HENRIQUE PINHEIRO
Secretário de Acompanhamento Econômico
Ministério da Fazenda
Ed. Sede, Bloco "P", 3° andar, sala 324
70048-900 - BRASÍLIA/DF
ILtIJI o Lii!
SEAWMF
RECEBhlT
-f
Senhor Secretário
De ordem, encaminho a
versão pública, de interesse da empresa
08012.001157/2009-71.
À
Documentação de n° 08012.002663/2011-01,
R, INC. referente ao Ato de Concentração,?4_ ? J
Atenciosamente,
JONAS
Chefe &
Esplanada dos Ministérios - Ministério da Justiça Fone: 61; 3321-7800/3:
1 - 5 andar—sala 538 - Cep: 70064900— Brasília-L)F
5— e-mail: sde1rni.pov.br
lia
MINISTÉRIO DA JUSTIÇA
SECRETARIA DÉ DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
I
OFICIO N° '
/2011/SDE/GAB
Brasília, 04 de março de 201f?
L
A Sua Senhoria o Senhor
FERNANDO DE MAGALHÃES FURL
Presidente do Conselho Administrativo de
Ministério da Justiça
Brasília - DF
0
jEconômica
85
3-
CADE/MJ
08700001379/201151
0%
£4
Senhor Presidente,
De ordem, encaminho a V
versão pública, de interesse da empresa
08012.001157/2009-71.
Documentação de n° 08012.002663/2011-01,
R, INC. referente ao Ato de Concentração n
Atenciosamente,
S
JONASi
Chefe do
SOUSA
uM! SDE
- Ministério da Justiça - E )T-5° andar — sala 538—Cep: 70064-900Fone: 613321-78001332 195—e-mail: sdeinjgov.br
à
MLNISTEWO DA JUSTIÇA
SECRETARIA DE DIREITO ECONÔMICO
GABINETE DO SECRETÁRIO
OFÍCIO N° '1
/2011/SDE/GAB
Brasifia, 04 de março de 201*
A Sua Senhoria o Senhor
FERNANDO DE MAGALHÃES FURLAN
Presidente do Conselho Administrativo de Dei a Econômica
Ministério da Justiça
Brasília - DF
-- -
a
CADE/MJ
08700001379/201151
li
Senhor Presidente,
De ordem, encaminho a V
versão pública, de interesse da empresa P
08012.001157/2009-71.
Documentação de n° 08012.002663/2011-01,
R, INC. referente ao Ato de Concentração n°
Atenciosamente,
JONATtE1Ãfl1$4ttii
buJX
Chefe do Prbtocol6/ Processual! SDE
7
a
e
Ministério da Justiça
-
TERMO DE ENCERRAMENTO DE VOLUME
11
SISTEMA DE GERENCIAMENTO DE DOCUMENTOS/PROCESSOS
MJDOC
SDE/GAB/CAPRO - Coordenação de Apoioasw
TERMO DE
DE VOLUME
Pública
Ao(s) 12 dia(s) do mês de
Julho
de1 2011, procede o encerramento deste volume,
no do Processo 08012.001157/2009-71, contendo 248 folhas, abrindo-se em seguida o volume n°2.
Para constar, eu NILCEIA MARTINS DE SOUZA, sobrescrevo e assino.
Carimbo e
iTéiMartins de So
Agente Administrativo e
Mat. 0161048
1
1
.ti
Emitido por NILCEIA MARTINS DE souzAI:
Data: 12/07/2011
Hora: 17:21
Ministério da Justiça
Página 1 de 1
a
Ministério da Justiça
DE VOLUME
TERMO DE
DE GEFENCIA14ENTO DE DOCUMENTOS/PROCESSOS
MJDOC
SPE/GAB/CAPRO - Coordenação de ApoioajuE
DE VOLUME
TERMO DE
2011, procede o encerramento deste volume,
abrindo-se em seguida o volume no 2.
, sobrescrevo e assino.
Julho
Ao(s) 12 dia(s) do mês de
n° do Processo 08012.001157/2009-71, contendo 248
Para constar, eu NILCEIA MARTINS DË S
Carimbo e
.céta Martrn$ de Souza
Agente Admi4istrativo y
Mat. 016048
,1
Data: 12/07/2011
Emitido por: NILCEIA MARTINS DE SOUZA
Hora: 17:21
Ministério da Justiça
li
Página 1 de 1